


**CUMULATIVE
SUPPLEMENT 12
DECEMBER 2012**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Cumulative Supplement 12

December 2012

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	.vi
1.5 Availability of the Edition	vii
1.6 Report of Counts for the Prescription Drug Product List	viii
1.7 Cumulative Supplement Legend	ix
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

**CUMULATIVE SUPPLEMENT 12
December 2012**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ABBOTT LABORATORIES (ABBOTT LABS) (ABBOTT)	ABBVIE INC (ABBVIE) (ABBVIE)
ABBOTT LABORATORIES HOSP PRODUCTS DIV (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT LABORATORIES PHARMACEUTICAL (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT PRODUCTS (ABBOTT)	ABBVIE INC (ABBVIE)
ABRAXIX PHARMACEUTICAL PRODUCTS (ABRAXIS PHARM)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)

APP PHARMACEUTICALS (APP PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
APP PHARMACEUTICALS LLC (APP PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
FOREST LABORATORIES (FOREST LABS)	PFIZER INC (PFIZER)
NEXUS PHARMACEUTICALS (NEXUS PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)
PFIZER CONSUMER HEALTHCARE (PFIZER CONS HLTHCARE)	PFIZER INC (PFIZER)
ROSS LABORATORIES DIV ABBOTT LABORATORIES (ROSS LABS)	ABBVIE INC (ABBVIE)
SOLVAY PHARMACEUTICALS (SOLVAY)	ABBVIE INC (ABBVIE)
UNIMED PHARMACEUTICALS INC (UNIMED PHARMS)	ABBVIE INC (ABBVIE)
WYETH CONSUMER HEALTHCARE (WYETH CONS)	PFIZER INC (PFIZER)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established

between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual

Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2011</u>	<u>MAR 2012</u>	<u>JUN 2012</u>	<u>SEPT 2012</u>	<u>DEC 2012</u>
DRUG PRODUCTS LISTED	14480	14711	14834	15160	15343
SINGLE SOURCE	2451 (16.9%)	2446 (16.6%)	2428 (16.4%)	2429 (16.0%)	2440 (15.9%)
MULTISOURCE	11953 (82.5%)	12187 (82.8%)	12328 (83.1%)	12653 (83.5%)	12825 (83.6%)
THERAPEUTICALLY EQUIVALENT	11792 (81.4%)	12037 (81.8%)	12187 (82.2%)	12509 (82.5%)	12683 (82.7%)

NOT THERAPEUTICALLY EQUIVALENT	161 (1.1%)	150 (1.0%)	141 (1.0%)	144 (0.9%)	142 (0.9%)
EXCEPTIONS ¹	76 (0.5%)	78 (0.5%)	78 (0.5%)	78 (0.5%)	78 (0.5%)
NEW MOLECULAR ENTITIES APPROVED	6	8	7	9	17
NUMBER OF APPLICANTS	810	826	826	836	835

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 32ND EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

1-1

ABACAVIR SULFATE

TABLET; ORAL

ABACAVIR SULFATE

>A>	AB	APOTEX INC	EQ 300MG BASE	A201570 001	Dec 17, 2012	Dec	NEWA
>A>	AB	AUROBINDO PHARMA LTD	EQ 300MG BASE	A077844 001	Dec 17, 2012	Dec	NEWA
	AB	MYLAN PHARMS INC	EQ 300MG BASE	A091294 001	Jun 18, 2012	Jun	NEWA
		ZIAGEN					
	AB	+ VIIIV HLTHCARE	EQ 300MG BASE	N020977 001	Dec 17, 1998	Jun	CFTG

ACARBOSE

TABLET; ORAL

ACARBOSE

	AB	EMCURE PHARMS LTD	25MG	A202271 001	Feb 07, 2012	Jan	NEWA
	AB		50MG	A202271 002	Feb 07, 2012	Jan	NEWA
	AB		100MG	A202271 003	Feb 07, 2012	Jan	NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

>D>		NEXGEN PHARMA	300MG;50MG	A090956 001	Aug 23, 2011	Dec	CRLD
>A>		+	300MG;50MG	A090956 001	Aug 23, 2011	Dec	CRLD
		BUTAPAP					
		+ MIKART	325MG;50MG	A089987 001	Oct 26, 1992	Jun	CRLD
		PHRENILIN					
		@ VALEANT	325MG;50MG	A087811 001	Jun 19, 1985	Jun	DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	AA	LANNETT HOLDINGS INC	325MG;50MG;40MG	A200243 001	Sep 13, 2012	Aug	NEWA
--	----	----------------------	-----------------	-------------	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

		NEXGEN PHARMA INC	300MG;50MG;40MG;30MG	A076560 002	Jul 19, 2012	Jul	NEWA
--	--	-------------------	----------------------	-------------	--------------	-----	------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	AA	+ PHARM ASSOC	120MG/5ML;12MG/5ML	A087508 001		Jan	CRLD
--	----	---------------	--------------------	-------------	--	-----	------

SUSPENSION; ORAL

CAPITAL AND CODEINE

		+ VALEANT	120MG/5ML;12MG/5ML	A086024 001		Jan	CTEC
--	--	-----------	--------------------	-------------	--	-----	------

		+ VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024 001		Jun	CAHN
--	--	----------------------	--------------------	-------------	--	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

		@ NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366 001	Jan 23, 2002	Jun	DISC
--	--	-----------------	-----------------------	-------------	--------------	-----	------

	AA	VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343 001	Jan 25, 2012	Jan	NEWA
--	----	------------	-----------------------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA	AUROLIFE PHARMA LLC	325MG;5MG	A201013 001	Apr 11, 2012	Mar	NEWA
--	----	---------------------	-----------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	AUROLIFE PHARMA LLC	325MG;7.5MG	A201013 002	Apr 11, 2012	Mar	NEWA
AA		325MG;10MG	A201013 003	Apr 11, 2012	Mar	NEWA
	@ VINTAGE PHARMS LLC	500MG;5MG	A040281 001	Sep 30, 1998	Sep	CAHN
	@	500MG;7.5MG	A040280 001	Sep 30, 1998	Sep	CAHN
	@	650MG;7.5MG	A040280 002	Sep 30, 1998	Sep	CAHN
	@	650MG;10MG	A040280 003	Sep 30, 1998	Sep	CAHN
	@	750MG;7.5MG	A040281 002	Sep 30, 1998	Sep	CAHN
	VICODIN					
	@ ABBVIE	500MG;5MG	A088058 001	Jan 07, 1983	Nov	DISC
AA	+	500MG;5MG	A088058 001	Jan 07, 1983	Sep	CAHN
	VICODIN ES					
	@ ABBVIE	750MG;7.5MG	A089736 001	Dec 09, 1988	Nov	DISC
AA	+	750MG;7.5MG	A089736 001	Dec 09, 1988	Sep	CAHN
	VICODIN HP					
	@ ABBVIE	660MG;10MG	A040117 001	Sep 23, 1996	Nov	DISC
AA		660MG;10MG	A040117 001	Sep 23, 1996	Sep	CAHN
	ZYDONE					
	+ VINTAGE PHARMS LLC	400MG;5MG	A040288 001	Nov 27, 1998	Sep	CAHN
	+	400MG;7.5MG	A040288 002	Nov 27, 1998	Sep	CAHN
	+	400MG;10MG	A040288 003	Nov 27, 1998	Sep	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

	@ VINTAGE PHARMS LLC	500MG;5MG	A040303 001	Dec 30, 1999	Sep	CAHN
--	----------------------	-----------	-------------	--------------	-----	------

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ACTAVIS TOTOWA	325MG;7.5MG	A040800 001	Apr 03, 2012	Mar	NEWA
AA		325MG;10MG	A040800 002	Apr 03, 2012	Mar	NEWA
AA	ALVOGEN INC	325MG;7.5MG	A202677 001	Jul 26, 2012	Jul	NEWA
AA		325MG;10MG	A202677 002	Jul 26, 2012	Jul	NEWA
	PERCOCET					
AA	+ VINTAGE PHARMS LLC	325MG;2.5MG	A040330 001	Jun 25, 1999	Sep	CAHN
AA	+	325MG;5MG	A040330 002	Jun 25, 1999	Sep	CAHN
	@	325MG;5MG	A085106 002		Sep	CAHN
AA	+	325MG;7.5MG	A040434 001	Nov 23, 2001	Sep	CAHN
AA	+	325MG;10MG	A040434 002	Nov 23, 2001	Sep	CAHN
AA	+	500MG;7.5MG	A040341 001	Jul 26, 1999	Sep	CAHN
AA	+	650MG;10MG	A040341 002	Jul 26, 1999	Sep	CAHN

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

WYGESIC

	@ CARACO	650MG;65MG	A084999 001		Oct	CAHN
--	----------	------------	-------------	--	-----	------

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALVOGEN INC	325MG;37.5MG	A202076 001	Mar 30, 2012	Mar	NEWA	
>A>	AB	MICRO LABS LTD INDIA	325MG;37.5MG	A201952 001	Dec 14, 2012	Dec	NEWA
AB	ZYDUS PHARMS USA INC	325MG;37.5MG	A090460 001	Sep 06, 2012	Aug	NEWA	

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	A200880	001	May 09, 2012	Apr	NEWA
AP	+ X GEN PHARMS	EQ 500MG BASE/VIAL	A040784	001	Dec 10, 2008	Apr	CRLD
	DIAMOX						
	@ TEVA WOMENS	EQ 500MG BASE/VIAL	N009388	001	Dec 05, 1990	Apr	DISC

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE

AP	+ CUMBERLAND PHARMS	6GM/30ML (200MG/ML)	N021539	001	Jan 23, 2004	Oct	CFTG
	ACETYLCYSTEINE						
AP	INNOPHARMA INC	6GM/30ML (200MG/ML)	A200644	001	Nov 07, 2012	Oct	NEWA
	SOLUTION; INHALATION, ORAL						
	ACETYLCYSTEINE						
AN	INNOPHARMA INC	20%	A203853	001	Jun 21, 2012	Jun	NEWA

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

	+ FOREST LABS INC	0.375MG/INH	N202450	001	Jul 23, 2012	Jul	NEWA
--	-------------------	-------------	---------	-----	--------------	-----	------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

	@ HERITAGE PHARMS INC	200MG	A074889	001	Oct 31, 1997	May	CAHN
--	-----------------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

	@ HERITAGE PHARMS INC	400MG	A074891	001	Oct 31, 1997	May	CAHN
--	-----------------------	-------	---------	-----	--------------	-----	------

	@	800MG	A074891	002	Oct 31, 1997	May	CAHN
--	---	-------	---------	-----	--------------	-----	------

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

	+ HIKMA MAPLE	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997	Oct	CAHN
		EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997	Oct	CAHN
	ACYCLOVIR SODIUM						
AP	HIKMA MAPLE	EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997	Oct	CAHN
AP		EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997	Oct	CAHN

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB	FOUGERA PHARMS	0.1%	A090824	001	Jun 30, 2010	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

GEL; TOPICAL

ADAPALENE

AB	TOLMAR	0.3%	A200298	001	Jun 14, 2012	Jun	NEWA
----	--------	------	---------	-----	--------------	-----	------

DIFFERIN

AB	+ GALDERMA LABS LP	0.3%	N021753	001	Jun 19, 2007	Jun	CFTG
----	--------------------	------	---------	-----	--------------	-----	------

LOTION; TOPICAL

DIFFERIN

	+ GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010	Apr	CAHN
--	--------------------	------	---------	-----	--------------	-----	------

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

AP	HIKMA MAPLE	3MG/ML	A076500	001	Jun 16, 2004	Oct	CAHN
	@	3MG/ML	A076501	001	Jun 16, 2004	Oct	CAHN
	@ TEVA PARENTERAL	3MG/ML	A078676	001	Jul 31, 2008	Mar	DISC
	@	3MG/ML	A076564	001	Jun 16, 2004	Jan	DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Sep	CAHN
----	-------------	----------------	---------	-----	--------------	-----	------

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN	RITEDOSE CORP	EQ 0.083% BASE;0.017%	A202496	001	Oct 01, 2012	Sep	NEWA
	@ SANDOZ INC	EQ 0.083% BASE;0.017%	A076867	001	Dec 21, 2006	Apr	DISC
AN	TEVA PHARMS	EQ 0.083% BASE;0.017%	A076724	001	Dec 31, 2007	Sep	CAHN

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	FOUGERA PHARMS	0.05%	A076973	001	Jul 12, 2005	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	FOUGERA PHARMS	0.05%	A076884	001	Jul 18, 2005	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

ALENDRONATE SODIUM

TABLET, EFFERVESCENT; ORAL

BINOSTO

+	MISSION PHARMA	EQ 70MG BASE	N202344	001	Mar 12, 2012	Mar	NEWA
---	----------------	--------------	---------	-----	--------------	-----	------

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	10MG	A079060	001	Aug 30, 2012	Aug	NEWA
AB	INVAGEN PHARMS	10MG	A090284	001	Jan 17, 2012	Jan	NEWA
AB	WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Jul	NEWA

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

@	GENZYME	80 UNITS/ML	N020057	003	Apr 05, 1991	Mar	DISC
---	---------	-------------	---------	-----	--------------	-----	------

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	MYLAN PHARMS INC	0.25MG	A074046	001	Oct 19, 1993	Sep	CAHN
AB		0.5MG	A074046	002	Oct 19, 1993	Sep	CAHN
AB		1MG	A074046	003	Oct 19, 1993	Sep	CAHN
AB		2MG	A074046	004	May 07, 1997	Sep	CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@	SANDOZ INC	0.5MG	A077777	001	Jun 30, 2006	Mar	DISC
---	------------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ SANDOZ INC	1MG	A077777 002	Jun 30, 2006	Mar	DISC
@	2MG	A077777 003	Jun 30, 2006	Mar	DISC
@	3MG	A077777 004	Jun 30, 2006	Mar	DISC
@ VINTAGE PHARMS	0.5MG	A078442 001	Oct 15, 2007	Jul	DISC
@	1MG	A078442 002	Oct 15, 2007	Jul	DISC
@	2MG	A078442 003	Oct 15, 2007	Jul	DISC
@	3MG	A078442 004	Oct 15, 2007	Jul	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

AB	UCB INC	0.25MG	N021726 001	Jan 19, 2005	Jan	CAHN
AB		0.5MG	N021726 002	Jan 19, 2005	Jan	CAHN
AB	+	1MG	N021726 003	Jan 19, 2005	Jan	CAHN
AB		2MG	N021726 004	Jan 19, 2005	Jan	CAHN

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

>A>	@ ACTIENT PHARMS	0.005MG/VIAL	N020649 001	Jun 12, 1997	Dec	CAHN
>A>	AP	0.01MG/VIAL	N020649 002	Jun 12, 1997	Dec	CAHN
>A>	+	0.01MG/VIAL	N020649 005	Jul 30, 1998	Dec	CAHN
>A>	+	0.02MG/VIAL	N020649 006	Jul 30, 1998	Dec	CAHN
>A>	AP	0.02MG/VIAL	N020649 003	Jun 12, 1997	Dec	CAHN
>A>	+	0.04MG/VIAL	N020649 007	Jul 30, 1998	Dec	CAHN
>A>	AP	0.04MG/VIAL	N020649 004	Jun 12, 1997	Dec	CAHN
>D>	@ SCHWARZ PHARMA	0.005MG/VIAL	N020649 001	Jun 12, 1997	Dec	CAHN
>D>	+	0.01MG/VIAL	N020649 005	Jul 30, 1998	Dec	CAHN
>D>	AP	0.01MG/VIAL	N020649 002	Jun 12, 1997	Dec	CAHN
>D>	+	0.02MG/VIAL	N020649 006	Jul 30, 1998	Dec	CAHN
>D>	AP	0.02MG/VIAL	N020649 003	Jun 12, 1997	Dec	CAHN
>D>	AP	0.04MG/VIAL	N020649 004	Jun 12, 1997	Dec	CAHN
>D>	+	0.04MG/VIAL	N020649 007	Jul 30, 1998	Dec	CAHN

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+	CUBIST PHARMS	12MG	N021775 001	May 20, 2008	Feb	CAHN
---	---------------	------	-------------	--------------	-----	------

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076065 001	May 15, 2003	Jan	CAHN
----	---	----------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

AMCINONIDE

+	FOUGERA PHARMS	0.1%	A076329 001	Nov 06, 2002	Jan	CAHN
---	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076096 001	Nov 19, 2002	Jan	CAHN
----	---	----------------	------	-------------	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@	HIKMA MAPLE	EQ 50MG BASE/ML	A063274 001	May 18, 1992	Oct	CAHN
@		EQ 250MG BASE/ML	A063275 001	May 18, 1992	Oct	CAHN
@	HOSPIRA	EQ 50MG BASE/ML	A063263 001	Nov 30, 1994	Jun	DISC

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN	15% (300GM/2000ML)	A091112 002	Apr 13, 2012	Mar	NEWA
	15% (150GM/1000ML)	A091112 001	Apr 13, 2012	Mar	NEWA
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER					
BAXTER HLTHCARE	15% (15GM/100ML)	A020512 001	Aug 30, 1996	Jun	CAHN
NOVAMINE 15%					
@ HOSPIRA INC	15% (75GM/500ML)	N017957 004	Nov 28, 1986	Mar	CPOT

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

@ CLOVER PHARMS	250MG/ML	N015229 002		Mar	CAHN
-----------------	----------	-------------	--	-----	------

SYRUP; ORAL

AMICAR

AA + CLOVER PHARMS	1.25GM/5ML	N015230 002		Mar	CAHN
--------------------	------------	-------------	--	-----	------

TABLET; ORAL

AMICAR

AB CLOVER PHARMS	500MG	N015197 001		Mar	CAHN
+	1GM	N015197 002	Jun 24, 2004	Mar	CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ BEDFORD	50MG/ML	A076018 001	Oct 15, 2002	Jun	DISC
@ BEDFORD LABS	50MG/ML	A076299 001	Oct 24, 2002	Jun	DISC
@ TEVA PARENTERAL	50MG/ML	A076163 001	Sep 05, 2003	Jan	DISC

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB MURTY PHARMS	200MG	A077069 001	Apr 08, 2005	May	CAHN
AB	400MG	A077069 002	Apr 08, 2005	May	CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB CARACO	10MG	A040816 002	Jun 27, 2008	Apr	NEWA
AB	50MG	A040816 003	Jun 27, 2008	Apr	NEWA
AB	75MG	A040816 004	Jun 27, 2008	Apr	NEWA
AB	100MG	A040816 005	Jun 27, 2008	Apr	NEWA
AB	150MG	A040816 006	Jun 27, 2008	Apr	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297 002	Dec 10, 1986	Feb	CTEC
+	EQ 25MG BASE;10MG	A071297 001	Dec 10, 1986	Feb	CRLD
LIMBITROL					
@ VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949 001		Feb	DISC
LIMBITROL DS					
@ VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949 002		Feb	DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380 001	Apr 13, 2012	Mar	NEWA
AB		EQ 10MG BASE	A201380 002	Apr 13, 2012	Mar	NEWA
	@ SANDOZ	EQ 2.5MG BASE	A076859 001	Sep 10, 2007	Oct	DISC
	@	EQ 5MG BASE	A076859 002	Sep 10, 2007	Oct	DISC
	@	EQ 10MG BASE	A076859 003	Sep 10, 2007	Oct	DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 2.5MG BASE;10MG	A202239 001	Sep 05, 2012	Aug	NEWA
AB		EQ 5MG BASE;10MG	A202239 002	Sep 05, 2012	Aug	NEWA
AB		EQ 5MG BASE;20MG	A202239 003	Sep 05, 2012	Aug	NEWA
AB		EQ 5MG BASE;40MG	A202239 004	Sep 05, 2012	Aug	NEWA
AB		EQ 10MG BASE;20MG	A202239 005	Sep 05, 2012	Aug	NEWA
AB		EQ 10MG BASE;40MG	A202239 006	Sep 05, 2012	Aug	NEWA

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

EXFORGE HCT

AB	NOVARTIS	5MG;12.5MG;160MG	N022314 001	Apr 30, 2009	Sep	CFTG
AB		5MG;25MG;160MG	N022314 002	Apr 30, 2009	Sep	CFTG
AB		10MG;12.5MG;160MG	N022314 003	Apr 30, 2009	Sep	CFTG
AB		10MG;25MG;160MG	N022314 004	Apr 30, 2009	Sep	CFTG
AB	+	10MG;25MG;320MG	N022314 005	Apr 30, 2009	Sep	CFTG

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435 001	Sep 25, 2012	Sep	NEWA
AB		5MG;25MG;160MG	A200435 002	Sep 25, 2012	Sep	NEWA
AB		10MG;12.5MG;160MG	A200435 005	Sep 25, 2012	Sep	NEWA
AB		10MG;25MG;160MG	A200435 003	Sep 25, 2012	Sep	NEWA
AB		10MG;25MG;320MG	A200435 004	Sep 25, 2012	Sep	NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

>A>	HOUSTON CYCLOTRON	3.75-260mCi/ML	A203543 001	Dec 14, 2012	Dec	NEWA
-----	-------------------	----------------	-------------	--------------	-----	------

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	WATSON LABS INC	EQ 12% BASE	A076829 001	Feb 07, 2006	Oct	CAHN
----	-----------------	-------------	-------------	--------------	-----	------

LOTION; TOPICAL

AMMONIUM LACTATE

AB	WATSON LABS INC	EQ 12% BASE	A075575 001	Jun 11, 2002	Oct	CAHN
----	-----------------	-------------	-------------	--------------	-----	------

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	AM ANTIBIOTICS	250MG	A062058 001		Oct	CAHN
AB		500MG	A062058 002		Oct	CAHN

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

@ RANBAXY LABS LTD

600MG

A065159 001 Dec 04, 2003 Apr DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SANDOZ INC	200MG/5ML;EQ 28.5MG BASE/5ML	A065098 001	Dec 16, 2002	Jul	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065098 002	Dec 16, 2002	Jul	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065358 001	Aug 13, 2007	Jul	CAHN

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569 001	Jan 20, 2012	Jan	NEWA
AB		500MG;EQ 125MG BASE	A091569 002	Jan 20, 2012	Jan	NEWA
AB		875MG;EQ 125MG BASE	A091568 001	Jan 20, 2012	Jan	NEWA
AB	SANDOZ INC	500MG;EQ 125MG BASE	A065117 001	Nov 27, 2002	Jul	CAHN
AB		875MG;EQ 125MG BASE	A065093 001	Nov 21, 2002	Jul	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

AB	SHIRE	2.5MG;2.5MG;2.5MG;2.5MG	N021303 001	Oct 11, 2001	Jun	CFTG
----	-------	-------------------------	-------------	--------------	-----	------

ADDERALL XR 15

AB	SHIRE	3.75MG;3.75MG;3.75MG;3.75MG	N021303 006	May 22, 2002	Jun	CFTG
----	-------	-----------------------------	-------------	--------------	-----	------

ADDERALL XR 20

AB	SHIRE	5MG;5MG;5MG;5MG	N021303 002	Oct 11, 2001	Jun	CFTG
----	-------	-----------------	-------------	--------------	-----	------

ADDERALL XR 25

AB	SHIRE	6.25MG;6.25MG;6.25MG;6.25MG	N021303 004	May 22, 2002	Jun	CFTG
----	-------	-----------------------------	-------------	--------------	-----	------

ADDERALL XR 30

AB	+ SHIRE	7.5MG;7.5MG;7.5MG;7.5MG	N021303 003	Oct 11, 2001	Jun	CFTG
----	---------	-------------------------	-------------	--------------	-----	------

ADDERALL XR 5

AB	SHIRE	1.25MG;1.25MG;1.25MG;1.25MG	N021303 005	May 22, 2002	Jun	CFTG
----	-------	-----------------------------	-------------	--------------	-----	------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302 001	Jun 22, 2012	Jun	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077302 002	Jun 22, 2012	Jun	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077302 003	Jun 22, 2012	Jun	NEWA
AB		5MG;5MG;5MG;5MG	A077302 004	Jun 22, 2012	Jun	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077302 005	Jun 22, 2012	Jun	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077302 006	Jun 22, 2012	Jun	NEWA

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

>A>	ARBOR PHARMS INC	5MG	A200166 001	Aug 09, 2012	Dec	CAHN
>A>	+	10MG	A200166 002	Aug 09, 2012	Dec	CAHN
>D>	INDEPENDENCE PHARMS	5MG	A200166 001	Aug 09, 2012	Dec	CAHN
		5MG	A200166 001	Aug 09, 2012	Jul	NEWA
>D>	+	10MG	A200166 002	Aug 09, 2012	Dec	CAHN
	+	10MG	A200166 002	Aug 09, 2012	Jul	NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

+	ALKOPHARMA USA	50MG/VIAL	N050729 001	Nov 22, 1996	May	CAHN
+		100MG/VIAL	N050729 002	Nov 22, 1996	May	CAHN

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	ANTIBIOTIC	EQ 250MG BASE/VIAL	A090354 001	Dec 28, 2009	Aug	CAHN
AP		EQ 500MG BASE/VIAL	A090354 002	Dec 28, 2009	Aug	CAHN
AP		EQ 1GM BASE/VIAL	A090354 003	Dec 28, 2009	Aug	CAHN
AP		EQ 2GM BASE/VIAL	A090354 004	Dec 28, 2009	Aug	CAHN
	@ HIKMA MAPLE	EQ 125MG BASE/VIAL	A062692 001	Jun 24, 1986	Oct	CAHN
	@	EQ 250MG BASE/VIAL	A062692 002	Jun 24, 1986	Oct	CAHN
	@	EQ 500MG BASE/VIAL	A062692 003	Jun 24, 1986	Oct	CAHN
	@	EQ 1GM BASE/VIAL	A062692 004	Jun 24, 1986	Oct	CAHN
	@	EQ 2GM BASE/VIAL	A062692 005	Jun 24, 1986	Oct	CAHN
	@	EQ 10GM BASE/VIAL	A062692 006	Jun 24, 1986	Oct	CAHN
>A>	AP	IBI	EQ 125MG BASE/VIAL	A062797 001	Jul 12, 1993	Dec CAHN
>A>	AP		EQ 2GM BASE/VIAL	A062797 002	Jul 12, 1993	Dec CAHN
>D>	AP	INSTITUTO BIOCHEMICO	EQ 125MG BASE/VIAL	A062797 001	Jul 12, 1993	Dec CAHN
>D>	AP		EQ 2GM BASE/VIAL	A062797 002	Jul 12, 1993	Dec CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	HIKMA MAPLE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074 001	Mar 19, 2002	Oct	CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074 002	Mar 19, 2002	Oct	CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065076 001	Mar 19, 2002	Oct	CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB	SHIRE LLC	EQ 0.5MG BASE	N020333 001	Mar 14, 1997	Jan	CAHN
	ANAGRELIDE HYDROCHLORIDE					
AB	MYLAN PHARMS INC	EQ 0.5MG BASE	A077613 001	Jun 27, 2006	Sep	CAHN
AB		EQ 1MG BASE	A077613 002	Jun 27, 2006	Sep	CAHN
	@ SANDOZ INC	EQ 0.5MG BASE	A076683 001	Apr 18, 2005	Mar	DISC
	@	EQ 1MG BASE	A076683 002	Apr 18, 2005	Mar	DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	APOTEX INC	1MG	A200654 001	May 11, 2012	Apr	NEWA
AB	IMPAX LABS INC	1MG	A091242 001	May 31, 2012	May	NEWA

>A> APIXABAN

>A> TABLET; ORAL

>A> ELIQUIS

>A>	BRISTOL MYERS SQUIBB	2.5MG	N202155 001	Dec 28, 2012	Dec	NEWA
>A>	+	5MG	N202155 002	Dec 28, 2012	Dec	NEWA

APREPITANT

CAPSULE; ORAL

APREPITANT

AB	SANDOZ	40MG	A090999 001	Sep 24, 2012	Sep	NEWA
AB		80MG	A090999 002	Sep 24, 2012	Sep	NEWA
AB		125MG	A090999 003	Sep 24, 2012	Sep	NEWA

CAPSULE; ORALEMEND

AB	MERCK	40MG	N021549 003	Jun 30, 2006	Sep	CFTG
AB		80MG	N021549 001	Mar 26, 2003	Sep	CFTG
AB	+	125MG	N021549 002	Mar 26, 2003	Sep	CFTG

APROTINININJECTABLE; INJECTIONTRASYLOL

@	BAYER HLTHCARE	10,000KIU/ML	N020304 001	Dec 29, 1993	May	DISC
---	----------------	--------------	-------------	--------------	-----	------

ARGATROBANINJECTABLE; INJECTIONACOVA

AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883 001	Jun 30, 2000	Jan	CTNA
AP		ARGATROBAN					
AP		HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049 001	Jan 05, 2012	Jan	NEWA

ARMODAFINILTABLET; ORALARMODAFINIL

AB	MYLAN PHARMS INC	50MG	A200043 001	Jun 01, 2012	May	NEWA
AB		150MG	A200043 002	Jun 01, 2012	May	NEWA
AB		250MG	A200043 003	Jun 01, 2012	May	NEWA
	WATSON LABS INC	100MG	A200156 002	Aug 29, 2012	Aug	NEWA
		200MG	A200156 004	Aug 29, 2012	Aug	NEWA
	NUVIGIL					
AB	CEPHALON	50MG	N021875 001	Jun 15, 2007	May	CFTG
AB		150MG	N021875 003	Jun 15, 2007	May	CFTG
AB	+	250MG	N021875 004	Jun 15, 2007	May	CFTG

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATEFOR SOLUTION; ORALASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

AA	NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM	A090145 001	Jan 25, 2012	Nov	CPOT	
		;7.5GM					
AA		4.7GM;100GM;1.015GM;5.9GM;2.691GM	A090145 001	Jan 25, 2012	Jan	NEWA	
		;7.5GM					
	MOVIPREP						
AA	+	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM	N021881 001	Aug 02, 2006	Jan	CFTG
			;7.5GM				

ASENAPINE MALEATETABLET; SUBLINGUALSAPHRIS

	ORGANON SUB MERCK	EQ 5MG BASE	N022117 001	Aug 13, 2009	Jul	CAHN
+		EQ 10MG BASE	N022117 002	Aug 13, 2009	Jul	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATECAPSULE; ORALBUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@	VINTAGE PHARMS LLC	325MG;50MG;40MG;30MG	A075351 001	Mar 05, 1999	Sep	CAHN
---	--------------------	----------------------	-------------	--------------	-----	------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

@ SANDOZ 385MG;30MG;25MG A074817 001 Nov 27, 1996 Oct DISC

INVAGESIC FORTE

@ SANDOZ 770MG;60MG;50MG A074817 002 Nov 27, 1996 Oct DISC

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB PROSAM LABS 325MG;200MG A040252 001 Dec 10, 1997 Feb CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB PROSAM LABS 325MG;200MG;16MG A040283 001 Dec 29, 1998 Feb CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

@ ZYDUS PHARMS USA INC 18MG A079017 001 Sep 17, 2010 Jun DISC

@ 25MG A079017 002 Sep 17, 2010 Jun DISC

@ 40MG A079017 003 Sep 17, 2010 Jun DISC

@ 60MG A079017 004 Sep 17, 2010 Jun DISC

@ 80MG A079017 005 Sep 17, 2010 Jun DISC

@ 100MG A079017 006 Sep 17, 2010 Jun DISC

STRATTERA

LILLY 10MG N021411 002 Nov 26, 2002 Jun CTEC

18MG N021411 003 Nov 26, 2002 Jun CTEC

25MG N021411 004 Nov 26, 2002 Jun CTEC

40MG N021411 005 Nov 26, 2002 Jun CTEC

+ 60MG N021411 006 Nov 26, 2002 Jun CTEC

80MG N021411 007 Feb 14, 2005 Jun CTEC

100MG N021411 008 Feb 14, 2005 Jun CTEC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB APOTEX INC EQ 10MG BASE A090548 001 May 29, 2012 May NEWA

AB EQ 20MG BASE A090548 002 May 29, 2012 May NEWA

AB EQ 40MG BASE A090548 003 May 29, 2012 May NEWA

AB EQ 80MG BASE A090548 004 May 29, 2012 May NEWA

AB DR REDDYS LABS LTD EQ 10MG BASE A091650 001 Jul 17, 2012 Jul NEWA

AB EQ 20MG BASE A091650 002 Jul 17, 2012 Jul NEWA

AB EQ 40MG BASE A091650 003 Jul 17, 2012 Jul NEWA

AB EQ 80MG BASE A202357 001 Jul 17, 2012 Jul NEWA

AB MYLAN PHARMS INC EQ 10MG BASE A091226 001 May 29, 2012 May NEWA

AB EQ 20MG BASE A091226 002 May 29, 2012 May NEWA

AB EQ 40MG BASE A091226 003 May 29, 2012 May NEWA

AB EQ 80MG BASE A091226 004 May 29, 2012 May NEWA

AB SANDOZ INC EQ 10MG BASE A077575 001 May 29, 2012 May NEWA

AB EQ 20MG BASE A077575 002 May 29, 2012 May NEWA

AB EQ 40MG BASE A077575 003 May 29, 2012 May NEWA

AB EQ 80MG BASE A077575 004 May 29, 2012 May NEWA

@ TEVA PHARMS EQ 10MG BASE A078773 001 May 29, 2012 Nov DISC

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	TEVA PHARMS	EQ 10MG BASE	A078773 001	May 29, 2012	May	NEWA
	@	EQ 20MG BASE	A078773 002	May 29, 2012	Nov	DISC
AB		EQ 20MG BASE	A078773 002	May 29, 2012	May	NEWA
	@	EQ 40MG BASE	A078773 003	May 29, 2012	Nov	DISC
AB		EQ 40MG BASE	A078773 003	May 29, 2012	May	NEWA
	@	EQ 80MG BASE	A078773 004	May 29, 2012	Nov	DISC
AB		EQ 80MG BASE	A078773 004	May 29, 2012	May	NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+	BEDFORD	10MG/ML	A074901 001	Jul 18, 1997	Feb	CTEC
AP		HOSPIRA INC	10MG/ML	A090761 001	Oct 18, 2012	Oct	NEWA
AP		SAGENT PHARMS	10MG/ML	A091489 001	Feb 17, 2012	Feb	NEWA

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	+	BEDFORD	10MG/ML	A074900 001	Jul 18, 1997	Feb	CTEC
AP		HOSPIRA INC	10MG/ML	A090782 001	Oct 18, 2012	Oct	NEWA
AP		SAGENT PHARMS	10MG/ML	A091488 001	Feb 17, 2012	Feb	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	+	ROXANE	0.025MG/5ML; 2.5MG/5ML	A087708 001	May 03, 1982	Apr	CRLD
		LOMOTIL					
		@ GD SEARLE LLC	0.025MG/5ML; 2.5MG/5ML	N012699 001		Apr	DISC

AVANAFIL

TABLET; ORAL

STENDRA

VIVUS

		VIVUS	50MG	N202276 001	Apr 27, 2012	Apr	NEWA
			100MG	N202276 002	Apr 27, 2012	Apr	NEWA
	+		200MG	N202276 003	Apr 27, 2012	Apr	NEWA

AXITINIB

TABLET; ORAL

INLYTA

PFIZER

		PFIZER	1MG	N202324 001	Jan 27, 2012	Jan	NEWA
	+		5MG	N202324 002	Jan 27, 2012	Jan	NEWA

AZELAIC ACID

GEL; TOPICAL

FINACEA

>D>	+	BAYER HLTHCARE	15%	N021470 001	Dec 24, 2002	Dec	CAHN
	+		15%	N021470 001	Dec 24, 2002	Jun	CAHN
>A>	+	BHP DERMATOLOGY	15%	N021470 001	Dec 24, 2002	Dec	CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		ALCON PHARMA	0.05%	A202305 001	May 31, 2012	May	NEWA
----	--	--------------	-------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

ASTEPRO

AB	+	MEDA PHARMS	EQ 0.1876MG BASE/SPRAY	N022371 001	Aug 31, 2009	Aug	CFTG
----	---	-------------	------------------------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

AB	APOTEX INC	EQ 0.1876MG BASE/SPRAY	A201846 001	Aug 31, 2012	Aug	NEWA
AB	SUN PHARMA GLOBAL	EQ 0.125MG BASE/SPRAY	A090423 001	May 23, 2012	May	NEWA

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

DYMISTA

+	MEDA PHARMS	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236 001	May 01, 2012	May	NEWA
---	-------------	---------------------------------------	-------------	--------------	-----	------

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

	TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL	N200796 001	Feb 25, 2011	Apr	CAHN
+		EQ 80MG MEDOXOMIL	N200796 002	Feb 25, 2011	Apr	CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

	TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL;12.5MG	N202331 001	Dec 20, 2011	Apr	CAHN
+		EQ 40MG MEDOXOMIL;25MG	N202331 002	Dec 20, 2011	Apr	CAHN

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

@	SANDOZ	EQ 100MG BASE/5ML	A065297 001	Sep 18, 2006	Oct	DISC
@		EQ 200MG BASE/5ML	A065297 002	Sep 18, 2006	Oct	DISC

INJECTABLE; INJECTION

AZITHROMYCIN

@	PLIVA HRVATSKA DOO	EQ 500MG BASE/VIAL	A065265 001	Jan 18, 2007	Jul	DISC
@	TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809 001	Dec 19, 2006	Jun	DISC
@		EQ 2.5GM BASE/VIAL	N050809 002	Dec 19, 2006	Jun	DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT	AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213 001	Jul 25, 2012	Jul	NEWA	
AT	+	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068 001	Oct 30, 1995	Jul	CTEC

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

	CNS THERAPS INC	1MG/ML	N022462 004	Jun 22, 2012	Jun	NEWA
--	-----------------	--------	-------------	--------------	-----	------

TABLET; ORAL

BACLOFEN

AB	MYLAN PHARMS INC	10MG	A090334 001	Feb 18, 2010	Sep	CAHN
AB		20MG	A090334 002	Feb 18, 2010	Sep	CAHN
AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
AB		20MG	A077088 001	Oct 31, 2007	Feb	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

@	UCB INC	10MG	N021589 001	Oct 30, 2003	Jan	CAHN
@		20MG	N021589 002	Oct 30, 2003	Jan	CAHN

BALSALAZIDE DISODIUM

TABLET; ORAL

GLIAZO

+	SALIX PHARMS	1.1GM	N022205	001	Feb 03, 2012	Feb	NEWA
---	--------------	-------	---------	-----	--------------	-----	------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL

QNASL

+	TEVA BRANDED PHARM	0.08MG/ACTUATION	N202813	001	Mar 23, 2012	Sep	CPOT
---	--------------------	------------------	---------	-----	--------------	-----	------

+		0.08MG/ACTIVATION	N202813	001	Mar 23, 2012	Mar	NEWA
---	--	-------------------	---------	-----	--------------	-----	------

>A> BEDAQUILINE FUMARATE

>A> TABLET; ORAL

>A> SIRTURO

>A>	+	JANSSEN THERAP	EQ 100MG BASE	N204384	001	Dec 28, 2012	Dec	NEWA
-----	---	----------------	---------------	---------	-----	--------------	-----	------

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

LOTENSIN

AB		US PHARMS HOLDINGS I	5MG	N019851	001	Jun 25, 1991	Sep	CAHN
----	--	----------------------	-----	---------	-----	--------------	-----	------

AB			10MG	N019851	002	Jun 25, 1991	Sep	CAHN
----	--	--	------	---------	-----	--------------	-----	------

AB			20MG	N019851	003	Jun 25, 1991	Sep	CAHN
----	--	--	------	---------	-----	--------------	-----	------

AB	+		40MG	N019851	004	Jun 25, 1991	Sep	CAHN
----	---	--	------	---------	-----	--------------	-----	------

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	MYLAN PHARMS INC	5MG;6.25MG	A076612	001	Feb 11, 2004	Oct	DISC
---	------------------	------------	---------	-----	--------------	-----	------

@		10MG;12.5MG	A076612	002	Feb 11, 2004	Oct	DISC
---	--	-------------	---------	-----	--------------	-----	------

@		20MG;12.5MG	A076612	003	Feb 11, 2004	Oct	DISC
---	--	-------------	---------	-----	--------------	-----	------

@		20MG;25MG	A076612	004	Feb 11, 2004	Oct	DISC
---	--	-----------	---------	-----	--------------	-----	------

LOTENSIN HCT

AB		US PHARMS HOLDINGS I	5MG;6.25MG	N020033	001	May 19, 1992	Sep	CAHN
----	--	----------------------	------------	---------	-----	--------------	-----	------

AB			10MG;12.5MG	N020033	002	May 19, 1992	Sep	CAHN
----	--	--	-------------	---------	-----	--------------	-----	------

AB			20MG;12.5MG	N020033	004	May 19, 1992	Sep	CAHN
----	--	--	-------------	---------	-----	--------------	-----	------

AB	+		20MG;25MG	N020033	003	May 19, 1992	Sep	CAHN
----	---	--	-----------	---------	-----	--------------	-----	------

BENZONATATE

CAPSULE; ORAL

BENZONATATE

@	NESHER PHARMS	100MG	A040795	001	Oct 31, 2007	Jun	DISC
---	---------------	-------	---------	-----	--------------	-----	------

@		200MG	A040795	002	Oct 31, 2007	Jun	DISC
---	--	-------	---------	-----	--------------	-----	------

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

BT	+	VALEANT INTL	5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Apr	CAHN
----	---	--------------	---------------	---------	-----	--------------	-----	------

AB			5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Apr	CAHN
----	--	--	---------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB		MYLAN PHARMS INC	5%;EQ 1% BASE	A065443	001	Aug 11, 2009	Sep	CAHN
----	--	------------------	---------------	---------	-----	--------------	-----	------

AB		PERRIGO ISRAEL	5%;1.2%	A090979	001	Jun 26, 2012	Jun	NEWA
----	--	----------------	---------	---------	-----	--------------	-----	------

DUAC

AB	+	STIEFEL	5%;1.2%	N050741	001	Aug 26, 2002	Jun	CFTG
----	---	---------	---------	---------	-----	--------------	-----	------

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB	+	VALEANT INTL	5%;3%	N050557	001	Oct 26, 1984	Jan	CAHN
		BENZAMYCIN PAK						
	+	VALEANT INTL	5%;3%	N050769	001	Nov 27, 2000	Jun	CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA		EMCURE PHARMS LTD	50MG	A202061	001	Jan 27, 2012	Jan	NEWA
----	--	-------------------	------	---------	-----	--------------	-----	------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP		APP PHARMS LLC	1MG/ML	A090233	001	Jul 28, 2009	May	CAHN
----	--	----------------	--------	---------	-----	--------------	-----	------

COGENTIN

AP	+	OAK PHARMS AKORN	1MG/ML	N012015	001		Feb	CAHN
----	---	------------------	--------	---------	-----	--	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE

AA		EXCELLIUM	0.5MG	A090168	001	Nov 28, 2012	Nov	NEWA
AA			1MG	A090168	002	Nov 28, 2012	Nov	NEWA
AA			2MG	A090168	003	Nov 28, 2012	Nov	NEWA
		@ LANNETT HOLDINGS INC	0.5MG	A088877	001	Apr 11, 1985	Jan	DISC
		@	1MG	A088894	001	Apr 11, 1985	Jan	DISC
		@	2MG	A088895	001	Apr 11, 1985	Jan	DISC
AA		PROSAM LABS	0.5MG	A040699	001	Feb 14, 2008	Feb	CMFD
AA			1MG	A040705	001	Feb 14, 2008	Feb	CMFD
AA			2MG	A040706	001	Feb 14, 2008	Feb	CMFD
AA	+	USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Jan	CRLD
AA	+		1MG	A040103	002	Dec 12, 1996	Jan	CRLD
AA	+		2MG	A040103	003	Dec 12, 1996	Jan	CRLD

BETAMETHASONE

SYRUP; ORAL

CELESTONE

		@ SCHERING	0.6MG/5ML	N014215	002		May	DISC
--	--	------------	-----------	---------	-----	--	-----	------

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137	001	Jun 26, 1984	Jan	CAHN
----	---	----------------	---------------	---------	-----	--------------	-----	------

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215	001	Dec 09, 2003	Jan	CAHN
----	--	----------------	---------------	---------	-----	--------------	-----	------

DIPROLENE AF

>A>	AB	+	MERCK SHARP DOHME	EQ 0.05% BASE	N019555	001	Apr 27, 1987	Dec	CAHN
-----	----	---	-------------------	---------------	---------	-----	--------------	-----	------

>D>	AB	+	SCHERING	EQ 0.05% BASE	N019555	001	Apr 27, 1987	Dec	CAHN
-----	----	---	----------	---------------	---------	-----	--------------	-----	------

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276	001	May 13, 2003	Jan	CAHN
----	---	----------------	---------------	---------	-----	--------------	-----	------

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A077111	001	May 21, 2007	Jan	CAHN
----	--	----------------	---------------	---------	-----	--------------	-----	------

LOTION, AUGMENTED; TOPICAL

DIPROLENE

>A>	AB	+	MERCK SHARP DOHME	EQ 0.05% BASE	N019716	001	Aug 01, 1988	Dec	CAHN
>D>	AB	+	SCHERING	EQ 0.05% BASE	N019716	001	Aug 01, 1988	Dec	CAHN

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

	AB		FOUGERA PHARMS	EQ 0.05% BASE	A075373	001	Jun 22, 1999	Jan	CAHN
--	----	--	----------------	---------------	---------	-----	--------------	-----	------

DIPROLENE

>A>	AB	+	MERCK SHARP DOHME	EQ 0.05% BASE	N018741	001	Jul 27, 1983	Dec	CAHN
>D>	AB	+	SCHERING	EQ 0.05% BASE	N018741	001	Jul 27, 1983	Dec	CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

>A>	AB		TOLMAR	0.064%;0.005%	A201615	001	Jan 14, 2013	Dec	NEWA
-----	----	--	--------	---------------	---------	-----	--------------	-----	------

TACLONEX

>D>		+	LEO PHARM	0.064%;0.005%	N021852	001	Jan 09, 2006	Dec	CFTG
>A>	AB	+	LEO PHARMA AS	0.064%;0.005%	N021852	001	Jan 09, 2006	Dec	CFTG

SUSPENSION; TOPICAL

TACLONEX

		+	LEO PHARM	0.064%;0.005%	N022185	001	May 09, 2008	Oct	CTNA
--	--	---	-----------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

	AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502	001	Jun 05, 2001	Jan	CAHN
--	----	--	----------------	------------------	---------	-----	--------------	-----	------

LOTRISONE

	AB	+	MERCK SHARP DOHME	EQ 0.05% BASE;1%	N018827	001	Jul 10, 1984	Oct	CAHN
--	----	---	-------------------	------------------	---------	-----	--------------	-----	------

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

	AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516	001	Jun 16, 2005	Jan	CAHN
--	----	--	----------------	------------------	---------	-----	--------------	-----	------

LOTRISONE

	AB	+	SCHERING CORP	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb	CAHN
--	----	---	---------------	------------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

	AB		PERRIGO	EQ 0.12% BASE	A078337	001	Nov 26, 2012	Nov	NEWA
--	----	--	---------	---------------	---------	-----	--------------	-----	------

LUXIQ

	AB	+	STIEFEL	EQ 0.12% BASE	N020934	001	Feb 28, 1999	Nov	CFTG
		+		EQ 0.12% BASE	N020934	001	Feb 28, 1999	Jan	CAHN

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

	AB		TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Jan	CAHN
	AB	+		10MG	N019982	001	Jul 31, 1992	Jan	CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ZIAC

>D>	AB		DURAMED PHARMS BARR	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Dec	CAHN
>D>	AB			5MG;6.25MG	N020186	001	Mar 26, 1993	Dec	CAHN
>D>	AB	+		10MG;6.25MG	N020186	002	Mar 26, 1993	Dec	CAHN
>A>	AB		TEVA WOMENS	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Dec	CAHN
>A>	AB			5MG;6.25MG	N020186	001	Mar 26, 1993	Dec	CAHN

		TABLET; ORAL							
		ZIAC							
>A>	AB	+	TEVA WOMENS	10MG;6.25MG	N020186	002	Mar 26, 1993	Dec	CAHN
		<u>BOCEPREVIR</u>							
		CAPSULE; ORAL							
		VICTRELIS							
		+	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Mar	CAHN
		<u>BORTEZOMIB</u>							
		INJECTABLE; INTRAVENOUS, SUBCUTANEOUS							
		VELCADE							
		+	MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003	Jan	CDFR
		<u>BOSENTAN</u>							
		TABLET; ORAL							
		TRACLEER							
			ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001	May	CAHN
		+		125MG	N021290	002	Nov 20, 2001	May	CAHN
		<u>BOSUTINIB MONOHYDRATE</u>							
		TABLET; ORAL							
		BOSULIF							
			WYETH PHARMS INC	EQ 100MG BASE	N203341	001	Sep 04, 2012	Sep	NEWA
		+		EQ 500MG BASE	N203341	002	Sep 04, 2012	Sep	NEWA
		<u>BRETYLIUM TOSYLATE</u>							
		INJECTABLE; INJECTION							
		BRETYLIUM TOSYLATE							
		@	HIKMA MAPLE	50MG/ML	A070546	001	May 14, 1986	Oct	CAHN
		@		50MG/ML	A070545	001	May 14, 1986	Oct	CAHN
		<u>BROMFENAC SODIUM</u>							
		SOLUTION/DROPS; OPHTHALMIC							
		BROMFENAC SODIUM							
>D>			COASTAL PHARMS	0.09%	A201211	001	May 11, 2011	Dec	CTEC
>A>	AT			0.09%	A201211	001	May 11, 2011	Dec	CTEC
>A>	AT		PHARMAFORCE	0.09%	A202030	001	Jan 09, 2013	Dec	NEWA
		<u>BROMOCRIPTINE MESYLATE</u>							
		CAPSULE; ORAL							
		PARLODEL							
AB	+		US PHARMS HOLDINGS I	EQ 5MG BASE	N017962	002	Mar 01, 1982	Sep	CAHN
		TABLET; ORAL							
		PARLODEL							
AB	+		US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001		Sep	CAHN
		<u>BUDESONIDE</u>							
		POWDER, METERED; INHALATION							
		PULMICORT							
		@	ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997	Jun	DISC
		SUSPENSION; INHALATION							
		BUDESONIDE							
AN			TEVA PHARMS	0.25MG/2ML	A077519	001	Nov 18, 2008	Sep	CAHN
AN				0.5MG/2ML	A077519	002	Nov 18, 2008	Sep	CAHN
AN			WATSON LABS INC	0.25MG/2ML	A078404	001	Jul 31, 2012	Jul	NEWA

SUSPENSION; INHALATION

BUDESONIDE

AN		WATSON LABS INC	0.5MG/2ML	A078404 002	Jul 31, 2012	Jul	NEWA
----	--	-----------------	-----------	-------------	--------------	-----	------

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

+		ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929 001	Jul 21, 2006	Jan	CDFR
+			0.16MG/INH;0.0045MG/INH	N021929 002	Jul 21, 2006	Jan	CDFR

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP		HIKMA MAPLE	0.25MG/ML	A079196 001	Apr 30, 2008	Oct	CAHN
----	--	-------------	-----------	-------------	--------------	-----	------

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

		@ PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496 001	Oct 28, 2011	Jul	DISC
--	--	---------------------	------------------------	-------------	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

>A>	AP	SAGENT AGILA	0.25%	A091503 001	Oct 18, 2011	Dec	CAHN
>A>	AP		0.5%	A091503 002	Oct 18, 2011	Dec	CAHN
>D>	AP	SAGENT STRIDES	0.25%	A091503 001	Oct 18, 2011	Dec	CAHN
>D>	AP		0.5%	A091503 002	Oct 18, 2011	Dec	CAHN
		BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
>A>	AP	SAGENT AGILA	0.25%	A091487 002	Oct 18, 2011	Dec	CAHN
>A>	AP		0.5%	A091487 001	Oct 18, 2011	Dec	CAHN
>A>	AP		0.75%	A091487 003	Oct 18, 2011	Dec	CAHN
>D>	AP	SAGENT STRIDES	0.25%	A091487 002	Oct 18, 2011	Dec	CAHN
>D>	AP		0.5%	A091487 001	Oct 18, 2011	Dec	CAHN
>D>	AP		0.75%	A091487 003	Oct 18, 2011	Dec	CAHN

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	+	ROXANE	EQ 8MG BASE	A078633 002	Oct 08, 2009	Aug	CRLD
		SUBUTEX					
		@ RECKITT BENCKISER	EQ 2MG BASE	N020732 002	Oct 08, 2002	Aug	DISC
		@	EQ 8MG BASE	N020732 003	Oct 08, 2002	Aug	DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL

SUBOXONE

		RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410 001	Aug 30, 2010	Apr	CAIN
			EQ 4MG BASE;EQ 1MG BASE	N022410 003	Aug 10, 2012	Aug	NEWA
+			EQ 8MG BASE;EQ 2MG BASE	N022410 002	Aug 30, 2010	Apr	CAIN
			EQ 12MG BASE;EQ 3MG BASE	N022410 004	Aug 10, 2012	Aug	NEWA

TABLET; SUBLINGUAL

SUBOXONE

		RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733 001	Oct 08, 2002	Apr	CPOT
+			EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002	Apr	CPOT

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

BX	IMPAX LABS	300MG	A077415 002	Dec 15, 2006	Sep	CTEC
AB1	WOCKHARDT LTD	100MG	A201331 001	Aug 30, 2012	Aug	NEWA
AB3		150MG	A202189 001	Nov 21, 2012	Nov	NEWA
AB1		150MG	A201331 002	Aug 30, 2012	Aug	NEWA
AB1		200MG	A201331 003	Aug 30, 2012	Aug	NEWA
	FORFIVO XL					
+	EDGEMONT PHARMS LLC	450MG	N022497 001	Nov 10, 2011	Mar	CAHN
	WELLBUTRIN SR					
AB1	GLAXOSMITHKLINE	150MG	N020358 003	Oct 04, 1996	Sep	CRLD
AB1	+	200MG	N020358 004	Jun 14, 2002	Sep	CRLD
	WELLBUTRIN XL					
AB3	VALEANT INTL	150MG	N021515 001	Aug 28, 2003	Sep	CRLD
AB3	+	300MG	N021515 002	Aug 28, 2003	Sep	CRLD

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

	@ APOTEX	5MG	A075521 001	Apr 05, 2002	Mar	DISC
	@	10MG	A075521 002	Apr 05, 2002	Mar	DISC
	@	15MG	A075521 003	Apr 05, 2002	Mar	DISC
	@ EGIS	5MG	A075119 001	Mar 14, 2002	Mar	DISC
	@	10MG	A075119 002	Mar 14, 2002	Mar	DISC
	@	15MG	A075119 003	Jan 23, 2003	Mar	DISC
	@ NESHER PHARMS	5MG	A075572 001	Feb 27, 2002	Jun	DISC
	@	10MG	A075572 002	Feb 27, 2002	Jun	DISC
	@	15MG	A075572 003	Feb 27, 2002	Jun	DISC
	@ PROSAM LABS	5MG	A075388 001	May 09, 2002	Mar	DISC
AB		5MG	A075388 001	May 09, 2002	Feb	CMFD
	@	10MG	A075388 002	May 09, 2002	Mar	DISC
AB		10MG	A075388 002	May 09, 2002	Feb	CMFD
	@	15MG	A075388 003	May 09, 2002	Mar	DISC
AB		15MG	A075388 003	May 09, 2002	Feb	CMFD
AB		30MG	A078302 001	Dec 17, 2007	Feb	CMFD

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

AB	PERRIGO ISRAEL	2%	A200923 001	May 18, 2012	Nov	CMFD
	@	2%	A200923 001	May 18, 2012	Apr	NEWA
	GYNAZOLE-1					
AB	+	KV PHARM	N019881 001	Feb 07, 1997	Nov	CTEC

CABOZANTINIB S-MALATE

CAPSULE; ORAL

COMETRIQ

EXELIXIS

	EQ 20MG BASE		N203756 001	Nov 29, 2012	Nov	NEWA
+	EQ 80MG BASE		N203756 002	Nov 29, 2012	Nov	NEWA

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 001	Sep 21, 1999	Jan	CAHN
----	---	--------------	---------------------------------------	-------------	--------------	-----	------

CAFFEINE CITRATE

AP		SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090827 001	Aug 29, 2012	Aug	NEWA
----	--	---------------	---------------------------------------	-------------	--------------	-----	------

SOLUTION; ORAL

CAFCIT

AA	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 002	Apr 12, 2000	Jan	CAHN
----	---	--------------	---------------------------------------	-------------	--------------	-----	------

CAFFEINE CITRATE

AA		SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A091102 001	Aug 29, 2012	Aug	NEWA
----	--	---------------	---------------------------------------	-------------	--------------	-----	------

CALCIPOTRIENE

CREAM; TOPICAL

CALCIPOTRIENE

AB		TOLMAR	0.005%	A200935 001	May 30, 2012	May	NEWA
----	--	--------	--------	-------------	--------------	-----	------

DOVONEX

AB	+	LEO PHARMA AS	0.005%	N020554 001	Jul 22, 1996	May	CFTG
----	---	---------------	--------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CALCIPOTRIENE

AT		FOUGERA PHARMS	0.005%	A078305 001	May 06, 2008	Jan	CAHN
----	--	----------------	--------	-------------	--------------	-----	------

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB		PADDOCK LLC	EQ 169MG CALCIUM	A091312 001	Jun 01, 2012	May	NEWA
----	--	-------------	------------------	-------------	--------------	-----	------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	+	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N018681 001	Dec 27, 1982	Oct	CRLD
----	---	---------	---	-------------	--------------	-----	------

AT	+	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N018921 001	Apr 03, 1984	Oct	CRLD
----	---	-----------------	---	-------------	--------------	-----	------

AT	+		20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N019933 001	Aug 29, 1989	Oct	CRLD
----	---	--	---	-------------	--------------	-----	------

AT	+	HOSPIRA	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N019416 001	Jan 17, 1986	Oct	CRLD
----	---	---------	---	-------------	--------------	-----	------

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

AB		ASTRAZENECA	16MG;12.5MG	N021093 001	Sep 05, 2000	Nov	CFTG
----	--	-------------	-------------	-------------	--------------	-----	------

AB			32MG;12.5MG	N021093 002	Sep 05, 2000	Nov	CFTG
----	--	--	-------------	-------------	--------------	-----	------

AB	+		32MG;25MG	N021093 003	May 16, 2008	Nov	CFTG
----	---	--	-----------	-------------	--------------	-----	------

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB		APOTEX INC	16MG;12.5MG	A202884 001	Dec 04, 2012	Nov	NEWA
----	--	------------	-------------	-------------	--------------	-----	------

AB			32MG;12.5MG	A202884 002	Dec 04, 2012	Nov	NEWA
----	--	--	-------------	-------------	--------------	-----	------

AB		MYLAN LABS	16MG;12.5MG	A090704 001	Dec 04, 2012	Nov	NEWA
----	--	------------	-------------	-------------	--------------	-----	------

AB			32MG;12.5MG	A090704 002	Dec 04, 2012	Nov	NEWA
----	--	--	-------------	-------------	--------------	-----	------

AB			32MG;25MG	A090704 003	Dec 04, 2012	Nov	NEWA
----	--	--	-----------	-------------	--------------	-----	------

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@	VINTAGE PHARMS LLC	12.5MG	A074418	001	Feb 13, 1996	Sep	CAHN
@		25MG	A074418	002	Feb 13, 1996	Sep	CAHN
@		50MG	A074418	003	Feb 13, 1996	Sep	CAHN
@		100MG	A074418	004	Feb 13, 1996	Sep	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

@	VINTAGE PHARMS LLC	25MG;15MG	A074788	001	Dec 29, 1997	Sep	CAHN
@		25MG;25MG	A074788	002	Dec 29, 1997	Sep	CAHN
@		50MG;15MG	A074788	004	Dec 29, 1997	Sep	CAHN
@		50MG;25MG	A074788	003	Dec 29, 1997	Sep	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	TEVA PHARMS	100MG	A078592	001	Sep 20, 2012	Sep	NEWA
AB		200MG	A078592	002	Sep 20, 2012	Sep	NEWA
AB		300MG	A078592	003	Sep 20, 2012	Sep	NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085	001	May 10, 2012	Apr	NEWA
AB		37.5MG;200MG;150MG	A079085	002	May 10, 2012	Apr	NEWA
AB	WOCKHARDT LTD	12.5MG;200MG;50MG	A090786	001	Nov 20, 2012	Nov	NEWA
AB		18.75MG;200MG;75MG	A090833	001	Nov 20, 2012	Nov	NEWA
AB		25MG;200MG;100MG	A090833	002	Nov 20, 2012	Nov	NEWA
AB		31.25MG;200MG;125MG	A090833	003	Nov 20, 2012	Nov	NEWA
AB		37.5MG;200MG;150MG	A090833	004	Nov 20, 2012	Nov	NEWA
AB		50MG;200MG;200MG	A090833	005	Nov 20, 2012	Nov	NEWA
	STALEVO 100						
AB	ORION PHARMA	25MG;200MG;100MG	N021485	002	Jun 11, 2003	Apr	CFTG
	STALEVO 125						
AB	ORION PHARMA	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008	Nov	CFTG
	STALEVO 150						
AB	ORION PHARMA	37.5MG;200MG;150MG	N021485	003	Jun 11, 2003	Apr	CFTG
	STALEVO 200						
AB	+ ORION PHARMA	50MG;200MG;200MG	N021485	004	Aug 02, 2007	Nov	CFTG
	STALEVO 50						
AB	+ ORION PHARMA	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003	Nov	CFTG
	STALEVO 75						
AB	ORION PHARMA	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008	Nov	CFTG

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

PARCOPA

AB	UCB INC	10MG;100MG	A076699	001	Aug 27, 2004	Jan	CAHN
AB		25MG;100MG	A076699	002	Aug 27, 2004	Jan	CAHN
AB	+	25MG;250MG	A076699	003	Aug 27, 2004	Jan	CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006	Mar	CAHN
AP		150MG/VIAL	A077383 002	Jan 27, 2006	Mar	CAHN
AP		450MG/VIAL	A077383 003	Jan 27, 2006	Mar	CAHN
AP	ONCO THERAPIES LTD	50MG/VIAL	A091510 001	May 29, 2012	May	NEWA
AP		150MG/VIAL	A091510 002	May 29, 2012	May	NEWA
AP		450MG/VIAL	A091510 003	May 29, 2012	May	NEWA
	PARAPLATIN					
	@ CORDEN PHARMA	50MG/VIAL	N019880 001	Mar 03, 1989	Feb	CAHN
	@	150MG/VIAL	N019880 002	Mar 03, 1989	Feb	CAHN
	@	450MG/VIAL	N019880 003	Mar 03, 1989	Feb	CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012	Jan	NEWA
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861 001	Jan 18, 2007	Mar	CAHN
AP		150MG/15ML (10MG/ML)	A077861 002	Jan 18, 2007	Mar	CAHN
AP		450MG/45ML (10MG/ML)	A077861 003	Jan 18, 2007	Mar	CAHN
AP		600MG/60ML (10MG/ML)	A077861 004	Jan 18, 2007	Mar	CAHN

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

+	ONYX PHARMS	60MG/VIAL	N202714 001	Jul 20, 2012	Jul	NEWA
---	-------------	-----------	-------------	--------------	-----	------

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN
----	-------------	-------	-------------	--------------	-----	------

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

>A>	+	ARBOR PHARMS INC	7.7MG	N020637 001	Sep 23, 1996	Dec	CAHN
>D>	+	EISAI INC	7.7MG	N020637 001	Sep 23, 1996	Dec	CAHN

CEFACLOR

CAPSULE; ORAL

CEFACLOR

@ RANBAXY

@

EQ 250MG BASE	A064156 001	Aug 28, 1997	Apr	DISC
EQ 500MG BASE	A064156 002	Aug 28, 1997	Apr	DISC

FOR SUSPENSION; ORAL

CEFACLOR

@ RANBAXY

EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Apr	DISC
AB + EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Feb	CTEC
@ EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Apr	DISC
AB + EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Feb	CTEC
@ EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Apr	DISC
AB + EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Feb	CTEC
@ EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Apr	DISC
AB + EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Feb	CTEC

FOR SUSPENSION; ORAL

CEFACLOR

AB	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412 001	Feb 17, 2012	Feb	NEWA
AB		EQ 187MG BASE/5ML	A065412 002	Feb 17, 2012	Feb	NEWA
AB		EQ 250MG BASE/5ML	A065412 003	Feb 17, 2012	Feb	NEWA
AB		EQ 375MG BASE/5ML	A065412 004	Feb 17, 2012	Feb	NEWA

TABLET, CHEWABLE; ORAL

RANICLOR

@	RANBAXY LABS LTD	EQ 125MG BASE	A065092 001	Dec 22, 2003	Apr	DISC
@		EQ 187MG BASE	A065092 002	Dec 22, 2003	Apr	DISC
@		EQ 250MG BASE	A065092 003	Dec 22, 2003	Apr	DISC
@		EQ 375MG BASE	A065092 004	Dec 22, 2003	Apr	DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

@	RANBAXY LABS LTD	EQ 500MG BASE	A065015 001	Jun 22, 1999	Apr	DISC
---	------------------	---------------	-------------	--------------	-----	------

FOR SUSPENSION; ORAL

CEFADROXIL

AB	HIKMA PHARMS	EQ 250MG BASE/5ML	A091036 001	Nov 28, 2012	Nov	NEWA
AB		EQ 500MG BASE/5ML	A091036 002	Nov 28, 2012	Nov	NEWA

TABLET; ORAL

CEFADROXIL

@	RANBAXY	EQ 1GM BASE	A065018 001	Apr 23, 1999	Apr	DISC
+	TEVA PHARMS	EQ 1GM BASE	A062774 001	Apr 08, 1987	Aug	CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

B	BRAUN	EQ 2GM BASE/VIAL	N050779 003	Jan 13, 2012	May	NEWA
---	-------	------------------	-------------	--------------	-----	------

CEFAZOLIN SODIUM

@	CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	A065280 001	Mar 18, 2009	Nov	DISC	
@		EQ 1GM BASE/VIAL	A065280 002	Mar 18, 2009	Nov	DISC	
@		EQ 10GM BASE/VIAL	A065295 001	Mar 18, 2009	Nov	DISC	
@		EQ 20GM BASE/VIAL	A065296 001	Mar 18, 2009	Nov	DISC	
>D>	AP +	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064169 001	Aug 14, 1998	Dec	DISC
>A>	@		EQ 500MG BASE/VIAL	A064169 001	Aug 14, 1998	Dec	DISC
>D>	AP +		EQ 1GM BASE/VIAL	A064169 002	Aug 14, 1998	Dec	DISC
>A>	@		EQ 1GM BASE/VIAL	A064169 002	Aug 14, 1998	Dec	DISC
>D>	AP +		EQ 10GM BASE/VIAL	A064170 001	Mar 18, 1998	Dec	DISC
>A>	@		EQ 10GM BASE/VIAL	A064170 001	Mar 18, 1998	Dec	DISC
>D>	AP +		EQ 20GM BASE/VIAL	A064170 002	Mar 18, 1998	Dec	DISC
>A>	@		EQ 20GM BASE/VIAL	A064170 002	Mar 18, 1998	Dec	DISC
@	HIKMA MAPLE	EQ 250MG BASE/VIAL	A062807 001	Jan 12, 1988	Oct	CAHN	
@		EQ 500MG BASE/VIAL	A062807 002	Jan 12, 1988	Oct	CAHN	
@		EQ 1GM BASE/VIAL	A062807 003	Jan 12, 1988	Oct	CAHN	
@		EQ 5GM BASE/VIAL	A062807 004	Jan 12, 1988	Oct	CAHN	
@		EQ 10GM BASE/VIAL	A062807 005	Jan 12, 1988	Oct	CAHN	
@		EQ 20GM BASE/VIAL	A062807 006	Jan 12, 1988	Oct	CAHN	
@	TEVA PHARMS	EQ 250MG BASE/VIAL	A063016 001	Mar 14, 1989	Oct	CAHN	
@		EQ 500MG BASE/VIAL	A063016 002	Mar 14, 1989	Oct	CAHN	
@		EQ 1GM BASE/VIAL	A063016 003	Mar 14, 1989	Oct	CAHN	
@		EQ 5GM BASE/VIAL	A063018 001	Mar 05, 1990	Oct	CAHN	
@		EQ 10GM BASE/VIAL	A063018 002	Mar 05, 1990	Oct	CAHN	

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

	VANSEN PHARMA	200MG	N021222 001	Aug 29, 2001	Mar	CAHN
+		400MG	N021222 002	Jul 21, 2008	Mar	CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A202268 001	Jul 30, 2012	Jul	NEWA
AP		EQ 2GM BASE/VIAL	A202268 002	Jul 30, 2012	Jul	NEWA

CEFIXIME

CAPSULE; ORAL

SUPRAX

+	LUPIN LTD	400MG	N203195 001	Jun 01, 2012	Jun	NEWA
---	-----------	-------	-------------	--------------	-----	------

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

>D>	AP	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064200 001	Mar 24, 2000	Dec	DISC
>A>		@	EQ 500MG BASE/VIAL	A064200 001	Mar 24, 2000	Dec	DISC
>D>	AP		EQ 1GM BASE/VIAL	A064200 002	Mar 24, 2000	Dec	DISC
>A>		@	EQ 1GM BASE/VIAL	A064200 002	Mar 24, 2000	Dec	DISC
>D>	AP		EQ 2GM BASE/VIAL	A064200 003	Mar 24, 2000	Dec	DISC
>A>		@	EQ 2GM BASE/VIAL	A064200 003	Mar 24, 2000	Dec	DISC
>D>	AP		EQ 10GM BASE/VIAL	A064201 001	Mar 24, 2000	Dec	DISC
>A>		@	EQ 10GM BASE/VIAL	A064201 001	Mar 24, 2000	Dec	DISC
>D>		+	EQ 20GM BASE/VIAL	A064201 002	Mar 24, 2000	Dec	DISC
>A>		@	EQ 20GM BASE/VIAL	A064201 002	Mar 24, 2000	Dec	DISC
		CEFOTAXIME SODIUM					
		@ CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348 001	Jan 25, 2010	Nov	DISC
		CLAFORAN					
AP	+	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659 001	Jan 13, 1987	Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	A062659 002	Jan 13, 1987	Mar	CRLD

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

	AP	ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467 001	Aug 31, 2011	Jul	CAIN	
	AP		EQ 2GM BASE/VIAL	A065467 002	Aug 31, 2011	Jul	CAIN	
	AP		EQ 10GM BASE/VIAL	A065464 001	Aug 31, 2011	Jul	CAIN	
>D>	AP	+	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065012 001	Jul 03, 2000	Dec	DISC
>A>		@		EQ 1GM BASE/VIAL	A065012 001	Jul 03, 2000	Dec	DISC
>D>	AP	+		EQ 2GM BASE/VIAL	A065012 002	Jul 03, 2000	Dec	DISC
>A>		@		EQ 2GM BASE/VIAL	A065012 002	Jul 03, 2000	Dec	DISC
>D>	AP	+		EQ 10GM BASE/VIAL	A065011 001	Jul 03, 2000	Dec	DISC
>A>		@		EQ 10GM BASE/VIAL	A065011 001	Jul 03, 2000	Dec	DISC
	AP	HIKMA MAPLE	EQ 1GM BASE/VIAL	A065051 001	Sep 11, 2000	Oct	CAHN	
	AP		EQ 2GM BASE/VIAL	A065051 002	Sep 11, 2000	Oct	CAHN	
	AP		EQ 10GM BASE/VIAL	A065050 001	Sep 11, 2000	Oct	CAHN	

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

AB	AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409 001	Jun 08, 2007	Nov	CAHN
AB		EQ 100MG BASE/5ML	A065409 002	Jun 08, 2007	Nov	CRLD
AB	+ SANDOZ	EQ 100MG BASE/5ML	A090031 002	Jan 14, 2009	Nov	CRLD

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB	APOTEX INC	125MG/5ML	A065351 001	Feb 29, 2012	Feb	NEWA
AB		250MG/5ML	A065351 002	Feb 29, 2012	Feb	NEWA
	@ RANBAXY LABS LTD	125MG/5ML	A065202 001	Jun 30, 2006	Apr	DISC
	@	250MG/5ML	A065202 002	Jun 30, 2006	Apr	DISC
	CEFZIL					
	@ CORDEN PHARMA	125MG/5ML	N050665 001	Dec 23, 1991	Nov	CAHN
	@	250MG/5ML	N050665 002	Dec 23, 1991	Nov	CAHN

TABLET; ORAL

CEFPROZIL

@ RANBAXY LABS LTD

250MG

A065198 001 Dec 13, 2006 Apr DISC

@

500MG

A065198 002 Dec 13, 2006 Apr DISC

CEFZIL

@ CORDEN PHARMA

250MG

N050664 001 Dec 23, 1991 Feb CAHN

@

500MG

N050664 002 Dec 23, 1991 Feb CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

AP	+ COVIS PHARMA	500MG/VIAL	N050578 001	Jul 19, 1985	Apr	CAHN
AP	+	1GM/VIAL	N050578 002	Jul 19, 1985	Apr	CAHN
AP	+	2GM/VIAL	N050578 003	Jul 19, 1985	Apr	CAHN
AP	+	6GM/VIAL	N050578 004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

@ COVIS PHARMA

EQ 10MG BASE/ML

N050634 001 Apr 28, 1989 Apr CAHN

+

EQ 20MG BASE/ML

N050634 002 Apr 28, 1989 Apr CAHN

+

EQ 40MG BASE/ML

N050634 003 Apr 28, 1989 Apr CAHN

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

AP	AKORN INC	EQ 250MG BASE/VIAL	A065305 001	Jan 11, 2008	Oct	CAHN	
AP		EQ 500MG BASE/VIAL	A065305 002	Jan 11, 2008	Oct	CAHN	
AP		EQ 1GM BASE/VIAL	A065305 003	Jan 11, 2008	Oct	CAHN	
AP		EQ 2GM BASE/VIAL	A065305 004	Jan 11, 2008	Oct	CAHN	
	@ CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	A065294 001	Mar 26, 2007	Nov	DISC	
	@	EQ 500MG BASE/VIAL	A065294 002	Mar 26, 2007	Nov	DISC	
	@	EQ 1GM BASE/VIAL	A065294 003	Mar 26, 2007	Nov	DISC	
	@	EQ 2GM BASE/VIAL	A065294 004	Mar 26, 2007	Nov	DISC	
>D>	AP	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A065245 002	Feb 15, 2006	Dec	DISC
>A>	@		EQ 500MG BASE/VIAL	A065245 002	Feb 15, 2006	Dec	DISC
>D>	AP		EQ 1GM BASE/VIAL	A065245 003	Feb 15, 2006	Dec	DISC
>A>	@		EQ 1GM BASE/VIAL	A065245 003	Feb 15, 2006	Dec	DISC

INJECTABLE; IM-IV

CEFTRIAXONE

>D>	AP	FRESENIUS KABI USA	EQ 2GM BASE/VIAL	A065245 004	Feb 15, 2006	Dec	DISC
>A>		@	EQ 2GM BASE/VIAL	A065245 004	Feb 15, 2006	Dec	DISC
	AP	TEVA PHARMS	EQ 250MG BASE/VIAL	A065227 001	Mar 15, 2007	Oct	CAHN
	AP		EQ 500MG BASE/VIAL	A065227 002	Mar 15, 2007	Oct	CAHN
	AP		EQ 1GM BASE/VIAL	A065227 003	Mar 15, 2007	Oct	CAHN
	AP		EQ 2GM BASE/VIAL	A065227 004	Mar 15, 2007	Oct	CAHN

INJECTABLE; INJECTION

CEFTRIAXONE

>D>	AP	FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065252 001	Feb 15, 2006	Dec	DISC
>A>		@	EQ 10GM BASE/VIAL	A065252 001	Feb 15, 2006	Dec	DISC
	AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A202563 001	Aug 20, 2012	Aug	NEWA
	AP		EQ 2GM BASE/VIAL	A202563 002	Aug 20, 2012	Aug	NEWA
	AP	+ SANDOZ INC	EQ 1GM BASE/VIAL	A065204 001	May 03, 2005	Mar	CRLD
	AP	+	EQ 2GM BASE/VIAL	A065204 002	May 03, 2005	Mar	CRLD
>A>	AP	STRIDES ARCOLAB LTD	EQ 10GM BASE/VIAL	A091068 001	Jan 07, 2013	Dec	NEWA

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

		@ RANBAXY LABS LTD	EQ 125MG BASE	A065043 003	Feb 15, 2002	Apr	DISC
		@	EQ 250MG BASE	A065043 002	Feb 15, 2002	Apr	DISC
		@	EQ 500MG BASE	A065043 001	Feb 15, 2002	Apr	DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

>D>	AB	FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001 001	May 30, 2001	Dec	DISC
>A>		@	EQ 750MG BASE/VIAL	A065001 001	May 30, 2001	Dec	DISC
	AB	TEVA PHARMS	EQ 750MG BASE/VIAL	A064192 002	Apr 16, 1998	Oct	CAHN
		ZINACEF					
	AB	+ COVIS PHARMA	EQ 750MG BASE/VIAL	N050558 002	Oct 19, 1983	Apr	CAHN

INJECTABLE; INJECTION

CEFUROXIME SODIUM

>D>	AP	FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001 002	May 30, 2001	Dec	DISC
>A>		@	EQ 1.5GM BASE/VIAL	A065001 002	May 30, 2001	Dec	DISC
>D>	AP		EQ 7.5GM BASE/VIAL	A065002 001	Sep 28, 1998	Dec	DISC
>A>		@	EQ 7.5GM BASE/VIAL	A065002 001	Sep 28, 1998	Dec	DISC
	AP	TEVA PHARMS	EQ 1.5GM BASE/VIAL	A064192 001	Apr 16, 1998	Oct	CAHN
	AP		EQ 7.5GM BASE/VIAL	A064191 001	Apr 16, 1998	Oct	CAHN
		ZINACEF					
	AP	+ COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558 003	Oct 19, 1983	Apr	CAHN
	AP	+	EQ 7.5GM BASE/VIAL	N050558 004	Oct 23, 1986	Apr	CAHN
		ZINACEF IN PLASTIC CONTAINER					
	+	COVIS PHARMA	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989	Apr	CAHN
	+		EQ 30MG BASE/ML	N050643 002	Apr 28, 1989	Apr	CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL

KEFLEX

		@ SHIONOGI INC	EQ 100MG BASE/ML	N050406 003		Jul	CAHN
		@	EQ 125MG BASE/5ML	N050406 001		Jul	CAHN
		@	EQ 250MG BASE/5ML	N050406 002		Jul	CAHN

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEPHAPIRIN SODIUM

@	HIKMA MAPLE	EQ 500MG BASE/VIAL	A062720 001	Jul 02, 1987	Oct	CAHN
@		EQ 1GM BASE/VIAL	A062720 002	Jul 02, 1987	Oct	CAHN
@		EQ 2GM BASE/VIAL	A062720 003	Jul 02, 1987	Oct	CAHN
@		EQ 20GM BASE/VIAL	A062720 004	Jul 02, 1987	Oct	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

	@	RANBAXY LABS LTD	5MG/5ML	A077472 001	Jun 18, 2008	Jul	DISC
AA		SILARX	5MG/5ML	A078876 001	May 11, 2012	Apr	NEWA

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

	+	ASPEN GLOBAL INC	2MG	N010669 002		May	CAHN
--	---	------------------	-----	-------------	--	-----	------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB		CORNERSTONE THERAP	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671 001	Jun 29, 2012	Jun	NEWA
----	--	--------------------	---	-------------	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

	+	HIKMA MAPLE	25MG/ML	A083329 001		Oct	CAHN
--	---	-------------	---------	-------------	--	-----	------

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

	@	DAVA PHARMS INC	25MG	A087451 001		Nov	CAHN
	@		50MG	A087450 001		Nov	CAHN

CHOLESTYRAMINE

POWDER; ORAL

LOCHOLEST

	@	SANDOZ	EQ 4GM RESIN/PACKET	A074561 001	Aug 15, 1996	Oct	DISC
--	---	--------	---------------------	-------------	--------------	-----	------

	@		EQ 4GM RESIN/SCOOPFUL	A074561 002	Aug 15, 1996	Oct	DISC
--	---	--	-----------------------	-------------	--------------	-----	------

LOCHOLEST LIGHT

	@	SANDOZ	EQ 4GM RESIN/SCOOPFUL	A074562 002	Aug 15, 1996	Oct	DISC
--	---	--------	-----------------------	-------------	--------------	-----	------

	@		EQ 4GM RESIN/PACKET	A074562 001	Aug 15, 1996	Oct	DISC
--	---	--	---------------------	-------------	--------------	-----	------

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

	+	MCPRF	4-33.1mCi/ML	N203155 001	Sep 12, 2012	Sep	NEWA
--	---	-------	--------------	-------------	--------------	-----	------

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

>D>		NYCOMED GMBH	0.08MG/INH	N021658 002	Jan 10, 2008	Dec	CAHN
			0.08MG/INH	N021658 002	Jan 10, 2008	May	CAHN

AEROSOL, METERED; INHALATION

ALVESCO

>D>	+	NYCOMED GMBH	0.16MG/INH	N021658 003	Jan 10, 2008	Dec	CAHN
	+		0.16MG/INH	N021658 003	Jan 10, 2008	May	CAHN
>A>		TAKEDA GMBH	0.08MG/INH	N021658 002	Jan 10, 2008	Dec	CAHN
>A>	+		0.16MG/INH	N021658 003	Jan 10, 2008	Dec	CAHN

AEROSOL, METERED; NASAL

ZETONNA

>D>	+	NYCOMED GMBH	0.037MG/INH	N202129 001	Jan 20, 2012	Dec	CAHN
	+		0.037MG/INH	N202129 001	Jan 20, 2012	Jan	NEWA
>A>	+	TAKEDA GMBH	0.037MG/INH	N202129 001	Jan 20, 2012	Dec	CAHN

SPRAY, METERED; NASAL

OMNARIS

>D>	+	NYCOMED GMBH	0.05MG/INH	N022004 001	Oct 20, 2006	Dec	CAHN
	+		0.05MG/INH	N022004 001	Oct 20, 2006	May	CAHN
>A>	+	TAKEDA GMBH	0.05MG/INH	N022004 001	Oct 20, 2006	Dec	CAHN

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	0.77%	A076435 001	Dec 29, 2004	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	0.77%	A077896 001	Jun 10, 2008	Jan	CAHN
AB		GLENMARK GENERICS	0.77%	A091595 001	Feb 29, 2012	Feb	NEWA

SHAMPOO; TOPICAL

CICLOPIROX

AT		FOUGERA PHARMS	1%	A090146 001	May 25, 2010	Jan	CAHN
AT		WATSON LABS INC	1%	A090490 001	Nov 24, 2009	Oct	CAHN

SOLUTION; TOPICAL

CICLOPIROX

AT		MYLAN PHARMS INC	8%	A078567 001	Sep 18, 2007	Feb	CAHN
----	--	------------------	----	-------------	--------------	-----	------

SUSPENSION; TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	0.77%	A076422 001	Aug 06, 2004	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

AP		EMCURE PHARMS LTD	EQ 75MG BASE/ML	A202501 001	Jul 26, 2012	Jul	NEWA
AP		MYLAN LLC	EQ 75MG BASE/ML	A201276 001	Jun 27, 2012	Jun	NEWA
AP	+	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638 001	Jun 26, 1996	Jun	CFTG

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB		BIOKEY	50MG	A077722 001	Sep 24, 2012	Sep	NEWA
AB			100MG	A077831 001	Sep 24, 2012	Sep	NEWA
AB		MYLAN PHARMS INC	50MG	A077019 001	Nov 23, 2004	Sep	CAHN
AB			100MG	A077019 002	Nov 23, 2004	Sep	CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ SANDOZ

200MG

A074506 001 Jan 24, 1996 Oct DISC

TABLET; ORAL

CIMETIDINE

@ SANDOZ	300MG	A074506 002	Jan 24, 1996	Oct	DISC
@	400MG	A074506 003	Jan 24, 1996	Oct	DISC
@	800MG	A074506 004	Jan 24, 1996	Oct	DISC
@ VINTAGE PHARMS LLC	200MG	A074281 001	May 17, 1994	Sep	CAHN
@	300MG	A074281 002	May 17, 1994	Sep	CAHN
@	400MG	A074281 003	May 17, 1994	Sep	CAHN
@	800MG	A074329 001	May 17, 1994	Sep	CAHN

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

@ HOSPIRA	EQ 300MG BASE/2ML	A074344 001	Jan 31, 1995	Jun	DISC
@	EQ 300MG BASE/2ML	A074345 001	Jan 31, 1995	Jun	DISC
@ VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005 001	Aug 31, 1994	Sep	CAHN

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ VINTAGE PHARMS LLC	EQ 300MG BASE/5ML	A074251 001	Dec 22, 1994	Sep	CAHN
----------------------	-------------------	-------------	--------------	-----	------

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@ TEVA PARENTERAL	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006	Mar	DISC
@	400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006	Jan	DISC

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	200MG/100ML	A077888 001	Mar 18, 2008	Jun	DISC
@	400MG/200ML	A077888 002	Mar 18, 2008	Jun	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@ PLIVA	EQ 100MG BASE	A076426 001	Jun 15, 2005	Jan	DISC
@	EQ 250MG BASE	A076426 002	Jun 15, 2005	Jan	DISC
@	EQ 500MG BASE	A076426 003	Jun 15, 2005	Jan	DISC
@	EQ 750MG BASE	A076426 004	Jun 15, 2005	Jan	DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701 002	Oct 31, 2007	Apr	NEWA
----	--------------------	-------------------------	-------------	--------------	-----	------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	SANDOZ INC	EQ 2MG BASE/ML	A200159 001	Feb 03, 2012	Jan	NEWA
AP	SANDOZ INC	EQ 2MG BASE/ML	A200154 001	Feb 03, 2012	Jan	NEWA
AP		EQ 10MG BASE/ML	A200154 002	Feb 03, 2012	Jan	NEWA
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 001	Dec 15, 1995	Jan	CFTG
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 003	Dec 15, 1995	Jan	CFTG
AP	+ ABBOTT	EQ 10MG BASE/ML	N020551 002	Dec 15, 1995	Jan	CFTG

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP	ONCO THERAPIES LTD	1MG/ML	A091062	001	Apr 18, 2012	Apr	NEWA
	@ TEVA PARENTERAL	1MG/ML	A074814	001	May 16, 2000	Mar	DISC

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

	MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007	Sep	CAHN
		EQ 20MG BASE	A077668	002	Feb 28, 2007	Sep	CAHN
+		EQ 40MG BASE	A077668	003	Feb 28, 2007	Sep	CAHN

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004	Sep	CAHN
AB		EQ 20MG BASE	A077037	002	Nov 05, 2004	Sep	CAHN
AB		EQ 40MG BASE	A077037	003	Nov 05, 2004	Sep	CAHN
	@ SANDOZ	EQ 10MG BASE	A077035	001	Oct 28, 2004	Aug	DISC
	@	EQ 20MG BASE	A077035	002	Oct 28, 2004	Aug	DISC
	@	EQ 40MG BASE	A077035	003	Oct 28, 2004	Aug	DISC
AB	TEVA PHARMS	EQ 10MG BASE	A077048	001	Nov 16, 2004	Aug	CAHN
AB		EQ 20MG BASE	A077048	002	Nov 16, 2004	Aug	CAHN
AB		EQ 40MG BASE	A077048	003	Nov 16, 2004	Aug	CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+	FERRING PHARMS AS	12GM/PACKET;3.5GM/PACKET;10MG/PAC KET	N202535	001	Jul 16, 2012	Jul	NEWA
---	-------------------	--	---------	-----	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB	AUROBINDO	250MG	A065489	001	Jul 25, 2012	Jul	NEWA
AB		500MG	A065489	002	Jul 25, 2012	Jul	NEWA

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

	@ SANDOZ	500MG	A065250	001	Aug 25, 2005	Aug	DISC
--	----------	-------	---------	-----	--------------	-----	------

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 75MG BASE	A091225	001	May 31, 2011	Sep	CAHN
AB		EQ 150MG BASE	A091225	002	May 31, 2011	Sep	CAHN
AB		EQ 300MG BASE	A091225	003	May 31, 2011	Sep	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	LYNE	EQ 75MG BASE/5ML	A201821	001	Aug 28, 2012	Aug	NEWA
----	------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 2% BASE	A065139	001	Dec 27, 2004	Jan	CAHN
----	----------------	------------	---------	-----	--------------	-----	------

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 1% BASE	A064160	001	Jan 28, 2000	Jan	CAHN
----	--	----------------	------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639	001	Aug 30, 1989	May	CFTG
AP	+		EQ 12MG BASE/ML	N050639	002	Aug 30, 1989	May	CFTG
AP	+		EQ 18MG BASE/ML	N050639	003	Apr 10, 1991	May	CFTG

CLINDAMYCIN PHOSPHATE

		@ HIKMA MAPLE	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989	Oct	CAHN
AP			EQ 150MG BASE/ML	A062889	001	Apr 25, 1988	Oct	CAHN
		@	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987	Oct	CAHN
		@	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988	Oct	CAHN

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		SANDOZ INC	EQ 6MG BASE/ML	A201692	001	May 31, 2012	May	NEWA
AP			EQ 12MG BASE/ML	A201692	002	May 31, 2012	May	NEWA
AP			EQ 18MG BASE/ML	A201692	003	May 31, 2012	May	NEWA

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 1% BASE	A065067	001	Jan 31, 2002	Jan	CAHN
----	--	----------------	------------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT		FOUGERA PHARMS	EQ 1% BASE	A065254	001	Feb 14, 2006	Jan	CAHN
		@ G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988	Oct	CAHN
		@ RENAISSANCE PHARMA	EQ 1% BASE	A064108	001	Sep 27, 1996	Sep	CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+	STIEFEL GSK	1.2%;0.025%	N050803	001	Jul 16, 2010	May	CRLD
----	---	-------------	-------------	---------	-----	--------------	-----	------

CLOBAZAM

>A> SUSPENSION; ORAL

>A> ONFI

>A>	+	LUNDBECK LLC	2.5MG/ML	N203993	001	Dec 14, 2012	Dec	NEWA
-----	---	--------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

ONFI

		LUNDBECK LLC	5MG	N202067	001	Oct 21, 2011	Mar	CAHN
			10MG	N202067	002	Oct 21, 2011	Mar	CAHN
	+		20MG	N202067	003	Oct 21, 2011	Mar	CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

AB1		PERRIGO ISRAEL	0.05%	A077763	001	Mar 10, 2008	Jul	CTEC
AB2			0.05%	A201402	001	Aug 14, 2012	Jul	NEWA

OLUX

AB1	+	STIEFEL LABS INC	0.05%	N021142	001	May 26, 2000	Jul	CTEC
-----	---	------------------	-------	---------	-----	--------------	-----	------

OLUX E

AB2	+	STIEFEL LABS INC	0.05%	N022013	001	Jan 12, 2007	Jul	CFTG
-----	---	------------------	-------	---------	-----	--------------	-----	------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

		@ G AND W LABS INC	0.05%	A074139	001	Aug 03, 1994	Jun	CAHN
		@ RENAISSANCE PHARMA	0.05%	A075338	001	Feb 09, 2001	Aug	CAHN
AB2		FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	Jan	CAHN

CREAM; TOPICAL

		CLOBETASOL PROPIONATE (EMOLLIENT)							
		@ RENAISSANCE PHARMA	0.05%		A075733	001	Aug 22, 2001	Aug	CAHN
		TEMOVATE							
AB1	+	FOUGERA PHARMS	0.05%		N019322	001	Dec 27, 1985	Jan	CAHN
		GEL; TOPICAL							
		CLOBETASOL PROPIONATE							
AB		FOUGERA PHARMS	0.05%		A075368	001	Feb 15, 2000	Jan	CAHN
		TEMOVATE							
AB	+	FOUGERA PHARMS	0.05%		N020337	001	Apr 29, 1994	Jan	CAHN
		LOTION; TOPICAL							
		CLOBETASOL PROPIONATE							
AB		TARO	0.05%		A200302	001	Jul 02, 2012	Jun	NEWA
		OINTMENT; TOPICAL							
		CLOBETASOL PROPIONATE							
AB		FOUGERA PHARMS	0.05%		A074407	001	Feb 23, 1996	Jan	CAHN
		@ RENAISSANCE PHARMA	0.05%		A075057	001	Aug 12, 1998	Aug	CAHN
		TEMOVATE							
AB	+	FOUGERA PHARMS	0.05%		N019323	001	Dec 27, 1985	Jan	CAHN
		SHAMPOO; TOPICAL							
		CLOBETASOL PROPIONATE							
AB		PERRIGO ISRAEL	0.05%		A090974	001	Aug 09, 2012	Jul	NEWA
		SOLUTION; TOPICAL							
		CLOBETASOL PROPIONATE							
AT		FOUGERA PHARMS	0.05%		A075391	001	Feb 08, 1999	Jan	CAHN
		@ G AND W LABS INC	0.05%		A074331	001	Dec 15, 1995	Jun	CAHN
		TEMOVATE							
AT	+	FOUGERA PHARMS	0.05%		N019966	001	Feb 22, 1990	Jan	CAHN

CLONAZEPAM

TABLET; ORAL

		CLONAZEPAM							
AB		MYLAN PHARMS INC	0.5MG		A074940	001	Oct 30, 1997	Sep	CAHN
AB			1MG		A074940	002	Oct 30, 1997	Sep	CAHN
AB			2MG		A074940	003	Oct 30, 1997	Sep	CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

		DURACLON							
AP		MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)		N020615	001	Oct 02, 1996	Feb	CAHN
AP	+		5 MG/10 ML (0.5 MG/ML)		N020615	002	Apr 27, 1999	Feb	CAHN
		TABLET, EXTENDED RELEASE; ORAL							
		KAPVAY							
		SHIONOGI INC	0.2MG		N022331	004	Sep 28, 2010	May	CMFD

CLOPIDOGREL BISULFATE

TABLET; ORAL

		CLOPIDOGREL BISULFATE							
AB		APOTEX INC	EQ 75MG BASE		A076274	001	May 17, 2012	Apr	NEWA
AB		AUROBINDO PHARMA LTD	EQ 75MG BASE		A090540	001	May 17, 2012	Apr	NEWA
AB		DR REDDYS LABS INC	EQ 75MG BASE		A076273	001	Jan 14, 2008	Mar	CMFD
AB		DR REDDYS LABS LTD	EQ 300MG BASE		A091023	001	May 17, 2012	Apr	NEWA
AB		GATE PHARMS	EQ 300MG BASE		A091216	001	May 17, 2012	Apr	NEWA
AB		MYLAN PHARMS INC	EQ 75MG BASE		A077665	001	May 17, 2012	Apr	NEWA
AB			EQ 300MG BASE		A077665	002	May 17, 2012	Apr	NEWA
AB		ROXANE	EQ 75MG BASE		A078004	001	May 17, 2012	Apr	NEWA

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	SUN PHARMA GLOBAL	EQ 75MG BASE	A090494 001	May 17, 2012	Apr	NEWA
AB	TEVA	EQ 75MG BASE	A076999 001	May 17, 2012	Apr	NEWA
AB	TEVA PHARMS	EQ 300MG BASE	A090625 001	May 17, 2012	Apr	NEWA
AB	TORRENT PHARMS LTD	EQ 75MG BASE	A090844 001	May 17, 2012	Apr	NEWA
AB	WOCKHARDT LTD	EQ 75MG BASE	A202266 001	Aug 14, 2012	Jul	NEWA
AB		EQ 300MG BASE	A202266 002	Nov 20, 2012	Nov	NEWA
AB	ZYDUS PHARMS USA INC	EQ 75MG BASE	A201686 001	Oct 10, 2012	Sep	NEWA

PLAVIX

AB	SANOFI AVENTIS US	EQ 75MG BASE	N020839 001	Nov 17, 1997	Mar	CTEC
AB	+	EQ 300MG BASE	N020839 002	Sep 20, 2007	Apr	CTEC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

	@ LUNDBECK LLC	3.75MG	N017105 001		Mar	CAHN
	@	7.5MG	N017105 002		Mar	CAHN
	@	15MG	N017105 003		Mar	CAHN

TABLET; ORAL

TRANXENE

AB	LUNDBECK LLC	3.75MG	N017105 006		Mar	CAHN
AB		7.5MG	N017105 007		Mar	CAHN
AB	+	15MG	N017105 008		Mar	CAHN

TRANXENE SD

	@ LUNDBECK LLC	11.25MG	N017105 005		Mar	CAHN
	@	22.5MG	N017105 004		Mar	CAHN

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

AB	FOUGERA PHARMS	1%	A078338 001	Sep 02, 2008	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

TROCHE/LOZENGE; ORAL

CLOTRIMAZOLE

>D>	AB	ROXANE	10MG	A076387 001	Jul 29, 2004	Dec	CRLD	
>A>	AB	+	10MG	A076387 001	Jul 29, 2004	Dec	CRLD	
>D>		MYCELEX						
>D>	AB	+	BAYER HLTHCARE	10MG	N018713 001	Jun 17, 1983	Dec	DISC
>A>		@		10MG	N018713 001	Jun 17, 1983	Dec	DISC

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

JAZZ

		12.5MG	N021590 004	May 30, 2007	Apr	CAHN
		25MG	N021590 001	Feb 10, 2004	Apr	CAHN
	@	50MG	N021590 003	Jun 03, 2005	Apr	CAHN
+		100MG	N021590 002	Feb 10, 2004	Apr	CAHN
		150MG	N021590 005	Jul 09, 2010	Apr	CAHN
		200MG	N021590 006	Jul 09, 2010	Apr	CAHN
	JAZZ PHARMS III	12.5MG	N021590 004	May 30, 2007	Jun	CAHN
		25MG	N021590 001	Feb 10, 2004	Jun	CAHN
	@	50MG	N021590 003	Jun 03, 2005	Jun	CAHN
+		100MG	N021590 002	Feb 10, 2004	Jun	CAHN
		150MG	N021590 005	Jul 09, 2010	Jun	CAHN
		200MG	N021590 006	Jul 09, 2010	Jun	CAHN

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

STRIBILD

+ GILEAD SCIENCES INC 150MG;150MG;200MG;300MG N203100 001 Aug 27, 2012 Aug NEWA

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA TRIS PHARMA INC 10MG/5ML;6.25MG/5ML A200386 001 Jun 29, 2012 Jun NEWA

COLCHICINE

TABLET; ORAL

COLCRYS

+ TAKEDA PHARMS USA 0.6MG N022352 001 Jul 29, 2009 Oct CAHN

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP EMCURE PHARMS LTD EQ 150MG BASE/VIAL A202359 001 Sep 28, 2012 Sep NEWA

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+ TEVA WOMENS 309MG/COPPER N018680 001 Nov 15, 1984 May CAHN

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

AP INNOPHARMA INC 0.25MG/VIAL A202147 001 Jun 29, 2012 Jun NEWA

AP SANDOZ 0.25MG/VIAL A202147 001 Jun 29, 2012 Sep CAHN

>A> CROFELEMER

>A> TABLET, DELAYED RELEASE; ORAL

>A> FULYZAQ

>A> + SALIX PHARMS 125MG N202292 001 Dec 31, 2012 Dec NEWA

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

@ KING PFIZER 0.8MG/INH N018887 001 Dec 05, 1985 Jun DISC

CONCENTRATE; ORAL

GASTROCROM

AA + JAZZ PHARMS COMMERCL 100MG/5ML N020479 001 Feb 29, 1996 Mar CAHN

AA + JAZZ PHARMS INTL 100MG/5ML N020479 001 Feb 29, 1996 Jun CAHN

AA + MEDA PHARMS 100MG/5ML N020479 001 Feb 29, 1996 Nov CAHN

SOLUTION; INHALATION

CROMOLYN SODIUM

AN + TEVA PHARMS 10MG/ML A075271 001 Jan 18, 2000 Sep CAHN

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

@ HIKMA MAPLE 1MG/ML A080515 002 Oct CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

>D>	AB	ANESTA AG	15MG	N021777 001	Feb 01, 2007	Dec	CAHN
>D>	AB	+	30MG	N021777 002	Feb 01, 2007	Dec	CAHN
>A>	AB	TEVA	15MG	N021777 001	Feb 01, 2007	Dec	CAHN
>A>	AB	+	30MG	N021777 002	Feb 01, 2007	Dec	CAHN

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	5MG	A073144 002	Feb 03, 2006	Jul	CRLD
AB	+	10MG	A073144 001	May 30, 1991	Jul	CRLD
AB	PROSAM LABS	5MG	A077291 001	Feb 03, 2006	Feb	CAHN
AB		10MG	A077209 001	Oct 04, 2005	Feb	CAHN
	FLEXERIL					
	@ JANSSEN RES AND DEV	5MG	N017821 001		Jul	DISC
	@	10MG	N017821 002		Jul	DISC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142 003		Apr	CRLD
AP	+		1GM/VIAL	N012142 004	Aug 30, 1982	Apr	CRLD
AP	+		2GM/VIAL	N012142 005	Aug 30, 1982	Apr	CRLD

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1	WATSON LABS INC	25MG	A065044 002	Dec 20, 2000	May	CAHN
AB1		100MG	A065044 001	Dec 20, 2000	May	CAHN

SOLUTION; ORAL

CYCLOSPORINE

AB1	ABBVIE	100MG/ML	A065025 001	Mar 03, 2000	Sep	CAHN
-----	--------	----------	-------------	--------------	-----	------

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYSTARAN

+	SIGMA TAU	EQ 0.44% BASE	N200740 001	Oct 02, 2012	Oct	NEWA
---	-----------	---------------	-------------	--------------	-----	------

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	ONCO THERAPIES LTD	100MG/ML	A201784 001	Jan 30, 2012	Jan	NEWA
----	--------------------	----------	-------------	--------------	-----	------

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682 001		Mar	CAHN
----	---	--------------	------------	-------------	--	-----	------

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

@	MIKAH PHARMA	25MG	A076686 001	Oct 24, 2005	Jul	CAHN
@		50MG	A076686 002	Oct 24, 2005	Jul	CAHN
@		100MG	A076686 003	Oct 24, 2005	Jul	CAHN

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

@ FERA PHARMS	0.5%	N019849	001	Dec 31, 1990	Jul	CTNA
---------------	------	---------	-----	--------------	-----	------

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL

PREZISTA

+ JANSSEN PRODS	EQ 100MG BASE/ML	N202895	001	Dec 16, 2011	Feb	CAHN
-----------------	------------------	---------	-----	--------------	-----	------

TABLET; ORAL

PREZISTA

JANSSEN PRODS	EQ 75MG BASE	N021976	004	Dec 18, 2008	Feb	CAHN
	EQ 150MG BASE	N021976	005	Dec 18, 2008	Feb	CAHN
@	EQ 300MG BASE	N021976	001	Jun 23, 2006	Feb	CAHN
	EQ 400MG BASE	N021976	003	Oct 21, 2008	Feb	CAHN
	EQ 600MG BASE	N021976	002	Feb 25, 2008	Nov	CRLD
+ JANSSEN PRODS	EQ 600MG BASE	N021976	002	Feb 25, 2008	Feb	CAHN
+ JANSSEN PRODS	EQ 800MG BASE	N021976	006	Nov 09, 2012	Nov	NEWA

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

@ COREPHARMA	150MG	N050261	002		Jul	DISC
--------------	-------	---------	-----	--	-----	------

@	300MG	N050261	003		Jul	DISC
---	-------	---------	-----	--	-----	------

DEMECLOCYCLINE HYDROCHLORIDE

AB + AMNEAL PHARM	300MG	A065425	002	Feb 27, 2008	Jul	CRLD
-------------------	-------	---------	-----	--------------	-----	------

DESFLURANE

LIQUID; INHALATION

SUPRANE

+ BAXTER HLTHCARE	99.9%	N020118	001	Sep 18, 1992	Jul	CAHN
-------------------	-------	---------	-----	--------------	-----	------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

NORPRAMIN

AB SANOFI AVENTIS US	50MG	N014399	003		Oct	CRLD
----------------------	------	---------	-----	--	-----	------

DESLORATADINE

SYRUP; ORAL

CLARINEX

>A> + MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	Dec	CAHN
-------------------------	----------	---------	-----	--------------	-----	------

>D> + SCHERING	0.5MG/ML	N021300	001	Sep 01, 2004	Dec	CAHN
----------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

CLARINEX

>A> AB + MERCK SHARP DOHME	5MG	N021165	001	Dec 21, 2001	Dec	CAHN
----------------------------	-----	---------	-----	--------------	-----	------

>D> AB + SCHERING PLOUGH	5MG	N021165	001	Dec 21, 2001	Dec	CAHN
--------------------------	-----	---------	-----	--------------	-----	------

DESLORATADINE

AB BELCHER PHARMS	5MG	A078355	001	Apr 19, 2012	Apr	NEWA
-------------------	-----	---------	-----	--------------	-----	------

AB MYLAN PHARMS INC	5MG	A078351	001	Feb 10, 2012	Jan	NEWA
---------------------	-----	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

>A> AB MERCK SHARP DOHME	2.5MG	N021312	002	Jul 14, 2005	Dec	CAHN
--------------------------	-------	---------	-----	--------------	-----	------

>A> AB +	5MG	N021312	001	Jun 26, 2002	Dec	CAHN
----------	-----	---------	-----	--------------	-----	------

>D> AB SCHERING	2.5MG	N021312	002	Jul 14, 2005	Dec	CAHN
-----------------	-------	---------	-----	--------------	-----	------

>D> AB +	5MG	N021312	001	Jun 26, 2002	Dec	CAHN
----------	-----	---------	-----	--------------	-----	------

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

>A>	AB	+	MERCK SHARP DOHME	5MG;240MG	N021605	001	Mar 03, 2005	Dec	CAHN
>D>	AB	+	SCHERING	5MG;240MG	N021605	001	Mar 03, 2005	Dec	CAHN

CLARINEX-D 12 HOUR

>A>		+	MERCK SHARP DOHME	2.5MG;120MG	N021313	001	Feb 01, 2006	Dec	CAHN
>D>		+	SCHERING	2.5MG;120MG	N021313	001	Feb 01, 2006	Dec	CAHN

DESMOPRESSIN ACETATE

SOLUTION; NASAL

DDAVP

AB	+	SANOFI AVENTIS US	0.01%	N017922	001			Mar	CFTG
----	---	-------------------	-------	---------	-----	--	--	-----	------

DESMOPRESSIN ACETATE

AB		SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012	Mar	NEWA	
----	--	----------------	-------	---------	-----	--------------	-----	------	--

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

AB		VINTAGE PHARMS LLC	0.15MG;0.03MG	A076675	001	Feb 25, 2011	Sep	CAHN	
----	--	--------------------	---------------	---------	-----	--------------	-----	------	--

MIRCETTE

AB	+	TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG	N020713	001	Apr 22, 1998	Jun	CAHN	
----	---	--------------------	--------------------------	---------	-----	--------------	-----	------	--

VIORELE

AB		GLENMARK GENERICS	0.15MG,N/A;0.02MG,0.01MG	A091346	001	Apr 02, 2012	Mar	NEWA	
----	--	-------------------	--------------------------	---------	-----	--------------	-----	------	--

DESONIDE

GEL; TOPICAL

DESONATE

>D>		+	BAYER HLTHCARE	0.05%	N021844	001	Oct 20, 2006	Dec	CAHN
		+		0.05%	N021844	001	Oct 20, 2006	Nov	CAHN
>A>		+	BHP DERMATOLOGY	0.05%	N021844	001	Oct 20, 2006	Dec	CAHN

LOTION; TOPICAL

DESONIDE

AB		FOUGERA PHARMS	0.05%	A075860	001	Mar 19, 2002	Jan	CAHN	
----	--	----------------	-------	---------	-----	--------------	-----	------	--

OINTMENT; TOPICAL

DESONIDE

AB		FOUGERA PHARMS	0.05%	A075751	001	Mar 12, 2001	Jan	CAHN	
----	--	----------------	-------	---------	-----	--------------	-----	------	--

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB		FOUGERA PHARMS	0.25%	A078369	001	Jun 29, 2010	Jan	CAHN	
----	--	----------------	-------	---------	-----	--------------	-----	------	--

TOPICORT

	+	TARO	0.05%	A073210	001	Nov 30, 1990	Apr	CTNA	
AB	+		0.25%	A073193	001	Nov 30, 1990	Sep	CTEC	
	+		0.25%	A073193	001	Nov 30, 1990	Apr	CTNA	
		@ TARO PHARMS NORTH	0.25%	N017856	001		Apr	DISC	

TOPICORT LP

		@ TARO PHARMS NORTH	0.05%	N018309	001		Apr	DISC	
--	--	---------------------	-------	---------	-----	--	-----	------	--

GEL; TOPICAL

TOPICORT

AB	+	TARO	0.05%	A074904	001	Jul 14, 1998	Apr	CTNA	
		@ TARO PHARMS NORTH	0.05%	N018586	001	Mar 29, 1982	Apr	DISC	

OINTMENT; TOPICALDESOXIMETASONE

AB		FOUGERA PHARMS	0.25%	A078657	001	Sep 28, 2012	Sep	NEWA	
AB	+	TARO	0.25%	A074286	001	Jun 07, 1996	Mar	CRLD	
<u>TOPICORT</u>									
AB	+	TARO	0.25%	A074286	001	Jun 07, 1996	Sep	CTEC	
	+		0.25%	A074286	001	Jun 07, 1996	Apr	CTNA	
	@	TARO PHARMS NORTH	0.25%	N018763	001	Sep 30, 1983	Mar	DISC	

DEXAMETHASONE SODIUM PHOSPHATEINJECTABLE; INJECTIONDEXAMETHASONE SODIUM PHOSPHATE

AP	+	APP PHARMS LLC	EQ 10MG PHOSPHATE/ML	A040572	001	Apr 22, 2005	Feb	CRLD
>D>		FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A040491	001	Apr 11, 2003	Dec	CRLD
>A>	+		EQ 10MG PHOSPHATE/ML	A040491	001	Apr 11, 2003	Dec	CRLD
	@	HIKMA MAPLE	EQ 4MG PHOSPHATE/ML	A084282	001		Oct	CAHN
AP	+		EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Oct	CAHN

DEXRAZOXANE HYDROCHLORIDEINJECTABLE; INJECTIONTOTECT

	+	APRICUS PHARMS	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Jun	CAHN
--	---	----------------	--------------------	---------	-----	--------------	-----	------

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE; ORALDEXEDRINE

AB		AMEDRA PHARMS	5MG	N017078	001		Nov	CAHN
AB			10MG	N017078	002		Nov	CAHN
AB	+		15MG	N017078	003		Nov	CAHN

DEXTROAMPHETAMINE SULFATE

AB		ACTAVIS ELIZABETH	5MG	A203901	001	Nov 30, 2012	Nov	NEWA
AB			10MG	A203901	002	Nov 30, 2012	Nov	NEWA
AB			15MG	A203901	003	Nov 30, 2012	Nov	NEWA

TABLET; ORALDEXTROAMPHETAMINE SULFATE

	@	NESHER PHARMS	5MG	A040365	001	Oct 31, 2002	Nov	DISC
	@		10MG	A040367	001	Oct 31, 2002	Nov	DISC
	@	VINTAGE PHARMS LLC	5MG	A040299	001	May 13, 1999	Sep	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDESYRUP; ORALPROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		TRIS PHARMA INC	15MG/5ML; 6.25MG/5ML	A091687	001	Jun 28, 2012	Jun	NEWA
----	--	-----------------	----------------------	---------	-----	--------------	-----	------

DIAZEPAMINJECTABLE; INJECTIONDIAZEPAM

	@	HIKMA MAPLE	5MG/ML	A070313	001	Dec 16, 1985	Jul	CAHN
	@		5MG/ML	A070311	001	Dec 16, 1985	Jul	CAHN
	@		5MG/ML	A070312	001	Dec 16, 1985	Jul	CAHN
	@		5MG/ML	A071308	001	Jul 17, 1987	Jul	CAHN
	@		5MG/ML	A071310	001	Jul 17, 1987	Jul	CAHN
	@		5MG/ML	A071309	001	Jul 17, 1987	Jul	CAHN
	@	HOSPIRA	5MG/ML	A071584	001	Oct 13, 1987	Apr	DISC

DICLOFENAC POTASSIUM

CAPSULE; ORAL

ZIPSOR

	+	DEPOMED INC	25MG	N022202 001	Jun 16, 2009	Jun	CAHN
--	---	-------------	------	-------------	--------------	-----	------

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB		MYLAN PHARMS INC	50MG	A075281 002	Feb 12, 2002	Sep	CAHN
AB			75MG	A075281 003	Feb 12, 2002	Sep	CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

AB		GD SEARLE LLC	50MG;0.2MG	N020607 001	Dec 24, 1997	Jun	CFTG
AB	+		75MG;0.2MG	N020607 002	Dec 24, 1997	Jun	CFTG
		DICLOFENAC SODIUM AND MISOPROSTOL					
AB		WATSON LABS INC	50MG;0.2MG	A201089 001	Jul 09, 2012	Jun	NEWA
AB			75MG;0.2MG	A201089 002	Jul 09, 2012	Jun	NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

AB		MYLAN PHARMS INC	125MG	A090788 001	Apr 08, 2010	Sep	CAHN
AB			200MG	A090788 002	Apr 08, 2010	Sep	CAHN
AB			250MG	A090788 003	Apr 08, 2010	Sep	CAHN
AB			400MG	A090788 004	Apr 08, 2010	Sep	CAHN

TABLET, CHEWABLE; ORAL

DIDANOSINE

		AUROBINDO	100MG	A077275 001	Aug 14, 2012	Jul	NEWA
			150MG	A077275 002	Aug 14, 2012	Jul	NEWA
	+		200MG	A077275 003	Aug 14, 2012	Nov	CRLD
			200MG	A077275 003	Aug 14, 2012	Jul	NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+	FOUGERA PHARMS	0.05%	A076263 001	Dec 20, 2002	Jan	CAHN
AB1	+		0.05%	A075187 001	Mar 30, 1998	Jan	CAHN

PSORCON

>A>		@ TARO	0.05%	N020205 001	Nov 20, 1992	Dec	CAHN
>D>		@ VALEANT PHARM NORTH	0.05%	N020205 001	Nov 20, 1992	Dec	CAHN
		@	0.05%	N020205 001	Nov 20, 1992	Nov	CAHN

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB		FOUGERA PHARMS	0.05%	A075374 001	Apr 27, 1999	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB		EMCURE PHARMS USA	500MG	A202845 001	Mar 08, 2012	Feb	NEWA
AB	+	TEVA	500MG	A073673 001	Jul 31, 1992	Feb	CTEC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP	HIKMA MAPLE	0.25MG/ML	A083391 001		Jul	CAHN
	@ HOSPIRA	0.25MG/ML	A040093 001	May 16, 1996	Jun	DISC

TABLET; ORAL

DIGOXIN

	@ MYLAN PHARMS INC	0.125MG	A040282 001	Dec 23, 1999	Jul	CAHN
	@	0.25MG	A040282 002	Dec 23, 1999	Jul	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB4	ACTAVIS ELIZABETH	120MG	A091022 001	Sep 28, 2012	Sep	NEWA
AB4		180MG	A091022 002	Sep 28, 2012	Sep	NEWA
AB4		240MG	A091022 003	Sep 28, 2012	Sep	NEWA
AB4		300MG	A091022 004	Sep 28, 2012	Sep	NEWA
AB4		360MG	A091022 005	Sep 28, 2012	Sep	NEWA
AB4		420MG	A091022 006	Sep 28, 2012	Sep	NEWA
AB3	ACTAVIS INC	360MG	A202463 001	Dec 07, 2012	Nov	NEWA

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

AP	AGILA SPECLTS	5MG/ML	A075375 001	Sep 30, 1999	Sep	CAHN
AP	HIKMA FARMACEUTICA	5MG/ML	A202651 001	Aug 09, 2012	Jul	NEWA
AP	HIKMA MAPLE	5MG/ML	A078538 001	Dec 17, 2008	Jul	CAHN
	@ TEVA PARENTERAL	5MG/ML	A074894 001	Aug 26, 1997	Jan	DISC

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

+	FERRING CONTROLLED	10MG	N020411 001	Mar 30, 1995	Jul	CAHN
---	--------------------	------	-------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL

	@ MCNEIL CONS	50MG/ML	N006146 002		Mar	DISC
--	---------------	---------	-------------	--	-----	------

BENADRYL PRESERVATIVE FREE

	@ MCNEIL CONS	50MG/ML	N009486 001		Mar	DISC
--	---------------	---------	-------------	--	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

AP	+ BAXTER HLTHCARE	50MG/ML	A080817 002		Apr	CRLD
AP	+ HIKMA MAPLE	50MG/ML	A080817 002		Jul	CAHN
	@	50MG/ML	A083183 001		Jul	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP	HIKMA MAPLE	5MG/ML	A074521 001	Oct 18, 1996	Jul	CAHN
	@ TEVA PARENTERAL	5MG/ML	A074952 001	Nov 26, 1997	Jan	DISC

TABLET; ORAL

DIPYRIDAMOLE

AB	PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
AB		50MG	A040542 002	Apr 21, 2006	Feb	CAHN
AB		75MG	A040542 003	Apr 21, 2006	Feb	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

@ NESHER PHARMS	EQ 150MG BASE	A071200 001	Dec 15, 1987	Jun	DISC
-----------------	---------------	-------------	--------------	-----	------

DISULFIRAM

TABLET; ORAL

DISULFIRAM

>A>	AB	VINTAGE PHARMS	250MG	A091563 001	Dec 31, 2012	Dec	NEWA
>A>	AB		500MG	A091563 002	Dec 31, 2012	Dec	NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB	DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161 001	Mar 15, 2012	Feb	NEWA
AB	REDDYS	EQ 500MG VALPROIC ACID	A090070 001	Mar 12, 2012	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACCORD HLTHCARE	20MG/ML (20MG/ML)	N201195 003	Apr 20, 2012	Apr	NEWA
AP		20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011	Jan	CTEC
AP		80MG/4ML (20MG/ML)	N201195 004	Apr 20, 2012	Apr	NEWA
AP		80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011	Jan	CTEC
AP		160MG/8ML (20MG/ML)	N201195 005	Apr 20, 2012	Apr	NEWA
AP	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012	Jan	NEWA
AP		80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012	Jan	NEWA
AP	TAXOTERE					
AP	+ SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449 003	Aug 03, 2010	Apr	CTEC
AP	+	80MG/4ML (20MG/ML)	N020449 004	Aug 02, 2010	Apr	CTEC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	INDICUS PHARMA	5MG	A201634 001	Jun 13, 2012	Jul	NEWA
AB		10MG	A201634 002	Jun 13, 2012	Jul	NEWA
AB	MACLEODS PHARMS LTD	5MG	A201146 001	Aug 17, 2012	Aug	NEWA
AB		10MG	A201146 002	Aug 17, 2012	Aug	NEWA
AB	MYLAN PHARMS INC	5MG	A090521 001	May 31, 2011	Sep	CAHN
AB		10MG	A090521 002	May 31, 2011	Sep	CAHN
AB	PRINSTON INC	5MG	A200292 001	May 31, 2011	Jun	CAHN
AB		10MG	A200292 002	May 31, 2011	Jun	CAHN
AB	ZYDUS PHARMS USA INC	5MG	A090100 001	Oct 24, 2012	Oct	NEWA
AB		10MG	A090100 002	Oct 24, 2012	Oct	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

>A>	AB	MACLEODS PHARMS LTD	5MG	A201787 001	Dec 14, 2012	Dec	NEWA
>A>	AB		10MG	A201787 002	Dec 14, 2012	Dec	NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT PF

+	MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667 001	Feb 01, 2012	Feb	NEWA
AT	TEVA PHARMS	EQ 2% BASE;EQ 0.5% BASE	A078704 001	Sep 28, 2009	Sep	CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ NESHER PHARMS	EQ 1MG BASE	A075609 001	Oct 18, 2000	Feb	DISC
@	EQ 2MG BASE	A075609 002	Oct 18, 2000	Feb	DISC
@	EQ 4MG BASE	A075609 003	Oct 18, 2000	Feb	DISC
@	EQ 8MG BASE	A075609 004	Oct 18, 2000	Feb	DISC

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

@ DAVA PHARMS INC	EQ 10MG BASE	A071685 001	Jan 05, 1988	Nov	CAHN
@	EQ 25MG BASE	A071686 001	Jan 05, 1988	Nov	CAHN
@	EQ 50MG BASE	A071673 001	Jan 05, 1988	Nov	CAHN
@	EQ 75MG BASE	A071674 001	Jan 05, 1988	Nov	CAHN
@	EQ 100MG BASE	A071675 001	Jan 05, 1988	Nov	CAHN
@	EQ 150MG BASE	A071676 001	Jan 05, 1988	Nov	CAHN

CREAM; TOPICAL

ZONALON

+ FOUGERA PHARMS	5%	N020126 001	Apr 01, 1994	Jan	CAHN
------------------	----	-------------	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ALVOGEN INC	2MG/ML	A065515 001	Nov 08, 2012	Oct	NEWA
AP	ONCO THERAPIES LTD	2MG/ML	A200901 001	Feb 14, 2012	Jan	NEWA
AP	SANDOZ INC	2MG/ML	A200146 001	Jul 18, 2012	Jul	NEWA
AP	SUN PHARM INDS	2MG/ML	A091418 001	Feb 15, 2012	Jan	NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

+ JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718 001	Nov 17, 1995	Jan	CAHN
+	50MG/25ML (2MG/ML)	N050718 002	Jun 13, 2000	Jan	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	MYLAN PHARMS INC	EQ 150MG BASE	A202778 001	Jun 08, 2012	May	NEWA
	@ SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000	Mar	DISC
	@	EQ 100MG BASE	A065032 002	Jun 30, 2000	Mar	DISC
	MONODOX					
AB	AQUA PHARMS	EQ 50MG BASE	N050641 002	Feb 10, 1992	Jul	CAHN
AB		EQ 75MG BASE	N050641 003	Oct 18, 2006	Jul	CAHN
AB	+	EQ 100MG BASE	N050641 001	Dec 29, 1989	Jul	CAHN

TABLET; ORAL

DOXYCYCLINE

@ SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006	Mar	DISC
@	EQ 75MG BASE	A065353 002	Nov 27, 2006	Mar	DISC
@	EQ 100MG BASE	A065353 003	Nov 27, 2006	Mar	DISC

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

DOXYCYCLINE

@ HIKMA MAPLE	EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983	Jul	CAHN	
@	EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983	Jul	CAHN	
AP	PFIZER	EQ 100MG BASE/VIAL	A091406 001	Aug 21, 2012	Aug	NEWA

INJECTABLE; INJECTIONDOXYCYCLINE HYCLATE

@ HIKMA MAPLE

EQ 100MG BASE/VIAL

A062992 001 Feb 16, 1989 Jul CAHN

@

EQ 200MG BASE/VIAL

A062992 002 Feb 16, 1989 Jul CAHN

TABLET; ORALDOXYCYCLINE HYCLATE

AB LARKEN LABS

EQ 20MG BASE

A065287 001 Feb 28, 2006 Apr CMFD

AB WATSON LABS INC FL

EQ 100MG BASE

A062421 001 Feb 02, 1983 Oct CAHN

TABLET, DELAYED RELEASE; ORALDORYX

AB + MAYNE PHARMA

EQ 150MG BASE

N050795 003 Jun 20, 2008 Jan CTEC

DOXYCYCLINE HYCLATE

AB MYLAN PHARMS INC

EQ 150MG BASE

A091052 001 Feb 08, 2012 Jan NEWA

DROSPIRENONE; ESTRADIOLTABLET; ORALANGELIQ

BAYER HLTHCARE

0.25MG;0.5MG

N021355 001 Feb 29, 2012 Feb NEWA

DROSPIRENONE; ETHINYL ESTRADIOLTABLET; ORAL-28DROSPIRENONE AND ETHINYL ESTRADIOL

>A> AB LUPIN LTD

3MG;0.03MG

A201663 001 Dec 18, 2012 Dec NEWA

ECONAZOLE NITRATECREAM; TOPICALECONAZOLE NITRATE

AB + FOUGERA PHARMS

1%

A076075 001 Nov 26, 2002 Jan CAHN

ELTROMBOPAG OLAMINETABLET; ORALPROMACTA

GLAXOSMITHKLINE

EQ 100MG ACID

N022291 005 Nov 16, 2012 Nov NEWA

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORALCOMPLERA

+ GILEAD SCIENCES INC

200MG;EQ 25MG BASE;300MG

N202123 001 Aug 10, 2011 Apr CAIN

ENALAPRIL MALEATETABLET; ORALENALAPRIL MALEATE

@ SANDOZ INC

2.5MG

A075621 001 Aug 22, 2000 Feb DISC

@

2.5MG

A075496 001 Aug 22, 2000 Jan DISC

@

5MG

A075621 002 Aug 22, 2000 Feb DISC

@

5MG

A075496 002 Aug 22, 2000 Jan DISC

@

10MG

A075621 003 Aug 22, 2000 Feb DISC

@

10MG

A075459 001 Aug 22, 2000 Jan DISC

@

20MG

A075621 004 Aug 22, 2000 Feb DISC

@

20MG

A075459 002 Aug 22, 2000 Jan DISC

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDETABLET; ORALENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@ SANDOZ INC

5MG;12.5MG

A076116 001 Sep 19, 2001 Mar DISC

@

10MG;25MG

A076116 002 Sep 19, 2001 Mar DISC

ENFLURANE

LIQUID; INHALATION

ETHRANE

AN	+	BAXTER HLTHCARE	99.9%		N017087 001			Jul	CAHN
----	---	-----------------	-------	--	-------------	--	--	-----	------

ENTACAPONE

TABLET; ORAL

COMTAN

AB	+	ORION PHARMA	200MG		N020796 001	Oct 19, 1999	Jul	CFTG
	+		200MG		N020796 001	Oct 19, 1999	May	CAHN

ENTACAPONE

AB		SUN PHARMA GLOBAL	200MG		A090690 001	Jul 16, 2012	Jul	NEWA
AB		WOCKHARDT LTD	200MG		A078941 001	Aug 16, 2012	Jul	NEWA

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

	+	ASTELLAS	40MG		N203415 001	Aug 31, 2012	Sep	CAHN
	+	MEDIVATION	40MG		N203415 001	Aug 31, 2012	Aug	NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT		LUITPOLD	0.05%		A090951 001	Oct 31, 2011	Mar	CAHN
----	--	----------	-------	--	-------------	--------------	-----	------

EPINEPHRINE

INJECTABLE; IM-SC

ADRENACLICK

>A>	BX	+	AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800 003	Nov 25, 2009	Dec	CAHN
>A>	BX	+		EQ 0.3MG/DELIVERY	N020800 004	Nov 25, 2009	Dec	CAHN
>D>	BX	+	COREPHARMA	EQ 0.15MG/DELIVERY	N020800 003	Nov 25, 2009	Dec	CAHN
	BX	+		EQ 0.15MG/DELIVERY	N020800 003	Nov 25, 2009	Mar	CAHN
>D>	BX	+		EQ 0.3MG/DELIVERY	N020800 004	Nov 25, 2009	Dec	CAHN
	BX	+		EQ 0.3MG/DELIVERY	N020800 004	Nov 25, 2009	Mar	CAHN

AUVI-Q

BX	+	INTELLIJECT	EQ 0.15MG/DELIVERY		N201739 002	Aug 10, 2012	Aug	NEWA
BX			EQ 0.3MG/DELIVERY		N201739 001	Aug 10, 2012	Aug	NEWA
BX	+	SANOFI AVENTIS US	EQ 0.15MG/DELIVERY		N201739 002	Aug 10, 2012	Nov	CAHN
BX			EQ 0.3MG/DELIVERY		N201739 001	Aug 10, 2012	Nov	CAHN

TWINJECT 0.15

>A>	BX	+	AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800 002	May 28, 2004	Dec	CAHN
>D>	BX	+	COREPHARMA	EQ 0.15MG/DELIVERY	N020800 002	May 28, 2004	Dec	CAHN
	BX	+		EQ 0.15MG/DELIVERY	N020800 002	May 28, 2004	Mar	CAHN

TWINJECT 0.3

>A>	BX	+	AMEDRA PHARMS	EQ 0.3MG/DELIVERY	N020800 001	May 30, 2003	Dec	CAHN
>D>	BX	+	COREPHARMA	EQ 0.3MG/DELIVERY	N020800 001	May 30, 2003	Dec	CAHN
	BX	+		EQ 0.3MG/DELIVERY	N020800 001	May 30, 2003	Mar	CAHN

>A> INJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

>A> ADRENALIN

>A>	+	JHP PHARMS	1MG/ML		N204200 001	Dec 07, 2012	Dec	NEWA
-----	---	------------	--------	--	-------------	--------------	-----	------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

		@ HIKMA MAPLE	0.01MG/ML;1%		A080406 001		Sep	CAHN
--	--	---------------	--------------	--	-------------	--	-----	------

INJECTABLE; INJECTION

		LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE							
		@ HIKMA MAPLE	0.01MG/ML;2%	A080406	002		Sep	CAHN	
		OCTOCAINE							
AP	+	SEPTODONT	0.01MG/ML;2%	A084048	001		May	CRLD	
		XYLOCAINE DENTAL WITH EPINEPHRINE							
		@ DENTSPLY PHARM	0.01MG/ML;2%	N021381	001		May	DISC	
		@	0.02MG/ML;2%	N021381	002		May	DISC	

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

		EPIRUBICIN HYDROCHLORIDE							
AP		CIPLA LTD	200MG/100ML (2MG/ML)	A065361	002	Oct 22, 2007	Mar	CAHN	
AP			50MG/25ML (2MG/ML)	A065361	001	Oct 22, 2007	Mar	CAHN	
AP		HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075	001	Mar 25, 2010	Mar	CAHN	
AP			200MG/100ML (2MG/ML)	A090075	002	Mar 25, 2010	Mar	CAHN	
AP		ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	Mar	NEWA	
AP			200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	Mar	NEWA	

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

		VELETRI							
		ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Jun	NEWA	
	+		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	May	CAHN	

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

		ERYC							
AB		WARNER CHILCOTT LLC	250MG	A062338	001		Jun	CAHN	
		GEL; TOPICAL							
		E-GLADES							
		@ COREPHARMA	2%	A065009	001	Mar 18, 2002	Jul	DISC	
		@ RENAISSANCE PHARMA	2%	A065009	001	Mar 18, 2002	Aug	CAHN	
		ERYTHROMYCIN							
AT		FOUGERA PHARMS	2%	A064184	001	Sep 30, 1997	Jan	CAHN	
		SOLUTION; TOPICAL							
		C-SOLVE-2							
AT		FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Jan	CMFD	
		ERYTHROMYCIN							
		@ RENAISSANCE PHARMA	2%	A064127	001	Feb 14, 1997	Aug	CAHN	
		SWAB; TOPICAL							
		ERYCETE							
		@ JOHNSON AND JOHNSON	2%	N050594	001	Feb 15, 1985	Apr	CAHN	
		ERYTHROMYCIN							
AT	+	FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006	Jan	CAHN	
		@ RENAISSANCE PHARMA	2%	A064128	001	Jul 03, 1996	Sep	CAHN	

ESCITALOPRAM OXALATE

SOLUTION; ORAL

		ESCITALOPRAM OXALATE							
AA		AMNEAL PHARMS	EQ 5MG BASE/5ML	A202227	001	Mar 14, 2012	Feb	NEWA	
AA		AUROBINDO PHARMA LTD	EQ 5MG BASE/5ML	A079062	001	Apr 02, 2012	Mar	NEWA	
AA		HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221	001	Jun 12, 2012	May	NEWA	
AA		TARO	EQ 5MG BASE/5ML	A079121	001	May 03, 2012	Apr	NEWA	
		LEXAPRO							
AA	+	FOREST LABS	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Feb	CFTG	

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	ACCORD HLTHCARE	EQ 5MG BASE	A202389 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A202389 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A202389 003	Sep 11, 2012	Aug	NEWA
AB	APOTEX INC	EQ 5MG BASE	A078777 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078777 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078777 003	Sep 11, 2012	Aug	NEWA
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A090432 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A090432 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A090432 003	Sep 11, 2012	Aug	NEWA
AB	HIKMA PHARMS	EQ 5MG BASE	A078766 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078766 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078766 003	Sep 11, 2012	Aug	NEWA
AB	INVAGEN PHARMS	EQ 5MG BASE	A078604 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078604 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078604 003	Sep 11, 2012	Aug	NEWA
AB	IVAX SUB TEVA PHARMS	EQ 5MG BASE	A076765 001	Mar 14, 2012	Feb	NEWA
AB		EQ 10MG BASE	A076765 002	Mar 14, 2012	Feb	NEWA
AB		EQ 20MG BASE	A076765 003	Mar 14, 2012	Feb	NEWA
AB	JUBILANT ORGANOSYS	EQ 5MG BASE	A202280 001	Sep 12, 2012	Aug	NEWA
AB		EQ 10MG BASE	A202280 002	Sep 12, 2012	Aug	NEWA
AB		EQ 20MG BASE	A202280 003	Sep 12, 2012	Aug	NEWA
AB	LUPIN LTD	EQ 5MG BASE	A078169 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078169 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078169 003	Sep 11, 2012	Aug	NEWA
AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A202210 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A202210 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A202210 003	Sep 11, 2012	Aug	NEWA
AB	STI PHARMA LLC	EQ 5MG BASE	A077512 001	Sep 12, 2012	Aug	NEWA
AB		EQ 10MG BASE	A077512 002	Sep 12, 2012	Aug	NEWA
AB		EQ 20MG BASE	A077512 003	Sep 12, 2012	Aug	NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE	A090939 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A090939 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A090939 003	Sep 11, 2012	Aug	NEWA
AB	ZYDUS PHARMS USA INC	EQ 5MG BASE	A077734 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A077734 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A077734 003	Sep 11, 2012	Aug	NEWA
LEXAPRO						
AB	FOREST LABS	EQ 5MG BASE	N021323 001	Aug 14, 2002	Feb	CFTG
AB		EQ 10MG BASE	N021323 002	Aug 14, 2002	Feb	CFTG
AB	+	EQ 20MG BASE	N021323 003	Aug 14, 2002	Feb	CFTG

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

	@ BAXTER HLTHCARE	10MG/ML	N019386 003	Aug 15, 1988	Jun	CAHN
AP	+	10MG/ML	N019386 006	Feb 25, 2003	Jun	CAHN
	@	20MG/ML	N019386 007	May 28, 2003	Jun	CAHN
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	2GM/100ML	N019386 005	Jan 27, 2003	Jun	CAHN
BREVIBLOC IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	1GM/100ML	N019386 004	Feb 16, 2001	Jun	CAHN

ESOMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

ASTRAZENECA	EQ 2.5MG BASE/PACKET	N021957 003	Dec 15, 2011	Jun	NEWA
	EQ 5MG BASE/PACKET	N021957 004	Dec 15, 2011	Jun	NEWA

ESTRADIOL

CREAM; VAGINAL

ESTRACE

+ WARNER CHILCOTT US	0.01%	A086069 001	Jan 31, 1984	Jun	CAHN
----------------------	-------	-------------	--------------	-----	------

FILM, EXTENDED RELEASE; TRANSDERMAL

MINIVELLE

NOVEN	0.0375MG/24HR	N203752 001	Oct 29, 2012	Oct	NEWA
	0.05MG/24HR	N203752 003	Oct 29, 2012	Oct	NEWA
	0.075MG/24HR	N203752 002	Oct 29, 2012	Oct	NEWA
+	0.1MG/24HR	N203752 004	Oct 29, 2012	Oct	NEWA

GEL, METERED; TRANSDERMAL

ELESTRIN

+ JAZZ PHARMS COMMERCL	0.06% (0.87GM/ACTIVATION)	N021813 001	Dec 15, 2006	Jun	CAHN
+ JAZZ PHARMS II	0.06% (0.87GM/ACTIVATION)	N021813 001	Dec 15, 2006	Sep	CAHN
+ MEDA PHARMS	0.06% (0.87GM/ACTIVATION)	N021813 001	Dec 15, 2006	Oct	CAHN

TABLET; ORAL

>D>	ESTRACE				
>D>	AB	BRISTOL MYERS SQUIBB	1MG	A084499 001	Dec DISC
>A>		@	1MG	A084499 001	Dec DISC
>D>	AB	+	2MG	A084500 001	Dec DISC
>A>		@	2MG	A084500 001	Dec DISC
	ESTRADIOL				
>D>	AB	BARR	2MG	A040197 003	Oct 22, 1997 Dec CRLD
>A>	AB	+ BARR LABS INC	2MG	A040197 003	Oct 22, 1997 Dec CRLD

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

WARNER IRELAND	EQ 0.05MG BASE/24HR	N021367 001	Mar 20, 2003	May	CAHN
+	EQ 0.1MG BASE/24HR	N021367 002	Mar 20, 2003	May	CAHN

TABLET; ORAL

FEMTRACE

WARNER CHILCOTT LLC	0.45MG	N021633 001	Aug 20, 2004	Jun	CAHN
	0.9MG	N021633 002	Aug 20, 2004	Jun	CAHN
+	1.8MG	N021633 003	Aug 20, 2004	Jun	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB	TEVA PHARMS USA	0.5MG;0.1MG	A200747 001	Mar 08, 2012	Feb NEWA
----	-----------------	-------------	-------------	--------------	----------

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

TEVA BRANDED PHARM	0.3MG	N020992 001	Jun 21, 2002	Jun	CAHN
	0.45MG	N020992 005	Feb 05, 2004	Jun	CAHN
	0.625MG	N020992 002	Mar 24, 1999	Jun	CAHN
	0.9MG	N020992 003	Mar 24, 1999	Jun	CAHN
+	1.25MG	N020992 004	Mar 13, 2000	Jun	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	LUPIN LTD	0.03MG;0.15MG	A091440	001	Oct 23, 2012	Oct	NEWA
+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	May	CRLD
LOSEASONIQUE							
AB	TEVA BRANDED PHARM	0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008	Jun	CAHN
LYBREL							
	@ WYETH PHARMS INC	0.02MG;0.09MG	N021864	001	May 22, 2007	May	DISC
PREVEN EMERGENCY CONTRACEPTIVE KIT							
	@ TEVA BRANDED PHARM	0.05MG;0.25MG	N020946	001	Sep 01, 1998	Jun	CAHN
SEASONALE							
AB	+ TEVA BRANDED PHARM	0.03MG;0.15MG	N021544	001	Sep 05, 2003	Jul	CAHN
SEASONIQUE							
AB	+ TEVA BRANDED PHARM	0.03MG,0.01MG;0.15MG,N/A	N021840	001	May 25, 2006	Jun	CAHN

TABLET; ORAL-21

NORDETTE-21

	@ TEVA BRANDED PHARM	0.03MG;0.15MG	N018668	001	May 10, 1982	Jun	CAHN
--	----------------------	---------------	---------	-----	--------------	-----	------

TABLET; ORAL-28

FALMINA

AB1	NOVAST LABS LTD	0.02MG;0.1MG	A090721	001	Mar 28, 2012	Mar	NEWA
-----	-----------------	--------------	---------	-----	--------------	-----	------

KURVELO

AB	LUPIN LTD	0.03MG;0.15MG	A091408	001	Oct 17, 2012	Oct	NEWA
----	-----------	---------------	---------	-----	--------------	-----	------

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A>	AB	FAMY CARE LTD	0.03MG;0.15MG	A091663	001	Dec 21, 2012	Dec	NEWA
-----	----	---------------	---------------	---------	-----	--------------	-----	------

MARLISSA

AB	GLENMARK GENERICS	0.03MG;0.15MG	A091452	001	Feb 29, 2012	Feb	NEWA
----	-------------------	---------------	---------	-----	--------------	-----	------

MYZILRA

AB	VINTAGE PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A077502	001	Nov 23, 2011	May	CDFR
----	----------------	---	---------	-----	--------------	-----	------

AB	VINTAGE PHARMS LLC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A077502	001	Nov 23, 2011	Sep	CAHN
----	--------------------	---	---------	-----	--------------	-----	------

NORDETTE-28

AB	+ TEVA BRANDED PHARM	0.03MG;0.15MG	N018782	001	Jul 21, 1982	Jun	CAHN
----	----------------------	---------------	---------	-----	--------------	-----	------

ORSYTHIA

AB1	VINTAGE PHARMS LLC	0.02MG;0.1MG	A077099	001	May 11, 2011	Sep	CAHN
-----	--------------------	--------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

+	JANSSEN PHARMS	0.75MG;6MG	N021180	001	Nov 20, 2001	Jun	CPOT
---	----------------	------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

ALYACEN 1/35

AB	GLENMARK GENERICS	0.035MG;1MG	A091634	001	Jan 19, 2012	Jan	NEWA
----	-------------------	-------------	---------	-----	--------------	-----	------

ALYACEN 7/7/7

AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A091636	001	Jan 19, 2012	Jan	NEWA
----	-------------------	--	---------	-----	--------------	-----	------

CYCLAFEM 1/35

AB	VINTAGE PHARMS LLC	0.035MG;1MG	A076337	001	Nov 12, 2010	Sep	CAHN
----	--------------------	-------------	---------	-----	--------------	-----	------

CYCLAFEM 7/7/7

AB	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076338	001	Nov 16, 2010	Sep	CAHN
----	--------------------	--	---------	-----	--------------	-----	------

GILDAGIA

AB	VINTAGE PHARMS	0.035MG;0.4MG	A078376	001	Nov 06, 2012	Nov	CTNA
----	----------------	---------------	---------	-----	--------------	-----	------

TABLET; ORAL-28

	NORETHINDRONE AND ETHINYL ESTRADIOL							
AB	VINTAGE PHARMS	0.035MG;0.4MG	A078376	001	Nov 06, 2012	Oct	NEWA	
	OVCON-35							
AB	+ WARNER CHILCOTT LLC	0.035MG;0.4MG	N017716	001		Jun	CAHN	
	OVCON-50							
	+ WARNER CHILCOTT LLC	0.05MG;1MG	N017576	001		Jun	CAHN	
	WERA							
AB	NOVAST LABS LTD	0.035MG;0.5MG	A091204	001	Mar 27, 2012	Mar	NEWA	
	TABLET, CHEWABLE; ORAL							
	FEMCON FE							
AB	+ WARNER CHILCOTT LLC	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jun	CAHN	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

	FEMHRT							
	WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jun	CAHN	
AB	+	0.005MG;1MG	N021065	002	Oct 15, 1999	Jun	CAHN	
	LO LOESTRIN FE							
	+ WARNER CHILCOTT LLC	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jun	CAHN	

TABLET; ORAL-21

	ESTROSTEP 21							
	@ WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996	Jun	CAHN	
	LOESTRIN 21 1.5/30							
AB	WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875	001		Jun	CAHN	
	LOESTRIN 21 1/20							
AB	WARNER CHILCOTT LLC	0.02MG;1MG	N017876	001		Jun	CAHN	

TABLET; ORAL-28

	ESTROSTEP FE							
AB	+ WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Jun	CAHN	
	GILDESS FE 1.5/30							
AB	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	001	Apr 28, 2005	Sep	CAHN	
	GILDESS FE 1/20							
AB	VINTAGE PHARMS LLC	0.02MG;1MG	A077077	001	May 20, 2005	Sep	CAHN	
	LOESTRIN FE 1.5/30							
AB	+ WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355	001		Jun	CAHN	

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

	MONO-LINYAH							
AB	NOVAST LABS LTD	0.035MG;0.25MG	A090523	001	May 23, 2012	May	NEWA	
	NORGESTIMATE AND ETHINYL ESTRADIOL							
AB	GLENMARK GENERICS	0.035MG;0.25MG	A200538	001	Apr 05, 2012	Mar	NEWA	
AB	LUPIN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A200541	001	Jun 25, 2012	Jun	NEWA	
	PREVIFEM							
AB	VINTAGE PHARMS LLC	0.035MG;0.25MG	A076334	001	Jan 09, 2004	Sep	CAHN	
	TRI-LINYAH							
AB	NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090524	001	May 30, 2012	May	NEWA	
	TRI-PREVIFEM							
AB	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076335	001	Mar 26, 2004	Sep	CAHN	

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

ELINEST

AB	NOVAST LABS LTD	0.03MG;0.3MG	A091105 001	Mar 28, 2012	Mar	NEWA
----	-----------------	--------------	-------------	--------------	-----	------

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB	ZYDUS PHARMS USA INC	250MG	A200892 001	Sep 25, 2012	Sep	NEWA
----	----------------------	-------	-------------	--------------	-----	------

ETHOTOIN

TABLET; ORAL

PEGANONE

+	LUNDBECK LLC	250MG	N010841 001		Aug	CAHN
---	--------------	-------	-------------	--	-----	------

@		500MG	N010841 003		Aug	CAHN
---	--	-------	-------------	--	-----	------

ETODOLAC

CAPSULE; ORAL

ETODOLAC

@	VINTAGE PHARMS LLC	200MG	A074842 001	Jul 17, 1997	Sep	CAHN
---	--------------------	-------	-------------	--------------	-----	------

@		300MG	A074842 002	Jul 17, 1997	Sep	CAHN
---	--	-------	-------------	--------------	-----	------

TABLET; ORAL

ETODOLAC

AB	PROSAM LABS	400MG	A074819 001	Feb 28, 1997	Feb	CMFD
----	-------------	-------	-------------	--------------	-----	------

AB		500MG	A074819 002	Apr 28, 1998	Feb	CMFD
----	--	-------	-------------	--------------	-----	------

@	VINTAGE PHARMS LLC	400MG	A074841 001	Jun 27, 1997	Sep	CAHN
---	--------------------	-------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

@	ACTAVIS ELIZABETH	400MG	A075696 001	Jul 31, 2000	Oct	CAHN
---	-------------------	-------	-------------	--------------	-----	------

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

AP	MYLAN INSTITUTIONAL	2MG/ML	A091297 001	Jun 20, 2012	Jun	NEWA
----	---------------------	--------	-------------	--------------	-----	------

ETOPOSIDE

CAPSULE; ORAL

VEPESID

@	CORDEN PHARMA	50MG	N019557 001	Dec 30, 1986	Feb	CAHN
---	---------------	------	-------------	--------------	-----	------

@		100MG	N019557 002	Dec 30, 1986	Feb	CAHN
---	--	-------	-------------	--------------	-----	------

INJECTABLE; INJECTION

ETOPOSIDE

AP	+ APP PHARMS LLC	20MG/ML	A074983 001	Sep 30, 1998	Mar	CRLD
----	------------------	---------	-------------	--------------	-----	------

AP	BEDFORD	20MG/ML	A074290 001	Jul 17, 1995	Mar	CRLD
----	---------	---------	-------------	--------------	-----	------

VEPESID

@	CORDEN PHARMA	20MG/ML	N018768 001	Nov 10, 1983	Feb	CAHN
---	---------------	---------	-------------	--------------	-----	------

ETRAVIRINE

TABLET; ORAL

INTELENCE

	JANSSEN R AND D	25MG	N022187 003	Mar 26, 2012	Mar	NEWA
--	-----------------	------	-------------	--------------	-----	------

		100MG	N022187 001	Jan 18, 2008	Feb	CAHN
--	--	-------	-------------	--------------	-----	------

+		200MG	N022187 002	Dec 22, 2010	Feb	CAHN
---	--	-------	-------------	--------------	-----	------

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS 7.5MG N022334 004 Mar 30, 2012 Apr NEWA

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

NOVARTIS PHARM 2MG N203985 001 Aug 29, 2012 Aug NEWA

3MG N203985 002 Aug 29, 2012 Aug NEWA

+ 5MG N203985 003 Aug 29, 2012 Aug NEWA

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

+ AMYLIN 2MG/VIAL N022200 001 Jan 27, 2012 Jan NEWA

EZETIMIBE

TABLET; ORAL

ZETIA

+ MSD INTL GMBH 10MG N021445 001 Oct 25, 2002 Feb CAHN

+ MSP SINGAPORE 10MG N021445 001 Oct 25, 2002 Jan CAHN

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSD INTL 10MG;10MG N021687 001 Jul 23, 2004 Jan CAHN

10MG;20MG N021687 002 Jul 23, 2004 Jan CAHN

10MG;40MG N021687 003 Jul 23, 2004 Jan CAHN

+ 10MG;80MG N021687 004 Jul 23, 2004 Jan CAHN

EZOGABINE

TABLET; ORAL

POTIGA

GLAXOSMITHKLINE 50MG N022345 001 Jun 10, 2011 May CAHN

200MG N022345 002 Jun 10, 2011 May CAHN

300MG N022345 003 Jun 10, 2011 May CAHN

+ 400MG N022345 004 Jun 10, 2011 May CAHN

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB MACLEODS PHARMS LTD 125MG A201022 001 Jan 12, 2012 Jan NEWA

AB 250MG A201022 002 Jan 12, 2012 Jan NEWA

AB 500MG A201022 003 Jan 12, 2012 Jan NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP + HIKMA MAPLE 10MG/ML A075799 001 Apr 30, 2002 Jul CAHN

AP + 10MG/ML A075488 001 Apr 16, 2001 Jul CAHN

FAMOTIDINE PRESERVATIVE FREE

AP + HIKMA MAPLE 10MG/ML A075789 001 Apr 30, 2002 Jul CAHN

AP + 10MG/ML A075486 001 Apr 16, 2001 Jul CAHN

SUSPENSION; ORAL

FAMOTIDINE

>A> AB NOVEL LABS INC 40MG/5ML A201695 001 Dec 17, 2012 Dec NEWA

TABLET; ORAL

FAMOTIDINE

@ MYLAN PHARMS INC

20MG

A075457 001 Apr 18, 2001 Oct DISC

@

40MG

A075457 002 Apr 18, 2001 Oct DISC

@ SANDOZ

20MG

A075607 001 May 10, 2001 Oct DISC

@

40MG

A075607 002 May 10, 2001 Oct DISC

PEPCID

AB MARATHON PHARMS

20MG

N019462 001 Oct 15, 1986 Jan CAHN

AB +

40MG

N019462 002 Oct 15, 1986 Jan CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

@ UCB INC

20MG

N021712 001 Sep 24, 2004 Jan CAHN

@

40MG

N021712 002 Sep 24, 2004 Jan CAHN

FEBUXOSTAT

TABLET; ORAL

ULORIC

TAKEDA PHARMS USA

40MG

N021856 001 Feb 13, 2009 Apr CAHN

+

80MG

N021856 002 Feb 13, 2009 Apr CAHN

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

>A> AB AUROBINDO PHARMA LTD

2.5MG

A203417 001 Jan 17, 2013 Dec NEWA

>A> AB

5MG

A203417 002 Jan 17, 2013 Dec NEWA

>A> AB

10MG

A203417 003 Jan 17, 2013 Dec NEWA

AB VINTAGE PHARMS LLC

2.5MG

A200815 001 Oct 28, 2011 Sep CAHN

AB

5MG

A200815 002 Oct 28, 2011 Sep CAHN

AB

10MG

A200815 003 Oct 28, 2011 Sep CAHN

AB WOCKHARDT LTD

2.5MG

A091484 001 Aug 15, 2012 Jul NEWA

AB

5MG

A091484 002 Aug 15, 2012 Jul NEWA

AB

10MG

A091484 003 Aug 15, 2012 Jul NEWA

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

AB LUPIN ATLANTIS

43MG

N021695 001 Nov 30, 2004 Feb CFTG

AB +

130MG

N021695 003 Nov 30, 2004 Feb CFTG

FENOFIBRATE (MICRONIZED)

AB DR REDDYS LABS SA

43MG

A090859 001 Mar 01, 2012 Feb NEWA

AB

130MG

A090859 002 Mar 01, 2012 Feb NEWA

>A> AB MYLAN PHARMS INC

43MG

A202579 001 Jan 10, 2013 Dec NEWA

AB

67MG

A202676 001 Oct 23, 2012 Oct NEWA

>A> AB

130MG

A202579 002 Jan 10, 2013 Dec NEWA

AB

134MG

A202676 002 Oct 23, 2012 Oct NEWA

AB

200MG

A202676 003 Oct 23, 2012 Oct NEWA

TABLET; ORAL

FENOFIBRATE

AB IMPAX LABS

160MG

A076509 002 Mar 26, 2008 May CRLD

AB +

160MG

A076509 002 Mar 26, 2008 Mar CRLD

AB MYLAN PHARMS INC

48MG

A202856 001 Dec 07, 2012 Nov NEWA

AB

145MG

A202856 002 Dec 07, 2012 Nov NEWA

AB TEVA

54MG

A076433 001 May 13, 2005 May CMFD

@

54MG

A076433 001 May 13, 2005 Mar DISC

AB +

160MG

A076433 002 May 13, 2005 May CMFD

@

160MG

A076433 002 May 13, 2005 Mar DISC

TABLET; ORAL

FENOFIBRATE

AB	VALEANT INTL	48MG	A090715 001	Apr 05, 2012	Mar	NEWA
AB		145MG	A090715 002	Apr 05, 2012	Mar	NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

+	XSPIRE	EQ 200MG BASE	N017604 003		Aug	CAHN
	@	EQ 300MG BASE	N017604 002		Aug	CAHN
		EQ 400MG BASE	N017604 004	Jul 21, 2009	Aug	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB	AVEVA	100MCG/HR	A077449 004	Oct 20, 2008	Jun	CAHN
AB	PAR PHARM INC	100MCG/HR	A077062 004	Aug 20, 2007	Nov	CAHN

FENTANYL-25

AB	AVEVA	25MCG/HR	A077449 001	Oct 20, 2008	Jun	CAHN
AB	PAR PHARM INC	25MCG/HR	A077062 001	Aug 20, 2007	Nov	CAHN

FENTANYL-50

AB	AVEVA	50MCG/HR	A077449 002	Oct 20, 2008	Jun	CAHN
AB	PAR PHARM INC	50MCG/HR	A077062 002	Aug 20, 2007	Nov	CAHN

FENTANYL-75

AB	AVEVA	75MCG/HR	A077449 003	Oct 20, 2008	Jun	CAHN
AB	PAR PHARM INC	75MCG/HR	A077062 003	Aug 20, 2007	Nov	CAHN

SPRAY; SUBLINGUAL

SUBSYS

INSYS THERAP

		0.1MG	N202788 001	Jan 04, 2012	Mar	CPOT
		0.1MCG	N202788 001	Jan 04, 2012	Jan	NEWA
		0.2MG	N202788 002	Jan 04, 2012	Mar	CPOT
		0.2MCG	N202788 002	Jan 04, 2012	Jan	NEWA
+		0.4MG	N202788 003	Jan 04, 2012	Mar	CPOT
+		0.4MCG	N202788 003	Jan 04, 2012	Jan	NEWA
		0.6MG	N202788 004	Jan 04, 2012	Mar	CPOT
		0.6MCG	N202788 004	Jan 04, 2012	Jan	NEWA
		0.8MG	N202788 005	Jan 04, 2012	Mar	CPOT
		0.8MCG	N202788 005	Jan 04, 2012	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

ARCHIMEDES

		EQ 0.1MG BASE	N022569 001	Jun 30, 2011	Jan	CPOT
+		EQ 0.4MG BASE	N022569 002	Jun 30, 2011	Jan	CPOT

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

AB	PAR PHARM	EQ 0.2MG BASE	A077312 001	Oct 30, 2009	Feb	CAHN
AB		EQ 0.4MG BASE	A077312 002	Oct 30, 2009	Feb	CAHN
AB		EQ 0.6MG BASE	A077312 003	Oct 30, 2009	Feb	CAHN
AB		EQ 0.8MG BASE	A077312 004	Oct 30, 2009	Feb	CAHN
AB		EQ 1.2MG BASE	A077312 005	Oct 30, 2009	Feb	CAHN
AB		EQ 1.6MG BASE	A077312 006	Oct 30, 2009	Feb	CAHN

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

@	AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416	001	Aug 30, 1996	Jun	DISC
---	-----------------	-------------------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

AB	+	SANOFI AVENTIS US	30MG/5ML	N021963	001	Oct 16, 2006	Jul	CFTG
----	---	-------------------	----------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

AB		ACTAVIS MID ATLANTIC	30MG/5ML	A201311	001	Jul 25, 2012	Jul	NEWA
----	--	----------------------	----------	---------	-----	--------------	-----	------

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10-50ML (13.5-51MCI/ML)	N202008	003	Apr 06, 2012	Jun	CPOT
+		10-50ML (13.5-51MCI/ML)	N202008	003	Apr 06, 2012	Apr	NEWA
+		10-30ML (13.5-51MCI/ML)	N202008	002	Apr 06, 2012	Apr	NEWA
+		10ML (13.5-51MCI/ML)	N202008	001	Apr 06, 2012	Apr	NEWA

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Aug	CAHN
AP			400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Aug	CAHN
AP		HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764	001	Jan 30, 2012	Jan	NEWA
AP			400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012	Jan	NEWA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Aug	CAHN
	@		400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Aug	CAHN
AP		HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698	001	Jan 30, 2012	Jan	NEWA
AP			400MG/200ML (2MG/ML)	A078698	002	Jan 30, 2012	Jan	NEWA
AP		TEVA PHARMS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005	Oct	CAHN
AP			400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005	Oct	CAHN

TABLET; ORAL

FLUCONAZOLE

AB		HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	Jul	CAHN
AB			100MG	A078423	002	Mar 07, 2011	Jul	CAHN
AB			150MG	A078423	003	Mar 07, 2011	Jul	CAHN
AB			200MG	A078423	004	Mar 07, 2011	Jul	CAHN
	@	MYLAN PHARMS INC	50MG	A076042	001	Jul 29, 2004	Oct	DISC
	@		100MG	A076042	002	Jul 29, 2004	Oct	DISC
	@		150MG	A076042	003	Jul 29, 2004	Oct	DISC
	@		200MG	A076042	004	Jul 29, 2004	Oct	DISC
	@	PLIVA	50MG	A076424	001	Jul 29, 2004	Feb	DISC
	@		100MG	A076424	002	Jul 29, 2004	Feb	DISC
	@		150MG	A076424	003	Jul 29, 2004	Feb	DISC
	@		200MG	A076424	004	Jul 29, 2004	Feb	DISC
	@	RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004	Apr	DISC
	@		100MG	A076386	002	Jul 29, 2004	Apr	DISC
	@		150MG	A076386	003	Jul 29, 2004	Apr	DISC
	@		200MG	A076386	004	Jul 29, 2004	Apr	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

@ GENZYME CORP

50MG/VIAL

N020038 001 Apr 18, 1991 Mar DISC

FLUDARABINE PHOSPHATE

AP + HOSPIRA

50MG/VIAL

A077790 001 Apr 06, 2007 Mar CRLD

AP ONCO THERAPIES LTD

50MG/VIAL

A200648 001 Oct 16, 2012 Oct NEWA

TABLET; ORAL

OFORTA

@ SANOFI AVENTIS US

10MG

N022273 001 Dec 18, 2008 May DISC

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP HIKMA MAPLE

0.5MG/5ML (0.1MG/ML)

A076787 002 Oct 12, 2004 Jul CAHN

AP

1MG/10ML (0.1MG/ML)

A076787 001 Oct 12, 2004 Jul CAHN

AP SAGENT PHARMS

0.5MG/5ML (0.1MG/ML)

A090584 001 Aug 28, 2012 Aug NEWA

AP

1MG/10ML (0.1MG/ML)

A090584 002 Aug 28, 2012 Aug NEWA

@ TEVA PARENTERAL

0.5MG/5ML (0.1MG/ML)

A076589 002 Oct 12, 2004 Jan DISC

@

1MG/10ML (0.1MG/ML)

A076589 001 Oct 12, 2004 Jan DISC

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+ ACTON PHARMS

EQ 78MG BASE/INH

N021247 001 Jan 27, 2006 Jul CPOT

SPRAY, METERED; NASAL

FLUNISOLIDE

AB HI TECH PHARMA CO

0.025MG/SPRAY

A077704 001 Aug 03, 2006 Aug CAHN

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT IDENTI PHARMS INC

0.01%

A091306 001 Oct 17, 2011 Jan CPOT

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

AB1 G AND W LABS INC

0.05%

A073085 001 Feb 14, 1992 Sep CAHN

AB1 + TARO

0.05%

N019117 001 Jun 26, 1984 Oct CRLD

FLUOCINONIDE EMULSIFIED BASE

AB2 FOUGERA PHARMS

0.05%

A076586 001 Jun 23, 2004 Jan CAHN

@ G AND W LABS INC

0.05%

A074204 001 Jun 13, 1995 May CAHN

AB2 + TARO

0.05%

A072494 001 Jan 19, 1989 Oct CRLD

LIDEX

@ MEDICIS

0.05%

N016908 002 Oct DISC

LIDEX-E

@ MEDICIS

0.05%

N016908 003 Oct DISC

OINTMENT; TOPICAL

FLUOCINONIDE

AB FOUGERA PHARMS

0.05%

A074905 001 Aug 26, 1997 Jan CAHN

SOLUTION; TOPICAL

FLUOCINONIDE

AT G AND W LABS INC

0.05%

A071535 001 Dec 02, 1988 Sep CAHN

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 25%

AKORN

EQ 500MG BASE/2ML (EQ 250MG
BASE/ML)

N022186 002 Aug 08, 2008 Oct CMFD

FLUOROURACIL

CREAM; TOPICAL

CARAC

>A>	+	VALEANT BERMUDA	0.5%	N020985	001	Oct 27, 2000	Dec	CAHN
>D>	+	VALEANT INTL	0.5%	N020985	001	Oct 27, 2000	Dec	CAHN
	+		0.5%	N020985	001	Oct 27, 2000	Jul	CAHN

FLUOROPLEX

+ AQUA PHARMS

1%

N016988 001 Jan CAHN

INJECTABLE; INJECTION

FLUOROURACIL

AP		ONCO THERAPIES LTD	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Jul	NEWA
AP			1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Jul	NEWA
AP			2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012	Jul	NEWA
AP			5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012	Jul	NEWA
	@	SPECTRUM PHARMS	50MG/ML	A087792	001	Oct 13, 1982	Sep	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1		HERITAGE PHARMS INC	EQ 10MG BASE	A201336	001	Oct 01, 2012	Sep	NEWA
AB1			EQ 20MG BASE	A201336	002	Oct 01, 2012	Sep	NEWA
AB			EQ 40MG BASE	A201336	003	Oct 01, 2012	Sep	NEWA
AB1		MYLAN PHARMS INC	EQ 10MG BASE	A075577	001	Jan 29, 2002	Sep	CAHN
AB1			EQ 20MG BASE	A075577	002	Jan 29, 2002	Sep	CAHN

PROZAC

AB1		ELI LILLY AND CO	EQ 10MG BASE	N018936	006	Dec 23, 1992	Apr	CAHN
AB1			EQ 20MG BASE	N018936	001	Dec 29, 1987	Apr	CAHN
AB	+		EQ 40MG BASE	N018936	003	Jun 15, 1999	Apr	CAHN
	@		EQ 60MG BASE	N018936	004	Jun 15, 1999	Apr	CAHN

SARAFEM

AB2		ELI LILLY AND CO	EQ 10MG BASE	N018936	007	Jul 06, 2000	Apr	CAHN
AB2	+		EQ 20MG BASE	N018936	008	Jul 06, 2000	Apr	CAHN

TABLET; ORAL

SARAFEM

WARNER CHILCOTT LLC

EQ 10MG BASE

N021860 001 May 19, 2006 Jun CAHN

EQ 15MG BASE

N021860 002 May 19, 2006 Jun CAHN

+

EQ 20MG BASE

N021860 003 May 19, 2006 Jun CAHN

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		PAR PHARM	EQ 25MG BASE;EQ 3MG BASE	A077742	001	Nov 02, 2012	Oct	NEWA
AB			EQ 25MG BASE;EQ 6MG BASE	A077742	002	Nov 02, 2012	Oct	NEWA
AB			EQ 25MG BASE;EQ 12MG BASE	A077742	003	Nov 02, 2012	Oct	NEWA
AB			EQ 50MG BASE;EQ 6MG BASE	A077742	004	Nov 02, 2012	Oct	NEWA
AB			EQ 50MG BASE;EQ 12MG BASE	A077742	005	Nov 02, 2012	Oct	NEWA
AB		SANDOZ	EQ 25MG BASE;EQ 3MG BASE	A078901	005	Nov 16, 2012	Nov	NEWA
AB			EQ 25MG BASE;EQ 6MG BASE	A078901	001	Nov 16, 2012	Nov	NEWA
AB			EQ 25MG BASE;EQ 12MG BASE	A078901	003	Nov 16, 2012	Nov	NEWA

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB	SANDOZ	EQ 50MG BASE;EQ 6MG BASE	A078901 002	Nov 16, 2012	Nov	NEWA
AB		EQ 50MG BASE;EQ 12MG BASE	A078901 004	Nov 16, 2012	Nov	NEWA
AB	TEVA PHARMS	EQ 25MG BASE;EQ 6MG BASE	A077528 001	Jun 19, 2012	Jun	NEWA
AB		EQ 25MG BASE;EQ 12MG BASE	A077528 002	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE;EQ 6MG BASE	A077528 003	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE;EQ 12MG BASE	A077528 004	Jun 19, 2012	Jun	NEWA

SYMBYAX

AB	LILLY	EQ 25MG BASE;EQ 3MG BASE	N021520 001	Apr 09, 2007	Oct	CFTG
AB		EQ 25MG BASE;EQ 6MG BASE	N021520 002	Dec 24, 2003	Jun	CFTG
AB		EQ 25MG BASE;EQ 12MG BASE	N021520 004	Dec 24, 2003	Jun	CFTG
AB	+	EQ 50MG BASE;EQ 6MG BASE	N021520 003	Dec 24, 2003	Jun	CFTG
AB		EQ 50MG BASE;EQ 12MG BASE	N021520 005	Dec 24, 2003	Jun	CFTG

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+	AQUA PHARMS	0.025%	N012806 003		Aug	CRLD
		0.025%	N012806 003		Jul	CAHN
+		0.05%	N012806 002		Aug	CRLD
		0.05%	N012806 002		Jul	CAHN
	WATSON PHARMS	0.05%	N012806 002		Apr	CMFD

LOTION; TOPICAL

CORDRAN

+	AQUA PHARMS	0.05%	N013790 001		Jul	CAHN
---	-------------	-------	-------------	--	-----	------

OINTMENT; TOPICAL

CORDRAN

@	AQUA PHARMS	0.025%	N012806 004		Jul	CAHN
@		0.05%	N012806 001		Jul	CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	+	IVAX SUB TEVA PHARMS	125MG	A075780 001	Sep 19, 2001	Mar	CRLD
		@ SANDOZ	125MG	A075818 001	Sep 18, 2001	Oct	DISC
AB		SANDOZ INC	125MG	A075818 001	Sep 18, 2001	Mar	CRLD
AB		WATSON LABS INC FL	125MG	A075820 001	Sep 18, 2001	Sep	CAHN

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	0.05%	N019958 001	Dec 18, 1990	Jan	CAHN
AB		FLUTICASONE PROPIONATE					
AB		FOUGERA PHARMS	0.05%	A076451 001	May 14, 2004	Jan	CAHN
		@ NESHER PHARMS	0.05%	A076865 001	Sep 10, 2004	Jun	DISC

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB		FOUGERA PHARMS	0.005%	A076300 001	May 14, 2004	Jan	CAHN
----	--	----------------	--------	-------------	--------------	-----	------

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	EQ 20MG BASE	A090595 001	Apr 11, 2012	Mar	NEWA
AB		EQ 40MG BASE	A090595 002	Apr 11, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 20MG BASE	A078407 001	Jun 12, 2012	May	NEWA

<u>CAPSULE; ORAL</u>							
FLUVASTATIN SODIUM							
AB	TEVA PHARMS	EQ 40MG BASE	A078407	002	Jun 12, 2012	May NEWA	
LESCOL							
AB	NOVARTIS	EQ 20MG BASE	N020261	001	Dec 31, 1993	Mar CFTG	
AB	+	EQ 40MG BASE	N020261	002	Dec 31, 1993	Mar CFTG	
<u>FLUVOXAMINE MALEATE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
LUVOX CR							
	JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Jun CAHN	
	+	150MG	N022033	002	Feb 28, 2008	Jun CAHN	
<u>FOMEPIZOLE</u>							
INJECTABLE; INJECTION							
FOMEPIZOLE							
AP	MYLAN LLC	1.5GM/1.5ML (1GM/ML)	A078639	001	Mar 03, 2008	Sep CAHN	
<u>FORMOTEROL FUMARATE</u>							
SOLUTION; INHALATION							
PERFORMIST							
	+	MYLAN SPECLT	0.02MG/2ML	N022007	001	May 11, 2007	Sep CAHN
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE</u>							
AEROSOL, METERED; INHALATION							
DULERA							
	+	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010	Jun CAHN
	+		0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010	Jun CAHN
<u>FOSINOPRIL SODIUM</u>							
TABLET; ORAL							
FOSINOPRIL SODIUM							
	@	RANBAXY LABS LTD	10MG	A076580	001	Apr 23, 2004	Apr DISC
	@		20MG	A076580	002	Apr 23, 2004	Apr DISC
	@		40MG	A076580	003	Apr 23, 2004	Apr DISC
MONOPRIL							
	@	BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Mar DISC
	@		20MG	N019915	003	May 16, 1991	Mar DISC
	@		40MG	N019915	004	Mar 28, 1995	Mar DISC
<u>FOSINOPRIL; HYDROCHLOROTHIAZIDE</u>							
TABLET; ORAL							
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE							
AB	EMCURE PHARMS INDIA	10MG;12.5MG	A079025	001	Sep 17, 2010	Oct CAHN	
AB		20MG;12.5MG	A079025	002	Sep 17, 2010	Oct CAHN	
<u>FOSPHENYTOIN SODIUM</u>							
INJECTABLE; INJECTION							
FOSPHENYTOIN SODIUM							
AP	HIKMA MAPLE	EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jul CAHN	
	@	TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	Mar DISC
<u>FOSPROPOFOL DISODIUM</u>							
SOLUTION; INTRAVENOUS							
LUSEDRA							
	@	EISAI INC	1050MG/30ML (35MG/ML)	N022244	001	Dec 12, 2008	Jul DISC

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@	HIKMA MAPLE	10MG/ML	A071439 001	Sep 14, 1990	Sep	CAHN
@		10MG/ML	N018267 001		Sep	CAHN
@	HOSPIRA	10MG/ML	A070578 001	Jul 08, 1987	Jun	DISC

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

AA	ACELLA PHARMS LLC	250MG/5ML	A076403 001	May 01, 2012	Jun	CAHN
AA	AMNEAL PHARMS	250MG/5ML	A202024 001	Mar 23, 2012	Mar	NEWA
AA	KIEL	250MG/5ML	A076403 001	May 01, 2012	Apr	NEWA

TABLET; ORAL

GABAPENTIN

AB	INVAGEN PHARMS	600MG	A202764 001	Oct 16, 2012	Oct	NEWA
AB		800MG	A202764 002	Oct 16, 2012	Oct	NEWA
AB	MYLAN PHARMS INC	600MG	A090335 001	Jun 01, 2010	Sep	CAHN
AB		800MG	A090335 002	Jun 01, 2010	Sep	CAHN

GANCICLOVIR

CAPSULE; ORAL

GANCICLOVIR

@	RANBAXY LABS LTD	250MG	A076457 001	Jun 27, 2003	Apr	DISC
@		500MG	A076457 002	Jun 27, 2003	Apr	DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP	EMCURE PHARMS LTD	EQ 200MG BASE/VIAL	A202063 001	Sep 11, 2012	Aug	NEWA
AP		EQ 1GM BASE/VIAL	A202063 002	Sep 11, 2012	Aug	NEWA
AP	HAMELN RDS GMBH	EQ 200MG BASE/VIAL	A090663 001	Sep 10, 2012	Aug	NEWA
AP		EQ 1GM BASE/VIAL	A090663 002	Sep 10, 2012	Aug	NEWA
+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795 001	Aug 04, 2011	Apr	CTNA
+		1GM/26.3ML (38MG/ML)	N200795 002	Aug 04, 2011	Apr	CTNA
+		2GM/52.6ML (38MG/ML)	N200795 003	Aug 04, 2011	Apr	CTNA
AP	TEVA PHARMS	EQ 200MG BASE/VIAL	A077983 002	Jan 25, 2011	Oct	CAHN
AP		EQ 1GM BASE/VIAL	A077983 001	Jan 25, 2011	Oct	CAHN

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

@	HIKMA MAPLE	EQ 10MG BASE/ML	A062251 002		Sep	CAHN
@		EQ 40MG BASE/ML	A062251 001		Sep	CAHN

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	AUROBINDO PHARMA LTD	1MG	A202759 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A202759 002	Jun 29, 2012	Jun	NEWA
AB		4MG	A202759 003	Jun 29, 2012	Jun	NEWA
AB	MICRO LABS USA	1MG	A091220 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A091220 002	Jun 29, 2012	Jun	NEWA
		3MG	A091220 003	Jun 29, 2012	Jun	NEWA
AB		4MG	A091220 004	Jun 29, 2012	Jun	NEWA

TABLET; ORAL

GLIMEPIRIDE

		MICRO LABS USA	6MG	A091220 005	Jun 29, 2012	Jun	NEWA
AB			8MG	A091220 006	Jun 29, 2012	Jun	NEWA
		@ RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005	Apr	DISC
		@	2MG	A076875 002	Oct 06, 2005	Apr	DISC
		@	4MG	A076875 003	Oct 06, 2005	Apr	DISC
		@	8MG	A076875 004	Oct 06, 2005	Apr	DISC

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

>D>	+	TAKEDA PHARMS USA	2MG;30MG	N021925 001	Jul 28, 2006	Dec	CFTG
>A>	AB	+	2MG;30MG	N021925 001	Jul 28, 2006	Dec	CFTG
		+	2MG;30MG	N021925 001	Jul 28, 2006	Aug	CAHN
>D>			4MG;30MG	N021925 002	Jul 28, 2006	Dec	CFTG
>A>	AB		4MG;30MG	N021925 002	Jul 28, 2006	Dec	CFTG
			4MG;30MG	N021925 002	Jul 28, 2006	Aug	CAHN
>A>		PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE					
>A>	AB	SANDOZ	2MG;30MG	A201049 001	Jan 04, 2013	Dec	NEWA
>A>	AB		4MG;30MG	A201049 002	Jan 04, 2013	Dec	NEWA

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

		@ VINTAGE PHARMS LLC	5MG	A074378 001	Nov 28, 1994	Sep	CAHN
		@	10MG	A074378 002	Nov 28, 1994	Sep	CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB		HERITAGE PHARMS INC	1.25MG;250MG	A079009 001	Jun 03, 2009	Sep	CAHN
AB			2.5MG;500MG	A079009 002	Jun 03, 2009	Sep	CAHN
AB			5MG;500MG	A079009 003	Jun 03, 2009	Sep	CAHN

GLYCOPYRROLATE

SOLUTION; ORAL

CUVPOSA

	+	MERZ PHARMS	1MG/5ML	N022571 001	Jul 28, 2010	Aug	CAHN
--	---	-------------	---------	-------------	--------------	-----	------

TABLET; ORAL

GLYCOPYRROLATE

AA		EXCELLIUM	1MG	A090195 001	Sep 21, 2012	Sep	NEWA
AA			2MG	A090195 002	Sep 21, 2012	Sep	NEWA
AA		NEXGEN PHARMA	1.5MG	A091522 001	Mar 12, 2012	Feb	NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262 001	Dec 31, 2007	Mar	CAHN
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258 001	Jun 30, 2008	Mar	CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258 002	Jun 30, 2008	Mar	CAHN
AP		HIKMA MAPLE	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177 001	Dec 31, 2007	Sep	CAHN
>A>	AP	SAGENT AGILA	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A091137 002	Apr 09, 2010	Dec	CAHN
>D>	AP	SAGENT STRIDES	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A091137 002	Apr 09, 2010	Dec	CAHN

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	+	APP PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096	001	Jun 30, 2008	Apr	CRLD
		@ TEVA PARENTERAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	Apr	DISC

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB	+	VALEANT PHARM NORTH	125MG/5ML	A062483	001	Jan 26, 1984	Feb	CAHN
----	---	---------------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

GRIFULVIN V

	@	VALEANT INTL	125MG	A062279	001		Jul	CAHN
	@		250MG	A062279	002		Jul	CAHN
+			500MG	A062279	003		Jul	CAHN
	@	VALEANT LUXEMBOURG	125MG	A062279	001		Oct	CAHN
	@		250MG	A062279	002		Oct	CAHN

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRIFULVIN V

AB	+	VALEANT PHARM NORTH	125MG/5ML	A062483	001	Jan 26, 1984	Oct	CAIN
----	---	---------------------	-----------	---------	-----	--------------	-----	------

GRISEOFULVIN

AB		ACTAVIS MID ATLANTIC	125MG/5ML	A065394	001	Jul 06, 2007	Oct	CAIN
AB		IVAX SUB TEVA PHARMS	125MG/5ML	A065354	001	Sep 10, 2007	Oct	CAIN
AB		PERRIGO CO TENNESSEE	125MG/5ML	A065200	001	Mar 02, 2005	Oct	CAIN
AB		VINTAGE PHARMS	125MG/5ML	A065438	001	Oct 08, 2010	Oct	CAIN

TABLET; ORAL

GRIFULVIN V

AB	+	VALEANT LUXEMBOURG	500MG	A062279	003		Oct	CAHN
----	---	--------------------	-------	---------	-----	--	-----	------

GRISEOFULVIN

AB		SIGMAPHARM LABS LLC	500MG	A202482	001	Oct 22, 2012	Oct	NEWA
----	--	---------------------	-------	---------	-----	--------------	-----	------

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

GRISEOFULVIN, ULTRAMICROSIZE

AB		SIGMAPHARM LABS LLC	125MG	A202545	001	Oct 22, 2012	Oct	NEWA
AB			250MG	A202545	002	Oct 22, 2012	Oct	NEWA

GRIS-PEG

AB		PEDINOL	125MG	N050475	001		Oct	CTEC
AB	+		250MG	N050475	002		Oct	CTEC

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 1MG BASE	A200881	001	Oct 05, 2012	Sep	NEWA
AB			EQ 2MG BASE	A200881	002	Oct 05, 2012	Sep	NEWA
AB			EQ 3MG BASE	A200881	003	Oct 05, 2012	Sep	NEWA
AB			EQ 4MG BASE	A200881	004	Oct 05, 2012	Sep	NEWA

INTUNIV

AB		SHIRE	EQ 1MG BASE	N022037	001	Sep 02, 2009	Sep	CFTG
AB			EQ 2MG BASE	N022037	002	Sep 02, 2009	Sep	CFTG
AB			EQ 3MG BASE	N022037	003	Sep 02, 2009	Sep	CFTG
AB	+		EQ 4MG BASE	N022037	004	Sep 02, 2009	Sep	CFTG

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

GUANIDINE HYDROCHLORIDE

>A>	MERCK SHARP DOHME	125MG	N001546 001	Dec	CAHN
>D>	SCHERING	125MG	N001546 001	Dec	CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A077001 001	Dec 16, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A076903 001	Dec 16, 2004	Jan	CAHN
	@ VENUS PHARMS	0.05%	A077109 001	Jun 14, 2005	Jun	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	B BRAUN	200 UNITS/100ML	N019953 001	Jul 20, 1992	Jul	CRLD
----	---	---------	-----------------	-------------	--------------	-----	------

HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	2,000 UNITS/100ML	N018814 002	Jul 09, 1985	Mar	DISC
--	---	-----------------	-------------------	-------------	--------------	-----	------

HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	4,000 UNITS/100ML	N018814 001	Oct 31, 1983	Mar	DISC
--	---	-----------------	-------------------	-------------	--------------	-----	------

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	4,000 UNITS/100ML	N019952 001	Jul 20, 1992	Jul	CRLD
----	---	---------	-------------------	-------------	--------------	-----	------

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	5,000 UNITS/100ML	N018814 003	Jul 09, 1985	Mar	DISC
--	---	-----------------	-------------------	-------------	--------------	-----	------

@ 10,000 UNITS/100ML

				N018814 004	Jul 02, 1987	Mar	DISC
--	--	--	--	-------------	--------------	-----	------

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	5,000 UNITS/100ML	N019952 004	Jul 20, 1992	Jul	CRLD
----	---	---------	-------------------	-------------	--------------	-----	------

AP	+		10,000 UNITS/100ML	N019952 005	Jul 20, 1992	Jul	CRLD
----	---	--	--------------------	-------------	--------------	-----	------

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+	PHOTOCURE ASA	100MG/VIAL	N022555 001	May 28, 2010	May	CAHN
---	---------------	------------	-------------	--------------	-----	------

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

	@	AKORN INC	150 UNITS/ML	N021716 001	Oct 25, 2005	Jun	DISC
--	---	-----------	--------------	-------------	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AB	ALKEM LABS LTD	10MG	A200737 001	Dec 07, 2012	Nov	NEWA
AB		25MG	A200737 002	Dec 07, 2012	Nov	NEWA
AB		50MG	A200737 003	Dec 07, 2012	Nov	NEWA
AB		100MG	A200737 004	Dec 07, 2012	Nov	NEWA

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	LANNETT HOLDINGS INC	12.5MG	A091662 001	Jan 27, 2012	Jan	NEWA
----	----------------------	--------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	ACCORD HLTHCARE	12.5MG	A202556 001	Sep 24, 2012	Sep	NEWA
AB		25MG	A202556 002	Sep 24, 2012	Sep	NEWA
AB		50MG	A202556 003	Sep 24, 2012	Sep	NEWA

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

>D>	@ SANOFI AVENTIS	12.5MG;75MG	N020758 001	Sep 30, 1997	Dec	CAHN
>D>	AB +	12.5MG;150MG	N020758 002	Sep 30, 1997	Dec	CAHN
	AB +	12.5MG;150MG	N020758 002	Sep 30, 1997	Mar	CFTG
>D>	AB +	12.5MG;300MG	N020758 003	Aug 31, 1998	Dec	CAHN
	AB +	12.5MG;300MG	N020758 003	Aug 31, 1998	Mar	CFTG
	+	12.5MG;300MG	N020758 003	Aug 31, 1998	Feb	CRLD
>D>	@	25MG;300MG	N020758 004	Mar 15, 2005	Dec	CAHN
>A>	@ SANOFI AVENTIS US	12.5MG;75MG	N020758 001	Sep 30, 1997	Dec	CAHN
>A>	AB +	12.5MG;150MG	N020758 002	Sep 30, 1997	Dec	CAHN
>A>	AB +	12.5MG;300MG	N020758 003	Aug 31, 1998	Dec	CAHN
>A>	@	25MG;300MG	N020758 004	Mar 15, 2005	Dec	CAHN

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;150MG	A091370 001	Oct 15, 2012	Oct	NEWA
AB		12.5MG;300MG	A091370 002	Oct 15, 2012	Oct	NEWA
AB	APOTEX INC	12.5MG;150MG	A201505 001	Oct 15, 2012	Oct	NEWA
AB		12.5MG;300MG	A201505 002	Oct 15, 2012	Oct	NEWA
AB	DR REDDYS LABS LTD	12.5MG;150MG	A203500 001	Sep 27, 2012	Sep	NEWA
AB		12.5MG;300MG	A203500 002	Sep 27, 2012	Sep	NEWA
AB	MACLEODS PHARMS LTD	12.5MG;150MG	A202414 001	Sep 27, 2012	Sep	NEWA
AB		12.5MG;300MG	A202414 002	Sep 27, 2012	Sep	NEWA
AB	MYLAN PHARMS INC	12.5MG;150MG	A077969 001	Sep 27, 2012	Sep	NEWA
AB		12.5MG;300MG	A077969 002	Sep 27, 2012	Sep	NEWA
AB	ROXANE	12.5MG;150MG	A090351 001	Oct 15, 2012	Oct	NEWA
AB		12.5MG;300MG	A090351 002	Oct 15, 2012	Oct	NEWA
AB	SANDOZ	12.5MG;150MG	A077446 001	Sep 27, 2012	Sep	NEWA
AB		12.5MG;300MG	A077446 002	Sep 27, 2012	Sep	NEWA
AB	TEVA	12.5MG;150MG	A077369 001	Mar 30, 2012	Mar	NEWA
AB		12.5MG;300MG	A077369 002	Mar 30, 2012	Mar	NEWA
	@	25MG;300MG	A077369 003	Mar 30, 2012	Apr	DISC
		25MG;300MG	A077369 003	Mar 30, 2012	Mar	NEWA
AB	WATSON LABS INC	12.5MG;150MG	A091539 001	Oct 22, 2012	Oct	NEWA
AB		12.5MG;300MG	A091539 002	Oct 22, 2012	Oct	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;50MG	A091617 001	Feb 17, 2012	Feb	NEWA
AB		12.5MG;100MG	A091617 002	Feb 17, 2012	Feb	NEWA
AB		25MG;100MG	A091617 003	Feb 17, 2012	Feb	NEWA
AB	ALEMBIC PHARMS LTD	12.5MG;50MG	A091617 001	Feb 17, 2012	Sep	CAHN
AB		12.5MG;100MG	A091617 002	Feb 17, 2012	Sep	CAHN
AB		25MG;100MG	A091617 003	Feb 17, 2012	Sep	CAHN
AB	CADISTA PHARMS	12.5MG;50MG	A201845 001	Sep 18, 2012	Sep	NEWA
AB		12.5MG;100MG	A201845 002	Sep 18, 2012	Sep	NEWA
AB		25MG;100MG	A201845 003	Sep 18, 2012	Sep	NEWA
AB	MACLEODS PHARMS LTD	12.5MG;50MG	A202289 001	Aug 09, 2012	Jul	NEWA
AB		12.5MG;100MG	A202289 002	Aug 09, 2012	Jul	NEWA

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE					
AB	MACLEODS PHARMS LTD	25MG;100MG	A202289	003	Aug 09, 2012 Jul NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL					
	ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006 Jan CMFD
		12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006 Jan CMFD
+		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006 Apr CRLD
		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006 Jan CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT					
AB	US PHARMS HOLDINGS I	25MG;50MG	N018303	001	Dec 31, 1984 Sep CAHN
AB	+	25MG;100MG	N018303	002	Dec 31, 1984 Sep CAHN
	@	50MG;100MG	N018303	003	Dec 31, 1984 Sep CAHN
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE					
AB	MYLAN	50MG;100MG	A076792	003	Aug 20, 2004 Jan CTEC
AB	SUN PHARM INDS	25MG;50MG	A090654	001	Jan 19, 2012 Jan NEWA
AB		25MG;100MG	A090654	002	Jan 19, 2012 Jan NEWA
AB		50MG;100MG	A090654	003	Jan 19, 2012 Jan NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	@ PADDOCK LLC	12.5MG;7.5MG	A090096	001	Sep 25, 2008 Jan DISC
	@	12.5MG;15MG	A090096	002	Sep 25, 2008 Jan DISC
	@	25MG;15MG	A090096	003	Sep 25, 2008 Jan DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT					
AB	NOVARTIS	12.5MG;80MG	N020818	001	Mar 06, 1998 Sep CFTG
AB		12.5MG;160MG	N020818	002	Mar 06, 1998 Sep CFTG
AB		12.5MG;320MG	N020818	004	Apr 28, 2006 Sep CFTG
AB		25MG;160MG	N020818	003	Jan 17, 2002 Sep CFTG
AB	+	25MG;320MG	N020818	005	Apr 28, 2006 Sep CFTG
VALSARTAN AND HYDROCHLOROTHIAZIDE					
AB	MYLAN PHARMS INC	12.5MG;80MG	A078020	001	Sep 21, 2012 Sep NEWA
AB		12.5MG;160MG	A078020	002	Sep 21, 2012 Sep NEWA
AB		12.5MG;320MG	A078020	004	Sep 21, 2012 Sep NEWA
AB		25MG;160MG	A078020	003	Sep 21, 2012 Sep NEWA
AB		25MG;320MG	A078020	005	Sep 21, 2012 Sep NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYTONE					
	@ VALEANT INTL	1%	A080472	003	Sep CAHN
	@	2.5%	A080472	004	Sep CAHN
NUTRACORT					
	@ DOW PHARM	0.5%	A080442	002	Jun CAHN
	@	1%	A080442	003	Jun CAHN

LOTION; TOPICAL									
CETACORT									
	@ DOW PHARM	0.5%		A080426 002			Jun	CAHN	
	@	1%		A080426 001			Jun	CAHN	
HYDROCORTISONE									
AT	+ FOUGERA PHARMS	2.5%		A040351 001	Jul 25, 2000		Jan	CAHN	
HYTONE									
	@ VALEANT INTL	1%		A080473 003			Sep	CAHN	
	@	2.5%		A080473 004	Nov 30, 1982		Sep	CAHN	
NUTRACORT									
	@ DOW PHARM	0.5%		A080443 002			Jun	CAHN	
AT		1%		A080443 003			Jun	CAHN	
AT		2.5%		A087644 001	Aug 24, 1982		Jun	CAHN	
OINTMENT; TOPICAL									
HYDROCORTISONE									
AT	+ FOUGERA PHARMS	1%		A080692 001			Jan	CAHN	
TABLET; ORAL									
HYDROCORTISONE									
AB	AMEDRA PHARMS	5MG		A040646 001	Mar 30, 2007	Nov	CAHN		
AB		10MG		A040646 002	Mar 30, 2007	Nov	CAHN		
AB		20MG		A040646 003	Mar 30, 2007	Nov	CAHN		
<u>HYDROCORTISONE ACETATE; UREA</u>									
CREAM; TOPICAL									
CARMOL HC									
AT	FOUGERA PHARMS	1%;10%		A080505 001			Jan	CAHN	
<u>HYDROCORTISONE BUTYRATE</u>									
CREAM; TOPICAL									
LOCOID									
AB	+ PRECISION DERMAT	0.1%		N018514 001	Mar 31, 1982	Jun	CAHN		
LOCOID LIPOCREAM									
	+ PRECISION DERMAT	0.1%		N020769 001	Sep 08, 1997	Jun	CAHN		
LOTION; TOPICAL									
LOCOID									
	+ PRECISION DERMAT	0.1%		N022076 001	May 18, 2007	May	CAHN		
OINTMENT; TOPICAL									
LOCOID									
AB	+ PRECISION DERMAT	0.1%		N018652 001	Oct 29, 1982	May	CAHN		
SOLUTION; TOPICAL									
LOCOID									
AT	+ PRECISION DERMAT	0.1%		N019116 001	Feb 25, 1987	Jun	CAHN		
<u>HYDROCORTISONE VALERATE</u>									
CREAM; TOPICAL									
HYDROCORTISONE VALERATE									
AB	+ TARO	0.2%		A075042 001	Aug 25, 1998	Mar	CRLD		
WESTCORT									
	@ RANBAXY	0.2%		N017950 001		Mar	DISC		
OINTMENT; TOPICAL									
HYDROCORTISONE VALERATE									
AB	FOUGERA PHARMS	0.2%		A075085 001	Jul 31, 2001	Jan	CAHN		

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	ALCON PHARMS LTD	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423 001	Aug 25, 1983	Sep	CAHN
----	------------------	-------------------------------------	-------------	--------------	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

AB	+ SHIRE LLC	50MG	N011949 001		Jan	CAHN
----	-------------	------	-------------	--	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ NESHER PHARMS 2MG

A077311 001 Nov 09, 2005 Jun DISC

@ 4MG

A077311 002 Nov 09, 2005 Jun DISC

@ 8MG

A077311 003 Nov 09, 2005 Jun DISC

TABLET, EXTENDED RELEASE; ORAL

EXALGO

MALLINCKRODT INC 32MG

N021217 004 Aug 24, 2012 Aug NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

@ SANDOZ 200MG

A040150 001 Jan 27, 1996 Oct DISC

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

@ STI PHARMA LLC 10MG/5ML

A086880 001 Feb CAHN

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ MIKAH PHARMA 10MG

A040600 001 Dec 28, 2004 Jul CAHN

@ 25MG

A040602 001 Dec 28, 2004 Jul CAHN

@ 50MG

A040604 001 Dec 28, 2004 Jul CAHN

HYDROXYZINE PAMOATE

SUSPENSION; ORAL

VISTARIL

@ PFIZER EQ 25MG HCL/5ML

N011795 001 Jul DISC

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

AB	+ HOFFMANN LA ROCHE	EQ 150MG BASE	N021455 002	Mar 24, 2005	Mar	CFTG
----	---------------------	---------------	-------------	--------------	-----	------

IBANDRONATE SODIUM

AB	APOTEX INC	EQ 150MG BASE	A078948 001	Mar 19, 2012	Mar	NEWA
AB	DR REDDYS LABS LTD	EQ 150MG BASE	A078997 001	Apr 30, 2012	Apr	NEWA
AB	MUTUAL PHARM CO INC	EQ 150MG BASE	A078996 001	Aug 15, 2012	Jul	NEWA
AB	MYLAN PHARMS INC	EQ 150MG BASE	A078995 001	Mar 19, 2012	Mar	NEWA
AB	ORCHID HLTHCARE	EQ 150MG BASE	A078998 001	Mar 19, 2012	Mar	NEWA
AB	WATSON LABS INC	EQ 150MG BASE	A079003 001	Mar 20, 2012	Mar	NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

@ NORTHSTAR HLTHCARE	400MG	A078132 001	Sep 10, 2007	Jun	DISC
@	600MG	A078132 002	Sep 10, 2007	Jun	DISC
@	800MG	A078132 003	Sep 10, 2007	Jun	DISC
@ OHM LABS	400MG	A070818 001	Dec 26, 1985	Jun	DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903 001	Apr 13, 2006	Mar	CAHN
----------------	---------------------------------------	-------------	--------------	-----	------

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+ AMARIN PHARMA INC	1GM	N202057 001	Jul 26, 2012	Jul	NEWA
---------------------	-----	-------------	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

AP ONCO THERAPIES LTD	1MG/ML	A200144 001	Oct 11, 2012	Sep	NEWA
@ TEVA PARENTERAL	5MG/VIAL	A065037 003	May 01, 2002	Mar	DISC
@	10MG/VIAL	A065037 002	May 01, 2002	Mar	DISC
@	20MG/VIAL	A065037 001	May 01, 2002	Mar	DISC

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

AP ONCO THERAPIES LTD	1GM/20ML (50MG/ML)	A201689 001	Nov 26, 2012	Nov	NEWA
AP	3GM/60ML (50MG/ML)	A201689 002	Nov 26, 2012	Nov	NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB EXCELLIUM	10MG	A040903 001	Oct 24, 2012	Oct	NEWA
AB	25MG	A040903 002	Oct 24, 2012	Oct	NEWA
AB	50MG	A040903 003	Oct 24, 2012	Oct	NEWA
AB PROSAM LABS	10MG	A040753 001	Feb 28, 2008	Feb	CMFD
AB	25MG	A040752 001	Feb 28, 2008	Feb	CMFD
AB	50MG	A040751 001	Feb 28, 2008	Feb	CMFD

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB APOTEX INC	5%	A091308 001	Apr 06, 2012	Mar	NEWA
AB FOUGERA PHARMS	5%	A078548 001	Feb 25, 2010	Jan	CAHN
AB GLENMARK GENERICS	5%	A201994 001	Mar 06, 2012	Feb	NEWA

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

AB MYLAN PHARMS INC	1.25MG	A075105 001	Jul 23, 1998	Sep	CAHN
AB	2.5MG	A075105 002	Jul 23, 1998	Sep	CAHN

TABLET; ORAL

INDAPAMIDE

@ SANDOZ 1.25MG
@ 2.5MG

A074594 001 May 23, 1996 Oct DISC
A074594 002 May 23, 1996 Oct DISC

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB HETERO LABS LTD III 75MG

A201807 001 Sep 28, 2012 Sep NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP + LUNDBECK LLC EQ 1MG BASE/VIAL

N018878 001 Jan 30, 1985 Mar CAHN

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

LEO PHARMA AS 0.015%
+ 0.05%

N202833 001 Jan 23, 2012 Jan NEWA
N202833 002 Jan 23, 2012 Jan NEWA

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG MIX 70/30

+ NOVO NORDISK INC 700 UNITS/10ML;300 UNITS/10ML

N021172 001 Nov 01, 2001 Nov CPOT

NOVOLOG MIX 70/30 FLEXPEN

+ NOVO NORDISK INC 210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)

N021172 004 May 03, 2002 Nov NEWA

NOVOLOG MIX 70/30 PENFILL

@ NOVO NORDISK INC 210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)

N021172 003 Nov 01, 2001 Nov NEWA

@ 210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)

N021172 002 Nov 01, 2001 Nov NEWA

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

+ NOVO NORDISK INC 1000 UNITS/10ML (100 UNITS/ML)

N020986 001 Jun 07, 2000 Nov CPOT

NOVOLOG FLEXPEN

+ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N020986 003 Jan 19, 2001 Nov NEWA

NOVOLOG INNOLET

@ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N020986 004 Apr 23, 2004 Nov NEWA

NOVOLOG PENFILL

+ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N020986 002 Jun 07, 2000 Nov NEWA

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR

+ NOVO NORDISK INC 1000 UNITS/10ML (100 UNITS/ML)

N021536 001 Jun 16, 2005 Nov CPOT

LEVEMIR FLEXPEN

+ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N021536 002 Jun 16, 2005 Nov NEWA

LEVEMIR INNOLET

@ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N021536 003 Jun 16, 2005 Nov NEWA

LEVEMIR PENFILL

@ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML)

N021536 004 Jun 16, 2005 Nov NEWA

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50 PEN

@ LILLY 50 UNITS/ML;50 UNITS/ML N021018 003 Dec 22, 1999 Jun DISC

HUMALOG MIX 75/25 PEN

@ LILLY 75 UNITS/ML;25 UNITS/ML N021017 003 Dec 22, 1999 Jun DISC

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG PEN

@ LILLY 100 UNITS/ML N020563 002 Aug 06, 1998 Jun DISC

IOTHALAMATE SODIUM I-125

INJECTABLE; INJECTION

GLOFIL-125

ISOTEX 250-300uCi/ML N017279 001 Oct CMFD

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

AN TEVA PHARMS 0.02% A075313 001 Feb 07, 2000 Sep CAHN

IRBESARTAN

TABLET; ORAL

AVAPRO

AB SANOFI AVENTIS US 75MG N020757 001 Sep 30, 1997 Mar CFTG

AB 150MG N020757 002 Sep 30, 1997 Mar CFTG

AB + 300MG N020757 003 Sep 30, 1997 Mar CFTG

IRBESARTAN

AB ALEMBIC PHARMS LTD 75MG A091236 001 Oct 15, 2012 Oct NEWA

AB 150MG A091236 002 Oct 15, 2012 Oct NEWA

AB 300MG A091236 003 Oct 15, 2012 Oct NEWA

AB APOTEX INC 75MG A200832 001 Oct 15, 2012 Oct NEWA

AB 150MG A200832 002 Oct 15, 2012 Oct NEWA

AB 300MG A200832 003 Oct 15, 2012 Oct NEWA

AB AUROBINDO PHARMA LTD 75MG A203081 001 Sep 27, 2012 Sep NEWA

AB 150MG A203081 002 Sep 27, 2012 Sep NEWA

AB 300MG A203081 003 Sep 27, 2012 Sep NEWA

AB CIPLA LTD 75MG A077205 001 Nov 14, 2012 Oct NEWA

AB 150MG A077205 002 Nov 14, 2012 Oct NEWA

AB 300MG A077205 003 Nov 14, 2012 Oct NEWA

AB DR REDDYS LABS LTD 75MG A203161 001 Sep 27, 2012 Sep NEWA

AB 150MG A203161 002 Sep 27, 2012 Sep NEWA

AB 300MG A203161 003 Sep 27, 2012 Sep NEWA

AB HETERO LABS LTD V 75MG A202910 001 Sep 27, 2012 Sep NEWA

AB 150MG A202910 002 Sep 27, 2012 Sep NEWA

AB 300MG A202910 003 Sep 27, 2012 Sep NEWA

AB LUPIN LTD 75MG A201531 001 Oct 15, 2012 Oct NEWA

AB 150MG A201531 002 Oct 15, 2012 Oct NEWA

AB 300MG A201531 003 Oct 15, 2012 Oct NEWA

AB MACLEODS PHARMS LTD 75MG A202254 001 Oct 03, 2012 Sep NEWA

AB 150MG A202254 002 Oct 03, 2012 Sep NEWA

AB 300MG A202254 003 Oct 03, 2012 Sep NEWA

AB MYLAN PHARMS INC 75MG A200461 001 Sep 27, 2012 Sep NEWA

AB 150MG A200461 002 Sep 27, 2012 Sep NEWA

TABLET; ORAL

IRBESARTAN

AB	MYLAN PHARMS INC	300MG	A200461 003	Sep 27, 2012	Sep	NEWA
AB	PRINSTON INC	75MG	A203071 001	Sep 27, 2012	Sep	NEWA
AB		150MG	A203071 002	Sep 27, 2012	Sep	NEWA
AB		300MG	A203071 003	Sep 27, 2012	Sep	NEWA
AB	ROXANE	75MG	A090201 001	Oct 15, 2012	Oct	NEWA
AB		150MG	A090201 002	Oct 15, 2012	Oct	NEWA
AB		300MG	A090201 003	Oct 15, 2012	Oct	NEWA
AB	SANDOZ	75MG	A077466 001	Sep 27, 2012	Sep	NEWA
AB		150MG	A077466 002	Sep 27, 2012	Sep	NEWA
AB		300MG	A077466 003	Sep 27, 2012	Sep	NEWA
AB	TEVA PHARMS	75MG	A077159 001	Mar 30, 2012	Mar	NEWA
AB		150MG	A077159 002	Mar 30, 2012	Mar	NEWA
AB		300MG	A077159 003	Mar 30, 2012	Mar	NEWA
AB	WATSON LABS INC	75MG	A090720 001	Oct 12, 2012	Sep	NEWA
AB		150MG	A090720 002	Oct 12, 2012	Sep	NEWA
AB		300MG	A090720 003	Oct 12, 2012	Sep	NEWA
AB	ZYDUS PHARMS USA INC	75MG	A079213 001	Sep 27, 2012	Sep	NEWA
AB		150MG	A079213 002	Sep 27, 2012	Sep	NEWA
AB		300MG	A079213 003	Sep 27, 2012	Sep	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	CIPLA LTD	40MG/2ML (20MG/ML)	A077219 001	Feb 20, 2008	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A077219 002	Feb 20, 2008	Mar	CAHN
AP	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771 001	Feb 14, 2012	Jan	NEWA
AP		100MG/5ML (20MG/ML)	A200771 002	Feb 14, 2012	Jan	NEWA
AP	HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Mar	CAHN
AP	TEVA PARENTERAL	40MG/2ML (20MG/ML)	A090101 002	Feb 27, 2008	Jun	NEWA
AP		100MG/5ML (20MG/ML)	A090101 003	Feb 27, 2008	Jun	NEWA
AP		500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Jun	CMFD
	@	500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Mar	DISC

ISOFLURANE

LIQUID; INHALATION

FORANE

AN	+ BAXTER HLTHCARE	99.9%	N017624 001		Jul	CAHN
----	-------------------	-------	-------------	--	-----	------

ISOSORBIDE MONONITRATE

TABLET; ORAL

MONOKET

AB	KREMERS URBAN PHARMS	10MG	N020215 002	Jun 30, 1993	Oct	CAHN
AB	+	20MG	N020215 001	Jun 30, 1993	Oct	CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

>D>	AB	ALKERMES GAINESVILLE	60MG	A075041 001	Sep 22, 1998	Dec	DISC
>A>		@	60MG	A075041 001	Sep 22, 1998	Dec	DISC
	AB		60MG	A075041 001	Sep 22, 1998	Jun	CAHN
		@ SKYEPHARMA AG	60MG	A075166 001	Oct 07, 1999	Jan	DISC

ISOSULFAN BLUE

INJECTABLE; INJECTION
ISOSULFAN BLUE

AP MYLAN INSTITUTIONAL 1% A090874 001 Jul 20, 2010 Oct CAHN

ISOTRETINOIN

CAPSULE; ORAL
ABSORICA

BX CIPHER 10MG N021951 001 May 25, 2012 Sep CTEC
10MG N021951 001 May 25, 2012 May NEWA
BX 20MG N021951 002 May 25, 2012 Sep CTEC
20MG N021951 002 May 25, 2012 May NEWA
BX 30MG N021951 003 May 25, 2012 Sep CTEC
30MG N021951 003 May 25, 2012 May NEWA
BX 40MG N021951 004 May 25, 2012 Sep CTEC
40MG N021951 004 May 25, 2012 May NEWA

MYORISAN

AB DOUGLAS PHARMS 10MG A076485 001 Jan 19, 2012 Jan NEWA
AB 20MG A076485 002 Jan 19, 2012 Jan NEWA
AB 40MG A076485 003 Jan 19, 2012 Jan NEWA

ITRACONAZOLE

CAPSULE; ORAL
ITRACONAZOLE

AB MYLAN PHARMS INC 100MG A200463 001 Jul 20, 2012 Jul NEWA

TABLET; ORAL
ONMEL

>A> + MERZ PHARMS 200MG N022484 001 Apr 29, 2010 Dec CAHN
>D> + STIEFEL LABS INC 200MG N022484 001 Apr 29, 2010 Dec CAHN

IVACAFTOR

TABLET; ORAL
KALYDECO

+ VERTEX PHARMS 150MG N203188 001 Jan 31, 2012 Jan NEWA

IVERMECTIN

LOTION; TOPICAL
SKLICE

>D> + SANOFI PASTEUR 0.5% N202736 001 Feb 07, 2012 Dec CAHN
+ 0.5% N202736 001 Feb 07, 2012 Feb NEWA
>A> + SANOFI PASTEUR INC 0.5% N202736 001 Feb 07, 2012 Dec CAHN

TABLET; ORAL
STROMECTOL

+ MERCK SHARP DOHME 3MG N050742 002 Oct 08, 1998 Nov CAHN
@ 6MG N050742 001 Nov 22, 1996 Nov CAHN

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN

@ HIKMA MAPLE EQ 75MG BASE/2ML A062324 001 Sep CAHN
@ EQ 500MG BASE/2ML A062324 002 Sep CAHN
@ EQ 1GM BASE/3ML A062324 003 Sep CAHN

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

AB	FOUGERA PHARMS	2%	A076294 001	Apr 28, 2004	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

	DORADO PHARMA	25MG	A074014 001	Jan 29, 1993	Jul	CAHN
AB		50MG	A074014 002	Jan 29, 1993	Jul	CAHN
AB		75MG	A074014 003	Jan 29, 1993	Jul	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

	@ ALKERMES GAINESVILLE	200MG	A074879 001	Dec 10, 1997	Oct	DISC
AB		200MG	A074879 001	Dec 10, 1997	Jun	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	HIKMA MAPLE	15MG/ML	A075772 001	Jul 21, 2004	Sep	CAHN
AP		15MG/ML	A075299 001	Nov 03, 1999	Sep	CAHN
AP		30MG/ML	A075772 002	Jul 21, 2004	Sep	CAHN
AP		30MG/ML	A075299 002	Nov 03, 1999	Sep	CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	5MG/ML	A090699 001	Apr 03, 2012	Mar	NEWA
----	------------------	--------	-------------	--------------	-----	------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	PAR FORM	100MG	A200908 001	Jul 10, 2012	Jun	NEWA
AB		200MG	A200908 002	Jul 10, 2012	Jun	NEWA
AB		300MG	A200908 003	Jul 10, 2012	Jun	NEWA

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

+	CUMBERLAND PHARMS	10GM/PACKET	A074712 001	Dec 10, 1997	Jun	CAHN
+		20GM/PACKET	A074712 002	Dec 10, 1997	Jun	CAHN

SOLUTION; ORAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090503 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

SOLUTION; ORAL, RECTAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090502 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418 001	May 15, 2012	Apr	NEWA
AB	LUPIN LTD	150MG;300MG	A090246 001	May 15, 2012	Apr	NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	25MG	A090169 001	May 12, 2012	Apr	NEWA
AB		100MG	A090169 002	May 12, 2012	Apr	NEWA
AB		150MG	A090169 003	May 12, 2012	Apr	NEWA
AB		200MG	A090169 004	May 12, 2012	Apr	NEWA
BX	UPSHER SMITH	25MG	A078310 001	Feb 04, 2009	Aug	CTEC
BX		100MG	A078310 002	Feb 04, 2009	Aug	CTEC
BX		150MG	A078310 003	Feb 04, 2009	Aug	CTEC
BX		200MG	A078310 004	Feb 04, 2009	Aug	CTEC

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

>D>	SMITHKLINE BEECHAM	25MG	N022115 001	May 29, 2009	Dec	CFTG
>A>	AB	25MG	N022115 001	May 29, 2009	Dec	CFTG
>D>	+	50MG	N022115 002	May 29, 2009	Dec	CFTG
>A>	AB +	50MG	N022115 002	May 29, 2009	Dec	CFTG
>D>		100MG	N022115 003	May 29, 2009	Dec	CFTG
>A>	AB	100MG	N022115 003	May 29, 2009	Dec	CFTG
>D>		200MG	N022115 004	May 29, 2009	Dec	CFTG
>A>	AB	200MG	N022115 004	May 29, 2009	Dec	CFTG
>D>		250MG	N022115 006	Jun 21, 2011	Dec	CFTG
>A>	AB	250MG	N022115 006	Jun 21, 2011	Dec	CFTG
>D>		300MG	N022115 005	Apr 14, 2010	Dec	CFTG
>A>	AB	300MG	N022115 005	Apr 14, 2010	Dec	CFTG
>A>	LAMOTRIGINE					
>A>	AB ANCHEN PHARMS	25MG	A201374 001	Dec 26, 2012	Dec	NEWA
>A>	AB	50MG	A201374 002	Dec 26, 2012	Dec	NEWA
>A>	AB	100MG	A201374 003	Dec 26, 2012	Dec	NEWA
>A>	AB	200MG	A201374 004	Dec 26, 2012	Dec	NEWA
>A>	AB	250MG	A201374 005	Dec 26, 2012	Dec	NEWA
>A>	AB	300MG	A201374 006	Dec 26, 2012	Dec	NEWA
>A>	AB WOCKHARDT LTD	25MG	A202498 001	Jan 04, 2013	Dec	NEWA
>A>	AB	50MG	A202498 002	Jan 04, 2013	Dec	NEWA
>A>	AB	100MG	A202498 003	Jan 04, 2013	Dec	NEWA
>A>	AB	200MG	A202498 004	Jan 04, 2013	Dec	NEWA
>A>	AB	300MG	A202498 005	Jan 04, 2013	Dec	NEWA

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SOMATULINE DEPOT

+	IPSEN INC	EQ 60MG BASE	N022074 001	Aug 30, 2007	Apr	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	Apr	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	Apr	CAHN
+	IPSEN PHARMA	EQ 60MG BASE	N022074 001	Aug 30, 2007	May	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	May	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	May	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

AB	MYLAN PHARMS INC	15MG	A090763 001	Nov 10, 2009	Sep	CAHN
AB		30MG	A090763 002	Nov 10, 2009	Sep	CAHN
>A>	AB NATCO PHARMA LTD	15MG	A201921 001	Dec 18, 2012	Dec	NEWA
>A>	AB	30MG	A201921 002	Dec 18, 2012	Dec	NEWA

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

AB	WOCKHARDT USA	15MG	A202176 001	Sep 14, 2012	Aug	NEWA
AB		30MG	A202176 002	Sep 14, 2012	Aug	NEWA

PREVACID

AB	TAKEDA PHARMS USA	15MG	N020406 001	May 10, 1995	Mar	CAHN
AB	+	30MG	N020406 002	May 10, 1995	Mar	CAHN

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

	@ TEVA PHARMS	15MG	A078730 001	Oct 15, 2010	Mar	DISC
	@	30MG	A078730 002	Oct 15, 2010	Mar	DISC

PREVACID

	TAKEDA PHARMS USA	15MG	N021428 001	Aug 30, 2002	Mar	CTEC
+		30MG	N021428 002	Aug 30, 2002	Mar	CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

	@ SHIRE LLC	EQ 250MG BASE	N021468 001	Oct 26, 2004	Feb	CAHN
		EQ 500MG BASE	N021468 002	Oct 26, 2004	Feb	CAHN
		EQ 750MG BASE	N021468 003	Nov 23, 2005	Feb	CAHN
+		EQ 1GM BASE	N021468 004	Nov 23, 2005	Feb	CAHN

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT	AKORN	0.005%	A090887 001	Jul 19, 2011	Sep	CAHN
----	-------	--------	-------------	--------------	-----	------

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

	CELGENE	15MG	N021880 003	Jun 29, 2006	Sep	CRLD
--	---------	------	-------------	--------------	-----	------

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	APOTEX INC	2.5MG	A091303 001	Apr 19, 2012	Apr	NEWA
AB	VINTAGE PHARMS LLC	2.5MG	A090789 001	Jun 03, 2011	Sep	CAHN

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

	@ TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278 001	Sep 28, 1993	Mar	DISC
--	-------------------	-------------------	-------------	--------------	-----	------

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	SAGENT PHARMS	EQ 50MG BASE/VIAL	A200753 001	Sep 06, 2012	Aug	NEWA
AP		EQ 100MG BASE/VIAL	A200753 002	Sep 06, 2012	Aug	NEWA
AP		EQ 200MG BASE/VIAL	A200753 003	Sep 06, 2012	Aug	NEWA
AP		EQ 350MG BASE/VIAL	A200855 001	Sep 06, 2012	Aug	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

+	ABBOTT ENDOCRINE	3.75MG/VIAL	N020011 001	Oct 22, 1990	May	CAHN
+		7.5MG/VIAL	N019732 001	Jan 26, 1989	May	CAHN
+		11.25MG/VIAL	N020708 001	Mar 07, 1997	May	CAHN

>A> LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

>A> INJECTABLE, TABLET; INJECTION, ORAL

>A> LUPANETA PACK

>A> ABBVIE ENDOCRINE 3.75MG/VIAL,N/A;N/A,5MG N203696 001 Dec 14, 2012 Dec NEWA

>A> + 11.25MG/VIAL,N/A;N/A,5MG N203696 002 Dec 14, 2012 Dec NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP APP PHARMS LLC 500MG/5ML (100MG/ML) A090813 001 May 26, 2010 May CAHN

AP HOSPIRA INC 500MG/ML (100MG/ML) A202869 001 Apr 06, 2012 Mar NEWA

AP LUITPOLD 500MG/5ML (100MG/ML) A202143 001 Jan 31, 2012 Aug CAHN

AP PHARMAFORCE 500MG/5ML (100MG/ML) A202143 001 Jan 31, 2012 Jan NEWA

AP X GEN PHARMS 500MG/5ML (100MG/ML) A091485 001 Aug 05, 2011 Jul CAHN

SOLUTION; ORAL

LEVETIRACETAM

AA HI-TECH PHARMACAL 100MG/ML A090601 001 Feb 28, 2012 Feb NEWA

AA VINTAGE PHARMS 100MG/ML A090079 001 Apr 11, 2012 Mar NEWA

TABLET; ORAL

LEVETIRACETAM

AB LOTUS PHARM CO LTD 500MG A090906 001 Nov 05, 2010 Jul CAHN

AB WATSON LABS INC 250MG A078797 002 Jan 15, 2009 Apr NEWA

AB 500MG A078797 003 Jan 15, 2009 Apr NEWA

AB 750MG A078797 004 Jan 15, 2009 Apr NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB BOCA PHARMA 500MG A201464 001 May 25, 2012 May NEWA

AB 750MG A201464 002 May 25, 2012 May NEWA

AB ROUSES POINT PHARMS 500MG A202524 001 Aug 27, 2012 Aug NEWA

AB 750MG A202524 002 Aug 27, 2012 Aug NEWA

AB SANDOZ 500MG A091668 001 Nov 01, 2012 Oct NEWA

AB 750MG A091668 002 Nov 01, 2012 Oct NEWA

AB TORRENT PHARMS LTD 500MG A091338 001 May 29, 2012 May NEWA

AB 750MG A091338 002 May 29, 2012 May NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB HETERO LABS LTD III 5MG A091264 001 Jun 29, 2012 Jun NEWA

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

AB CIPLA LTD 250MG A076890 001 Mar 30, 2012 Mar NEWA

AB 500MG A076890 002 Mar 30, 2012 Mar NEWA

AB 750MG A076890 003 Mar 30, 2012 Mar NEWA

AB MACLEODS PHARMS LTD 250MG A200839 001 Mar 22, 2012 Mar NEWA

AB 500MG A200839 002 Mar 22, 2012 Mar NEWA

AB 750MG A200839 003 Mar 22, 2012 Mar NEWA

AB ORCHID HLTHCARE 250MG A202200 001 Jan 30, 2012 Jan NEWA

AB 500MG A202200 002 Jan 30, 2012 Jan NEWA

AB 750MG A202200 003 Jan 30, 2012 Jan NEWA

AB ZYDUS PHARMS USA INC 250MG A077652 001 Sep 07, 2012 Aug NEWA

AB 500MG A077652 002 Sep 07, 2012 Aug NEWA

AB 750MG A077652 003 Sep 07, 2012 Aug NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

FUSILEV

@ SPECTRUM PHARMS

EQ 250MG BASE/25ML (EQ 10MG
BASE/ML)

N020140 003 Apr 29, 2011 Jun DISC

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

AB WATSON LABS INC

1.5MG

A200670 001 Jul 12, 2012 Jun NEWA

PLAN B

AB + @ TEVA BRANDED PHARM

0.75MG

N021045 001 Jul 28, 1999 May CAHN

AB + 0.75MG

N021045 002 Aug 24, 2006 May CAHN

PLAN B ONE-STEP

AB + DURAMED

1.5MG

N021998 001 Jul 10, 2009 Jun CFTG

LIDOCAINE

PATCH; TOPICAL

LIDOCAINE

AB WATSON LABS INC

5%

A200675 001 Aug 23, 2012 Aug NEWA

LIDODERM

AB + TEIKOKU PHARMA USA

5%

N020612 001 Mar 19, 1999 Aug CFTG

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

@ HIKMA MAPLE

1%

A080407 001 Sep CAHN

@

2%

A080407 002 Sep CAHN

AP PFIZER

0.5%

A091056 001 Dec 08, 2010 Sep CAHN

AP 0.5%

A091058 001 Sep 30, 2010 Sep CAHN

AP 1%

A091058 002 Sep 30, 2010 Sep CAHN

AP 1%

A091056 002 Dec 08, 2010 Sep CAHN

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

@ HIKMA MAPLE

1%

A084625 001 Sep CAHN

@

2%

A084625 002 Sep CAHN

AP PFIZER

2%

A090665 001 Sep 27, 2010 Sep CAHN

XYLOCAINE DENTAL

@ DENTSPLY PHARM

2%

N021380 001 May DISC

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB FOUGERA PHARMS

2.5%;2.5%

A076453 001 Aug 18, 2003 Jan CAHN

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+ GALDERMA LABS LP

7%;7%

N021717 001 Jun 29, 2006 Jun CTNA

LINACLOTIDE

CAPSULE; ORAL

LINZESS

FOREST LABS INC

145MCG

N202811 001 Aug 30, 2012 Aug NEWA

+ 290MCG

N202811 002 Aug 30, 2012 Aug NEWA

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

	BOEHRINGER INGELHEIM	2.5MG;500MG	N201281 001	Jan 30, 2012	Jan	NEWA
		2.5MG;850MG	N201281 002	Jan 30, 2012	Jan	NEWA
+		2.5MG;1GM	N201281 003	Jan 30, 2012	Jan	NEWA

LINEZOLID

INJECTABLE; INJECTION

LINEZOLID

AP	TEVA PHARMS	200MG/100ML	A200222 001	Jun 22, 2012	Jun	NEWA
AP	+ PHARMACIA AND UPJOHN	200MG/100ML	N021131 001	Apr 18, 2000	Jun	CFTG

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

AB	SIGMAPHARM LABS LLC	EQ 0.005MG BASE	A200295 001	Nov 29, 2012	Nov	NEWA
AB		EQ 0.025MG BASE	A200295 002	Nov 29, 2012	Nov	NEWA
AB		EQ 0.05MG BASE	A200295 003	Nov 29, 2012	Nov	NEWA

LISINOPRIL

TABLET; ORAL

LISINOPRIL

>D>	AB	LEK PHARMS	2.5MG	A075999 001	Jul 01, 2002	Dec	DISC
>A>		@	2.5MG	A075999 001	Jul 01, 2002	Dec	DISC
>D>	AB		5MG	A075999 002	Jul 01, 2002	Dec	DISC
>A>		@	5MG	A075999 002	Jul 01, 2002	Dec	DISC
>D>	AB		10MG	A075999 003	Jul 01, 2002	Dec	DISC
>A>		@	10MG	A075999 003	Jul 01, 2002	Dec	DISC
>D>	AB		20MG	A075999 004	Jul 01, 2002	Dec	DISC
>A>		@	20MG	A075999 004	Jul 01, 2002	Dec	DISC
>D>	AB		30MG	A075999 005	Jul 01, 2002	Dec	DISC
>A>		@	30MG	A075999 005	Jul 01, 2002	Dec	DISC
>D>	AB		40MG	A075999 006	Jul 01, 2002	Dec	DISC
>A>		@	40MG	A075999 006	Jul 01, 2002	Dec	DISC

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	MYLAN PHARMS INC	300MG	A202288 001	Jun 29, 2012	Jun	NEWA
AB		450MG	A202219 001	Aug 08, 2012	Jul	NEWA

>A> LOMITAPIDE MESYLATE

>A> CAPSULE; ORAL

>A> JUXTAPID

>A>		AEGERION	EQ 5MG BASE	N203858 001	Dec 21, 2012	Dec	NEWA
>A>			EQ 10MG BASE	N203858 002	Dec 21, 2012	Dec	NEWA
>A>	+		EQ 20MG BASE	N203858 003	Dec 21, 2012	Dec	NEWA

LOMUSTINE

CAPSULE; ORAL

CEENU

BRISTOL MYERS SQUIBB

@

10MG

10MG

N017588 001

N017588 001

Jun CMFD

May DISC

CAPSULE; ORAL

	CEENU							
	BRISTOL MYERS SQUIBB	40MG		N017588	002		Jun	CMFD
	@	40MG		N017588	002		May	DISC
	+	100MG		N017588	003		Jun	CMFD
	@	100MG		N017588	003		May	DISC

LORAZEPAM

CONCENTRATE; ORAL

	LORAZEPAM							
AA	HI-TECH PHARMA CO	2MG/ML		A200169	001	Jan 30, 2012	Jan	NEWA

INJECTABLE; INJECTION

	LORAZEPAM							
	@ BEDFORD	2MG/ML		A077076	001	Jul 13, 2005	Jun	DISC
	@	4MG/ML		A077076	002	Jul 13, 2005	Jun	DISC
	@ HIKMA MAPLE	2MG/ML		A074496	001	Sep 28, 1998	Sep	CAHN
	@	4MG/ML		A074496	002	Sep 28, 1998	Sep	CAHN
	@ HOSPIRA	2MG/ML		A074300	001	Apr 12, 1994	Jun	DISC

TABLET; ORAL

	LORAZEPAM							
AB	SANDOZ	0.5MG		A071403	001	Apr 21, 1987	Nov	CAHN
AB		1MG		A071404	001	Apr 21, 1987	Nov	CAHN
AB		2MG		A071141	001	Apr 21, 1987	Nov	CAHN

LORCASERIN HYDROCHLORIDE

TABLET; ORAL

BELVIQ

	ARENA PHARMS INC	10MG		N022529	001	Jun 27, 2012	Jun	NEWA
	EISAI INC	10MG		N022529	001	Jun 27, 2012	Jul	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	CADISTA PHARMS	25MG		A201170	001	Sep 18, 2012	Sep	NEWA
AB		50MG		A201170	002	Sep 18, 2012	Sep	NEWA
AB		100MG		A201170	003	Sep 18, 2012	Sep	NEWA
AB	MACLEODS PHARMS LTD	25MG		A202230	001	May 30, 2012	May	NEWA
AB		50MG		A202230	002	May 30, 2012	May	NEWA
AB		100MG		A202230	003	May 30, 2012	May	NEWA
AB	MICRO LABS LTD INDIA	25MG		A091541	001	Sep 24, 2012	Sep	NEWA
AB		50MG		A091541	002	Sep 24, 2012	Sep	NEWA
AB		100MG		A091541	003	Sep 24, 2012	Sep	NEWA

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX

	BAUSCH AND LOMB	0.5%		N202872	001	Sep 28, 2012	Sep	NEWA
--	-----------------	------	--	---------	-----	--------------	-----	------

LOXAPINE

>A>	POWDER; INHALATION							
>A>	ADASUVE							
>A>	+ ALEXZA PHARMS	10MG		N022549	001	Dec 21, 2012	Dec	NEWA

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

@ MIKAH PHARMA	EQ 5MG BASE	A076868 001	Aug 04, 2005	Jul	CAHN
@	EQ 10MG BASE	A076868 002	Aug 04, 2005	Jul	CAHN
@	EQ 25MG BASE	A076868 003	Aug 04, 2005	Jul	CAHN
@	EQ 50MG BASE	A076868 004	Aug 04, 2005	Jul	CAHN

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

+ DISCOVERY LABS	8.5ML	N021746 001	Mar 06, 2012	Apr	NEWA
------------------	-------	-------------	--------------	-----	------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

SUNOVION PHARMS INC	20MG	N200603 003	Dec 07, 2011	Oct	CRLD
+	20MG	N200603 003	Dec 07, 2011	Aug	CRLD
	20MG	N200603 003	Dec 07, 2011	Apr	NEWA
+	40MG	N200603 001	Oct 28, 2010	Oct	CRLD
	40MG	N200603 001	Oct 28, 2010	Aug	CRLD
+	40MG	N200603 001	Oct 28, 2010	Apr	CRLD
	80MG	N200603 002	Oct 28, 2010	Apr	CRLD
	120MG	N200603 004	Apr 26, 2012	Apr	NEWA

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

@ EMD SERONO	75 IU/VIAL	N021322 001	Oct 08, 2004	Jun	DISC
--------------	------------	-------------	--------------	-----	------

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLON

+ MYLAN LLC	EQ 85MG BASE/GM	N016763 001		Jun	CAHN
-------------	-----------------	-------------	--	-----	------

FOR SOLUTION; TOPICAL

SULFAMYLON

+ MYLAN LLC	5%	N019832 003	Jun 05, 1998	Jun	CAHN
-------------	----	-------------	--------------	-----	------

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

@ SANTARUS	343MG;20MG;750MG	N022456 001	Dec 04, 2009	Jun	DISC
@	343MG;40MG;750MG	N022456 002	Dec 04, 2009	Jun	DISC

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

HOSPIRA	20GM/500ML (40MG/ML)	N020309 004	Jan 18, 1995	Jan	NEWA
	40GM/1000ML(40MG/ML)	N020309 005	Jan 18, 1995	Jan	NEWA

MALATHION

LOTION; TOPICAL

MALATHION

AT	MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009	Feb	CAHN
AT	SUVEN LIFE	0.5%	A091559 001	May 23, 2012	May	NEWA

MANNITOL

POWDER; INHALATION

ARIDOL KIT

+	PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010	May	CAHN
---	---------------	----------------------------	---------	-----	--------------	-----	------

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+	IPSEN INC	40MG/4ML (10MG/ML)	N021839	001	Aug 30, 2005	May	CAHN
---	-----------	--------------------	---------	-----	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	12.5MG	A200294	001	Apr 13, 2012	Mar	NEWA
AA		25MG	A200294	002	Apr 13, 2012	Mar	NEWA
AA	MYLAN PHARMS INC	12.5MG	A202640	001	Sep 17, 2012	Sep	NEWA
AA		25MG	A202640	002	Sep 17, 2012	Sep	NEWA
AA		50MG	A202640	003	Sep 17, 2012	Sep	NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

@	TEVA PARENTERAL	150MG/ML	A076552	001	Oct 27, 2004	Apr	DISC
---	-----------------	----------	---------	-----	--------------	-----	------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090270	001	Jun 09, 2009	Sep	CAHN
----	---------------------	-------------------	---------	-----	--------------	-----	------

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

	@ ORCHID HLTHCARE	5MG	A090044	001	Mar 12, 2012	Mar	DISC
AB		5MG	A090044	001	Mar 12, 2012	Feb	NEWA
	@	10MG	A090044	002	Mar 12, 2012	Mar	DISC
AB		10MG	A090044	002	Mar 12, 2012	Feb	NEWA
	NAMENDA						
	FOREST LABS	5MG	N021487	001	Oct 16, 2003	Mar	CTEC
AB		5MG	N021487	001	Oct 16, 2003	Feb	CTEC
	+	10MG	N021487	002	Oct 16, 2003	Mar	CTEC
AB	+	10MG	N021487	002	Oct 16, 2003	Feb	CTEC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

AP	HIKMA MAPLE	25MG/ML	A080455	007		Sep	CAHN
AP		25MG/ML	A080445	001		Sep	CAHN
AP		50MG/ML	A080445	002		Sep	CAHN
AP		50MG/ML	A080455	008		Sep	CAHN
AP		75MG/ML	A080455	009		Sep	CAHN
AP		75MG/ML	A080445	003		Sep	CAHN
AP		100MG/ML	A080455	010		Sep	CAHN
AP		100MG/ML	A080445	004		Sep	CAHN
	MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE						
AP	HIKMA MAPLE	10MG/ML	A081002	001	Jul 30, 1993	Sep	CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

@ DENTSPLY PHARM 3%

A088653 001 Aug 21, 1984 May DISC

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

@ AQUA PHARMS 2%;0.01%

N020922 001 Dec 10, 1999 Jun DISC

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

@ APTALIS PHARMA US 500MG

N021252 001 Jan 05, 2001 Jul CAHN

1GM

N021252 002 Nov 05, 2004 Jul CAHN

ROWASA

@ MEDA PHARMS 500MG

N019919 001 Dec 18, 1990 Jan CAHN

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP MYLAN INSTITUTIONAL 100MG/ML

A076488 001 Mar 08, 2012 Feb NEWA

AP SAGENT AGILA 100MG/ML

A090913 001 Apr 13, 2010 Oct CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB MARKSANS PHARMA 500MG

A090888 001 Mar 12, 2012 Feb NEWA

AB 850MG

A090888 002 Mar 12, 2012 Feb NEWA

AB 1GM

A090888 003 Mar 12, 2012 Feb NEWA

AB MYLAN PHARMS INC 500MG

A075969 001 Jan 29, 2002 Sep CAHN

AB 850MG

A075969 002 Jan 29, 2002 Sep CAHN

AB 1GM

A075969 003 Jan 29, 2002 Sep CAHN

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1 AUROBINDO PHARMA LTD 500MG

A079118 001 Jul 20, 2012 Jul NEWA

AB 750MG

A079118 002 Jul 20, 2012 Jul NEWA

AB1 INVENTIA HLTHCARE 500MG

A201991 001 Jan 18, 2012 Jan NEWA

AB2 MYLAN PHARMS INC 500MG

A200690 001 Aug 01, 2012 Jul NEWA

AB 1GM

A200690 002 Aug 01, 2012 Jul NEWA

AB1 NOSTRUM PHARMS LLC 500MG

A076756 001 Jul 26, 2006 Oct CAHN

AB 750MG

A076756 002 Dec 12, 2011 Nov NEWA

@ RANBAXY LABS LTD 500MG

A076413 001 Jun 18, 2004 Apr DISC

@ 750MG

A077211 001 Jun 29, 2005 Apr DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB TAKEDA PHARMS USA 500MG;EQ 15MG BASE

N021842 001 Aug 29, 2005 Aug CAHN

AB + 850MG;EQ 15MG BASE

N021842 002 Aug 29, 2005 Aug CAHN

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

TAKEDA PHARMS USA 1GM;EQ 15MG BASE

N022024 001 May 12, 2009 Aug CAHN

+ 1GM;EQ 30MG BASE

N022024 002 May 12, 2009 Aug CAHN

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	BRISTOL MYERS SQUIBB	500MG;EQ 5MG BASE	N200678 001	Nov 05, 2010	Apr	CAIN
		1GM;EQ 2.5MG BASE	N200678 003	Nov 05, 2010	Apr	CAIN
+		1GM;EQ 5MG BASE	N200678 002	Nov 05, 2010	Apr	CAIN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044 001	Mar 30, 2007	May	CAHN
+		1GM;EQ 50MG BASE	N022044 002	Mar 30, 2007	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270 001	Feb 02, 2012	Feb	NEWA
		1GM;EQ 50MG BASE	N202270 002	Feb 02, 2012	Feb	NEWA
+		1GM;EQ 100MG BASE	N202270 003	Feb 02, 2012	Feb	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	BOCA PHARMA	5MG	A202068 001	Mar 07, 2012	Feb	NEWA
AB		10MG	A202068 002	Mar 07, 2012	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	SOLCO HLTHCARE	500MG	A086989 001		Mar	CMFD
AA		750MG	A086988 001		Mar	CMFD

ROBAXIN

>A>	AA	+	ACTIENT PHARMS	500MG	N011011 004	Dec	CAHN
>D>	AA	+	SCHWARZ PHARMA	500MG	N011011 004	Dec	CAHN

ROBAXIN-750

>A>	AA	+	ACTIENT PHARMS	750MG	N011011 006	Dec	CAHN
>D>	AA	+	SCHWARZ PHARMA	750MG	N011011 006	Dec	CAHN

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

>A>	+	JHP PHARMS	200MG/VIAL	N011559 004	Dec 21, 2012	Dec	NEWA
-----	---	------------	------------	-------------	--------------	-----	------

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266 001	Feb 26, 1999	Jan	CMFD
AP	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171 001	Feb 27, 2012	Feb	NEWA

METHOTREXATE SODIUM

AP	+	BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341 001	Sep 16, 1986	Feb	CTEC
----	---	---------	-------------------------------------	-------------	--------------	-----	------

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+	MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767 001	Apr 30, 2007	Feb	CAHN
AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040768 001	Apr 30, 2007	Sep	CAHN
AP	+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A040716 001	Apr 30, 2007	Sep	CAHN

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529 001	Mar 29, 2012	Mar	NEWA
AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529 002	Mar 29, 2012	Mar	NEWA
AP		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529 003	Mar 29, 2012	Mar	NEWA
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529 004	Mar 29, 2012	Mar	NEWA
AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530 001	Mar 29, 2012	Mar	NEWA

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

AA	BAYSHORE PHARMS LLC	2.5MG	A200602 001	Sep 24, 2012	Sep	NEWA
AA		5MG	A200602 002	Sep 24, 2012	Sep	NEWA

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

@ ABBOTT LABS PHARM 2.5MG

N012524 001 Mar DISC

@ 5MG

N012524 004 Mar DISC

METHYCLOTHIAZIDE

AB	+ MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982	Mar	CRLD
----	--------------------	-----	-------------	--------------	-----	------

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@ TEVA PARENTERAL 50MG/ML

A072974 001 Nov 22, 1991 Mar DISC

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

AP	+ US PHARMS HOLDINGS I	0.2MG/ML	N006035 004		Sep	CAHN
----	------------------------	----------	-------------	--	-----	------

TABLET; ORAL

METHERGINE

AB	+ US PHARMS HOLDINGS I	0.2MG	N006035 003		Sep	CAHN
----	------------------------	-------	-------------	--	-----	------

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

SALIX PHARMS 8MG/0.4ML

N021964 002 Sep 27, 2010 May CAHN

+ 12MG/0.6ML (12MG/0.6ML)

N021964 003 Apr 24, 2008 Jun NEWA

SOLUTION; SUBCUTANEOUS

RELISTOR

+ SALIX PHARMS 12MG/0.6ML (12MG/0.6ML)

N021964 001 Apr 24, 2008 May CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

AB	UCB INC	10MG	N021259 003	May 27, 2003	Jul	CFTG
AB2		20MG	N021259 001	Apr 03, 2001	Jul	CFTG
AB2		30MG	N021259 002	Jun 19, 2003	Jul	CFTG
AB2		40MG	N021259 004	Feb 19, 2006	Jul	CFTG
AB		50MG	N021259 005	Feb 19, 2006	Jul	CFTG
AB	+	60MG	N021259 006	Feb 19, 2006	Jul	CFTG

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB1	ACTAVIS	20MG	A078458 001	Dec 01, 2011	Jul	CTEC
AB1		30MG	A078458 002	Dec 01, 2011	Jul	CTEC
AB1		40MG	A078458 003	Dec 01, 2011	Jul	CTEC
AB1	BARR LABS INC	20MG	A079031 001	Jul 13, 2012	Jul	CTEC
AB		20MG	A079031 001	Jul 13, 2012	Jun	NEWA
AB1		30MG	A079031 002	Jul 13, 2012	Jul	CTEC
AB		30MG	A079031 002	Jul 13, 2012	Jun	NEWA
AB1		40MG	A079031 003	Jul 13, 2012	Jul	CTEC
AB		40MG	A079031 003	Jul 13, 2012	Jun	NEWA
AB	TEVA PHARMS	10MG	A077707 001	Jul 19, 2012	Jul	NEWA
AB2		20MG	A077707 002	Jul 19, 2012	Jul	NEWA
AB2		30MG	A077707 003	Jul 19, 2012	Jul	NEWA
AB2		40MG	A078873 001	Jul 19, 2012	Jul	NEWA
AB		50MG	A078873 002	Jul 19, 2012	Jul	NEWA
AB		60MG	A078873 003	Jul 19, 2012	Jul	NEWA

RITALIN LA

AB1	NOVARTIS	20MG	N021284 001	Jun 05, 2002	Jul	CTEC
AB1		30MG	N021284 002	Jun 05, 2002	Jul	CTEC
AB1 +		40MG	N021284 003	Jun 05, 2002	Jul	CTEC

FOR SUSPENSION, EXTENDED RELEASE; ORAL

QUILLIVANT XR

+	NEXTWAVE PHARMS	5MG/ML	N202100 001	Sep 27, 2012	Sep	NEWA
---	-----------------	--------	-------------	--------------	-----	------

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS INC	5MG	A090710 001	Mar 15, 2012	Feb	NEWA
AB		10MG	A090710 002	Mar 15, 2012	Feb	NEWA
AB		20MG	A090710 003	Mar 15, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

>D>	JANSSEN PHARMS	27MG	N021121 004	Apr 01, 2002	Dec	CFTG
>A>	AB	27MG	N021121 004	Apr 01, 2002	Dec	CFTG
>D>		36MG	N021121 002	Aug 01, 2000	Dec	CFTG
>A>	AB	36MG	N021121 002	Aug 01, 2000	Dec	CFTG
>D>	+	54MG	N021121 003	Dec 08, 2000	Dec	CFTG
>A>	AB +	54MG	N021121 003	Dec 08, 2000	Dec	CFTG

METADATE ER

@ UCB INC

>A>		10MG	A040306 001	Oct 20, 1999	Jul	DISC	
>A>	METHYLPHENIDATE HYDROCHLORIDE						
>A>	AB	MALLINCKRODT INC	27MG	A202608 001	Dec 28, 2012	Dec	NEWA
>A>	AB		36MG	A202608 002	Dec 28, 2012	Dec	NEWA
>A>	AB		54MG	A202608 003	Dec 28, 2012	Dec	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	HOSPIRA INC	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008	Aug	CAHN
AP		EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008	Aug	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

@ BEDFORD LABS

		EQ 40MG BASE/VIAL	A040662 001	Feb 21, 2007	Jun	DISC
	@	EQ 125MG BASE/VIAL	A040641 002	Feb 21, 2007	Jun	DISC
	@	EQ 500MG BASE/VIAL	A040709 001	Feb 21, 2007	Jun	DISC
	@	EQ 500MG BASE/VIAL	A040641 003	Feb 21, 2007	Jun	DISC
	@	EQ 1GM BASE/VIAL	A040641 004	Feb 21, 2007	Jun	DISC
	@	EQ 1GM BASE/VIAL	A040709 002	Feb 21, 2007	Jun	DISC

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

@ TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992	Mar	DISC
-------------------	--------------------	---------	-----	--------------	-----	------

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

AP	TEVA PARENTERAL	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Nov	CMFD
	@	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Jan	DISC

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB	PAR PHARM INC	EQ 10MG BASE	A070581	001	Oct 17, 1985	Oct	CAHN
----	---------------	--------------	---------	-----	--------------	-----	------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	DR REDDYS LABS LTD	EQ 25MG TARTRATE	A090617	001	Aug 01, 2012	Jul	NEWA
AB		EQ 50MG TARTRATE	A090617	002	Aug 01, 2012	Jul	NEWA
	@ NESHER PHARMS	EQ 100MG TARTRATE	A076640	002	May 18, 2007	Jun	DISC
	@	EQ 200MG TARTRATE	A076640	001	May 18, 2007	Jun	DISC
AB	REDDYS	EQ 100MG BASE	A078889	001	Aug 15, 2012	Jul	NEWA
AB		EQ 200MG BASE	A078889	002	Aug 15, 2012	Jul	NEWA
	@ SANDOZ	EQ 25MG TARTRATE	A076969	001	Jul 31, 2006	Aug	DISC
	@	EQ 50MG TARTRATE	A076969	002	May 18, 2007	Aug	DISC
	@	EQ 100MG TARTRATE	A076969	003	Mar 20, 2008	Aug	DISC
	@	EQ 200MG TARTRATE	A076969	004	Mar 20, 2008	Aug	DISC

METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR

AB	US PHARMS HOLDINGS I	50MG	N017963	001		Sep	CAHN
AB		100MG	N017963	002		Sep	CAHN

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A076408	001	May 28, 2004	Jan	CAHN
	NORITATE						
+	VALEANT BERMUDA	1%	N020743	001	Sep 26, 1997	Nov	CAHN
+	VALEANT INTL	1%	N020743	001	Sep 26, 1997	Apr	CAHN

GEL; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A077018	001	Jun 06, 2006	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

METRONIDAZOLE

@ HIKMA MAPLE	500MG/100ML	N018907	001	Mar 30, 1984	Sep	CAHN
---------------	-------------	---------	-----	--------------	-----	------

LOTION; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A077197	001	May 24, 2006	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

METYRAPONE

CAPSULE; ORAL

METOPIRONE

+	HRA PHARMA	250MG	N012911	002	Aug 09, 1996	Jun	CAHN
---	------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

METOPIRONE

@ HRA PHARMA

250MG

N012911 001

Jun CAHN

METYROSINE

CAPSULE; ORAL

DEMSEER

+ BIOVAIL TECHNOLOGIES 250MG

N017871 001

May CAHN

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+ VESTIQ PHARMS 50MG

N022404 001 Apr 16, 2010 Sep CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696 001	Feb 29, 2012	Feb	NEWA
AP		EQ 5MG BASE/ML	A090850 001	Jan 25, 2012	Jan	NEWA
AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075243 001	Jun 20, 2000	Sep	CAHN
AP		EQ 1MG BASE/ML	A075324 001	Jun 20, 2000	Sep	CAHN
AP		EQ 5MG BASE/ML	A075243 002	Jun 20, 2000	Sep	CAHN
AP		EQ 5MG BASE/ML	A075324 002	Jun 20, 2000	Sep	CAHN

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

>D>	AB	MYLAN	5MG	A076577 002	Sep 10, 2003	Dec	CRLD
>A>	AB	+ MYLAN PHARMS INC	5MG	A076577 002	Sep 10, 2003	Dec	CRLD
		PROAMATINE					
		@ SHIRE LLC	2.5MG	N019815 001	Sep 06, 1996	Nov	NEWA
	AB		2.5MG	N019815 001	Sep 06, 1996	Jan	CAHN
		@	5MG	N019815 002	Sep 06, 1996	Nov	DISC
	AB	+	5MG	N019815 002	Sep 06, 1996	Jan	CAHN
		@	10MG	N019815 003	Mar 20, 2002	Nov	NEWA
	AB		10MG	N019815 003	Mar 20, 2002	Jan	CAHN

MIFEPRISTONE

TABLET; ORAL

KORLYM

+ CORCEPT THERAP 300MG

N202107 001 Feb 17, 2012 Feb NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075530 001	May 28, 2002	Sep	CAHN	
	@	EQ 1MG BASE/ML	A075852 001	May 28, 2002	Sep	CAHN	
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@	HIKMA MAPLE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510 001	May 28, 2002	Sep	CAHN

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB	PRECISION DERMAT	EQ 50MG BASE	N050649 001	May 31, 1990	May	CAHN
	@	EQ 75MG BASE	N050649 003	Feb 12, 2001	May	CAHN

CAPSULE; ORAL						
MINOCIN						
AB	PRECISION DERMAT	EQ 100MG BASE	N050649	002	May 31, 1990	May CAHN
CAPSULE, EXTENDED RELEASE; ORAL						
XIMINO						
	RANBAXY LABS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Jul NEWA
		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Jul NEWA
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Jul NEWA
		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Jul NEWA
+		EQ 135MG BASE	N201922	005	Jul 11, 2012	Jul NEWA
INJECTABLE; INJECTION						
MINOCIN						
+	PRECISION DERMAT	EQ 100MG BASE/VIAL	N050444	001		May CAHN
+	REMPEX PHARMS INC	EQ 100MG BASE/VIAL	N050444	001		Nov CAHN
SUSPENSION; ORAL						
MINOCIN						
	@ PRECISION DERMAT	EQ 50MG BASE/5ML	N050445	001		May CAHN
TABLET, EXTENDED RELEASE; ORAL						
MINOCYCLINE HYDROCHLORIDE						
AB	AUROBINDO PHARMA LTD	EQ 45MG BASE	A202261	001	Nov 19, 2012	Nov NEWA
AB		EQ 90MG BASE	A202261	003	Nov 19, 2012	Nov NEWA
AB		EQ 135MG BASE	A202261	005	Nov 19, 2012	Nov NEWA
AB	BARR LABS INC	EQ 65MG BASE	A065485	004	May 18, 2012	Sep NEWA
AB		EQ 115MG BASE	A065485	005	May 18, 2012	Sep NEWA
AB	MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010	Sep CAHN
AB		EQ 90MG BASE	A090911	002	Jul 20, 2010	Sep CAHN
AB		EQ 135MG BASE	A090911	003	Jul 20, 2010	Sep CAHN
SOLODYN						
AB	MEDICIS	EQ 65MG BASE	N050808	004	Jul 23, 2009	Sep CFTG
AB		EQ 115MG BASE	N050808	005	Jul 23, 2009	Sep CFTG
<u>MIRABEGRON</u>						
TABLET, EXTENDED RELEASE; ORAL						
MYRBETRIQ						
	APGDI	25MG	N202611	001	Jun 28, 2012	Jun NEWA
+		50MG	N202611	002	Jun 28, 2012	Jun NEWA
<u>MIRTAZAPINE</u>						
TABLET; ORAL						
MIRTAZAPINE						
AB	MYLAN PHARMS INC	15MG	A076176	001	Jun 19, 2003	Sep CAHN
AB		30MG	A076176	002	Jun 19, 2003	Sep CAHN
AB		45MG	A076176	003	Jun 19, 2003	Sep CAHN
<u>MISOPROSTOL</u>						
TABLET; ORAL						
MISOPROSTOL						
AB	NOVEL LABS INC	0.1MG	A091667	001	Jul 25, 2012	Jul NEWA
AB		0.2MG	A091667	002	Jul 25, 2012	Jul NEWA
<u>MITOMYCIN</u>						
FOR SOLUTION; TOPICAL						
MITOSOL						
+	MOBIUS THERAP	0.2MG/VIAL	N022572	001	Feb 07, 2012	Feb NEWA

INJECTABLE; INJECTION

MITOMYCIN

AP	HIKMA MAPLE	5MG/VIAL	A064180 001	Dec 23, 1999	Sep	CAHN
AP		20MG/VIAL	A064180 002	Dec 23, 1999	Sep	CAHN

MITOXANTRONE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP	ONCO THERAPIES LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014 001	Dec 11, 2012	Nov	NEWA
----	--------------------	---------------------------------------	-------------	--------------	-----	------

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

@	FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008	Jun	DISC
---	----------------------	---------------------------------------	-------------	--------------	-----	------

@		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008	Jun	DISC
---	--	---	-------------	--------------	-----	------

@		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008	Jun	DISC
---	--	---------------------------------------	-------------	--------------	-----	------

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

@	STRIDES ARCOLAB LTD	EQ 2MG BASE/ML	A078562 001	Apr 30, 2009	Jun	CAHN
---	---------------------	----------------	-------------	--------------	-----	------

MODAFINIL

TABLET; ORAL

MODAFINIL

AB	ALEMBIC LTD	100MG	A202700 001	Oct 18, 2012	Oct	NEWA
AB		200MG	A202700 002	Oct 18, 2012	Oct	NEWA
AB	AUROBINDO PHARMA LTD	100MG	A202566 001	Sep 27, 2012	Sep	NEWA
AB		200MG	A202566 002	Sep 27, 2012	Sep	NEWA
AB	CARLSBAD	100MG	A076715 001	Nov 01, 2012	Oct	NEWA
AB		200MG	A076715 002	Nov 01, 2012	Oct	NEWA
AB	HIKMA PHARMS	100MG	A090543 001	Sep 26, 2012	Sep	NEWA
AB		200MG	A090543 002	Sep 26, 2012	Sep	NEWA
AB	MYLAN PHARMS INC	100MG	A076594 001	Jul 16, 2012	Jun	NEWA
AB		200MG	A076594 002	Jul 16, 2012	Jun	NEWA
AB	ORCHID HLTHCARE	100MG	A078963 001	Sep 26, 2012	Sep	NEWA
AB		200MG	A078963 002	Sep 26, 2012	Sep	NEWA

PROVIGIL

AB	CEPHALON	100MG	N020717 001	Dec 24, 1998	Jun	CFTG
AB	+	200MG	N020717 002	Dec 24, 1998	Jun	CFTG

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

AB	+	MERCK SHARP DOHME	0.1%	N019625 001	May 06, 1987	Jun	CAHN
AB		MOMETASONE FUROATE					
AB		FOUGERA PHARMS	0.1%	A076171 001	Apr 08, 2005	Jan	CAHN

LOTION; TOPICAL

ELOCON

AB	+	MERCK SHARP DOHME	0.1%	N019796 001	Mar 30, 1989	Jul	CAHN
AB		MOMETASONE FUROATE					
AB		FOUGERA PHARMS	0.1%	A075919 001	Nov 29, 2007	Jan	CAHN

OINTMENT; TOPICAL

ELOCON

AB	+	MERCK SHARP DOHME	0.1%	N019543	001	Apr 30, 1987	May	CAHN
		MOMETASONE FUROATE						
AB		FOUGERA PHARMS	0.1%	A077061	001	Mar 28, 2005	Jan	CAHN

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

AB		DR REDDYS LABS LTD	EQ 4MG BASE/PACKET	A202906	001	Sep 17, 2012	Sep	NEWA
>A>		MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012	Dec	NEWA
AB		TEVA PHARMS	EQ 4MG BASE/PACKET	A090955	001	Aug 03, 2012	Jul	NEWA

SINGULAIR

AB	+	MERCK	EQ 4MG BASE/PACKET	N021409	001	Jul 26, 2002	Jul	CFTG
----	---	-------	--------------------	---------	-----	--------------	-----	------

TABLET; ORAL

MONTELUKAST SODIUM

AB		ACCORD HLTHCARE	EQ 10MG BASE	A202717	001	Sep 21, 2012	Sep	NEWA
AB		APOTEX CORP	EQ 10MG BASE	A201294	001	Aug 03, 2012	Jul	NEWA
AB		AUROBINDO PHARMA LTD	EQ 10MG BASE	A202468	001	Aug 03, 2012	Jul	NEWA
AB		DR REDDYS LABS LTD	EQ 10MG BASE	A201582	001	Aug 06, 2012	Jul	NEWA
AB		ENDO PHARMS	EQ 10MG BASE	A091576	001	Aug 03, 2012	Jul	NEWA
AB		GLENMARK GENERICS	EQ 10MG BASE	A090926	001	Aug 03, 2012	Jul	NEWA
AB		KUDCO IRELAND	EQ 10MG BASE	A201522	001	Aug 03, 2012	Jul	NEWA
AB		MYLAN PHARMS INC	EQ 10MG BASE	A079103	001	Aug 03, 2012	Jul	NEWA
AB		ROXANE	EQ 10MG BASE	A090655	001	Aug 03, 2012	Jul	NEWA
AB		SANDOZ INC	EQ 10MG BASE	A200889	001	Aug 03, 2012	Jul	NEWA
AB		TEVA PHARMS	EQ 10MG BASE	A078605	001	Aug 03, 2012	Jul	NEWA
AB		TORRENT PHARMS LTD	EQ 10MG BASE	A201515	001	Aug 03, 2012	Jul	NEWA
AB		VINTAGE PHARMS LLC	EQ 10MG BASE	A091576	001	Aug 03, 2012	Oct	CAHN

SINGULAIR

AB	+	MERCK	EQ 10MG BASE	N020829	002	Feb 20, 1998	Jul	CFTG
----	---	-------	--------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB		APOTEX INC	EQ 4MG BASE	A201508	001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A201508	002	Aug 03, 2012	Jul	NEWA
AB		AUROBINDO PHARMA LTD	EQ 4MG BASE	A202096	001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A202096	002	Aug 03, 2012	Jul	NEWA
AB		DR REDDYS LABS LTD	EQ 4MG BASE	A201581	001	Aug 06, 2012	Jul	NEWA
AB			EQ 5MG BASE	A201581	002	Aug 06, 2012	Jul	NEWA
AB		ENDO PHARMS	EQ 4MG BASE	A091588	001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A091588	002	Aug 03, 2012	Jul	NEWA
AB		KUDCO IRELAND	EQ 4MG BASE	A200405	001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A200405	002	Aug 03, 2012	Jul	NEWA
AB		MYLAN PHARMS INC	EQ 4MG BASE	A079142	001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A079142	002	Aug 03, 2012	Jul	NEWA
AB		ROXANE	EQ 4MG BASE	A091128	001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A091128	002	Aug 03, 2012	Jul	NEWA
AB		SANDOZ INC	EQ 4MG BASE	A091414	001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A091414	002	Aug 03, 2012	Jul	NEWA
AB		TEVA PHARMS	EQ 4MG BASE	A078723	001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A078723	002	Aug 03, 2012	Jul	NEWA
AB		TORRENT PHARMS LTD	EQ 4MG BASE	A090984	001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A090984	002	Aug 03, 2012	Jul	NEWA
AB		VINTAGE PHARMS LLC	EQ 4MG BASE	A091588	001	Aug 03, 2012	Oct	CAHN
AB			EQ 5MG BASE	A091588	002	Aug 03, 2012	Oct	CAHN

TABLET, CHEWABLE; ORAL

SINGULAIR

AB	MERCK	EQ 4MG BASE	N020830 002	Mar 03, 2000	Jul	CFTG
AB	+	EQ 5MG BASE	N020830 001	Feb 20, 1998	Jul	CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

>A>	AB2	KING PFIZER	30MG	N021260 001	Mar 20, 2002	Dec	CTEC
>A>	AB2		45MG	N021260 005	Dec 18, 2008	Dec	CFTG
>A>	AB2		60MG	N021260 002	Mar 20, 2002	Dec	CTEC
>A>	AB2		75MG	N021260 006	Dec 18, 2008	Dec	CFTG
>A>	AB2		90MG	N021260 003	Mar 20, 2002	Dec	CFTG
>A>	AB2	+	120MG	N021260 004	Mar 20, 2002	Dec	CFTG
>D>	BX	KING PHARMS	30MG	N021260 001	Mar 20, 2002	Dec	CTEC
>D>			45MG	N021260 005	Dec 18, 2008	Dec	CFTG
>D>	BX		60MG	N021260 002	Mar 20, 2002	Dec	CTEC
>D>			75MG	N021260 006	Dec 18, 2008	Dec	CFTG
>D>			90MG	N021260 003	Mar 20, 2002	Dec	CFTG
>D>		+	120MG	N021260 004	Mar 20, 2002	Dec	CFTG

KADIAN

>D>	AB	ACTAVIS ELIZABETH	20MG	N020616 001	Jul 03, 1996	Dec	CTEC
>A>	AB1		20MG	N020616 001	Jul 03, 1996	Dec	CTEC
>D>	AB		30MG	N020616 004	Mar 09, 2001	Dec	CTEC
>A>	AB1		30MG	N020616 004	Mar 09, 2001	Dec	CTEC
			40MG	N020616 009	Jul 09, 2012	Jul	NEWA
>D>	AB		50MG	N020616 002	Jul 03, 1996	Dec	CTEC
>A>	AB1		50MG	N020616 002	Jul 03, 1996	Dec	CTEC
>D>	AB		60MG	N020616 005	Mar 09, 2001	Dec	CTEC
>A>	AB1		60MG	N020616 005	Mar 09, 2001	Dec	CTEC
			70MG	N020616 010	Jul 09, 2012	Jul	NEWA
>D>	AB		80MG	N020616 006	Oct 27, 2006	Dec	CTEC
>A>	AB1		80MG	N020616 006	Oct 27, 2006	Dec	CTEC
>D>	AB	+	100MG	N020616 003	Jul 03, 1996	Dec	CTEC
>A>	AB1	+	100MG	N020616 003	Jul 03, 1996	Dec	CTEC
			130MG	N020616 011	Jul 09, 2012	Jul	NEWA
			150MG	N020616 012	Jul 09, 2012	Jul	NEWA

MORPHINE SULFATE

>A>	AB2	ACTAVIS ELIZABETH	30MG	A079040 001	Jan 16, 2013	Dec	NEWA
>A>	AB2		45MG	A079040 002	Jan 16, 2013	Dec	NEWA
>A>	AB2		60MG	A079040 003	Jan 16, 2013	Dec	NEWA
>A>	AB2		75MG	A079040 004	Jan 16, 2013	Dec	NEWA
>A>	AB2		90MG	A079040 005	Jan 16, 2013	Dec	NEWA
>A>	AB2		120MG	A079040 006	Jan 16, 2013	Dec	NEWA
	AB	PAR PHARM INC	20MG	A200812 001	Nov 10, 2011	Nov	CAHN
	AB		30MG	A200812 002	Nov 10, 2011	Nov	CAHN
	AB		50MG	A200812 003	Nov 10, 2011	Nov	CAHN
	AB		60MG	A200812 004	Nov 10, 2011	Nov	CAHN
	AB		80MG	A200812 005	Nov 10, 2011	Nov	CAHN
	AB		100MG	A200812 006	Nov 10, 2011	Nov	CAHN

INJECTABLE; INJECTION

DURAMORPH PF

AP	+	HIKMA MAPLE	0.5MG/ML	N018565 001	Sep 18, 1984	Jun	CAHN
AP	+		1MG/ML	N018565 002	Sep 18, 1984	Jun	CAHN

INFUMORPH

+		HIKMA MAPLE	10MG/ML	N018565 003	Jul 19, 1991	Jun	CAHN
---	--	-------------	---------	-------------	--------------	-----	------

INJECTABLE; INJECTION						
INFUMORPH						
	+	HIKMA MAPLE	25MG/ML	N018565 004	Jul 19, 1991	Jun CAHN
INJECTABLE, LIPOSOMAL; EPIDURAL						
DEPODUR						
	@	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May CAHN
	@		15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May CAHN
	@		20MG/2ML (10MG/ML)	N021671 003	May 18, 2004	May CAHN
SOLUTION; ORAL						
MORPHINE SULFATE						
AA		PADDOCK LLC	100MG/5ML	A201574 001	Aug 06, 2012	Jul NEWA
TABLET, EXTENDED RELEASE; ORAL						
MORPHINE SULFATE						
AB		RANBAXY LABS LTD	15MG	A078761 001	May 11, 2012	Apr NEWA
AB			30MG	A078761 002	May 11, 2012	Apr NEWA
AB			60MG	A078761 003	May 11, 2012	Apr NEWA
AB			100MG	A078761 004	May 11, 2012	Apr NEWA
AB			200MG	A078761 005	May 11, 2012	Apr NEWA
AB		VINTAGE PHARMS LLC	15MG	A075295 001	Oct 28, 1998	Sep CAHN
AB			30MG	A075295 002	Oct 28, 1998	Sep CAHN
AB			60MG	A075295 003	Oct 28, 1998	Sep CAHN
AB			100MG	A075295 004	Sep 15, 2000	Sep CAHN
AB			200MG	A075295 005	Sep 15, 2000	Sep CAHN
ORAMORPH SR						
	@	XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994	May DISC
	@		30MG	N019977 001	Aug 15, 1991	May DISC
	@		60MG	N019977 002	Aug 15, 1991	May DISC
	@		100MG	N019977 003	Aug 15, 1991	May DISC
<u>MUPIROCIN</u>						
OINTMENT; TOPICAL						
MUPIROCIN						
AB		FOUGERA PHARMS	2%	A065192 001	Nov 30, 2005	Jan CAHN
<u>MYCOPHENOLATE MOFETIL</u>						
CAPSULE; ORAL						
MYCOPHENOLATE MOFETIL						
AB		VINTAGE PHARMS LLC	250MG	A090111 001	Dec 22, 2009	Sep CAHN
	@	ZYDUS PHARMS USA INC	250MG	A065433 001	May 04, 2009	Sep DISC
TABLET; ORAL						
MYCOPHENOLATE MOFETIL						
AB		VINTAGE PHARMS LLC	500MG	A090606 001	Jul 16, 2010	Sep CAHN
	@	ZYDUS PHARMS USA INC	500MG	A065477 001	May 04, 2009	Sep DISC
<u>MYCOPHENOLIC ACID</u>						
TABLET, DELAYED RELEASE; ORAL						
MYCOPHENOLIC ACID						
AB		APOTEX INC	180MG	A091558 001	Aug 21, 2012	Aug NEWA
MYFORTIC						
AB		NOVARTIS	180MG	N050791 001	Feb 27, 2004	Aug CFTG
<u>NABUMETONE</u>						
TABLET; ORAL						
NABUMETONE						
AB		MYLAN PHARMS INC	500MG	A090516 001	Jul 12, 2010	Sep CAHN
AB			750MG	A090516 002	Jul 12, 2010	Sep CAHN

TABLET; ORAL

NABUMETONE

AB	PROSAM LABS	500MG	A079093 001	Feb 27, 2009	Feb	CMFD
AB		750MG	A079093 002	Feb 27, 2009	Feb	CMFD

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP	ANTIBIOTICE	EQ 1GM BASE	A090560 001	Oct 03, 2011	Aug	CAHN
AP		EQ 2GM BASE	A090560 002	Oct 03, 2011	Aug	CAHN
AP	ASTRAL PHARM INDS	EQ 1GM BASE/VIAL	A090582 001	Aug 24, 2012	Aug	NEWA
AP		EQ 2GM BASE/VIAL	A090582 002	Aug 24, 2012	Aug	NEWA
AP		EQ 10GM BASE/VIAL	A090580 001	Aug 24, 2012	Aug	NEWA
>A>	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A091613 001	Dec 26, 2012	Dec	NEWA
>A>		EQ 2GM BASE/VIAL	A091613 002	Dec 26, 2012	Dec	NEWA
>A>		EQ 10GM BASE/VIAL	A091614 001	Dec 26, 2012	Dec	NEWA
AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A090582 001	Aug 24, 2012	Nov	CAHN
AP		EQ 2GM BASE/VIAL	A090582 002	Aug 24, 2012	Nov	CAHN
AP		EQ 10GM BASE/VIAL	A090580 001	Aug 24, 2012	Nov	CAHN

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+	MERZ PHARMS	2%	N019599 002	Jan 13, 2012	Jan	NEWA
---	-------------	----	-------------	--------------	-----	------

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@	HIKMA MAPLE	0.4MG/ML	A070299 001	Sep 24, 1986	Jun	CAHN
@		0.4MG/ML	A070496 001	Sep 24, 1986	Jun	CAHN
@		0.4MG/ML	A070298 001	Sep 24, 1986	Jun	CAHN

NALOXONE HYDROCHLORIDE

@	HIKMA MAPLE	0.02MG/ML	A071272 001	May 24, 1988	Jun	CAHN
@		1MG/ML	A071273 001	May 24, 1988	Jun	CAHN
@		1MG/ML	A071274 001	May 24, 1988	Jun	CAHN
@		1MG/ML	A071287 001	May 24, 1988	Jun	CAHN

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	50MG	A090356 001	Feb 24, 2012	Feb	NEWA
----	-------------------	------	-------------	--------------	-----	------

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

AB	MYLAN PHARMS INC	375MG	A075390 001	Apr 19, 2001	Sep	CAHN
AB		500MG	A075390 002	Apr 19, 2001	Sep	CAHN

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

AB	HOFFMANN LA ROCHE	EQ 250MG BASE	N018164 001		May	CAHN	
AB	+	HOFFMANN LA ROCHE	EQ 500MG BASE	N018164 003	Sep 30, 1987	May	CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

+	SMITHKLINE BEECHAM	500MG;EQ 85MG BASE	N021926 001	Apr 15, 2008	May	CAHN
---	--------------------	--------------------	-------------	--------------	-----	------

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	MYLAN PHARMS INC	EQ 1MG BASE	A202431 001	May 31, 2012	May	NEWA
AB		EQ 2.5MG BASE	A202431 002	May 31, 2012	May	NEWA
AB	ORCHID HLTHCARE	EQ 1MG BASE	A091441 001	Apr 30, 2012	Apr	NEWA
AB		EQ 2.5MG BASE	A091441 002	Apr 30, 2012	Apr	NEWA

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

@	TEVA PHARMS	60MG	A077467 001	Sep 09, 2009	Jul	DISC
@		120MG	A077467 002	Sep 09, 2009	Jul	DISC

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALOCRIL

AT	+	ALLERGAN	2%	N021009 001	Dec 08, 1999	Aug	CFTG
AT		NEDOCROMIL SODIUM					
AT		AKORN	2%	A090638 001	Aug 22, 2012	Aug	NEWA

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

NEPAFENAC

+	ALCON RES LTD	0.3%	N203491 001	Oct 16, 2012	Oct	NEWA
---	---------------	------	-------------	--------------	-----	------

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

AA		AUROBINDO	50MG/5ML	A077702 001	May 22, 2012	May	NEWA
AA	+	BOEHRINGER INGELHEIM	50MG/5ML	N020933 001	Sep 11, 1998	May	CFTG

TABLET; ORAL

NEVIRAPINE

AB		APOTEX INC	200MG	A203021 001	May 22, 2012	May	NEWA
AB		AUROBINDO	200MG	A077521 001	May 22, 2012	May	NEWA
AB		CIPLA	200MG	A077956 001	May 22, 2012	May	NEWA
AB		HETERO LABS LTD III	200MG	A078584 001	May 22, 2012	May	NEWA
AB		MICRO LABS LTD	200MG	A203080 001	May 22, 2012	May	NEWA
AB		MYLAN LABS	200MG	A078864 001	May 22, 2012	May	NEWA
AB		MYLAN PHARMS INC	200MG	A202523 001	May 22, 2012	May	NEWA
AB		PRINSTON INC	200MG	A078644 001	May 22, 2012	May	NEWA
AB		SCIEGEN PHARMS INC	200MG	A203176 001	May 22, 2012	May	NEWA
AB		STRIDES	200MG	A078195 001	May 22, 2012	May	NEWA
AB	+	BOEHRINGER INGELHEIM	200MG	N020636 001	Jun 21, 1996	May	CFTG
AB		VIRAMUNE					
AB		VIRAMUNE XR					
		BOEHRINGER INGELHEIM	100MG	N201152 002	Nov 08, 2012	Nov	NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

>D>	AB1	ACTAVIS	30MG	A077899 001	Dec 13, 2006	Dec	CAHN
>D>	AB1		60MG	A077899 002	Dec 13, 2006	Dec	CAHN
>D>	AB1		90MG	A077899 003	May 25, 2012	Dec	CAHN
	AB1		90MG	A077899 003	May 25, 2012	May	NEWA
>A>	AB1	PAR PHARM	30MG	A077899 001	Dec 13, 2006	Dec	CAHN
>A>	AB1		60MG	A077899 002	Dec 13, 2006	Dec	CAHN
>A>	AB1		90MG	A077899 003	May 25, 2012	Dec	CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

AB		ALMATICA	25MG	N016620 003		Jul	CAHN
AB			50MG	N016620 001		Jul	CAHN
AB	+		100MG	N016620 002		Jul	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB	+	ALMATICA	75MG;25MG	N020064 001	Dec 24, 1991	Jul	CAHN
		NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)					
		@ RANBAXY LABS LTD	75MG;25MG	A076951 001	Mar 30, 2005	Apr	DISC

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

AB1		MEDICIS	0.1MG/HR	A089771 001	Aug 30, 1996	Jul	CAHN
AB1			0.2MG/HR	A089772 001	Aug 30, 1996	Jul	CAHN
AB1			0.4MG/HR	A089773 001	Aug 30, 1996	Jul	CAHN
AB1			0.6MG/HR	A089774 001	Aug 30, 1996	Jul	CAHN
		NITROGLYCERIN					
AB2		HERCON PHARM	0.2MG/HR	A089884 001	Oct 30, 1998	Oct	CAHN
AB2			0.4MG/HR	A089885 001	Oct 30, 1998	Oct	CAHN
AB2			0.6MG/HR	A089886 001	Oct 30, 1998	Oct	CAHN

OINTMENT; INTRA-ANAL

RECTIV

+		APTALIS PHARMA	0.4%	N021359 001	Jun 21, 2011	Jan	CAHN
---	--	----------------	------	-------------	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

AXID

@ SMITHKLINE BEECHAM

@ 150MG

N019508 001 Apr 12, 1988 Mar DISC

NIZATIDINE

@ MYLAN PHARMS INC

@ 150MG

A075934 001 Jul 09, 2002 Apr DISC

@ 300MG

A075934 002 Jul 09, 2002 Apr DISC

AB + 300MG

A075806 002 Jul 05, 2002 Apr CRLD

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP		CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A040859 001	Mar 27, 2012	May	CAHN
AP		SINETICA	EQ 1MG BASE/ML	A040859 001	Mar 27, 2012	Mar	NEWA

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE

AB	AMNEAL PHARMS	5MG	A200275 001	Jul 30, 2012	Jul	NEWA
----	---------------	-----	-------------	--------------	-----	------

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT	FOUGERA PHARMS	100,000 UNITS/GM	A062129 001		Jan	CAHN
----	----------------	------------------	-------------	--	-----	------

AT	+ TARO	100,000 UNITS/GM	A064022 001	Jan 29, 1993	Aug	CRLD
----	--------	------------------	-------------	--------------	-----	------

OINTMENT; TOPICAL

NYSTATIN

AT	+ FOUGERA PHARMS	100,000 UNITS/GM	A062124 002	Sep 23, 1982	Jan	CAHN
----	------------------	------------------	-------------	--------------	-----	------

POWDER; TOPICAL

NYSTATIN

>A>	AT	GAVIS PHARMS	100,000 UNITS/GM	A065138 001	Jul 23, 2004	Dec	CAHN
-----	----	--------------	------------------	-------------	--------------	-----	------

		@ NESHER PHARMS	100,000 UNITS/GM	A065321 001	Aug 18, 2006	Jun	DISC
--	--	-----------------	------------------	-------------	--------------	-----	------

>D>	AT	PAR PHARM	100,000 UNITS/GM	A065138 001	Jul 23, 2004	Dec	CAHN
-----	----	-----------	------------------	-------------	--------------	-----	------

TABLET; ORAL

NYSTATIN

AA	HERITAGE PHARMS INC	500,000 UNITS	A062474 001	Dec 22, 1983	Oct	CMFD
----	---------------------	---------------	-------------	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

	@ G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367 001	May 28, 1985	Jun	CAHN
--	--------------------	-----------------------	-------------	--------------	-----	------

OINTMENT; TOPICAL

MYKACET

	@ G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733 001	Mar 09, 1987	Jun	CAHN
--	--------------------	-----------------------	-------------	--------------	-----	------

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

	@ SANDOZ	0.3%	A076848 001	Nov 25, 2008	Aug	DISC
--	----------	------	-------------	--------------	-----	------

TABLET; ORAL

OFLOXACIN

	@ RANBAXY LABS LTD	200MG	A076220 001	Sep 02, 2003	Apr	DISC
--	--------------------	-------	-------------	--------------	-----	------

	@	300MG	A076220 002	Sep 02, 2003	Apr	DISC
--	---	-------	-------------	--------------	-----	------

	@	400MG	A076220 003	Sep 02, 2003	Apr	DISC
--	---	-------	-------------	--------------	-----	------

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

AP	LUITPOLD	10MG/VIAL	A201741 001	Mar 20, 2012	Sep	CAHN
----	----------	-----------	-------------	--------------	-----	------

AP	PHARMAFORCE	10MG/VIAL	A201741 001	Mar 20, 2012	Mar	NEWA
----	-------------	-----------	-------------	--------------	-----	------

AP	SANDOZ INC	10MG/VIAL	A201588 001	Oct 24, 2011	Mar	CAHN
----	------------	-----------	-------------	--------------	-----	------

TABLET; ORAL

OLANZAPINE

AB	APOTEX INC	2.5MG	A090798 001	Apr 23, 2012	Apr	NEWA
----	------------	-------	-------------	--------------	-----	------

AB		5MG	A090798 002	Apr 23, 2012	Apr	NEWA
----	--	-----	-------------	--------------	-----	------

AB		7.5MG	A090798 003	Apr 23, 2012	Apr	NEWA
----	--	-------	-------------	--------------	-----	------

AB		10MG	A090798 004	Apr 23, 2012	Apr	NEWA
----	--	------	-------------	--------------	-----	------

AB		15MG	A090798 005	Apr 23, 2012	Apr	NEWA
----	--	------	-------------	--------------	-----	------

AB		20MG	A090798 006	Apr 23, 2012	Apr	NEWA
----	--	------	-------------	--------------	-----	------

AB	AUROBINDO PHARMA LTD	2.5MG	A202050 001	Apr 23, 2012	Apr	NEWA
----	----------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

OLANZAPINE

AB	AUROBINDO PHARMA LTD	5MG	A202050 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A202050 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A202050 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A202050 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A202050 006	Apr 23, 2012	Apr	NEWA
AB	DR REDDYS LABS LTD	2.5MG	A076255 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A076255 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A076255 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A076255 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A076133 001	Apr 23, 2012	Apr	NEWA
AB	MYLAN	2.5MG	A076866 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A076866 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A076866 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A076866 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A076866 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A076866 006	Apr 23, 2012	Apr	NEWA
AB	ORCHID HLTHCARE	2.5MG	A202287 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A202287 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A202287 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A202287 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A202287 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A202287 006	Apr 23, 2012	Apr	NEWA
AB	SUN PHARM INDS	2.5MG	A091038 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A091038 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091038 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091038 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091038 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091038 006	Apr 23, 2012	Apr	NEWA
AB	TORRENT PHARMS LTD	2.5MG	A091434 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A091434 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091434 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091434 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091434 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091434 006	Apr 23, 2012	Apr	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	BARR LABS INC	5MG	A077243 001	Jan 30, 2012	Jan	NEWA
AB		10MG	A077243 002	Jan 30, 2012	Jan	NEWA
AB		15MG	A077243 003	Jan 30, 2012	Jan	NEWA
AB		20MG	A077243 004	Jan 30, 2012	Jan	NEWA
AB	JUBILANT ORGANOSYS	5MG	A200221 001	Sep 12, 2012	Aug	NEWA
AB		10MG	A200221 002	Sep 12, 2012	Aug	NEWA
AB		15MG	A200221 003	Sep 12, 2012	Aug	NEWA
AB		20MG	A200221 004	Sep 12, 2012	Aug	NEWA
AB	SUN PHARM INDS	5MG	A090881 001	Feb 28, 2012	Feb	NEWA
AB		10MG	A090881 002	Feb 28, 2012	Feb	NEWA
AB		15MG	A090881 003	Feb 28, 2012	Feb	NEWA
AB		20MG	A090881 004	Feb 28, 2012	Feb	NEWA

OMACETAXINE MEPESUCCINATE

POWDER; SUBCUTANEOUS

SYNRIBO

+	IVAX INTL	3.5MG/VIAL	N203585 001	Oct 26, 2012	Oct	NEWA
---	-----------	------------	-------------	--------------	-----	------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	DR REDDYS LABS LTD	10MG	A078490 002	Mar 16, 2009	Apr	NEWA
AB		20MG	A078490 003	Mar 16, 2009	Apr	NEWA
AB	SANDOZ	10MG	A075757 001	Jan 28, 2003	Aug	CAHN
AB		20MG	A075757 002	Jan 28, 2003	Aug	CAHN
AB	ZYDUS PHARMS USA INC	10MG	A091352 001	Nov 19, 2012	Nov	NEWA
AB		20MG	A091352 002	Nov 19, 2012	Nov	NEWA
AB		40MG	A091352 003	Nov 19, 2012	Nov	NEWA

ONDANSETRON

FILM; ORAL

ZUPLENZ

	VESTIQ PHARMS	4MG	N022524 001	Jul 02, 2010	Sep	CAHN
+		8MG	N022524 002	Jul 02, 2010	Sep	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

@	NESHER PHARMS	4MG	A077717 001	Jun 25, 2007	Jun	DISC
@		8MG	A077717 002	Jun 25, 2007	Jun	DISC
@	PAR PHARM	4MG	A076506 001	Dec 26, 2006	Aug	DISC
@		8MG	A076506 002	Dec 26, 2006	Aug	DISC
@		16MG	A077406 001	Dec 26, 2006	Aug	DISC
@		24MG	A077406 002	Dec 26, 2006	Aug	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

>A>	AP	AUROBINDO PHARMA LTD	EQ 2MG BASE/ML	A202599 001	Dec 21, 2012	Dec	NEWA
	AP	GLAND PHARMA LTD	EQ 2MG BASE/ML	A090648 001	Jun 15, 2012	Jun	NEWA
	AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077365 001	Dec 26, 2006	Jun	CAHN
	@	SAGENT PHARMS	EQ 2MG BASE/ML	A078180 001	Mar 26, 2007	Aug	DISC
		ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER					
>D>	AP	TEVA PHARMS	EQ 0.64MG BASE/ML	A077480 001	Nov 22, 2006	Dec	DISC
>A>	@		EQ 0.64MG BASE/ML	A077480 001	Nov 22, 2006	Dec	DISC
		ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER					
	@	BAXTER HLTHCARE	EQ 0.64MG BASE/ML	N021915 002	Dec 27, 2006	Sep	DISC
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
>A>	AP	AUROBINDO PHARMA LTD	EQ 2MG BASE/ML	A202600 001	Dec 21, 2012	Dec	NEWA
>A>	AP	EMCURE PHARMS LTD	EQ 2MG BASE/ML	A078945 001	Jan 03, 2013	Dec	NEWA
	AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077541 001	Dec 26, 2006	Jun	CAHN

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

	DR REDDYS LABS LTD	EQ 16MG BASE	A076183 004	Dec 26, 2006	Sep	NEWA
@	PAR PHARM	EQ 4MG BASE	A077303 001	Jun 25, 2007	Aug	DISC
@		EQ 8MG BASE	A077303 002	Jun 25, 2007	Aug	DISC
@		EQ 24MG BASE	A077303 004	Jun 25, 2007	Aug	DISC
@	WEST WARD PHARM CORP	EQ 4MG BASE	A077545 001	Sep 06, 2007	Sep	DISC
@		EQ 8MG BASE	A077545 002	Sep 06, 2007	Sep	DISC
@		EQ 24MG BASE	A077545 003	Sep 06, 2007	Sep	DISC

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB	CNTY LINE PHARMS	100MG	A040249 001	Jan 29, 1999	Jul	CAHN
----	------------------	-------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB	INVAGEN PHARMS	100MG	A091158	001	Jul 27, 2012	Jul	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

+	ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Jan	CRLD
---	-------	----------------	---------	-----	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246	001	Mar 30, 2012	Mar	NEWA
AP		EQ 2GM BASE/VIAL	A091246	002	Mar 30, 2012	Mar	NEWA
AP		EQ 10GM BASE/VIAL	A091245	001	Mar 30, 2012	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Jul	NEWA
AP		100MG/VIAL	A078803	002	Aug 08, 2012	Jul	NEWA
AP	ONCO THERAPIES LTD	50MG/VIAL	A200979	001	Aug 08, 2012	Jul	NEWA
AP		50MG/10ML (5MG/ML)	A091358	001	Aug 07, 2012	Jul	NEWA
AP		100MG/VIAL	A200979	002	Aug 08, 2012	Jul	NEWA
AP		100MG/20ML (5MG/ML)	A091358	002	Aug 07, 2012	Jul	NEWA
	@ SANDOZ	50MG/VIAL	A090849	001	Apr 28, 2011	Nov	DISC
	@	100MG/VIAL	A090849	002	Apr 28, 2011	Nov	DISC
AP	+ TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Mar	CRLD
AP	+	100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Mar	CRLD

OXANDROLONE

TABLET; ORAL

OXANDROLONE

>D>	AB	SANDOZ	2.5MG	A076897	001	Dec 01, 2006	Dec	DISC
>A>		@	2.5MG	A076897	001	Dec 01, 2006	Dec	DISC
>D>	AB		10MG	A076897	002	Dec 01, 2006	Dec	DISC
>A>		@	10MG	A076897	002	Dec 01, 2006	Dec	DISC

OXAPROZIN

TABLET; ORAL

OXAPROZIN

@	MYLAN PHARMS INC	600MG	A075847	001	Feb 28, 2001	Oct	DISC
---	------------------	-------	---------	-----	--------------	-----	------

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

AB	AMNEAL PHARMS	300MG/5ML	A202961	001	Sep 17, 2012	Aug	NEWA
AB	ROXANE	300MG/5ML	A201193	001	Oct 03, 2012	Sep	NEWA

TABLET, EXTENDED RELEASE; ORAL

OXTELLAR XR

SUPERNUS PHARMS

		150MG	N202810	001	Oct 19, 2012	Oct	NEWA
		300MG	N202810	002	Oct 19, 2012	Oct	NEWA
+		600MG	N202810	003	Oct 19, 2012	Oct	NEWA

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+	FOUGERA PHARMS	EQ 1% BASE	N019828 001	Dec 30, 1988	Jan	CAHN
---	----------------	------------	-------------	--------------	-----	------

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+	WARNER CHILCOTT LLC	400MG	A087863 001	May 24, 1983	Jun	CAHN
+		600MG	A086742 001		Jun	CAHN

OXYBUTYNIN

GEL, METERED; TRANSDERMAL

ANTUROL

+	ARROW INTL	3%	N202513 001	Dec 07, 2011	Apr	CAHN
+	WATSON LABS INC	3%	N202513 001	Dec 07, 2011	Nov	CAHN
+		3%	N202513 001	Dec 07, 2011	Feb	CAHN

OXYBUTYNIN CHLORIDE

TABLET; ORAL

DITROPAN

@ JANSSEN PHARMS

5MG

N017577 001		Mar	DISC
-------------	--	-----	------

OXYBUTYNIN CHLORIDE

AB	+	VINTAGE PHARMS	5MG	A075079 001	Oct 31, 1997	Mar	CRLD
----	---	----------------	-----	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB	MYLAN PHARMS INC	15MG	A076644 002	May 10, 2007	Mar	NEWA
----	------------------	------	-------------	--------------	-----	------

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

AB	COASTAL PHARMS	5MG	A203107 001	Jul 26, 2012	Jul	NEWA	
AB	+	LEHIGH VALLEY	5MG	N200534 001	Oct 20, 2010	Jul	CFTG

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA	+	LEHIGH VALLEY	100MG/5ML	N200535 001	Oct 20, 2010	Jul	CFTG
AA	+	VISTAPHARM	5MG/5ML	N201194 001	Jan 12, 2012	Jan	NEWA
AA			100MG/5ML	A202537 001	Jul 30, 2012	Jul	NEWA

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	5MG	A202160 001	Nov 19, 2012	Nov	NEWA
AB		15MG	A202160 002	Nov 19, 2012	Nov	NEWA
AB		30MG	A202160 003	Nov 19, 2012	Nov	NEWA
AB	MALLINCKRODT INC	5MG	A076758 003	Mar 19, 2007	Apr	NEWA
AB	SUN PHARM INDS INC	10MG	A090659 005	Nov 06, 2012	Nov	NEWA
AB		20MG	A090659 004	Nov 06, 2012	Nov	NEWA

ROXICODONE

AB	MALLINCKRODT INC	5MG	N021011 003	May 15, 2009	Oct	CAHN
AB	+	15MG	N021011 001	Aug 31, 2000	Oct	CAHN
AB		30MG	N021011 002	Aug 31, 2000	Oct	CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@ ENDO PHARMS

5MG

N021610 001	Jun 22, 2006	May	DISC
-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

	ENDO PHARMS	7.5MG	N201655 002	Dec 09, 2011	Nov	CMFD
	@	7.5MG	N201655 002	Dec 09, 2011	Oct	DISC
	@	10MG	N021610 002	Jun 22, 2006	May	DISC
		15MG	N201655 004	Dec 09, 2011	Nov	CMFD
	@	15MG	N201655 004	Dec 09, 2011	Oct	DISC
	@	20MG	N021610 003	Jun 22, 2006	May	DISC
	@	30MG	N021610 007	Feb 29, 2008	May	DISC
+		40MG	N201655 007	Dec 09, 2011	Aug	CRLD
	@	40MG	N021610 004	Jun 22, 2006	May	DISC

OXYMORPHONE HYDROCHLORIDE

IMPAX LABS

	5MG	A079087 001	Jun 14, 2010	May	CTEC
	10MG	A079087 003	Jun 14, 2010	May	CTEC
	20MG	A079087 005	Jun 14, 2010	May	CTEC
	30MG	A079087 006	Jul 22, 2010	May	CTEC
	40MG	A079087 007	Jun 14, 2010	May	CTEC

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

	@ TEVA PARENTERAL	10USP UNITS/ML (10USP UNITS/ML)	A077453 001	Jan 24, 2008	Jan	DISC
	@	100USP UNITS/10ML (10USP UNITS/ML)	A077453 002	Jan 24, 2008	Mar	DISC

PITOCIN

JHP PHARMS

	500USP UNITS/50ML (10USP UNITS/ML)	N018261 003	Sep 05, 2012	Aug	NEWA
--	------------------------------------	-------------	--------------	-----	------

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP	TEVA PHARMS	6MG/ML	A075184 001	Jan 25, 2002	Oct	CAHN
	TAXOL					
	@ CORDEN PHARMA	6MG/ML	N020262 001	Dec 29, 1992	Mar	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

	@ NOVARTIS	30MG/VIAL	N020036 001	Oct 31, 1991	Mar	DISC
--	------------	-----------	-------------	--------------	-----	------

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBOTT LABS

	15,000USP UNITS;3,000USP UNITS;9,500USP UNITS	N020725 004	Jul 12, 2011	Jun	NEWA
	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725 001	Apr 30, 2009	Feb	CAHN
	60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725 002	Apr 30, 2009	Feb	CAHN
+	120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725 003	Apr 30, 2009	Feb	CAHN

PERTZYE

DIGESTIVE CARE INC

	30,250USP/UNITS;8,000USP/UNITS;28,750USP/UNITS	N022175 001	May 17, 2012	May	NEWA
+	60,500USP/UNITS;16,000USP/UNITS;57,500USP/UNITS	N022175 002	May 17, 2012	May	NEWA

ULTRESA

APTALIS PHARMA US

	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222 001	Mar 01, 2012	Mar	NEWA
--	---	-------------	--------------	-----	------

CAPSULE, DELAYED RELEASE; ORAL

ULTRESA

	APTALIS PHARMA US	41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222 002	Mar 01, 2012	Mar	NEWA
+		46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222 003	Mar 01, 2012	Mar	NEWA

ZENPEP

	APTALIS PHARMA US	16,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210 005	Jun 15, 2011	Apr	NEWA
		109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210 004	Aug 27, 2009	Apr	CRLD
+		136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210 006	Jul 13, 2011	Apr	NEWA

TABLET; ORAL

VIOKACE

	APTALIS PHARMA US	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542 001	Mar 01, 2012	Mar	NEWA
+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542 002	Mar 01, 2012	Mar	NEWA

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PANTOPRAZOLE SODIUM

AP	AKORN INC	EQ 40MG BASE/VIAL	A079197 001	Nov 08, 2012	Oct	NEWA
AP	+	PROTONIX IV				
	WYETH PHARMS INC	EQ 40MG BASE/VIAL	N020988 001	Mar 22, 2001	Oct	CFTG

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	APOTEX INC	EQ 20MG BASE	A090807 001	May 02, 2012	Apr	NEWA
AB		EQ 40MG BASE	A090807 002	May 02, 2012	Apr	NEWA
AB	AUROBINDO PHARMA LTD	EQ 20MG BASE	A202038 001	Sep 28, 2012	Sep	NEWA
AB		EQ 40MG BASE	A202038 002	Sep 28, 2012	Sep	NEWA
AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A200821 001	Feb 16, 2012	Jan	NEWA
AB		EQ 40MG BASE	A200821 002	Feb 16, 2012	Jan	NEWA
AB	MYLAN PHARMS INC	EQ 20MG BASE	A090970 001	Jan 19, 2011	Sep	CAHN
AB		EQ 40MG BASE	A090970 002	Jan 19, 2011	Sep	CAHN
AB	RANBAXY LABS LTD	EQ 20MG BASE	A200794 001	May 02, 2012	Apr	NEWA
AB		EQ 40MG BASE	A200794 002	May 02, 2012	Apr	NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010	Feb	CMFD
AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Feb	CMFD
AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Feb	CMFD
AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Feb	CMFD
AB	MYLAN PHARMS INC	EQ 10MG BASE	A075716 001	Mar 08, 2004	Sep	CAHN
AB		EQ 20MG BASE	A075716 002	Mar 08, 2004	Sep	CAHN
AB		EQ 30MG BASE	A075716 003	Mar 08, 2004	Sep	CAHN
AB		EQ 40MG BASE	A075716 004	Mar 08, 2004	Sep	CAHN
AB	PROSAM LABS	EQ 10MG BASE	A076968 001	Jun 21, 2010	Sep	CAHN
AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Sep	CAHN
AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Sep	CAHN
AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Sep	CAHN

>A> PASIREOTIDE DIASPARTATE
 >A> SOLUTION; SUBCUTANEOUS
 >A> SIGNIFOR
 >A> NOVARTIS EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML) N200677 001 Dec 14, 2012 Dec NEWA
 >A> EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML) N200677 002 Dec 14, 2012 Dec NEWA
 >A> + EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML) N200677 003 Dec 14, 2012 Dec NEWA

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL
 VOTRIENT
 >D> GLAXOSMITHKLINE EQ 200MG BASE N022465 001 Oct 19, 2009 Dec CRLD
 >A> + EQ 200MG BASE N022465 001 Oct 19, 2009 Dec CRLD
 >D> + EQ 400MG BASE N022465 002 Oct 19, 2009 Dec CRLD
 >A> + EQ 400MG BASE N022465 002 Oct 19, 2009 Dec CRLD

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL
 MACUGEN

+ VALEANT PHARMS LLC EQ 0.3MG ACID/0.09ML N021756 001 Dec 17, 2004 May CAHN

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

+ AFFYMAX EQ 10MG BASE/ML (EQ 10MG BASE/ML) N202799 007 Mar 27, 2012 Mar NEWA
 + EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N202799 008 Mar 27, 2012 Mar NEWA

OMONTYS PRESERVATIVE FREE

+ AFFYMAX EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) N202799 001 Mar 27, 2012 Mar NEWA
 + EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) N202799 002 Mar 27, 2012 Mar NEWA
 + EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) N202799 003 Mar 27, 2012 Mar NEWA
 + EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) N202799 004 Mar 27, 2012 Mar NEWA
 + EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) N202799 005 Mar 27, 2012 Mar NEWA
 + EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) N202799 006 Mar 27, 2012 Mar NEWA

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

>A> @ ACTIENT PHARMS 10MG N018976 001 Dec 30, 1987 Dec CAHN
 >A> + 20MG N018976 004 Jan 05, 1989 Dec CAHN
 >D> @ SCHWARZ PHARMA 10MG N018976 001 Dec 30, 1987 Dec CAHN
 >D> + 20MG N018976 004 Jan 05, 1989 Dec CAHN

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

AP IBI 5,000,000 UNITS/VIAL A065448 001 Aug 18, 2009 Sep CAHN
 AP 20,000,000 UNITS/VIAL A065448 002 Aug 18, 2009 Sep CAHN

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+	OAK PHARMS	50MG/ML	A083246 001		Feb	CAHN
---	------------	---------	-------------	--	-----	------

PERAMPANEL

TABLET; ORAL

FYCOMPA

EISAI INC

		2MG	N202834 001	Oct 20, 2012	Oct	NEWA
		4MG	N202834 002	Oct 22, 2012	Oct	NEWA
		6MG	N202834 003	Oct 22, 2012	Oct	NEWA
		8MG	N202834 004	Oct 22, 2012	Oct	NEWA
		10MG	N202834 005	Oct 22, 2012	Oct	NEWA
+		12MG	N202834 006	Oct 22, 2012	Oct	NEWA

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB	XOMA	2MG	N020184 001	Dec 30, 1993	Jan	CAHN
AB		4MG	N020184 002	Dec 30, 1993	Jan	CAHN
AB	+	8MG	N020184 003	Dec 30, 1993	Jan	CAHN

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB	+	RENAISSANCE PHARMA	5%	N019855 001	Aug 25, 1989	May	CAHN
----	---	--------------------	----	-------------	--------------	-----	------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

AB	+	WELLSPRING PHARM	10MG	N008708 001		Jun	CFTG
AB		PHENOXYBENZAMINE HYDROCHLORIDE		A201050 001	Jul 16, 2012	Jun	NEWA
		ROXANE	10MG				

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA		ELITE LABS	15MG	A202248 001	Sep 28, 2012	Sep	NEWA
AA			30MG	A202248 002	Sep 28, 2012	Sep	NEWA
AA		LANNETT	15MG	A087022 002	Jan 20, 2012	Feb	NEWA
	@	MIKAH PHARMA	15MG	A040460 001	Jan 14, 2003	Jul	CAHN
	@		30MG	A040448 001	Jan 22, 2003	Jul	CAHN
	@		30MG	A040227 001	Jun 18, 1997	Jul	CAHN
	@		37.5MG	A040228 001	Jun 19, 1997	Jul	CAHN

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

	@	ACTAVIS ELIZABETH	37.5MG	A040276 001	Nov 25, 1998	Oct	DISC
	@	MIKAH PHARMA	37.5MG	A040190 001	May 30, 1997	Jul	CAHN
AA		MIRROR PHARMS	37.5MG	A091451 001	Sep 21, 2012	Sep	NEWA
	@	SANDOZ INC	30MG	A088605 001	Sep 28, 1987	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

CITIUS PHARMS

		30MG	N202088 002	Jun 13, 2011	Apr	CRLD
+		37.5MG	N202088 003	Mar 27, 2012	Apr	CRLD
		37.5MG	N202088 003	Mar 27, 2012	Mar	NEWA

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

VIVUS	EQ 3.75MG BASE;23MG	N022580 001	Jul 17, 2012	Jul	NEWA
	EQ 7.5MG BASE;46MG	N022580 002	Jul 17, 2012	Jul	NEWA
	EQ 11.25MG BASE;69MG	N022580 003	Jul 17, 2012	Jul	NEWA
+	EQ 15MG BASE;92MG	N022580 004	Jul 17, 2012	Jul	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

+	LANNETT HOLDINGS INC EQ 15MG BASE	A040872 001	Jul 28, 2011	Jan	CRLD
+	EQ 30MG BASE	A040872 002	Jul 28, 2011	Jan	CRLD

PHENYLEPHRINE HYDROCHLORIDE

>A>	SOLUTION; IV (INFUSION)				
>A>	PHENYLEPHRINE HYDROCHLORIDE				
>A>	+	WEST WARD PHARM CORP 10MG/ML (10MG/ML)	N203826 001	Dec 20, 2012	Dec NEWA

PHENYTOIN

TABLET, CHEWABLE; ORAL

DILANTIN

>D>	+	PFIZER PHARMS 50MG	A084427 001		Dec CFTG
>A>	AB	+	A084427 001		Dec CFTG
>A>		PHENYTOIN			
>A>	AB	MYLAN PHARMS INC 50MG	A200691 001	Dec 26, 2012	Dec NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP	+	HIKMA MAPLE 50MG/ML	A084307 001		Jun CAHN
----	---	---------------------	-------------	--	----------

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	+	INTL MEDICATION 1MG/0.5ML	A083722 001		Feb CRLD
----	---	---------------------------	-------------	--	----------

TABLET; ORAL

MEPHYTON

	+	VALEANT PHARMS 5MG	N010104 003		Jun CAHN
--	---	--------------------	-------------	--	----------

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

	+	VALEANT BERMUDA 1%	N021302 001	Dec 13, 2001	Oct CAHN
--	---	--------------------	-------------	--------------	----------

PINDOLOL

TABLET; ORAL

PINDOLOL

	@	MYLAN PHARMS INC 5MG	A074013 001	Sep 24, 1992	May CAHN
	@	10MG	A074018 001	Sep 24, 1992	May CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

AB		TAKEDA PHARMS USA EQ 15MG BASE	N021073 001	Jul 15, 1999	Aug CFTG
----	--	--------------------------------	-------------	--------------	----------

TABLET; ORAL

ACTOS

	TAKEDA PHARMS USA	EQ 15MG BASE	N021073 001	Jul 15, 1999	Mar	CAHN
AB		EQ 30MG BASE	N021073 002	Jul 15, 1999	Aug	CFTG
		EQ 30MG BASE	N021073 002	Jul 15, 1999	Mar	CAHN
AB	+	EQ 45MG BASE	N021073 003	Jul 15, 1999	Aug	CFTG
	+	EQ 45MG BASE	N021073 003	Jul 15, 1999	Mar	CAHN

PIOGLITAZONE HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 15MG BASE	A076801 001	Aug 17, 2012	Aug	NEWA
AB		EQ 30MG BASE	A076801 002	Aug 17, 2012	Aug	NEWA
AB		EQ 45MG BASE	A076801 003	Aug 17, 2012	Aug	NEWA
AB	WATSON LABS	EQ 15MG BASE	A076798 001	Oct 26, 2012	Oct	NEWA
AB		EQ 30MG BASE	A076798 002	Oct 26, 2012	Oct	NEWA
AB		EQ 45MG BASE	A076798 003	Oct 26, 2012	Oct	NEWA

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

>A>	+	IBI	EQ 2GM BASE/VIAL	A065114 001	Nov 14, 2003	Dec	CAHN
>A>	+		EQ 3GM BASE/VIAL	A065114 002	Nov 14, 2003	Dec	CAHN
>A>	+		EQ 4GM BASE/VIAL	A065114 003	Nov 14, 2003	Dec	CAHN
>D>	+	ISTITUTO BIOCHIMICO	EQ 2GM BASE/VIAL	A065114 001	Nov 14, 2003	Dec	CAHN
>D>	+		EQ 3GM BASE/VIAL	A065114 002	Nov 14, 2003	Dec	CAHN
>D>	+		EQ 4GM BASE/VIAL	A065114 003	Nov 14, 2003	Dec	CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

@ PADDOCK LLC

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 A090769 001 Jun 07, 2010 Sep DISC
.86GM/BOT;22.74GM/BOT

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

@ PADDOCK LLC

240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 A090712 001 Feb 25, 2010 Sep DISC
.84GM/BOT;22.72GM/BOT

>A> PONATINIB HYDROCHLORIDE

>A> TABLET; ORAL

>A> ICLUSIG

>A>		ARIAD	EQ 15MG BASE	N203469 001	Dec 14, 2012	Dec	NEWA
>A>	+		EQ 45MG BASE	N203469 002	Dec 14, 2012	Dec	NEWA

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

K+10

@ FUTURE PAK

10MEQ

A070999 001 Oct 22, 1987 Mar DISC

KAON CL-10

@ SAVAGE LABS

10MEQ

N017046 002 Mar DISC

KLOR-CON M20

AB + UPSHER SMITH LABS 20MEQ A074726 001 Nov 20, 1998 Mar CRLD

KLOTRIX

@ APOTHECON

10MEQ

N017850 001 Mar DISC

POTASSIUM CHLORIDE

@ NESHER PHARMS

20MEQ

A076044 001 Apr 05, 2002 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

@ SCHERING	10MEQ	N019439 002	Jun 13, 1986	Mar	DISC
@	20MEQ	N019439 001	Jun 13, 1986	Mar	DISC

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

@ NOVA K	10MEQ/PACKET	N019647 002	Oct 13, 1988	Feb	CAHN
@	20MEQ/PACKET	N019647 001	Oct 13, 1988	Feb	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	APOTEX INC	0.125MG	A090151 001	Apr 30, 2012	Apr	NEWA
AB		0.25MG	A090151 002	Apr 30, 2012	Apr	NEWA
AB		0.5MG	A090151 003	Apr 30, 2012	Apr	NEWA
AB		0.75MG	A090151 006	Apr 30, 2012	Apr	NEWA
AB		1MG	A090151 004	Apr 30, 2012	Apr	NEWA
AB		1.5MG	A090151 005	Apr 30, 2012	Apr	NEWA
AB	AUROBINDO PHARMA LTD	0.125MG	A202633 001	Oct 26, 2012	Oct	NEWA
AB		0.25MG	A202633 002	Oct 26, 2012	Oct	NEWA
AB		0.5MG	A202633 003	Oct 26, 2012	Oct	NEWA
AB		0.75MG	A202633 004	Oct 26, 2012	Oct	NEWA
AB		1MG	A202633 005	Oct 26, 2012	Oct	NEWA
AB		1.5MG	A202633 006	Oct 26, 2012	Oct	NEWA
AB	MACLEODS PHARMS LTD	0.125MG	A202164 001	Sep 20, 2012	Sep	NEWA
AB		0.25MG	A202164 002	Sep 20, 2012	Sep	NEWA
AB		0.5MG	A202164 003	Sep 20, 2012	Sep	NEWA
AB		1MG	A202164 004	Sep 20, 2012	Sep	NEWA
AB		1.5MG	A202164 005	Sep 20, 2012	Sep	NEWA

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

>D>	AB	LEK PHARMS DD	10MG	A076397 003	Oct 23, 2006	Dec	DISC
>D>	AB		20MG	A076397 002	Oct 23, 2006	Dec	DISC
>D>	AB		40MG	A076397 001	Oct 23, 2006	Dec	DISC
>D>	AB		80MG	A077491 001	Feb 11, 2008	Dec	DISC
	AB	MYLAN PHARMS INC	10MG	A079187 001	May 27, 2010	Oct	CAHN
	AB		20MG	A079187 002	May 27, 2010	Oct	CAHN
	AB		40MG	A079187 003	May 27, 2010	Oct	CAHN
	AB		80MG	A079187 004	May 27, 2010	Oct	CAHN
		@ PLIVA HRVATSKA DOO	10MG	A077730 001	Nov 21, 2006	Jun	DISC
		@	20MG	A077730 002	Nov 21, 2006	Jun	DISC
		@	30MG	A077730 003	Nov 21, 2006	Jun	DISC
		@	40MG	A077730 005	Nov 21, 2006	Jun	DISC
		@ RANBAXY LABS LTD	10MG	A076445 001	Apr 23, 2007	Apr	DISC
		@	20MG	A076445 002	Apr 23, 2007	Apr	DISC
		@	40MG	A076445 003	Apr 23, 2007	Apr	DISC
		@	80MG	A076445 004	Apr 23, 2007	Apr	DISC
>A>		@ SANDOZ	10MG	A076397 003	Oct 23, 2006	Dec	DISC
>A>		@	20MG	A076397 002	Oct 23, 2006	Dec	DISC
>A>		@	40MG	A076397 001	Oct 23, 2006	Dec	DISC
>A>		@	80MG	A077491 001	Feb 11, 2008	Dec	DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

AB	TEVA PHARMS	EQ 2MG BASE	A071995 001	Sep 12, 1988	Nov	CAHN
AB		EQ 5MG BASE	A071745 001	Sep 12, 1988	Nov	CAHN

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT

>D>	AB	+	SANOFI AVENTIS US	0.1%	N020279 001	Oct 29, 1993	Dec	CAHN
>A>	AB	+	VALEANT BERMUDA	0.1%	N020279 001	Oct 29, 1993	Dec	CAHN

PREDNICARBATE

AB	FOUGERA PHARMS	0.1%	A077287 001	Sep 19, 2006	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

DERMATOP

>D>	AB	+	SANOFI AVENTIS US	0.1%	N019568 001	Sep 23, 1991	Dec	CAHN
>A>	AB	+	VALEANT BERMUDA	0.1%	N019568 001	Sep 23, 1991	Dec	CAHN

PREDNICARBATE

AB	FOUGERA PHARMS	0.1%	A077236 001	Mar 09, 2007	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA	+	HI TECH PHARMA CO	15MG/5ML	A040401 001	Feb 27, 2003	Jul	CRLD
		@ NESHER PHARMS	5MG/5ML	A040423 001	Oct 22, 2001	Jun	DISC
		@	15MG/5ML	A040364 001	Apr 10, 2002	Jun	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

AA	+	SETON PHARM	EQ 5MG BASE/5ML	N019157 001	May 28, 1986	Sep	CAHN
		PREDNISOLONE SODIUM PHOSPHATE					
	+	MISSION PHARMA	EQ 25MG BASE/5ML	A091396 001	Sep 13, 2010	Jul	CAHN
		@ NESHER PHARMS	EQ 5MG BASE/5ML	A076982 001	May 24, 2005	Jun	DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	WEST WARD PHARM CORP	50MG	A088465 001	Jun 01, 1984	Oct	CMFD
----	----------------------	------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

RAYOS

	HORIZON PHARMA	1MG	N202020 001	Jul 26, 2012	Jul	NEWA
		2MG	N202020 002	Jul 26, 2012	Jul	NEWA
+		5MG	N202020 003	Jul 26, 2012	Jul	NEWA

PREGABALIN

CAPSULE; ORAL

LYRICA

AB	PF PRISM	25MG	N021446 001	Dec 30, 2004	Jun	CFTG
		25MG	N021446 001	Dec 30, 2004	Jan	CAHN
AB		50MG	N021446 002	Dec 30, 2004	Jun	CFTG
		50MG	N021446 002	Dec 30, 2004	Jan	CAHN
AB		75MG	N021446 003	Dec 30, 2004	Jun	CFTG
		75MG	N021446 003	Dec 30, 2004	Jan	CAHN
AB		100MG	N021446 004	Dec 30, 2004	Oct	CFTG

CAPSULE; ORAL

LYRICA

	PF PRISM	100MG		N021446 004	Dec 30, 2004	Jan	CAHN
AB		150MG		N021446 005	Dec 30, 2004	Jun	CFTG
		150MG		N021446 005	Dec 30, 2004	Jan	CAHN
AB		200MG		N021446 006	Dec 30, 2004	Jun	CFTG
		200MG		N021446 006	Dec 30, 2004	Jan	CAHN
AB		225MG		N021446 007	Dec 30, 2004	Jun	CFTG
		225MG		N021446 007	Dec 30, 2004	Jan	CAHN
AB	+	300MG		N021446 008	Dec 30, 2004	Jun	CFTG
	+	300MG		N021446 008	Dec 30, 2004	Jan	CAHN

PREGABALIN

AB	LUPIN LTD	25MG		A091040 001	Jul 03, 2012	Jun	NEWA
AB		50MG		A091040 002	Jul 03, 2012	Jun	NEWA
AB		75MG		A091040 003	Jul 03, 2012	Jun	NEWA
AB		100MG		A091040 004	Jul 03, 2012	Jun	NEWA
AB		150MG		A091040 005	Jul 03, 2012	Jun	NEWA
AB		200MG		A091040 006	Jul 03, 2012	Jun	NEWA
AB		225MG		A091040 007	Jul 03, 2012	Jun	NEWA
AB		300MG		A091040 008	Jul 03, 2012	Jun	NEWA
AB	TEVA PHARMS	25MG		A091219 001	Jul 03, 2012	Jun	NEWA
AB		50MG		A091219 002	Jul 03, 2012	Jun	NEWA
AB		75MG		A091224 001	Jul 03, 2012	Jun	NEWA
AB		100MG		A091224 002	Jul 03, 2012	Jun	NEWA
AB		150MG		A091224 003	Jul 03, 2012	Jun	NEWA
AB		200MG		A091224 004	Jul 03, 2012	Jun	NEWA
AB		225MG		A091224 005	Jul 03, 2012	Jun	NEWA
AB		300MG		A091224 006	Jul 03, 2012	Jun	NEWA
AB	WATSON LABS INC	25MG		A091221 001	Jul 03, 2012	Jun	NEWA
AB		50MG		A091221 002	Jul 03, 2012	Jun	NEWA
AB		75MG		A091221 003	Jul 03, 2012	Jun	NEWA
AB		100MG		A091221 004	Jul 03, 2012	Jun	NEWA
AB		150MG		A091221 005	Jul 03, 2012	Jun	NEWA
AB		200MG		A091221 006	Jul 03, 2012	Jun	NEWA
AB		225MG		A091221 007	Jul 03, 2012	Jun	NEWA
AB		300MG		A091221 008	Jul 03, 2012	Jun	NEWA

SOLUTION; ORAL

LYRICA

+	PF PRISM	20MG/ML		N022488 001	Jan 04, 2010	Jan	CAHN
---	----------	---------	--	-------------	--------------	-----	------

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN DENTAL

	@ DENTSPLY PHARM	4%		N021382 001		May	DISC
	PRILOCAINE HYDROCHLORIDE						
+	SEPTODONT INC	4%		A079235 001	Sep 29, 2010	May	CRLD

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

	@ HIKMA MAPLE	100MG/ML		A089029 001	Apr 17, 1986	Jun	CAHN
	@	500MG/ML		A089030 001	Apr 17, 1986	Jun	CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

	@ HIKMA MAPLE	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jun	CAHN
AP	+	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jun	CAHN

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB		SOFGEN PHARMS	100MG	A200456	001	Sep 28, 2012	Sep	NEWA
AB			200MG	A200456	002	Sep 28, 2012	Sep	NEWA
AB		TEVA PHARMS	100MG	A202121	001	Feb 29, 2012	Feb	NEWA
AB			200MG	A202121	002	Feb 29, 2012	Feb	NEWA
		PROMETRIUM						
AB		ABBOTT LABS	100MG	N019781	001	May 14, 1998	Feb	CFTG
AB	+		200MG	N019781	002	Oct 15, 1999	Feb	CFTG

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

AP		HIKMA MAPLE	25MG/ML	A083312	001		Oct	CAHN
AP			50MG/ML	A083312	002		Oct	CAHN

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

AB		WATSON LABS INC	12.5MG	A040479	001	Jun 24, 2003	Oct	CAHN
AB			25MG	A040479	002	Jun 24, 2003	Oct	CAHN

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA		TRIS PHARMA INC	6.25MG/5ML	A091675	001	Jun 28, 2012	Jun	NEWA
----	--	-----------------	------------	---------	-----	--------------	-----	------

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

@	NESHER PHARMS	150MG
@		225MG
@		300MG

A076193	001	Feb 07, 2002	Jun	DISC
A076193	002	Feb 07, 2002	Jun	DISC
A076193	003	Feb 07, 2002	Jun	DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB		APTALIS PHARMATECH	60MG	A078703	001	Jul 15, 2011	Sep	CAHN
AB			80MG	A078703	002	Jul 15, 2011	Sep	CAHN
AB			120MG	A078703	003	Jul 15, 2011	Sep	CAHN
AB			160MG	A078703	004	Jul 15, 2011	Sep	CAHN

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

@	HIKMA MAPLE	10MG/ML
@		10MG/ML

A089474	001	Nov 05, 1986	Oct	CAHN
A089475	001	Nov 05, 1986	Oct	CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

AB		EPIC PHARMA LLC	5MG	A202220	001	Nov 19, 2012	Nov	NEWA
----	--	-----------------	-----	---------	-----	--------------	-----	------

TABLET; ORAL

	PROTRIPTYLINE HYDROCHLORIDE						
AB	EPIC PHARMA LLC	10MG	A202220	002	Nov 19, 2012	Nov	NEWA
	VIVACTIL						
	@ TEVA WOMENS R AND D	5MG	N016012	001		Jul	CAHN
	@	10MG	N016012	002		Jul	CAHN

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

	MESTINON						
AB	+ VALEANT PHARMS LLC	60MG	N009829	002		Jun	CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	MESTINON						
	+ VALEANT PHARMS LLC	180MG	N011665	001		Jun	CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

	QUETIAPINE FUMARATE						
AB	ACCORD HLTHCARE INC	EQ 25MG BASE	A202152	001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A202152	002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A202152	003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A202152	004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A202152	005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A202152	006	Mar 27, 2012	Mar	NEWA
AB	APOTEX INC	EQ 25MG BASE	A090960	001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090960	002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090960	003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090960	004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090960	005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090960	006	Mar 27, 2012	Mar	NEWA
AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388	001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A091388	002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A091388	003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A091388	004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A091388	005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A091388	006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A091388	007	Mar 27, 2012	Mar	NEWA
AB	DR REDDYS LABS LTD	EQ 25MG BASE	A077380	001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077380	002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077380	003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077380	004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077380	005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077380	006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077380	007	Mar 27, 2012	Mar	NEWA
AB	LUPIN LTD	EQ 25MG BASE	A201109	001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201109	002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201109	003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201109	004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201109	005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201109	006	Mar 27, 2012	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323	001	Mar 27, 2012	Mar	NEWA
AB	ROXANE	EQ 25MG BASE	A090120	001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090749	001	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090749	002	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090749	003	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090749	004	Mar 27, 2012	Mar	NEWA

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ROXANE	EQ 400MG BASE	A090749 005	Mar 27, 2012	Mar	NEWA
>A>	SANDOZ	EQ 25MG BASE	A078679 001	Dec 14, 2012	Dec	NEWA
>A>		EQ 50MG BASE	A078679 002	Dec 14, 2012	Dec	NEWA
>A>		EQ 100MG BASE	A078679 003	Dec 14, 2012	Dec	NEWA
>A>		EQ 150MG BASE	A078679 004	Dec 14, 2012	Dec	NEWA
>A>		EQ 200MG BASE	A078679 005	Dec 14, 2012	Dec	NEWA
>A>		EQ 300MG BASE	A078679 006	Dec 14, 2012	Dec	NEWA
>A>		EQ 400MG BASE	A078679 007	Dec 14, 2012	Dec	NEWA
AB	SUN PHARMA GLOBAL	EQ 25MG BASE	A201190 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201190 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201190 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201190 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201190 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201190 006	Mar 27, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 25MG BASE	A077745 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077745 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077745 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077745 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077745 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077745 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077745 007	Mar 27, 2012	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A200363 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A200363 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A200363 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A200363 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A200363 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A200363 006	Mar 27, 2012	Mar	NEWA
	SEROQUEL					
AB	+ ASTRAZENECA	EQ 25MG BASE	N020639 001	Sep 26, 1997	Mar	CFTG
AB		EQ 50MG BASE	N020639 007	Oct 04, 2005	Mar	CFTG
AB		EQ 100MG BASE	N020639 002	Sep 26, 1997	Mar	CFTG
AB		EQ 200MG BASE	N020639 003	Sep 26, 1997	Mar	CFTG
AB	+	EQ 300MG BASE	N020639 005	Jul 26, 2000	Mar	CFTG
AB		EQ 400MG BASE	N020639 006	Oct 04, 2005	Mar	CFTG

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@	SANDOZ	EQ 5MG BASE	A076803 001	Mar 02, 2005	Aug	DISC
@		EQ 10MG BASE	A076803 002	Mar 02, 2005	Aug	DISC
@		EQ 20MG BASE	A076803 003	Mar 02, 2005	Aug	DISC
@		EQ 40MG BASE	A076803 004	Mar 02, 2005	Aug	DISC

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

AB	+ AR HOLDING CO INC	324MG	N021799 001	Aug 12, 2005	Sep	CFTG
AB	+ MUTUAL PHARM CO INC	324MG	N021799 001	Aug 12, 2005	Nov	CAHN
	QUININE SULFATE					
>A>	MYLAN PHARMS INC	324MG	A202581 001	Dec 14, 2012	Dec	NEWA
AB	TEVA PHARMS	324MG	A091661 001	Sep 28, 2012	Sep	NEWA

RAMELTEON

TABLET; ORAL

ROZEREM

+	TAKEDA PHARMS USA	8MG	N021782	001	Jul 22, 2005	Jul	CAHN
---	-------------------	-----	---------	-----	--------------	-----	------

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

@	RANBAXY LABS LTD	5MG	A078849	001	Mar 06, 2009	Apr	DISC
---	------------------	-----	---------	-----	--------------	-----	------

@		10MG	A078849	002	Mar 06, 2009	Apr	DISC
---	--	------	---------	-----	--------------	-----	------

TABLET; ORAL

ALTACE

@	KING PFIZER	1.25MG	N022021	001	Feb 27, 2007	Jan	DISC
---	-------------	--------	---------	-----	--------------	-----	------

@		2.5MG	N022021	002	Feb 27, 2007	Jan	DISC
---	--	-------	---------	-----	--------------	-----	------

@		5MG	N022021	003	Feb 27, 2007	Jan	DISC
---	--	-----	---------	-----	--------------	-----	------

@		10MG	N022021	004	Feb 27, 2007	Jan	DISC
---	--	------	---------	-----	--------------	-----	------

RAMIPRIL

AB	MYLAN PHARMS INC	1.25MG	A090650	001	Jun 30, 2011	Sep	CAHN
----	------------------	--------	---------	-----	--------------	-----	------

AB		2.5MG	A090650	002	Jun 30, 2011	Sep	CAHN
----	--	-------	---------	-----	--------------	-----	------

AB		5MG	A090650	003	Jun 30, 2011	Sep	CAHN
----	--	-----	---------	-----	--------------	-----	------

AB		10MG	A090650	004	Jun 30, 2011	Sep	CAHN
----	--	------	---------	-----	--------------	-----	------

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

AP	+	COVIS PHARMA	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Mar	CAHN
----	---	--------------	-----------------	---------	-----	--------------	-----	------

ZANTAC IN PLASTIC CONTAINER

+	COVIS PHARMA	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Mar	CAHN
---	--------------	----------------	---------	-----	--------------	-----	------

@		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Mar	CAHN
---	--	--------------------	---------	-----	--------------	-----	------

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

@	RANBAXY	EQ 15MG BASE/ML	A078448	001	Dec 13, 2007	Sep	DISC
---	---------	-----------------	---------	-----	--------------	-----	------

REGORAFENIB

TABLET; ORAL

STIVARGA

+	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012	Sep	NEWA
---	----------------	------	---------	-----	--------------	-----	------

RIBAVIRIN

CAPSULE; ORAL

REBETOL

>A>	AB	+	MERCK SHARP DOHME	200MG	N020903	002	Jul 25, 2001	Dec	CAHN
-----	----	---	-------------------	-------	---------	-----	--------------	-----	------

>A>		+		200MG	N020903	001	Jun 03, 1998	Dec	CAHN
-----	--	---	--	-------	---------	-----	--------------	-----	------

>D>		+	SCHERING PLOUGH RES	200MG	N020903	001	Jun 03, 1998	Dec	CAHN
-----	--	---	---------------------	-------	---------	-----	--------------	-----	------

>D>	AB	+		200MG	N020903	002	Jul 25, 2001	Dec	CAHN
-----	----	---	--	-------	---------	-----	--------------	-----	------

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

AB		PROSAM LABS	300MG	N050429	001		Feb	CMFD
----	--	-------------	-------	---------	-----	--	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011	Feb	CAHN
---	---------------	--------------	---------	-----	--------------	-----	------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	WARNER CHILCOTT LLC	5MG	N020835 002	Apr 14, 2000	Jun	CAHN
AB		30MG	N020835 001	Mar 27, 1998	Jun	CAHN
AB	+	35MG	N020835 003	May 25, 2002	Jun	CAHN
	@	75MG	N020835 004	Apr 16, 2007	Jun	CAHN
	+	150MG	N020835 005	Apr 22, 2008	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL

ATELVIA

+	WARNER CHILCOTT LLC	35MG	N022560 001	Oct 08, 2010	Jun	CAHN
---	---------------------	------	-------------	--------------	-----	------

RISPERIDONE

SOLUTION; ORAL

RISPERIDONE

AA	TRIS PHARMA INC	1MG/ML	A079059 001	Dec 12, 2012	Nov	NEWA
----	-----------------	--------	-------------	--------------	-----	------

TABLET; ORAL

RISPERIDONE

AB	PROSAM LABS	0.25MG	A078071 001	Jun 17, 2009	Feb	CMFD
AB		0.5MG	A078071 002	Jun 17, 2009	Feb	CMFD
AB		1MG	A078071 003	Jun 17, 2009	Feb	CMFD
AB		2MG	A078071 004	Jun 17, 2009	Feb	CMFD
AB		3MG	A078071 005	Jun 17, 2009	Feb	CMFD
AB		4MG	A078071 006	Jun 17, 2009	Feb	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	TEVA	0.5MG	A076908 001	Mar 12, 2012	Feb	NEWA
AB		1MG	A076908 002	Mar 12, 2012	Feb	NEWA
AB		2MG	A076908 003	Mar 12, 2012	Feb	NEWA

RIVAROXABAN

TABLET; ORAL

XARELTO

	JANSSEN PHARMS	15MG	N022406 002	Nov 04, 2011	Nov	CMS1
	+	20MG	N022406 003	Nov 04, 2011	Nov	CMS1

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELON

	NOVARTIS	13.3MG/24HR	N022083 005	Aug 31, 2012	Aug	NEWA
--	----------	-------------	-------------	--------------	-----	------

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

AB	ALEMBIC PHARMS LTD	EQ 1.5MG BASE	A091689 001	Jun 12, 2012	May	NEWA
AB		EQ 3MG BASE	A091689 002	Jun 12, 2012	May	NEWA
AB		EQ 4.5MG BASE	A091689 003	Jun 12, 2012	May	NEWA
AB		EQ 6MG BASE	A091689 004	Jun 12, 2012	May	NEWA

RIZATRIPTAN BENZOATE

TABLET; ORAL

MAXALT

>D>	MERCK	EQ 5MG BASE	N020864 001	Jun 29, 1998	Dec	CFTG
>A>	AB	EQ 5MG BASE	N020864 001	Jun 29, 1998	Dec	CFTG
>D>	+	EQ 10MG BASE	N020864 002	Jun 29, 1998	Dec	CFTG

TABLET; ORAL

MAXALT

>A>	AB	+	MERCK	EQ 10MG BASE	N020864 002	Jun 29, 1998	Dec	CFTG
>A>			RIZATRIPTAN BENZOATE					
>A>	AB		APOTEX INC	EQ 5MG BASE	A202244 001	Dec 31, 2012	Dec	NEWA
>A>	AB			EQ 10MG BASE	A202244 002	Dec 31, 2012	Dec	NEWA
>A>	AB		AUROBINDO PHARMA LTD	EQ 5MG BASE	A202490 001	Dec 31, 2012	Dec	NEWA
>A>	AB			EQ 10MG BASE	A202490 002	Dec 31, 2012	Dec	NEWA
>A>	AB		GLENMARK GENERICS	EQ 5MG BASE	A201967 001	Dec 31, 2012	Dec	NEWA
>A>	AB			EQ 10MG BASE	A201967 002	Dec 31, 2012	Dec	NEWA
>A>	AB		MYLAN PHARMS INC	EQ 5MG BASE	A201993 001	Dec 31, 2012	Dec	NEWA
>A>	AB			EQ 10MG BASE	A201993 002	Dec 31, 2012	Dec	NEWA
>A>	AB		NATCO PHARMA LTD	EQ 5MG BASE	A200482 001	Dec 31, 2012	Dec	NEWA
>A>	AB			EQ 10MG BASE	A200482 002	Dec 31, 2012	Dec	NEWA
>A>	AB		SANDOZ	EQ 5MG BASE	A079230 001	Dec 31, 2012	Dec	NEWA
>A>	AB			EQ 10MG BASE	A079230 002	Dec 31, 2012	Dec	NEWA
>A>	AB		SUN PHARMA GLOBAL	EQ 5MG BASE	A202047 001	Dec 31, 2012	Dec	NEWA
>A>	AB			EQ 10MG BASE	A202047 002	Dec 31, 2012	Dec	NEWA
>A>	AB		TEVA PHARMS	EQ 5MG BASE	A077263 001	Dec 31, 2012	Dec	NEWA
>A>	AB			EQ 10MG BASE	A077263 002	Dec 31, 2012	Dec	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

>D>			MERCK	EQ 5MG BASE	N020865 001	Jun 29, 1998	Dec	CFTG
>A>	AB			EQ 5MG BASE	N020865 001	Jun 29, 1998	Dec	CFTG
>D>		+		EQ 10MG BASE	N020865 002	Jun 29, 1998	Dec	CFTG
>A>	AB	+		EQ 10MG BASE	N020865 002	Jun 29, 1998	Dec	CFTG
>A>			RIZATRIPTAN BENZOATE					
>A>	AB		MYLAN PHARMS INC	EQ 5MG BASE	A078173 001	Dec 31, 2012	Dec	NEWA
>A>	AB			EQ 10MG BASE	A078173 002	Dec 31, 2012	Dec	NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP			TAMARANG	50MG/5ML (10MG/ML)	A091115 001	Aug 27, 2012	Aug	NEWA
AP				100MG/10ML (10MG/ML)	A091115 002	Aug 27, 2012	Aug	NEWA
AP			TEVA PHARMS	50MG/5ML (10MG/ML)	A078717 001	Nov 26, 2008	Sep	CAHN
AP				100MG/10ML (10MG/ML)	A078717 002	Nov 26, 2008	Sep	CAHN

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB			APOTEX	EQ 0.25MG BASE	A079165 001	Feb 07, 2012	Jan	NEWA
AB				EQ 0.5MG BASE	A079165 002	Feb 07, 2012	Jan	NEWA
AB				EQ 1MG BASE	A079165 003	Feb 07, 2012	Jan	NEWA
AB				EQ 2MG BASE	A079165 004	Feb 07, 2012	Jan	NEWA
AB				EQ 3MG BASE	A079165 005	Feb 07, 2012	Jan	NEWA
AB				EQ 4MG BASE	A079165 006	Feb 07, 2012	Jan	NEWA
AB				EQ 5MG BASE	A079165 007	Feb 07, 2012	Jan	NEWA
AB			ORCHID HLTHCARE	EQ 0.25MG BASE	A079229 001	Nov 28, 2012	Nov	NEWA
AB				EQ 0.5MG BASE	A079229 002	Nov 28, 2012	Nov	NEWA
AB				EQ 1MG BASE	A079229 003	Nov 28, 2012	Nov	NEWA
AB				EQ 2MG BASE	A079229 004	Nov 28, 2012	Nov	NEWA
AB				EQ 3MG BASE	A079229 005	Nov 28, 2012	Nov	NEWA
AB				EQ 4MG BASE	A079229 006	Nov 28, 2012	Nov	NEWA
AB				EQ 5MG BASE	A079229 007	Nov 28, 2012	Nov	NEWA

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

AB	+	SMITHKLINE BEECHAM	EQ 2MG BASE	N022008 001	Jun 13, 2008	Apr	CFTG
AB			EQ 4MG BASE	N022008 003	Jun 13, 2008	Apr	CFTG
AB			EQ 6MG BASE	N022008 006	Apr 10, 2009	Apr	CFTG
AB			EQ 8MG BASE	N022008 004	Jun 13, 2008	Apr	CFTG
AB			EQ 12MG BASE	N022008 005	Oct 31, 2008	Apr	CFTG

ROPINIROLE HYDROCHLORIDE

AB		ACTAVIS	EQ 2MG BASE	A090869 001	May 17, 2012	Apr	NEWA
AB			EQ 4MG BASE	A090869 002	May 17, 2012	Apr	NEWA
AB			EQ 6MG BASE	A090869 003	May 17, 2012	Apr	NEWA
AB			EQ 8MG BASE	A090869 004	May 17, 2012	Apr	NEWA
AB			EQ 12MG BASE	A090869 005	May 17, 2012	Apr	NEWA
AB		DR REDDYS LABS LTD	EQ 2MG BASE	A201576 001	Jun 06, 2012	May	NEWA
AB			EQ 4MG BASE	A201576 002	Jun 06, 2012	May	NEWA
AB			EQ 6MG BASE	A201576 003	Jun 06, 2012	May	NEWA
AB			EQ 8MG BASE	A201576 004	Jun 06, 2012	May	NEWA
AB			EQ 12MG BASE	A201576 005	Jun 06, 2012	May	NEWA
AB		MYLAN PHARMS INC	EQ 2MG BASE	A200462 001	Oct 15, 2012	Oct	NEWA
			EQ 3MG BASE	A200462 002	Oct 15, 2012	Oct	NEWA
AB			EQ 4MG BASE	A200462 003	Oct 15, 2012	Oct	NEWA
AB			EQ 6MG BASE	A200462 004	Oct 15, 2012	Oct	NEWA
AB			EQ 8MG BASE	A200462 005	Oct 15, 2012	Oct	NEWA
AB			EQ 12MG BASE	A200462 006	Oct 15, 2012	Oct	NEWA
AB		SANDOZ INC	EQ 2MG BASE	A201047 001	Jun 06, 2012	May	NEWA
AB			EQ 4MG BASE	A201047 003	Jun 06, 2012	May	NEWA
AB			EQ 6MG BASE	A201047 004	Jun 06, 2012	May	NEWA
AB			EQ 8MG BASE	A201047 005	Jun 06, 2012	May	NEWA
AB			EQ 12MG BASE	A201047 006	Jun 06, 2012	May	NEWA
AB		WATSON LABS INC	EQ 2MG BASE	A200431 001	Jun 06, 2012	May	NEWA
AB			EQ 4MG BASE	A200431 002	Jun 06, 2012	May	NEWA
AB			EQ 6MG BASE	A200431 003	Jun 06, 2012	May	NEWA
AB			EQ 8MG BASE	A200431 004	Jun 06, 2012	May	NEWA
AB			EQ 12MG BASE	A200431 005	Jun 06, 2012	May	NEWA
AB		WOCKHARDT LTD	EQ 2MG BASE	A091395 001	Aug 27, 2012	Aug	NEWA
AB			EQ 4MG BASE	A091395 002	Aug 27, 2012	Aug	NEWA
AB			EQ 6MG BASE	A091395 003	Aug 27, 2012	Aug	NEWA
AB			EQ 8MG BASE	A091395 004	Aug 27, 2012	Aug	NEWA
AB			EQ 12MG BASE	A091395 005	Aug 27, 2012	Aug	NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

		UCB INC	1MG/24HR	N021829 004	Apr 02, 2012	Apr	NEWA
			2MG/24HR	N021829 001	May 09, 2007	Apr	CMFD
			3MG/24HR	N021829 005	Apr 02, 2012	Apr	NEWA
			4MG/24HR	N021829 002	May 09, 2007	Apr	CMFD
			6MG/24HR	N021829 003	May 09, 2007	Apr	CMFD
	+		8MG/24HR	N021829 006	Apr 02, 2012	Apr	NEWA

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

	+	JAZZ EUSA PHARMA	50mCi/ML	N020570 001	Mar 28, 1997	Jul	CAHN
--	---	------------------	----------	-------------	--------------	-----	------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

@ VINTAGE PHARMS LLC 5MG

A074565 001 Aug 02, 1996 Sep CAHN

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+ VALEANT INTL 2%

N021385 001 Dec 10, 2003 Jan CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@ RANBAXY LABS LTD EQ 20MG BASE/ML

A078053 001 Feb 05, 2007 Aug DISC

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

@ MYLAN PHARMS INC EQ 25MG BASE

A076540 001 Mar 20, 2007 Oct DISC

AB EQ 25MG BASE

A078626 001 Jan 31, 2008 Sep CAHN

@ EQ 50MG BASE

A076540 002 Mar 20, 2007 Oct DISC

AB EQ 50MG BASE

A078626 002 Jan 31, 2008 Sep CAHN

@ EQ 100MG BASE

A076540 003 Mar 20, 2007 Oct DISC

AB EQ 100MG BASE

A078626 003 Jan 31, 2008 Sep CAHN

AB PROSAM LABS EQ 25MG BASE

A078175 001 Jul 21, 2010 Feb CMFD

AB EQ 50MG BASE

A078175 002 Jul 21, 2010 Feb CMFD

AB EQ 100MG BASE

A078175 003 Jul 21, 2010 Feb CMFD

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

>D> + PFIZER 10MG/ML

N203109 001 Aug 30, 2012 Dec CPOT

>A> + EQ 10MG BASE/ML

N203109 001 Aug 30, 2012 Dec CPOT

+ 10MG/ML

N203109 001 Aug 30, 2012 Aug NEWA

TABLET; ORAL

REVATIO

AB + PFIZER EQ 20MG BASE

N021845 001 Jun 03, 2005 Oct CFTG

SILDENAFIL CITRATE

AB APOTEX CORP EQ 20MG BASE

A091379 001 Nov 06, 2012 Oct NEWA

AB DR REDDYS LABS LTD EQ 20MG BASE

A202598 001 Nov 06, 2012 Oct NEWA

AB MYLAN PHARMS INC EQ 20MG BASE

A201150 001 Nov 09, 2012 Oct NEWA

>A> AB TEVA PHARMS EQ 20MG BASE

A078380 001 Jan 07, 2013 Dec NEWA

AB TORRENT PHARMS LTD EQ 20MG BASE

A091479 001 Nov 06, 2012 Oct NEWA

AB WATSON LABS INC EQ 20MG BASE

A202503 001 Nov 06, 2012 Oct NEWA

SILODOSIN

CAPSULE; ORAL

RAPAFLO

+ WATSON LABS 4MG

N022206 001 Oct 08, 2008 Oct CRLD

8MG

N022206 002 Oct 08, 2008 Oct CRLD

SILVER SULFADIAZINE

CREAM; TOPICAL

THERMAZENE

AB THEPHARMANETWORK LLC 1%

N018810 001 Dec 23, 1985 Jun CAHN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB	MYLAN PHARMS INC	5MG	A090868 001	Jun 08, 2010	Sep	CAHN
AB		10MG	A090868 002	Jun 08, 2010	Sep	CAHN
AB		20MG	A090868 003	Jun 08, 2010	Sep	CAHN
AB		40MG	A090868 004	Jun 08, 2010	Sep	CAHN
AB		80MG	A090868 005	Jun 08, 2010	Sep	CAHN
AB	PROSAM LABS	5MG	A078735 001	Aug 30, 2010	Feb	CMFD
AB		10MG	A078735 002	Aug 30, 2010	Feb	CMFD
AB		20MG	A078735 003	Aug 30, 2010	Feb	CMFD
AB		40MG	A078735 004	Aug 30, 2010	Feb	CMFD
AB		80MG	A078735 005	Aug 30, 2010	Feb	CMFD

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

	MERCK SHARP DOHME	10MG;EQ 50MG BASE	N202343 004	Sep 18, 2012	Sep	NEWA
		20MG;EQ 50MG BASE	N202343 005	Sep 18, 2012	Sep	NEWA
		40MG;EQ 50MG BASE	N202343 006	Sep 18, 2012	Sep	NEWA

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

	MERCK SHARP DOHME	EQ 25MG BASE	N021995 001	Oct 16, 2006	May	CAHN
		EQ 50MG BASE	N021995 002	Oct 16, 2006	May	CAHN
+		EQ 100MG BASE	N021995 003	Oct 16, 2006	May	CAHN

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

	@ MALLINCKRODT INC	460MG/GM;420MG/GM	N018509 001	Aug 07, 1985	Jan	CAHN
--	--------------------	-------------------	-------------	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP	HIKMA (MAPLE)	9MG/ML	A201850 001	Jan 20, 2012	Jan	NEWA
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	MEDEFIL	9MG/ML	N202832 001	Jan 06, 2012	Jan	NEWA

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPE SODIUM

	@ BRACCO	200uCi/ML	N013993 001		Jun	DISC
--	----------	-----------	-------------	--	-----	------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB	HIKMA PHARMS	62.5MG/5ML	A078215 001	Mar 31, 2011	May	CAHN
----	--------------	------------	-------------	--------------	-----	------

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

>A>						
>A>	+	HOUSTON CYCLOTRON	10-200mCi/ML	A203544 001	Dec 26, 2012	Dec
						NEWA

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

>A>	AA	+	CARDINAL HLTH 414	100uCi	N018671 001	May 27, 1982	Dec	CAHN
>A>	AA	+		200uCi	N018671 002	May 27, 1982	Dec	CAHN
>A>		+		400uCi	N018671 003	May 27, 1982	Dec	CAHN
			@ GE HEALTHCARE	100uCi	N017630 001		May	DISC
>D>	AA	+	SYNCOR PHARMS	100uCi	N018671 001	May 27, 1982	Dec	CAHN
>D>	AA	+		200uCi	N018671 002	May 27, 1982	Dec	CAHN
>D>				400uCi	N018671 003	May 27, 1982	Dec	CAHN
				400uCi	N018671 003	May 27, 1982	Oct	CMFD

SOLUTION; ORAL

SODIUM IODIDE I 123

@ GE HEALTHCARE

2mCi/ML

N017630 002 Jul DISC

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE

9-100mCi

N021305 006 May 19, 2005 Feb CAHN

@

2-200mCi

N021305 004 Nov 18, 2004 Jan DISC

SOLUTION; ORAL

HICON

@ JUBILANT DRAXIMAGE

1-500mCi/0.5ML

N021305 003 Jan 24, 2003 Feb DISC

@

1-250mCi/0.25ML

N021305 002 Jan 24, 2003 Feb DISC

@

1-1000mCi/ML

N021305 005 Apr 04, 2006 Feb DISC

+

250-1000mCi

N021305 007 Dec 05, 2011 Jan NEWA

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+ HOPE PHARMS 300MG/10ML (30MG/ML)

N203922 001 Feb 14, 2012 Feb NEWA

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+ JAZZ PHARMS 500MG/ML

N021196 001 Jul 17, 2002 Jun CAHN

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

@ CITRUSPHARMA

454GM/BOT

A040909 001 Dec 03, 2008 Jun DISC

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+ HOPE PHARMS 12.5GM/50ML (250MG/ML)

N203923 001 Feb 14, 2012 Feb NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN

@ NOVO NORDISK INC

5MG/1.5ML

N021148 001 Jun 20, 2000 Jul DISC

@

10MG/1.5ML

N021148 002 Jun 20, 2000 Jul DISC

@

15MG/1.5ML

N021148 003 Jun 20, 2000 Jul DISC

NORDITROPIN NORDIFLEX

@ NOVO NORDISK INC

5MG/1.5ML

N021148 004 Oct 01, 2004 Sep DISC

INJECTABLE; INJECTION

NORDITROPIN NORDIFLEX

@ NOVO NORDISK INC 10MG/1.5ML

N021148 005 Oct 01, 2004 Sep DISC

@ 15MG/1.5ML

N021148 006 Oct 01, 2004 Sep DISC

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

AB2 EPIC PHARMA INC 80MG

A077070 001 Nov 04, 2005 Jun CAHN

AB2 120MG

A077070 002 Nov 04, 2005 Jun CAHN

AB2 160MG

A077070 003 Nov 04, 2005 Jun CAHN

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+ PARAPRO LLC 0.9%

N022408 001 Jan 18, 2011 May CAHN

SUCCIMER

CAPSULE; ORAL

CHEMET

+ LUNDBECK LLC 100MG

N019998 002 Jan 30, 1991 Mar CAHN

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

AP HIKMA MAPLE EQ 0.05MG BASE/ML

A074413 001 Dec 15, 1995 Oct CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB FOUGERA PHARMS 10%

A077015 001 Nov 17, 2006 Jan CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ HIKMA MAPLE 80MG/ML;16MG/ML

A070627 001 Dec 29, 1987 Oct CAHN

@ 80MG/ML;16MG/ML

A070628 001 Dec 29, 1987 Oct CAHN

SUSPENSION; ORAL

SULFATRIM

@ STI PHARMA LLC 200MG/5ML;40MG/5ML

N018615 002 Jan 07, 1983 Aug CAHN

SULFATRIM PEDIATRIC

AB STI PHARMA LLC 200MG/5ML;40MG/5ML

N018615 001 Jan 07, 1983 Aug CAHN

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH

AB TEVA PHARMS 400MG;80MG

A070030 001 Jun 02, 1987 Nov CAHN

SULFANILAMIDE

CREAM; VAGINAL

AVC

+ JAZZ PHARMS COMMERCL 15%

N006530 003 Jan 27, 1987 Mar CAHN

+ JAZZ PHARMS II 15%

N006530 003 Jan 27, 1987 Jul CAHN

+ JAZZ PHARMS III 15%

N006530 003 Jan 27, 1987 Jun CAHN

+ MEDA PHARMS 15%

N006530 003 Jan 27, 1987 Nov CAHN

+ MEDPOINTE 15%

N006530 003 Jan 27, 1987 Oct CAHN

SUPPOSITORY; VAGINAL

AVC

@ JAZZ PHARMS COMMERCL	1.05GM	N006530 004	Jan 27, 1987	Mar	CAHN
@ JAZZ PHARMS II	1.05GM	N006530 004	Jan 27, 1987	Jul	CAHN
@ JAZZ PHARMS III	1.05GM	N006530 004	Jan 27, 1987	Jun	CAHN
@ MEDA PHARMS	1.05GM	N006530 004	Jan 27, 1987	Nov	CAHN
@ MEDPOINTE	1.05GM	N006530 004	Jan 27, 1987	Oct	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

BX	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010	Jun	CRLD
SUMATRIPTAN SUCCINATE						
AP	INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310 001	Aug 11, 2010	Mar	CAHN
AB	SUN PHARMA GLOBAL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358 001	Jun 21, 2011	Oct	CAHN
SUMAVEL DOSEPRO						
BX	+ ZOGENIX INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239 001	Jul 15, 2009	Jun	CTEC

TABLET; ORAL

SUMATRIPTAN SUCCINATE

AB	APOTEX INC	EQ 25MG BASE	A200263 001	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE	A200263 002	Jun 19, 2012	Jun	NEWA
AB		EQ 100MG BASE	A200263 003	Jun 19, 2012	Jun	NEWA

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

AB	ACCORD HLTHCARE	EQ 0.5MG BASE	A091195 001	Aug 31, 2011	Sep	CPOT
AB		EQ 1MG BASE	A091195 002	Aug 31, 2011	Sep	CPOT
AB		EQ 5MG BASE	A091195 003	Aug 31, 2011	Sep	CPOT
AB	PANACEA BIOTEC LTD	EQ 0.5MG BASE	A090802 001	Sep 28, 2012	Sep	NEWA
AB		EQ 1MG BASE	A090802 002	Sep 28, 2012	Sep	NEWA
AB		EQ 5MG BASE	A090802 003	Sep 28, 2012	Sep	NEWA

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+ MERCK SHARP DOHME	0.0015%	N202514 001	Feb 10, 2012	Feb	NEWA
---------------------	---------	-------------	--------------	-----	------

TALIGLUCERASE ALFA

POWDER; IV (INFUSION)

ELELYSO

+ PFIZER	200 UNITS/VIAL	N022458 001	May 01, 2012	May	NEWA
----------	----------------	-------------	--------------	-----	------

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

>A>	DARA BIOSCIENCES	EQ 10MG BASE/5ML	N021807 001	Oct 29, 2005	Dec	CAHN
>D>	ONCOGENERIX PHARMS	EQ 10MG BASE/5ML	N021807 001	Oct 29, 2005	Dec	CAHN
		EQ 10MG BASE/5ML	N021807 001	Oct 29, 2005	Aug	CMFD

TABLET; ORAL

TAMOXIFEN CITRATE

@ AEGIS PHARMS	EQ 10MG BASE	A076398 001	Mar 31, 2003	Jun	DISC
@	EQ 20MG BASE	A076398 002	Mar 31, 2003	Jun	DISC

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

TAMSULOSIN HYDROCHLORIDE

>A>	AB	ANCHEN PHARMS	0.4MG	A202010 001	Jan 04, 2013	Dec	NEWA
-----	----	---------------	-------	-------------	--------------	-----	------

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL

NUCYNTA

	+	JANSSEN PHARMS	EQ 20MG BASE/ML	N203794 001	Oct 15, 2012	Oct	NEWA
--	---	----------------	-----------------	-------------	--------------	-----	------

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

	+	STIEFEL LABS INC	0.1%	N202428 001	May 11, 2012	May	NEWA
--	---	------------------	------	-------------	--------------	-----	------

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

@ JUBILANT DRAXIMAGE

N/A

				N018035 001		May	CAHN
--	--	--	--	-------------	--	-----	------

DRAXIMAGE MDP-25

+ JUBILANT DRAXIMAGE

N/A

				N018035 002	Feb 27, 2004	May	CAHN
--	--	--	--	-------------	--------------	-----	------

>A> TEDUGLUTIDE RECOMBINANT

>A> POWDER; SUBCUTANEOUS

>A> GATTEX KIT

>A>		+	NPS PHARMS INC	5MG/VIAL	N203441 001	Dec 21, 2012	Dec	NEWA
-----	--	---	----------------	----------	-------------	--------------	-----	------

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB		NOVEL LABS INC	7.5MG	A071457 002	Jun 22, 2012	Jun	NEWA
----	--	----------------	-------	-------------	--------------	-----	------

AB			22.5MG	A071457 003	Jun 22, 2012	Jun	NEWA
----	--	--	--------	-------------	--------------	-----	------

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

AB		MERCK SHARP DOHME	5MG	N021029 001	Aug 11, 1999	Jun	CAHN
----	--	-------------------	-----	-------------	--------------	-----	------

AB			20MG	N021029 002	Aug 11, 1999	Jun	CAHN
----	--	--	------	-------------	--------------	-----	------

AB			100MG	N021029 003	Aug 11, 1999	Jun	CAHN
----	--	--	-------	-------------	--------------	-----	------

AB			140MG	N021029 005	Oct 19, 2006	Jun	CAHN
----	--	--	-------	-------------	--------------	-----	------

AB			180MG	N021029 006	Oct 19, 2006	Jun	CAHN
----	--	--	-------	-------------	--------------	-----	------

AB		+	250MG	N021029 004	Aug 11, 1999	Jun	CAHN
----	--	---	-------	-------------	--------------	-----	------

POWDER; INTRAVENOUS

TEMODAR

	+	MERCK SHARP DOHME	100MG/VIAL	N022277 001	Feb 27, 2009	Jun	CAHN
--	---	-------------------	------------	-------------	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

	+	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577 001	Jan 18, 2012	Jan	NEWA
--	---	---------------------	---------------	-------------	--------------	-----	------

TABLET; ORAL

VIREAD

		GILEAD SCIENCES INC	150MG	N021356 002	Jan 18, 2012	Apr	NEWA
--	--	---------------------	-------	-------------	--------------	-----	------

			200MG	N021356 003	Jan 18, 2012	Apr	NEWA
--	--	--	-------	-------------	--------------	-----	------

			250MG	N021356 004	Jan 18, 2012	Apr	NEWA
--	--	--	-------	-------------	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

@	RANBAXY LABS LTD	EQ 1MG BASE	A076021 001	Aug 22, 2002	Apr	DISC
@		EQ 2MG BASE	A076021 002	Aug 22, 2002	Apr	DISC
@		EQ 5MG BASE	A076021 003	Aug 22, 2002	Apr	DISC
@		EQ 10MG BASE	A076021 004	Aug 22, 2002	Apr	DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@	TEVA PARENTERAL	1MG/ML	A076853 001	Jul 20, 2004	Jan	DISC
---	-----------------	--------	-------------	--------------	-----	------

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	0.4%	A076712 001	Feb 18, 2005	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

SUPPOSITORY; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	80MG	A076850 001	Jul 12, 2006	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

TERIFLUNOMIDE

TABLET; ORAL

AUBAGIO

	SANOFI AVENTIS US	7MG	N202992 001	Sep 12, 2012	Sep	NEWA
+		14MG	N202992 002	Sep 12, 2012	Sep	NEWA

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

@	EMD SERONO	EQ 1MG BASE/VIAL	N022505 001	Nov 10, 2010	Jun	DISC
+		EQ 1MG BASE/VIAL	N022505 001	Nov 10, 2010	May	CAHN
+		EQ 2MG BASE/VIAL	N022505 002	Nov 29, 2011	Jun	NEWA

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

BX	+	ABBOTT LABS	1% (50MG/5GM PACKET)	N021015 002	Feb 28, 2000	Feb	CPOT
			1% (25MG/2.5GM PACKET)	N021015 001	Feb 28, 2000	Feb	CPOT
		ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309 002	Sep 07, 2012	Sep	NEWA
	+		1.62% (40.5MG/2.5GM PACKET)	N022309 003	Sep 07, 2012	Sep	NEWA

TESTIM

BX	+	AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454 001	Oct 31, 2002	Feb	CPOT
----	---	-----------------	----------------------	-------------	--------------	-----	------

TESTOSTERONE

		TEVA PHARMS	25MG/2.5GM PACKET	N202763 001	Feb 14, 2012	Feb	NEWA
			50MG/5GM PACKET	N202763 002	Feb 14, 2012	Feb	NEWA

GEL, METERED; TRANSDERMAL

ANDROGEL

+	ABBOTT LABS	1% (1.25GM/ACTUATION)	N021015 003	Sep 26, 2003	Jun	CPOT
---	-------------	-----------------------	-------------	--------------	-----	------

FORTESTA

+	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463 001	Dec 29, 2010	Sep	CPOT
---	-------------	----------------------	-------------	--------------	-----	------

PELLET; IMPLANTATION

TESTOPEL

+	ACTIENT PHARMS	75MG	A080911 001		May	CAHN
---	----------------	------	-------------	--	-----	------

SOLUTION, METERED; TRANSDERMAL

AXIRON

+	ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504 001	Nov 23, 2010	Sep	CPOT
---	------------------	----------------------	-------------	--------------	-----	------

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

AO	HIKMA FARMACEUTICA	200MG/ML	A091244 001	May 01, 2012	Apr	NEWA
AO	MYLAN INSTITUTIONAL	200MG/ML	A040652 001	Dec 11, 2006	Feb	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

TESTOSTERONE ENANTHATE

AO	HIKMA FARMACEUTICA	200MG/ML	A091120 001	Sep 18, 2012	Sep	NEWA
AO	MYLAN INSTITUTIONAL	200MG/ML	A040647 001	Oct 05, 2009	Feb	CAHN

TETRABENAZINE

TABLET; ORAL

XENAZINE

	VALEANT BERMUDA	12.5MG	N021894 001	Aug 15, 2008	Oct	CAHN
+		25MG	N021894 002	Aug 15, 2008	Oct	CAHN
	VALEANT PHARMS	12.5MG	N021894 001	Aug 15, 2008	Apr	CAHN
+		25MG	N021894 002	Aug 15, 2008	Apr	CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+	FOUGERA PHARMS	0.05%	A086576 002		Jan	CAHN
		0.1%	A086576 001		Jan	CAHN

SPRAY; NASAL

TYZINE

+	FOUGERA PHARMS	0.1%	A086576 003		Jan	CAHN
---	----------------	------	-------------	--	-----	------

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

	ACTIENT PHARMS	100MG	A087942 001	Aug 22, 1983	Nov	CAHN
		200MG	A087943 001	Aug 22, 1983	Nov	CAHN
		300MG	A087944 001	Aug 22, 1983	Nov	CAHN
+		400MG	A081034 001	Feb 28, 1992	Nov	CAHN
	UCB INC	100MG	A087942 001	Aug 22, 1983	May	CTEC
		200MG	A087943 001	Aug 22, 1983	May	CTEC
		300MG	A087944 001	Aug 22, 1983	May	CTEC
+		400MG	A081034 001	Feb 28, 1992	May	CRLD

THEOPHYLLINE

@ INWOOD LABS

@

@

@

@

		100MG	A040052 001	Feb 14, 1994	May	DISC
		125MG	A040052 002	Feb 14, 1994	May	DISC
		200MG	A040052 003	Feb 14, 1994	May	DISC
		300MG	A040052 004	Feb 14, 1994	May	DISC

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	4MG/ML	N018649 007	Jul 26, 1982	Mar	DISC
@		40MG/100ML	N018649 001	Jul 26, 1982	Mar	DISC
@		80MG/100ML	N018649 002	Jul 26, 1982	Mar	DISC
@		160MG/100ML	N018649 003	Jul 26, 1982	Mar	DISC
@		200MG/100ML	N018649 004	Jul 26, 1982	Mar	DISC

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	320MG/100ML	N018649 006	Nov 13, 1985	Mar	DISC
@	400MG/100ML	N018649 005	Jul 26, 1982	Mar	DISC

SOLUTION; ORAL

THEOPHYLLINE

AA + SILARX	80MG/15ML	A091156 001	Apr 13, 2011	Jun	CTEC
AA TRIS PHARMA INC	80MG/15ML	A091586 001	Jun 15, 2012	Jun	NEWA

TABLET; ORAL

THEOLAIR

+ MEDICIS	125MG	A086399 001		Jul	CAHN
+	250MG	A086399 002		Jul	CAHN

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

@ INWOOD LABS	450MG	A040034 001	Apr 28, 1995	Oct	DISC
UNIPHYL					
@ RHODES PHARMS	400MG	A087571 001	Sep 01, 1982	Sep	CAHN
@	600MG	A040086 001	Apr 15, 1996	Sep	CAHN

THIAMINE HYDROCHLORIDEINJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

@ HIKMA MAPLE	100MG/ML	A080575 001		Oct	CAHN
AP MYLAN INSTITUTIONAL	100MG/ML	A091623 001	Jun 25, 2012	Jun	NEWA

TIAGABINE HYDROCHLORIDETABLET; ORAL

GABITRIL

@ CEPHALON	6MG	N020646 006	Nov 29, 2005	Jan	DISC
@	8MG	N020646 007	Nov 29, 2005	Jan	DISC
@	10MG	N020646 008	Nov 29, 2005	Jan	DISC

TICLOPIDINE HYDROCHLORIDETABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

@ SANDOZ	250MG	A075326 001	Aug 20, 1999	Oct	DISC
----------	-------	-------------	--------------	-----	------

TINIDAZOLETABLET; ORAL

TINDAMAX

AB MISSION PHARMA	250MG	N021618 001	May 17, 2004	Apr	CFTG
AB +	500MG	N021618 002	May 17, 2004	Apr	CFTG

TINIDAZOLE

AB NOVEL LABS INC	250MG	A202044 001	Apr 30, 2012	Apr	NEWA
AB	500MG	A202044 002	Apr 30, 2012	Apr	NEWA
AB ROXANE	250MG	A201172 001	Apr 30, 2012	Apr	NEWA
AB	500MG	A201172 002	Apr 30, 2012	Apr	NEWA

TINZAPARIN SODIUMINJECTABLE; INJECTION

INNOHEP

@ LEO PHARMA AS	20,000 IU/ML	N020484 001	Jul 14, 2000	Jun	DISC
-----------------	--------------	-------------	--------------	-----	------

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB	APOTEX INC	EQ 2MG BASE	A078868 001	Feb 03, 2012	Jan	NEWA
AB		EQ 4MG BASE	A078868 002	Feb 03, 2012	Jan	NEWA
AB		EQ 6MG BASE	A078868 003	Feb 03, 2012	Jan	NEWA
AB	MYLAN LABS	EQ 2MG BASE	A091502 001	Nov 09, 2012	Oct	NEWA
AB		EQ 4MG BASE	A091502 002	Nov 09, 2012	Oct	NEWA
AB		EQ 6MG BASE	A091502 003	Nov 09, 2012	Oct	NEWA
ZANAFLEX						
AB	ACORDA	EQ 2MG BASE	N021447 001	Aug 29, 2002	Jan	CFTG
AB		EQ 4MG BASE	N021447 002	Aug 29, 2002	Jan	CFTG
AB	+	EQ 6MG BASE	N021447 003	Aug 29, 2002	Jan	CFTG

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 2MG BASE	A076282 001	Dec 16, 2003	Sep	CAHN
AB		EQ 4MG BASE	A076282 002	Dec 16, 2003	Sep	CAHN
AB	PROSAM LABS	EQ 2MG BASE	A076281 001	Oct 20, 2003	Feb	CMFD
AB		EQ 4MG BASE	A076281 002	Oct 20, 2003	Feb	CMFD
AB	SANDOZ INC	EQ 2MG BASE	A076280 001	Nov 26, 2002	Feb	NEWA
AB	UNICHEM LABS LTD	EQ 2MG BASE	A091283 001	Nov 28, 2012	Nov	NEWA
AB		EQ 4MG BASE	A091283 002	Nov 28, 2012	Nov	NEWA

TOBRAMYCIN

SOLUTION; INHALATION

BETHKIS

	CHIESI PHARMS INC	300MG/4ML	N201820 001	Oct 12, 2012	Oct	NEWA
	CORNERSTONE THERAP	300MG/4ML	N201820 001	Oct 12, 2012	Nov	CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

	@ APOTHECON	EQ 10MG BASE/ML	A064021 001	May 31, 1994	Sep	DISC
	@ HIKMA MAPLE	EQ 10MG BASE/ML	A063128 001	Nov 27, 1991	Oct	CAHN
	@	EQ 10MG BASE/ML	A063113 001	Apr 26, 1991	Oct	CAHN
	@	EQ 40MG BASE/ML	A063118 001	Jul 29, 1991	Oct	CAHN
	@	EQ 40MG BASE/ML	A063127 001	Nov 27, 1991	Oct	CAHN
AP		EQ 40MG BASE/ML	A063117 001	Apr 26, 1991	Oct	CAHN
AP	PFIZER	EQ 40MG BASE/ML	A065407 001	Mar 11, 2008	Sep	CAHN

TOFACITINIB CITRATE

TABLET; ORAL

XELJANZ

+	PFIZER	EQ 5MG BASE	N203214 001	Nov 06, 2012	Nov	NEWA
---	--------	-------------	-------------	--------------	-----	------

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+	MYLAN PHARMS INC	500MG	A086445 001		Mar	CRLD
	@ WATSON LABS	500MG	A087318 001		Mar	DISC
	@	500MG	A086109 001		Mar	DISC

TOLCAPONE

TABLET; ORAL

TASMAR

+	VALEANT PHARMS LLC	100MG	N020697 001	Jan 29, 1998	May	CAHN
	@	200MG	N020697 002	Jan 29, 1998	May	CAHN

TOLTERODINE TARTRATE

TABLET; ORAL

DETROL

AB	PHARMACIA AND UPJOHN	1MG	N020771 001	Mar 25, 1998	Sep	CFTG
AB	+	2MG	N020771 002	Mar 25, 1998	Sep	CFTG

TOLTERODINE TARTRATE

AB	APOTEX CORP	1MG	A200164 001	Sep 25, 2012	Sep	NEWA
AB		2MG	A200164 002	Sep 25, 2012	Sep	NEWA
AB	MYLAN PHARMS INC	1MG	A202641 001	Nov 27, 2012	Nov	NEWA
AB		2MG	A202641 002	Nov 27, 2012	Nov	NEWA

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

>D>	AP	INNOPHARMA INC	EQ 4MG BASE/VIAL	A201166 001	Aug 08, 2012	Dec	CAHN
	AP		EQ 4MG BASE/VIAL	A201166 001	Aug 08, 2012	Jul	NEWA
>A>	AP	MYLAN LLC	EQ 4MG BASE/VIAL	A201166 001	Aug 08, 2012	Dec	CAHN
	AP	ONCO THERAPIES LTD	EQ 4MG BASE/VIAL	A091542 001	Aug 28, 2012	Aug	NEWA

SOLUTION; INTRAVENOUS

TOPOTECAN

>D>	+	HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582 001	Feb 02, 2011	Dec	CTEC
>A>	AP	+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582 001	Feb 02, 2011	Dec	CTEC
>A>	AP	TEVA PHARMS	EQ 4MG BASE/4ML (1MG/ML)	N022453 001	Dec 20, 2012	Dec	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	IPCA LABS LTD	50MG	A201973 001	Nov 16, 2012	Nov	NEWA
AB	MYLAN PHARMS INC	50MG	A075980 001	Nov 21, 2002	Sep	CAHN
	@ SANDOZ	50MG	A075968 001	Jun 25, 2002	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB2	ACTAVIS	100MG	A091609 001	Jun 27, 2012	Jun	NEWA
AB2		200MG	A091609 002	Jun 27, 2012	Jun	NEWA
AB2		300MG	A091609 003	Jun 27, 2012	Jun	NEWA
AB2	ANCHEN PHARMS	100MG	A200491 001	Jun 27, 2012	Jun	NEWA
AB2		200MG	A200491 002	Jun 27, 2012	Jun	NEWA
AB2		300MG	A200491 003	Jun 27, 2012	Jun	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

+	SHIONOGI INC	50MG	N021693 001	May 05, 2005	Mar	CTNA
---	--------------	------	-------------	--------------	-----	------

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP	APP PHARMS LLC	100MG/ML	A091596 001	Mar 02, 2012	May	CAHN
AP	LUITPOLD	100MG/ML	A201885 001	Aug 10, 2011	Sep	CAHN
AP	NEXUS PHARMS	100MG/ML	A091596 001	Mar 02, 2012	Feb	NEWA

TABLET; ORAL

LYSTEDA

>D>	+	FERRING PHARMS AS	650MG	N022430	001	Nov 13, 2009	Dec	CFTG
>A>	AB	+	650MG	N022430	001	Nov 13, 2009	Dec	CFTG
>A>		TRANEXAMIC ACID						
>A>	AB	WATSON LABS INC FL	650MG	A202093	001	Dec 27, 2012	Dec	NEWA

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

AB	+	COVIS PHARMA	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jan	CAHN
----	---	--------------	--------------	---------	-----	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB		MYLAN PHARMS INC	50MG	A090514	001	Jun 02, 2009	Sep	CAHN
AB			100MG	A090514	002	Jun 02, 2009	Sep	CAHN
AB			150MG	A090514	003	Jun 02, 2009	Sep	CAHN
AB			300MG	A090514	004	Jun 02, 2009	Sep	CAHN

TRETINOIN

CAPSULE; ORAL

TRETINOIN

AB		ANCHEN PHARMS	10MG	A201687	001	Oct 24, 2012	Oct	NEWA
AB	+	BARR LABS INC	10MG	A077684	001	Jun 22, 2007	Oct	CTEC

CREAM; TOPICAL

AVITA

AB		MYLAN PHARMS INC	0.025%	N020404	003	Jan 14, 1997	Jun	CAHN
----	--	------------------	--------	---------	-----	--------------	-----	------

RENOVA

	+	VALEANT INTL	0.02%	N021108	001	Aug 31, 2000	Jan	CAHN
AB2	+		0.05%	N019963	001	Dec 29, 1995	Jan	CAHN

RETIN-A

AB	+	VALEANT INTL	0.025%	N019049	001	Sep 16, 1988	Jan	CAHN
AB1	+		0.05%	N017522	001		Jan	CAHN
AB	+		0.1%	N017340	001		Jan	CAHN

TRETINOIN

AB		PRECISION DERMAT	0.025%	A075264	001	Dec 24, 1998	May	CAHN
	+		0.0375%	A090098	001	Mar 22, 2010	May	CAHN
AB1			0.05%	A075265	001	Dec 24, 1998	May	CAHN
			0.075%	A202209	001	Oct 11, 2012	Sep	NEWA
AB			0.1%	A075213	001	Dec 24, 1998	May	CAHN
AB2		SUNEVA MEDCL	0.05%	A076498	001	Sep 15, 2005	May	CAHN

GEL; TOPICAL

RETIN-A

AB	+	VALEANT INTL	0.01%	N017955	001		Jan	CAHN
AB	+		0.025%	N017579	002		Jan	CAHN

TRETINOIN

AB		PRECISION DERMAT	0.01%	A075589	001	Jun 11, 2002	May	CAHN
AB			0.025%	A075529	001	Feb 22, 2000	May	CAHN

SOLUTION; TOPICAL

RETIN-A

AT	+	VALEANT INTL	0.05%	N016921	001		Jan	CAHN
----	---	--------------	-------	---------	-----	--	-----	------

SWAB; TOPICAL

RETIN-A

		@ VALEANT INTL	0.05%	N016921	002		Jan	CAHN
--	--	----------------	-------	---------	-----	--	-----	------

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

@ ABBOTT 0.1MG/INH N018117 001 Apr 23, 1982 May DISC

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A085692 001		Jan	CAHN
AT		0.1%	A085692 003		Jan	CAHN
AT	+	0.5%	A085692 002		Jan	CAHN

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A040467 001	Apr 21, 2003	Jan	CAHN
AT		0.1%	A040467 002	Apr 21, 2003	Jan	CAHN
AT	+	0.025%	A088450 001	Apr 01, 1985	Oct	CRLD

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A085691 001		Jan	CAHN
AT		0.1%	A085691 003		Jan	CAHN
AT		0.5%	A085691 002		Jan	CAHN

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

AB TEVA PHARMS 0.055MG/SPRAY A078104 001 Jul 30, 2009 Mar CAHN

TRIAZOLAM

TABLET; ORAL

TRIAZOLAM

AB	MYLAN PHARMS INC	0.125MG	A074031 001	Mar 25, 1994	Sep	CAHN
AB		0.25MG	A074031 002	Mar 25, 1994	Sep	CAHN

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

AT ALCON PHARMS LTD 1% A074311 001 Oct 06, 1995 Sep CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

@ HOSPIRA 100MG/ML A088804 001 Apr 03, 1987 Jun DISC

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

AB + ALLERGAN 60MG N022103 001 Aug 03, 2007 Sep CFTG

TROSPIUM CHLORIDE

AB WATSON LABS INC FL 60MG A091289 001 Oct 12, 2012 Sep NEWA

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

>D>	@ SUCAMPO PHARMS	0.15%	N021214 001	Aug 03, 2000	Dec	CMFD
>A>		0.15%	N021214 001	Aug 03, 2000	Dec	CMFD

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	JUBILANT ORGANOSYS	EQ 500MG BASE	A201506 001	Apr 03, 2012	Mar	NEWA
AB		EQ 1GM BASE	A201506 002	Apr 03, 2012	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 500MG BASE	A078518 001	May 24, 2010	Sep	CAHN
AB		EQ 1GM BASE	A078518 002	May 24, 2010	Sep	CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	50MG/ML	N022257 001	Aug 28, 2009	May	CAHN
---	-------------------	---------	-------------	--------------	-----	------

TABLET; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304 001	Mar 29, 2001	May	CAHN
---	-------------------	---------------	-------------	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

AB	VIROPHARMA	EQ 125MG BASE	N050606 001	Apr 15, 1986	Mar	CFTG
AB	+	EQ 250MG BASE	N050606 002	Apr 15, 1986	Mar	CFTG

VANCOMYCIN HYDROCHLORIDE

AB	AKORN	EQ 125MG BASE	A065478 001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065478 002	Apr 09, 2012	Mar	NEWA
AB	APP PHARMS LLC	EQ 125MG BASE	A065453 001	Jun 18, 2012	Jun	NEWA
AB		EQ 250MG BASE	A065453 002	Jun 18, 2012	Jun	NEWA
AB	STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490 001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065490 002	Apr 09, 2012	Mar	NEWA
AB	WATSON LABS	EQ 125MG BASE	A065510 001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065510 002	Apr 09, 2012	Mar	NEWA

INJECTABLE; INJECTION

VANCOLED

@	HIKMA MAPLE	EQ 500MG BASE/VIAL	A062682 001	Jul 22, 1986	Oct	CAHN
@		EQ 1GM BASE/VIAL	A062682 002	Mar 30, 1988	Oct	CAHN
@		EQ 2GM BASE/VIAL	A062682 003	May 11, 1988	Oct	CAHN
@		EQ 5GM BASE/VIAL	A062682 004	May 11, 1988	Oct	CAHN
@		EQ 10GM BASE/VIAL	A062682 005	May 11, 1988	Oct	CAHN

VANCOMYCIN HYDROCHLORIDE

@	HIKMA MAPLE	EQ 500MG BASE/VIAL	A062879 001	Aug 02, 1988	Oct	CAHN
@		EQ 1GM BASE/VIAL	A062879 002	Aug 02, 1988	Oct	CAHN
AP	SAGENT PHARMS	EQ 5GM BASE/VIAL	A200837 001	Aug 10, 2012	Jul	NEWA
AP	SANDOZ INC	EQ 5GM BASE/VIAL	A201048 001	Aug 10, 2012	Jul	NEWA
AP		EQ 10GM BASE/VIAL	A201048 002	Aug 10, 2012	Jul	NEWA

VANDETANIB

TABLET; ORAL

CAPRELSA

	IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Feb	CTNA
+		300MG	N022405 002	Apr 06, 2011	Feb	CTNA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

AB	BAYER HLTHCARE	2.5MG	N021400 003	Aug 19, 2003	Apr	CFTG
AB		5MG	N021400 001	Aug 19, 2003	Apr	CFTG

TABLET; ORAL

LEVITRA

AB	BAYER HLTHCARE	10MG	N021400 002	Aug 19, 2003	Apr	CFTG
AB	+	20MG	N021400 004	Aug 19, 2003	Apr	CFTG

VARDENAFIL HYDROCHLORIDE

AB	TEVA PHARMS	2.5MG	A091347 001	May 03, 2012	Apr	NEWA
AB		5MG	A091347 002	May 03, 2012	Apr	NEWA
AB		10MG	A091347 003	May 03, 2012	Apr	NEWA
AB		20MG	A091347 004	May 03, 2012	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	BEDFORD	10MG/VIAL	A075549 001	Jun 13, 2000	Jun	CRLD
AP		20MG/VIAL	A075549 002	Jun 13, 2000	Nov	CTEC
		20MG/VIAL	A075549 002	Jun 13, 2000	Jun	CRLD
	@ HIKMA MAPLE	10MG/VIAL	A075218 001	Aug 23, 1999	Oct	CAHN
	@	20MG/VIAL	A075218 002	Aug 23, 1999	Oct	CAHN
AP	+	SUN PHARMA GLOBAL	A079001 001	Jun 17, 2009	Jun	CRLD
AP	+		A079001 002	Jun 17, 2009	Jun	CRLD

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ANCHEN PHARMS	EQ 37.5MG BASE	A078087 001	Mar 16, 2012	Mar	NEWA
AB		EQ 75MG BASE	A078087 002	Mar 16, 2012	Mar	NEWA
AB		EQ 150MG BASE	A078087 003	Mar 16, 2012	Mar	NEWA

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	HERITAGE PHARMS INC	EQ 25MG BASE	A078554 001	Jan 09, 2009	Aug	CAHN
AB		EQ 37.5MG BASE	A078554 002	Jan 09, 2009	Aug	CAHN
AB		EQ 50MG BASE	A078554 003	Jan 09, 2009	Aug	CAHN
AB		EQ 75MG BASE	A078554 004	Jan 09, 2009	Aug	CAHN
AB		EQ 100MG BASE	A078554 005	Jan 09, 2009	Aug	CAHN

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

AB	+	PFIZER	120MG	N019152 003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152 002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152 001	Dec 16, 1986	Feb	CTNA

VERAPAMIL HYDROCHLORIDE

AB	APOTEX CORP	120MG	A200878 001	Apr 20, 2012	Apr	NEWA
AB		180MG	A200878 002	Apr 20, 2012	Apr	NEWA
AB		240MG	A200878 003	Apr 20, 2012	Apr	NEWA

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+	LUNDBECK LLC	500MG/PACKET	N022006 001	Aug 21, 2009	Apr	CAHN
---	--------------	--------------	-------------	--------------	-----	------

TABLET; ORAL

SABRIL

+	LUNDBECK LLC	500MG	N020427 001	Aug 21, 2009	Apr	CAHN
---	--------------	-------	-------------	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VLIBRYD

+	FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	Apr	CRLD
		40MG	N022567 003	Jan 21, 2011	Apr	CRLD

VINCRIStINE SULFATE

INJECTABLE, LIPOSOMAL; INTRAVENOUS

MARQIBO KIT

+	TALON THERAP	5MG/5ML (1MG/ML)	N202497 001	Aug 09, 2012	Aug	NEWA
---	--------------	------------------	-------------	--------------	-----	------

VINORELBINE

INJECTABLE; INJECTION

VINORELBINE

AP	ONCO THERAPIES LTD	EQ 10MG BASE/ML	A200148 001	Aug 31, 2012	Aug	NEWA
----	--------------------	-----------------	-------------	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

AP	HIKMA MAPLE	EQ 10MG BASE/ML	A075992 001	Jun 10, 2003	Oct	CAHN
AP	JIANGSU HANSOH PHARM	EQ 10MG BASE/ML	A091106 001	Sep 26, 2012	Sep	NEWA

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+	GENENTECH	150MG	N203388 001	Jan 30, 2012	Jan	NEWA
---	-----------	-------	-------------	--------------	-----	------

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

AP	+	PFIZER	200MG/VIAL	N021267 001	May 24, 2002	May	CFTG
----	---	--------	------------	-------------	--------------	-----	------

VORICONAZOLE

AP		SANDOZ INC	200MG/VIAL	A090862 001	May 30, 2012	May	NEWA
----	--	------------	------------	-------------	--------------	-----	------

TABLET; ORAL

VORICONAZOLE

AB		MYLAN PHARMS INC	50MG	A090547 001	Apr 22, 2010	Oct	CAHN
AB			200MG	A090547 002	Apr 22, 2010	Oct	CAHN
AB		TEVA PHARMS	50MG	A091658 001	Apr 06, 2012	Mar	NEWA
AB			200MG	A091658 002	Apr 06, 2012	Mar	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

@	JAZZ PHARMS COMMERCL	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004	Mar	CAHN
---	----------------------	------------------------	-------------	--------------	-----	------

@	JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004	Jun	CAHN
---	------------------	------------------------	-------------	--------------	-----	------

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+	JAZZ PHARMS COMMERCL	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004	Mar	CAHN
---	----------------------	------------------------	-------------	--------------	-----	------

+		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004	Mar	CAHN
---	--	------------------------	-------------	--------------	-----	------

+		500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004	Mar	CAHN
---	--	------------------------	-------------	--------------	-----	------

+	JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004	Jun	CAHN
---	------------------	------------------------	-------------	--------------	-----	------

+		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004	Jun	CAHN
---	--	------------------------	-------------	--------------	-----	------

+		500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004	Jun	CAHN
---	--	------------------------	-------------	--------------	-----	------

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

AB	HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011	Oct	CAHN
AB	MYLAN PHARMS INC	300MG	A078922	001	Feb 14, 2008	Sep	CAHN
	@ RANBAXY LABS LTD	300MG	A077327	001	Sep 19, 2005	Apr	DISC

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+ PFIZER	EQ 20MG BASE	N020825	001	Feb 05, 2001	Feb	CFTG
AB		EQ 40MG BASE	N020825	002	Feb 05, 2001	Feb	CFTG
AB		EQ 60MG BASE	N020825	003	Feb 05, 2001	Feb	CFTG
AB		EQ 80MG BASE	N020825	004	Feb 05, 2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

AB	APOTEX CORP	EQ 20MG BASE	A077561	001	Mar 02, 2012	Feb	NEWA
AB		EQ 40MG BASE	A077561	002	Mar 02, 2012	Feb	NEWA
AB		EQ 60MG BASE	A077561	003	Mar 02, 2012	Feb	NEWA
AB		EQ 80MG BASE	A077561	004	Mar 02, 2012	Feb	NEWA
AB	DR REDDYS LABS INC	EQ 20MG BASE	A077565	001	Mar 02, 2012	Feb	NEWA
AB		EQ 40MG BASE	A077565	002	Mar 02, 2012	Feb	NEWA
AB		EQ 60MG BASE	A077565	003	Mar 02, 2012	Feb	NEWA
AB		EQ 80MG BASE	A077565	004	Mar 02, 2012	Feb	NEWA
AB	LUPIN PHARMS	EQ 20MG BASE	A077560	001	Mar 02, 2012	Feb	NEWA
AB		EQ 40MG BASE	A077560	002	Mar 02, 2012	Feb	NEWA
AB		EQ 60MG BASE	A077560	003	Mar 02, 2012	Feb	NEWA
AB		EQ 80MG BASE	A077560	004	Mar 02, 2012	Feb	NEWA
AB	SANDOZ INC	EQ 20MG BASE	A077562	001	Jun 01, 2012	May	NEWA
AB		EQ 40MG BASE	A077562	002	Jun 01, 2012	May	NEWA
AB		EQ 60MG BASE	A077562	003	Jun 01, 2012	May	NEWA
AB		EQ 80MG BASE	A077562	004	Jun 01, 2012	May	NEWA
AB	WOCKHARDT LTD	EQ 20MG BASE	A090348	001	Sep 05, 2012	Aug	NEWA
AB		EQ 40MG BASE	A090348	002	Sep 05, 2012	Aug	NEWA
AB		EQ 60MG BASE	A090348	003	Sep 05, 2012	Aug	NEWA
AB		EQ 80MG BASE	A090348	004	Sep 05, 2012	Aug	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB	CIPLA LTD	5MG	A077388	001	Jul 30, 2012	Jul	NEWA
AB		10MG	A077388	002	Jul 30, 2012	Jul	NEWA
	@ MYLAN PHARMS INC	5MG	A078016	001	Apr 23, 2007	Oct	DISC
	@	10MG	A078016	002	Apr 23, 2007	Oct	DISC

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

AB	MYLAN PHARMS INC	25MG	A077647	001	Dec 22, 2005	Sep	CAHN
AB		50MG	A077647	002	Dec 22, 2005	Sep	CAHN
AB		100MG	A077647	003	Dec 22, 2005	Sep	CAHN

OTC DRUG PRODUCT LIST - 32ND EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

2-1

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

+ MCNEIL CONS 800MG;10MG;165MG N020958 001 Oct 16, 2000 Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@ RANBAXY LABS LTD 5MG/5ML A090183 002 Apr 24, 2008 Jul DISC

TRIS PHARMA INC 5MG/5ML A090572 001 Nov 16, 2012 Nov NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ RANBAXY LABS LTD 5MG/5ML A090183 001 Apr 24, 2008 Jul DISC

TRIS PHARMA INC 5MG/5ML A090572 002 Nov 16, 2012 Nov NEWA

TABLET, CHEWABLE; ORAL

CHILDREN'S ZYRTEC ALLERGY

MCNEIL CONS 5MG N021621 003 Nov 16, 2007 Oct CAHN

+ 10MG N021621 004 Nov 16, 2007 Oct CAHN

CHILDREN'S ZYRTEC HIVES RELIEF

MCNEIL CONS 5MG N021621 005 Nov 16, 2007 Oct CAHN

+ 10MG N021621 006 Nov 16, 2007 Oct CAHN

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ ACTAVIS ELIZABETH 5MG A078615 003 Dec 28, 2007 Oct DISC

@ 10MG A078615 004 Dec 28, 2007 Oct DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARM INDS LTD 5MG;120MG A090922 001 Sep 28, 2012 Sep NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ CAREFUSION 2%;70% (0.67ML) N021555 001 Oct 07, 2002 Aug CAHN

CHLORAPREP SINGLE SWABSTICK

+ CAREFUSION 2%;70% (1.75ML) N021555 002 May 10, 2005 Aug CAHN

CHLORAPREP TRIPLE SWABSTICK

+ CAREFUSION 2%;70% (5.25ML) N021555 003 Jun 10, 2009 Aug CAHN

CHLORASCUB MAXI SWABSTICK

+ PROF DSPLS 3.15%;70% (5.1ML) N021524 003 Jun 03, 2005 Mar CAHN

CHLORASCUB SWAB

+ PROF DSPLS 3.15%;70% (1ML) N021524 001 Jun 03, 2005 Mar CAHN

CHLORASCUB SWABSTICK

+ PROF DSPLS 3.15%;70% (1.6ML) N021524 002 Jun 03, 2005 Mar CAHN

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

>D> HH AND P 5.2MG/SPRAY A077976 001 Sep 07, 2007 Dec DISC

>A> @ 5.2MG/SPRAY A077976 001 Sep 07, 2007 Dec DISC

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

TRIS PHARMA INC	EQ 30MG HBR/5ML	A091135	001	May 25, 2012	May	NEWA
-----------------	-----------------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

STRIDES ARCOLAB LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012	Feb	NEWA
---------------------	--	---------	-----	--------------	-----	------

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

@ MCNEIL CONS	10MG	N020801	001	Sep 24, 1998	Mar	CAHN
---------------	------	---------	-----	--------------	-----	------

+ 20MG

N020801	002	Dec 17, 2007	Mar	CAHN
---------	-----	--------------	-----	------

TABLET; ORAL

FAMOTIDINE

@ SANDOZ	10MG	A076101	001	Oct 21, 2002	Oct	DISC
----------	------	---------	-----	--------------	-----	------

PEPCID AC

MCNEIL CONS	10MG	N020325	001	Apr 28, 1995	Mar	CAHN
-------------	------	---------	-----	--------------	-----	------

+ 20MG

N020325	002	Sep 23, 2003	Mar	CAHN
---------	-----	--------------	-----	------

PEPCID AC (GELTAB)

MCNEIL CONS	10MG	N020902	001	Aug 05, 1999	Mar	CAHN
-------------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012	Jan	NEWA
----------------	------	---------	-----	--------------	-----	------

WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012	Jan	NEWA
---------------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012	Jan	NEWA
----------------	------	---------	-----	--------------	-----	------

WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012	Jan	NEWA
---------------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012	Jan	NEWA
----------------	------	---------	-----	--------------	-----	------

	180MG	A091567	006	Feb 06, 2012	Jan	NEWA
--	-------	---------	-----	--------------	-----	------

WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012	Jan	NEWA
---------------	------	---------	-----	--------------	-----	------

	180MG	A079112	006	Feb 08, 2012	Jan	NEWA
--	-------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012	Jan	NEWA
----------------	------	---------	-----	--------------	-----	------

	180MG	A091567	005	Feb 06, 2012	Jan	NEWA
--	-------	---------	-----	--------------	-----	------

WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012	Jan	NEWA
---------------	------	---------	-----	--------------	-----	------

	180MG	A079112	005	Feb 08, 2012	Jan	NEWA
--	-------	---------	-----	--------------	-----	------

IBUPROFEN

CAPSULE; ORAL

ADVIL LIQUI-GELS

+ PFIZER	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	001	Apr 20, 1995	Nov	CAHN
----------	---------------------------------------	---------	-----	--------------	-----	------

ADVIL MIGRAINE LIQUI-GELS

+ PFIZER	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	002	Mar 16, 2000	Nov	CAHN
----------	---------------------------------------	---------	-----	--------------	-----	------

IBUPROFEN

ACCUCAPS INDS	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009	Jan	CAHN
---------------	---------------------------------------	---------	-----	--------------	-----	------

CAPSULE; ORAL						
IBUPROFEN						
PLD ACQUISITIONS	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009	Oct	CAHN
SUSPENSION/DROPS; ORAL						
PEDIATRIC ADVIL						
+ PFIZER	100MG/2.5ML	N020812	001	Jan 30, 1998	Nov	CAHN
SUSPENSION; ORAL						
CHILDREN'S ADVIL						
PFIZER	100MG/5ML	N020589	001	Jun 27, 1996	Nov	CAHN
CHILDREN'S ADVIL-FLAVORED						
PFIZER	100MG/5ML	N020589	002	Nov 07, 1997	Nov	CAHN
TABLET, CHEWABLE; ORAL						
CHILDREN'S ADVIL						
PFIZER	50MG	N020944	001	Dec 18, 1998	Nov	CAHN
JUNIOR STRENGTH ADVIL						
PFIZER	100MG	N020944	002	Dec 18, 1998	Nov	CAHN
TABLET; ORAL						
IBUPROFEN						
@ CONTRACT PHARMACAL	200MG	A073691	001	Feb 25, 1994	Oct	DISC
JUNIOR STRENGTH ADVIL						
PFIZER	100MG	N020267	002	Dec 13, 1996	Nov	CAHN
<u>IBUPROFEN SODIUM</u>						
TABLET; ORAL						
ADVIL						
+ PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803	001	Jun 12, 2012	Jun	NEWA
<u>LANSOPRAZOLE</u>						
CAPSULE, DELAYED REL PELLETS; ORAL						
LANSOPRAZOLE						
DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012	Apr	NEWA
PERRIGO R AND D	15MG	A202319	001	May 18, 2012	Apr	NEWA
WOCKHARDT LTD	15MG	A202727	001	May 18, 2012	Apr	NEWA
PREVACID 24 HR						
+ NOVARTIS	15MG	N022327	001	May 18, 2009	Apr	CFTG
<u>LEVONORGESTREL</u>						
TABLET; ORAL						
LEVONORGESTREL						
WATSON LABS INC	1.5MG	A200670	001	Jul 12, 2012	Jun	NEWA
PLAN B						
+ TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006	May	CAHN
PLAN B ONE-STEP						
+ DURAMED	1.5MG	N021998	001	Jul 10, 2009	Jun	CFTG
<u>LORATADINE</u>						
SYRUP; ORAL						
LORATADINE						
@ RANBAXY LABS LTD	1MG/ML	A076529	001	Aug 20, 2004	Jul	DISC
TABLET, ORALLY DISINTEGRATING; ORAL						
ALAVERT						
PFIZER	10MG	N021375	001	Dec 19, 2002	Nov	CAHN
LORATADINE						
PFIZER	10MG	A075822	001	Feb 10, 2003	Nov	CAHN

MENTHOL; METHYL SALICYLATE

PATCH; TOPICAL
SALONPAS

HISAMITSU PHARM CO 3%;10% N022029 002 Nov 05, 2012 Nov NEWA

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM
@ SANDOZ

EQ 200MG BASE A074646 001 Jan 13, 1997 Oct DISC

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NICOTINE

AVEVA 7MG/24HR A074612 002 Jul 28, 2003 Apr NEWA
14MG/24HR A074612 003 Oct 20, 1997 Apr NEWA

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL
NICOTINE POLACRILEX

PERRIGO R AND D EQ 2MG BASE A203690 001 Oct 09, 2012 Sep NEWA
EQ 4MG BASE A203690 002 Oct 09, 2012 Sep NEWA

NIZATIDINE

TABLET; ORAL
AXID AR

+ PFIZER 75MG N020555 001 May 09, 1996 Nov CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
POLYETHYLENE GLYCOL 3350

>A> EMCURE PHARMS USA 17GM/SCOOPFUL A202071 001 Dec 28, 2012 Dec NEWA
@ PADDOCK LLC 17GM/SCOOPFUL A090567 001 Oct 15, 2009 Sep DISC

POTASSIUM IODIDE

SOLUTION; ORAL
THYROSHIELD

+ ARCO PHARMS LLC 65MG/ML A077218 001 Jan 12, 2005 Oct CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

APOTEX INC EQ 150MG BASE A200172 001 May 31, 2012 May NEWA
SHASUN CHEMS EQ 75MG BASE A201745 001 Feb 29, 2012 Feb NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2012

NO DECEMBER 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2012 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ABACAVIR SULFATE</u>						
A091294 001					PC	Dec 16, 2012
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N202379 001	>A> 5604213	Feb 18, 2014	DS DP U-1314		>A> I-663	Dec 10, 2015
	>A> 5604213	Feb 18, 2014	DS DP U-1126			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001	8148356	May 21, 2026	DP			
<u>ACETYLCYSTEINE - ACETYLCYSTEINE</u>						
A200644 001					PC	May 29, 2013
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N202450 001	5840279	Jun 21, 2016	DP		NCE	Jul 23, 2017
	6071498	Jun 21, 2016	DP			
	6681768	Aug 07, 2022	DP			
	6750226	Sep 05, 2020	DS DP U-1264			
	7078412	Jul 16, 2020	DS DP U-1263			
	8051851	Apr 22, 2027	DP			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	8105618	Dec 23, 2022		U-1078		
	8129362	Jul 18, 2027		U-1078		
	8241649	Dec 23, 2022	DP			
<u>ALBUMIN HUMAN - OPTISON</u>						
N020899 001					M-120	Aug 17, 2015
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	6446627	Dec 18, 2017	DP			
	8132712	Sep 07, 2028	DP			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N020983 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>ALCAFTADINE - LASTACAFT</u>						
N022134 001	5468743	Nov 21, 2013	DS DP			
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N202344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 001	>A> 5559111	Jul 21, 2018	DS DP U-3			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 002	>A> 5559111	Jul 21, 2018	DS DP U-3			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 003	>A> 5559111	Jul 21, 2018	DS DP U-3			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 004	>A> 5559111	Jul 21, 2018	DS DP U-3			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 001	>A> 8183295	May 16, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 002	>A> 8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 003	>A> 8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 004	>A> 8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 005	>A> 8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 001	8168616	Jul 05, 2025	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 002	8168616	Jul 05, 2025	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	8112290	Jul 31, 2030				U-1225
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 001	>A> 5840722	Nov 24, 2015				U-821
	>A> 5840722	Nov 24, 2015				U-1297
	RE42462	Jul 29, 2018	DS			
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 002	>A> 5840722	Nov 24, 2015				U-821
	>A> 5840722	Nov 24, 2015				U-1297
	RE42462	Jul 29, 2018	DS			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N020965 001	8216289	May 01, 2018				U-289
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	8101599	May 16, 2023	DP			
<u>AMOXICILLIN - MOXATAG</u>						
N050813 001	>A> 8299052	May 07, 2027				U-1304
<u>APIXABAN - ELIQUIS</u>						
N202155 001					>A> NCE	Dec 28, 2017
<u>APIXABAN - ELIQUIS</u>						
N202155 002					>A> NCE	Dec 28, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREPITANT - EMEND</u>						
N021549 001	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N021549 002	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N021549 003	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	6589508	Apr 03, 2013	U-793			
	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N021248 001	8273379	Nov 10, 2018	U-1291			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE</u>						
A091211 001					PC	Mar 13, 2012
<u>AVANAFIL - STENDRA</u>						
N202276 001	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N202276 002	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N202276 003	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	7501409	May 05, 2023	DP			
<u>AXITINIB - INLYTA</u>						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AXITINIB - INLYTA</u>						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N202236 001	8163723	Aug 29, 2023	U-81		NC	May 01, 2015
	8163723	Aug 29, 2023	U-77			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-644			
	8168620	Feb 24, 2026	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 001	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N202813 001	5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N204384 001					>A> NCE	Dec 28, 2017
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2015
					PED	Sep 20, 2013
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2015
					PED	Sep 20, 2013
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N050819 001	8288434	Aug 05, 2029	DP U-124			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N022308 001	>A> 5447926	Apr 13, 2016	DS DP U-80			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N022185 001					I-659	Oct 17, 2015
<u>BIMATOPROST - LATISSE</u>						
N022369 001	8101161	May 25, 2024	U-1218			
	8101161	May 25, 2024	U-1217			
	8263054	Aug 25, 2023	U-1277			
<u>BIMATOPROST - LUMIGAN</u>						
N022184 001	8278353	Mar 16, 2025	DP			
	>A> 8299118	Mar 16, 2025	U-1295			
	>A> 8309605	Mar 16, 2025	U-1294			
	>A> 8309605	Mar 16, 2025	U-1293			
	>A> 8338479	Mar 16, 2025	DP U-1295			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Dec 15, 2014	DS DP U-1232			
	5196404	Dec 15, 2014	DS DP U-1040			
	5196404*PED	Jun 15, 2015				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	8119602	Mar 17, 2027	U-1233			
	RE43298	Feb 22, 2022	DS DP U-1128			
<u>BORTEZOMIB - VELCADE</u>						
N021602 001					NR	Jan 23, 2015
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N203341 001	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N203341 002	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8133890	Apr 19, 2022	U-1235			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	8143239	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	8143239	Jan 29, 2023	DP U-1073			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 001	>A> 8017150	Feb 13, 2023	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 002	>A> 8017150	Feb 13, 2023	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 003	>A> 8017150	Feb 13, 2023	DP		NDF	Aug 30, 2013
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 004	>A> 8017150	Feb 13, 2023	DP		NDF	Aug 30, 2013
<u>BUTOCONAZOLE NITRATE - BUTOCONAZOLE NITRATE</u>						
A200923 001					PC	May 14, 2013
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756 001	>A> 7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756 002	>A> 7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIPOTRIENE - SORILUX</u>						
N022563 001	8263580	May 26, 2026	DP U-1280		I-657	Sep 27, 2015
<u>CARFILZOMIB - KYPROLIS</u>						
N202714 001	7232818	Apr 14, 2025	DS DP		NCE	Jul 20, 2017
	7417042	Jun 07, 2026	DS DP		ODE	Jul 20, 2019
	7491704	Apr 14, 2025	U-1260			
	7737112	Dec 07, 2027	DP			
	8129346	Dec 25, 2026	U-1260			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207297	Apr 14, 2025	DS DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 001	8247400	Feb 10, 2031	DP U-282			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 002	8247400	Feb 10, 2031	DP U-282			
<u>CEVIMELINE HYDROCHLORIDE - CEVIMELINE</u>						
A091260 001					PC	Apr 06, 2013
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7717889	Feb 27, 2025	DP U-1022			
<u>CHOLINE C-11 - CHOLINE C-11</u>						
N203155 001					NCE W	Sep 12, 2017 Sep 12, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CICLOPIROX - LOPROX</u>						
N021159 001	8227490	Sep 16, 2017	U-1256			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N202535 001					NP	Jul 16, 2015
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	5856346	Jan 05, 2021	DS DP U-893			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	5856346	Jan 05, 2021	DS DP U-893			
<u>CLOBAZAM - ONFI</u>						
N203993 001					>A> NCE	Oct 21, 2016
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078223 001					PC	Jun 30, 2012
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078854 001					PC	Jun 30, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A077665 002					PC	Nov 13, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A091023 001					PC	Nov 13, 2012
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N203100 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	5922695	Jul 25, 2017	DS U-257			
	5935946	Jul 25, 2017	DS DP U-257			
	5977089	Jul 25, 2017	DS DP U-257			
	6043230	Jul 25, 2017	U-257			
	6642245	Nov 04, 2020	U-257			
	6703396	Mar 09, 2021	DS DP			
	7176220	Nov 20, 2023	DS DP U-257			
	7635704	Jan 12, 2026	DS DP U-257			
	8148374	Sep 03, 2029	DS DP U-1279			
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7964648	Oct 06, 2028	U-1161			
	8097655	Oct 06, 2028	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N202570 001	8217057	Nov 06, 2029	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N202570 002	8217057	Nov 06, 2029	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CROFELEMER - FULYZAQ</u>						
N202292 001	>A> 7323195	Jun 07, 2018	DP		>A> NCE	Dec 31, 2017
	>A> 7341744	Jun 16, 2018	U-1319			
<u>CYSTEAMINE HYDROCHLORIDE - CYSTARAN</u>						
N200740 001					NP ODE	Oct 02, 2015 Oct 02, 2019
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	8129342	Nov 28, 2020	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	>A> 5843946	Dec 01, 2015	DP U-1305			
	>A> 5843946	Dec 01, 2015	DP U-744			
	>A> 5843946	Dec 01, 2015	DP U-903			
	>A> 5843946	Dec 01, 2015	DP U-935			
	>A> 5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157	Jun 26, 2016	U-1305			
	>A> 6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1209			
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-1209			
	>A> 7470506	Jun 23, 2019	U-1305			
	>A> 7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	>A> 5843946	Dec 01, 2015	DP U-1305			
	>A> 5843946	Dec 01, 2015	DP U-744			
	>A> 5843946	Dec 01, 2015	DP U-903			
	>A> 5843946	Dec 01, 2015	DP U-935			
	>A> 5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157	Jun 26, 2016	U-1305			
	>A> 6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1209			
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-1209			
	>A> 7470506	Jun 23, 2019	U-1305			
	>A> 7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	>A> 5843946	Dec 01, 2015	DP U-1305			
	>A> 5843946	Dec 01, 2015	DP U-744			
	>A> 5843946	Dec 01, 2015	DP U-903			
	>A> 5843946	Dec 01, 2015	DP U-935			
	>A> 5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157	Jun 26, 2016	U-1305			
	>A> 6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1209			
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-1209			
	>A> 7470506	Jun 23, 2019	U-1305			
	>A> 7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	>A> 5843946	Dec 01, 2015	DP U-1305			
	>A> 5843946	Dec 01, 2015	DP U-744			
	>A> 5843946	Dec 01, 2015	DP U-903			
	>A> 5843946	Dec 01, 2015	DP U-935			
	>A> 5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157	Jun 26, 2016	U-1305			
	>A> 6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1209			
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-1209			
	>A> 7470506	Jun 23, 2019	U-1305			
	>A> 7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	>A> 5843946	Dec 01, 2015	DP U-1305			
	>A> 5843946	Dec 01, 2015	DP U-744			
	>A> 5843946	Dec 01, 2015	DP U-903			
	>A> 5843946	Dec 01, 2015	DP U-935			
	>A> 5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157	Jun 26, 2016	U-1305			
	>A> 6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1209			
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-1209			
	>A> 7470506	Jun 23, 2019	U-1305			
	>A> 7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 006	>A> 5843946	Dec 01, 2015	DP U-1305		D-129	Dec 13, 2013
	>A> 5843946	Dec 01, 2015	DP U-744		NPP	Dec 16, 2014
	>A> 5843946	Dec 01, 2015	DP U-903		PED	Jun 16, 2015
	>A> 5843946	Dec 01, 2015	DP U-935		PED	Jun 13, 2014
	>A> 5843946	Dec 01, 2015	DP U-1209			
	>A> 5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1305			
	>A> 6037157	Jun 26, 2016	U-935			
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157*PED	Dec 26, 2016				
	>A> 6248775	Aug 13, 2014	DS			
	>A> 6248775*PED	Feb 13, 2015	U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	>A> 6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1209			
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-935			
	>A> 6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-935			
	>A> 7470506	Jun 23, 2019	U-1209			
	>A> 7470506	Jun 23, 2019	U-1305			
	>A> 7470506*PED	Dec 23, 2019				
	>A> 7700645	Dec 26, 2026	DS DP			
	>A> 7700645*PED	Jun 26, 2027				
	>A> RE42889	Oct 19, 2016	DP			
	>A> RE42889*PED	Apr 19, 2017				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001	>A> 5843946	Dec 01, 2015	DP U-1305			
	>A> 5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157	Jun 26, 2016	U-1305			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017	U-1305			
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	May 18, 2021	DS DP U-943			
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N021313 001	8187630	Dec 19, 2020	DP U-1017			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 001	8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 002	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N050818 001	8101582	Dec 19, 2027	DP U-1082			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUDEXTA</u>						
N021879 001	8227484	Jul 17, 2023	U-1093			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	8110606	Feb 24, 2029	U-980			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N020947 001	8217078	Jul 10, 2029	U-1248			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	8153616	Jan 30, 2028	U-1240		I-648	Mar 14, 2015
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001					I-653 ODE	Jun 13, 2015 Jun 13, 2019
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N021394 001	8263647	May 30, 2022	DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 001	8247402	Mar 30, 2021	DS DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	8247402	Mar 30, 2021	DS DP			
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N202667 001					NP	Feb 01, 2015
<u>DOXERCALCIFEROL - HECTOROL</u>						
N021027 001	>A> 7148211	Sep 14, 2023	DP	Y		
<u>DOXERCALCIFEROL - HECTOROL</u>						
N021027 002	>A> 7148211	Sep 14, 2023	DP	Y		
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	8206740	Dec 24, 2025	DP U-925			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	5223510	Jul 26, 2013	DS DP U-992			
	5223510	Jul 26, 2013	DS DP U-1261			
	>A> 8318800	Jun 19, 2018	DP			
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 001					NS	Mar 01, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5811423	Aug 07, 2012	U-750			
	5811423	Aug 07, 2012	U-1170			
	5922695	Jul 25, 2017	DS U-750			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-750			
	5935946	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-750			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	U-750			
	6043230	Jul 25, 2017	U-1170			
	6642245	Nov 04, 2020	U-750			
	6642245	Nov 04, 2020	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> I-664	Nov 16, 2015
	>A> 6280959	Oct 30, 2018	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-930			
	>A> 8052993	Aug 01, 2027	DP U-930			
	>A> 8052993	Aug 01, 2027	DP U-1306			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> I-664	Nov 16, 2015
	>A> 6280959	Oct 30, 2018	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-930			
	>A> 8052994	Aug 01, 2027	DP U-930			
	>A> 8052994	Aug 01, 2027	DP U-1306			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> I-664	Nov 16, 2015
	>A> 6280959	Oct 30, 2018	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-930			
	>A> 8062665	Aug 01, 2027	DP U-930			
	>A> 8062665	Aug 01, 2027	DP U-1306			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 004	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> I-664	Nov 16, 2015
	>A> 6280959	Oct 30, 2018	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-930			
	>A> 8071129	Aug 01, 2027	DP U-930			
	>A> 8071129	Aug 01, 2027	DP U-1306			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 005	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> I-664	Nov 16, 2015
	>A> 6280959	Oct 30, 2018	DS DP U-1306		NCE	Nov 20, 2013
	>A> 7160870	Nov 20, 2022	DS DP U-1306		ODE	Nov 20, 2015
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7452874	May 24, 2021	DS DP			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-930			
	>A> 8052995	Aug 01, 2027	DP U-1306			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001	8080551	Apr 11, 2023	DS DP		NCE	May 20, 2016
	8101629	Aug 09, 2022	DP			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	5922695	Jul 25, 2017	DS U-1259			
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	DP U-541			
	6043230	Jul 25, 2017	DP U-1170			
	6043230	Jul 25, 2017	DP U-1259			
	6043230	Jul 25, 2017	DP U-248			
<u>ENTECAVIR - BARACLUDGE</u>						
N021797 001					NPP	Oct 12, 2015
<u>ENTECAVIR - BARACLUDGE</u>						
N021797 002					NPP	Oct 12, 2015
<u>ENTECAVIR - BARACLUDGE</u>						
N021798 001					NPP	Oct 12, 2015
<u>ENZALUTAMIDE - XTANDI</u>						
N203415 001	7709517	Aug 13, 2027	DS DP		NCE	Aug 31, 2017
	8183274	May 15, 2026	U-1281			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 001	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	>A> 8313466	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 002	>A> 8226610	Apr 10, 2029	DP			
	>A> 8231573	Nov 25, 2028	DP			
	>A> 8313466	Nov 23, 2024	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N022260 001	>A> 8318802	Feb 09, 2027	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N022260 002	>A> 8318802	Feb 09, 2027	DP			
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 001					PC	Jun 17, 2012
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 002					PC	Jun 17, 2012
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	8097648	Jan 22, 2021	U-1096			
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 001					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 002					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 003					PC	Sep 10, 2012
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 003	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 004	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESTRADIOL - MINIVELLE</u>						
N203752 001	>A> 6841716	Apr 27, 2020	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 002	>A> 6841716	Apr 27, 2020	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 003	>A> 6841716	Apr 27, 2020	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 004	>A> 6841716	Apr 27, 2020	DP			
<u>ESTRADIOL - VAGIFEM</u>						
N020908 002	>A> 5860946	Jul 01, 2017	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ETONOGESTREL - NEXPLANON</u>						
N021529 002					NP	May 31, 2014
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N022187 003	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237		NCE	Jan 18, 2013
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N022334 004	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 001	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	7297703*PED	Jun 06, 2020			PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 002	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	7297703*PED	Jun 06, 2020			PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 003	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	7297703*PED	Jun 06, 2020			PED	Apr 29, 2014
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	>A> 8329648	Aug 18, 2026	U-1313			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EZETIMIBE - ZETIA</u>						
N021445 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002					M-109	Jan 24, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	003				M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	004				M-109	Jan 24, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	001				M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	002				M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	003				M-112	Feb 09, 2015
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N022519	001	8309127	Jul 18, 2026	DP		
		>A> 8318202	Jul 18, 2026	DP		
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118	001	8124125	Oct 01, 2024	DP U-1234		
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118	002	8124125	Oct 01, 2024	DP U-1234		
<u>FENTANYL - SUBSYS</u>						
N202788	001				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	002				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	003				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	004				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	005				NP	Jan 04, 2015
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	001	8092832	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	002	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	003	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	004	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	005	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569	001	8216604	Oct 03, 2024		U-767	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 002	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 001	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	7579019	Jan 22, 2020	U-767			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	6858650	Jul 03, 2022	DS U-913			
	8088398	Jun 07, 2027	DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	6858650	Jul 03, 2022	DS U-913			
	8088398	Jun 07, 2027	DP U-913			
<u>FINASTERIDE - FINASTERIDE</u>						
A076436 001					>A> PC	Jul 01, 2013
<u>FINGOLIMOD - GILENYA</u>						
N022527 001	6004565	Sep 23, 2017	U-1086			
	>A> 8324283	Mar 29, 2026				
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N021112 001	8247395	Oct 22, 2022	DP			
<u>FLUOCINONIDE - VANOS</u>						
N021758 001	8232264	Mar 09, 2023	DP			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N022051 001	8062264	Apr 05, 2026	DP			
	8147461	Mar 10, 2025	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASON PROPRIONATE - FLOVENT HFA</u>						
N021433 002	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASON PROPRIONATE - FLOVENT HFA</u>						
N021433 003	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASON PROPRIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASON PROPRIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 002	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASON PROPRIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 003	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002	5512570	Mar 04, 2014	U-850			
	5538982	Jul 23, 2013	U-850			
	5716942	Feb 10, 2015	U-850			
	7214692	Sep 18, 2012	U-850			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	6204257	Jul 01, 2022	DS DP U-945			
<u>FULVESTRANT - FASLODEX</u>						
N021344 001	>A> 8329680	Jan 09, 2021	U-596		M-123	Nov 09, 2015
	>A> 8329680*PED	Jul 09, 2021				
<u>GABAPENTIN - GRALISE</u>						
N022544 001	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 002	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 001					I-654	Jul 06, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 002					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 003					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 004					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N021358 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N021358 002					I-654	Jul 06, 2015
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	6676929	May 04, 2020	DP			
<u>GADOXETATE DISODIUM - EOVISt</u>						
N022090 001	5798092	Aug 25, 2015	DS DP			
	6039931	Nov 13, 2021		U-1239		
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N022571 001					ODE	Jul 28, 2017
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 001					PC	Sep 26, 2012
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 002					PC	Sep 26, 2012
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 001					PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 002					PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 003					PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 004					PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 005					PC	Mar 20, 2013
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 004	5702725	Jul 07, 2014	DP U-1043		NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N202057 001	8188146	Jan 27, 2020	DS DP			
	8293727	Feb 09, 2030		U-1287		
	8293728	Feb 09, 2030		U-1287		
	8298554	Apr 29, 2030	DP			
	>A> 8314086	Feb 09, 2030		U-1287		
	>A> 8318715	Feb 09, 2030		U-1287		
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001					ODE	Dec 19, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002					ODE	Dec 19, 2015
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001	8236816	Dec 11, 2029	U-68			
	8299109	Dec 11, 2029	U-68			
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 002	8222270	Dec 11, 2029	U-68			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
	8278292	Feb 20, 2027	DS DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
	8278292	Feb 20, 2027	DS DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N021172 001	5866538	Jun 19, 2017	DP			
	5866538*PED	Dec 19, 2017				
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N021172 004	>A> 5547930	Sep 28, 2013	DS DP			
	>A> 5618913	Jun 07, 2014	DS DP			
	>A> 5618913*PED	Dec 07, 2014				
	>A> 5834422	Sep 28, 2013	DP U-471			
	>A> 5840680	Sep 28, 2013	DS DP U-471			
	>A> 5866538	Jun 19, 2017	DP			
	>A> 5866538*PED	Dec 19, 2017				
	>A> 6004297	Jan 28, 2019	DP			
	>A> RE41956	Jan 21, 2021	DP			
	>A> RE43834	Jan 28, 2019	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N021172 002	>A> 5547930	Sep 28, 2013	DS DP			
	>A> 5618913	Jun 07, 2014	DS DP			
	>A> 5618913*PED	Dec 07, 2014				
	>A> 5834422	Sep 28, 2013	DP U-471			
	>A> 5840680	Sep 28, 2013	DS DP U-471			
	>A> 5866538	Jun 19, 2017	DP			
	>A> 5866538*PED	Dec 19, 2017				
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N021172 003	>A> 5547930	Sep 28, 2013	DS DP			
	>A> 5618913	Jun 07, 2014	DS DP			
	>A> 5618913*PED	Dec 07, 2014				
	>A> 5834422	Sep 28, 2013	DP U-471			
	>A> 5840680	Sep 28, 2013	DS DP U-471			
	>A> 5866538	Jun 19, 2017	DP			
	>A> 5866538*PED	Dec 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N020986 003	>A> 5618913	Jun 07, 2014	DS DP			
	>A> 5618913*PED	Dec 07, 2014				
	>A> 5866538	Jun 20, 2017	DP			
	>A> 5866538*PED	Dec 20, 2017				
	>A> 6004297	Jan 28, 2019	DP			
	>A> 6004297*PED	Jul 28, 2019				
	>A> RE41956	Jan 21, 2021	DP			
	>A> RE41956*PED	Jul 21, 2021				
	>A> RE43834	Jan 28, 2019	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET</u>						
N020986 004	>A> 5618913	Jun 07, 2014	DS DP			
	>A> 5618913*PED	Dec 07, 2014				
	>A> 5866538	Jun 20, 2017	DP			
	>A> 5866538*PED	Dec 20, 2017				
	>A> RE41956	Jan 21, 2021	DP			
	>A> RE41956*PED	Jul 21, 2021				
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N020986 002	>A> 5618913	Jun 07, 2014	DS DP			
	>A> 5618913*PED	Dec 07, 2014				
	>A> 5626566	May 06, 2014	DP			
	>A> 5626566*PED	Nov 06, 2014				
	>A> 5693027	Dec 02, 2014	DP			
	>A> 5693027*PED	Jun 02, 2015				
	>A> 5866538	Jun 20, 2017	DP			
	>A> 5866538*PED	Dec 20, 2017				
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536 001	5750497	Jun 16, 2019	DS DP U-668		M-117 M-115	May 18, 2015 Apr 06, 2015
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N021536 002	>A> 5750497	Jun 16, 2019	DS DP U-668			
	>A> 5866538	Jun 20, 2017	DS DP			
	>A> 6004297	Jan 28, 2019	DP			
	>A> 6011007	Feb 02, 2014	DS DP U-668			
	>A> 6869930	Feb 02, 2014	DS DP U-668			
	>A> RE41956	Jan 21, 2021	DP			
	>A> RE43834	Jan 28, 2019	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET</u>						
N021536 003	>A> 5750497	Jun 16, 2019	DS DP U-668			
	>A> 5866538	Jun 20, 2017	DS DP			
	>A> 6011007	Feb 02, 2014	DS DP U-668			
	>A> 6869930	Feb 02, 2014	DS DP U-668			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL</u>						
N021536 004	>A> 5750497	Jun 16, 2019	DS DP U-668			
	>A> 5866538	Jun 20, 2017	DS DP			
	>A> 6011007	Feb 02, 2014	DS DP U-668			
	>A> 6869930	Feb 02, 2014	DS DP U-668			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50</u>						
N021018 001	>A> 5461031	Jun 16, 2014	DP U-948			
	>A> 5474978	Jun 16, 2014	DS DP U-948			
	>A> 5514646	May 07, 2013	DS DP U-1312			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N021018 002	>A> 5461031	Jun 16, 2014	DP U-948			
	>A> 5474978	Jun 16, 2014	DS DP U-948			
	>A> 5514646	May 07, 2013	DS DP U-1312			
	>A> 5747642	Jun 16, 2014	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25</u>						
N021017 001	>A> 5461031	Jun 16, 2014	DP U-948			
	>A> 5474978	Jun 16, 2014	DS DP U-948			
	>A> 5514646	May 07, 2013	DS DP U-1312			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N021017 002	>A> 5461031	Jun 16, 2014	DP U-948			
	>A> 5474978	Jun 16, 2014	DS DP U-948			
	>A> 5514646	May 07, 2013	DS DP U-1312			
	>A> 5747642	Jun 16, 2014	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG</u>						
N020563 001	>A> 5474978	Jun 16, 2014	DS DP U-948		NR	Oct 12, 2015
	>A> 5474978	Jun 16, 2014	DS DP U-534			
	>A> 5514646	May 07, 2013	DS DP U-534			
	>A> 5514646	May 07, 2013	DS DP U-1312			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N020563 003	>A> 5474978	Jun 16, 2014	DS DP U-948			
	>A> 5514646	May 07, 2013	DS DP U-1312			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG PEN</u>						
N020563 002					NR	Oct 12, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001	5310912	Feb 25, 2013	DS			
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 001					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 002					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 003					PC	Sep 26, 2012
<u>IRON SUCROSE - VENOFER</u>						
N021135 001					NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N021135 002					NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N021135 004					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	7435427	Sep 21, 2021	DP		NP	May 25, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	7495103	May 20, 2027	DS DP		NCE	Jan 31, 2017
	>A> 8324242	Apr 18, 2027		U-1311	ODE	Jan 31, 2019
<u>IVERMECTIN - SKLICE</u>						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
<u>KETOCONAZOLE - XOLEGEL</u>						
N021946 001	8232276	Nov 24, 2020	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	8008338*PED	Nov 24, 2027				
	8207215	May 28, 2024		U-1251		
	8207215*PED	Nov 28, 2024				
<u>LACOSAMIDE - VIMPAT</u>						
N022253 001	RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 002	RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 003	RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 004	RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022254 001	RE38551	Mar 17, 2022	DS DP U-911			
<u>LACOSAMIDE - VIMPAT</u>						
N022255 001	RE38551	Mar 17, 2022	DS DP U-914			
<u>LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE</u>						
A079081 001					PC	May 15, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS			U-1211
	6045501	Aug 28, 2018				U-1210
	6281230	Jul 24, 2016				U-1212
	6315720	Oct 23, 2020				U-1210
	6555554	Jul 24, 2016	DP			U-1211
	6561976	Aug 28, 2018				U-1210
	6561977	Oct 23, 2020				U-1210
	6755784	Oct 23, 2020				U-1210
	6908432	Aug 28, 2018				U-1210
	7189740	Apr 11, 2023				U-1215
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023				U-1216
	8204763	Aug 28, 2018				U-1249
	8288415	Jul 24, 2016	DS DP			
	>A> 8315886	Oct 23, 2020				U-1249
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS			U-1211
	6045501	Aug 28, 2018				U-1210
	6281230	Jul 24, 2016				U-1212
	6315720	Oct 23, 2020				U-1210
	6555554	Jul 24, 2016	DP			U-1211
	6561976	Aug 28, 2018				U-1210
	6561977	Oct 23, 2020				U-1210
	6755784	Oct 23, 2020				U-1210
	6908432	Aug 28, 2018				U-1210
	7189740	Apr 11, 2023				U-1215
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023				U-1216
	8204763	Aug 28, 2018				U-1249
	8288415	Jul 24, 2016	DS DP			
	>A> 8315886	Oct 23, 2020				U-1249
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS			U-1211
	6045501	Aug 28, 2018				U-1210
	6281230	Jul 24, 2016				U-1212
	6315720	Oct 23, 2020				U-1210
	6555554	Jul 24, 2016	DP			U-1211
	6561976	Aug 28, 2018				U-1210
	6561977	Oct 23, 2020				U-1210
	6755784	Oct 23, 2020				U-1210
	6908432	Aug 28, 2018				U-1210
	7189740	Apr 11, 2023				U-1215
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023				U-1216
	8204763	Aug 28, 2018				U-1249
	8288415	Jul 24, 2016	DS DP			
	>A> 8315886	Oct 23, 2020				U-1249

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
	8288415	Jul 24, 2016	DS DP			
	>A> 8315886	Oct 23, 2020			U-1249	
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
	8288415	Jul 24, 2016	DS DP			
	>A> 8315886	Oct 23, 2020			U-1249	
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 001					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 002					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 003					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 004					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021505 001					NPP PED	Dec 16, 2014 Jun 16, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022064 001	5698558	Jul 26, 2013	U-812			
	5698558*PED	Jan 26, 2014				
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022157 001	5698558	Jul 26, 2013	U-852			
	5698558*PED	Jan 26, 2014				
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N021623 001	6465709	Jul 07, 2020	DP			
<u>LINACLOTIDE - LINZESS</u>						
N202811 001	7304036	Jan 28, 2024	DS DP U-1278		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
<u>LINACLOTIDE - LINZESS</u>						
N202811 002	7304036	Jan 28, 2024	DS DP U-1278		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	6303661	Apr 24, 2017	U-774		M-121	Aug 13, 2015
	6303661	Apr 24, 2017	U-1270		M-118	Aug 13, 2015
	6890898	Feb 02, 2019	U-493			
	6890898	Feb 02, 2019	U-1270			
	7078381	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-1270			
	7459428	Feb 02, 2019	U-493			
	7459428	Feb 02, 2019	U-1270			
	8119648	Aug 12, 2023	U-774			
	8119648	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-775			
	8178541	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-1245			
	8178541	Aug 12, 2023	U-1244			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 001	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	>A> 6004297	Jan 28, 2019	DP		M-115	Apr 06, 2015
	8114833	Aug 13, 2025	DP			
	>A> RE41956	Jan 21, 2021	DP			
	>A> RE43834	Jan 28, 2019	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 001	>A> 5712279	Feb 21, 2015	DS U-1316		>A> NCE	Dec 21, 2017
	>A> 5739135	Apr 14, 2015	DS U-1317			
	>A> 6492365	Dec 10, 2019	U-1318			
	>A> 7932268	Aug 19, 2027	U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 002	>A> 5712279	Feb 21, 2015	DS U-1316		>A> NCE	Dec 21, 2017
	>A> 5739135	Apr 14, 2015	DS U-1317			
	>A> 6492365	Dec 10, 2019	U-1318			
	>A> 7932268	Aug 19, 2027	U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 003	>A> 5712279	Feb 21, 2015	DS U-1316		>A> NCE	Dec 21, 2017
	>A> 5739135	Apr 14, 2015	DS U-1317			
	>A> 6492365	Dec 10, 2019	U-1318			
	>A> 7932268	Aug 19, 2027	U-1317			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	>A> 8309613	Dec 24, 2024	U-688			
	>A> 8309613*PED	Jun 24, 2025				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	>A> 8309613	Dec 24, 2024	U-688			
	>A> 8309613*PED	Jun 24, 2025				
<u>LORCASERIN HYDROCHLORIDE - BELVIQ</u>						
N022529 001	6953787	Apr 10, 2023	DS DP U-1253		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	6953787	Apr 10, 2023	DS DP U-1252			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N202872 001					NDF	Sep 28, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOXAPINE - ADASUVE</u>						
N022549	001				>A> NDF	Dec 21, 2015
<u>LUBIPROSTONE - AMITIZA</u>						
N021908	001	8097649	Oct 16, 2020	DP		
		8097653	Nov 14, 2022	U-1214		
		8114890	Sep 05, 2020	DP		
	>A>	8338639	Jan 23, 2027	DP		
<u>LUBIPROSTONE - AMITIZA</u>						
N021908	002	8097649	Oct 16, 2020	DP		
		8114890	Sep 05, 2020	DP		
	>A>	8338639	Jan 23, 2027	DP		
<u>LUCINACTANT - SURFAXIN</u>						
N021746	001	>A> 5407914	Nov 17, 2013	DS DP	U-1242	
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603	001				D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603	002				D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603	003	5532372	Jul 02, 2013	DS	D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603	004	5532372	Jul 02, 2013	DS	D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u>						
N022372	001	>A> 6946149	Mar 07, 2023	DP	U-837	
<u>MESALAMINE - APRISO</u>						
N022301	001	>A> 8337886	Apr 20, 2018	DP	U-1310	
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N021748	002	>A> 8323692	Mar 23, 2025	DP		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842	001				M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842	002				M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406	001				PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406	002				PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410	001	8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410	002	8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410	003	8236345	Oct 07, 2022	DP		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 004	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 005	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 001	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 002	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001	8247425	Dec 31, 2030	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 002	8247425	Dec 31, 2030	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 003	8247425	Dec 31, 2030	U-1185			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 001	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 002	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 001					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 002					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 003					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N202100 001					NDF	Sep 27, 2015
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	7651698	Sep 11, 2022	U-1051			
<u>MIFEPRISTONE - KORLYM</u>						
N202107 001					NP ODE	Feb 17, 2015 Feb 17, 2019
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	6602911	Jan 14, 2023	U-882			
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N050781 001	6682348	Mar 29, 2022	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 001	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023		U-913		
	7982049	Nov 04, 2023	DP			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 002	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023		U-913		
	7982049	Nov 04, 2023	DP			
<u>MITOMYCIN - MITOSOL</u>						
N022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 001	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 002	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001					NPP	Mar 26, 2015
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 001	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 002	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N019599 002					NS	Jan 13, 2015
<u>NEPAFENAC - NEPAFENAC</u>						
N203491 001					NP	Oct 16, 2015
<u>NEPAFENAC - NEVANAC</u>						
N021862 001	>A> 8324281	Dec 02, 2025	DP			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 001					NPP	Nov 08, 2015
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 002					NPP NDF	Nov 08, 2015 Mar 25, 2014
<u>NICOTINE - NICODERM CQ</u>						
N020165 004	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 005	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 006	8075911	May 22, 2021	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N018612 002	>A> 8323683	Apr 30, 2028				
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N020066 002	>A> 8323683	Apr 30, 2028	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	8163904	Aug 23, 2028	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	8163904	Aug 23, 2028	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
	8282966	Jun 30, 2029	U-1286			
	8282966*PED	Dec 30, 2029				
	8291904	Jan 06, 2031	DP U-1226			
	8291904*PED	Jul 06, 2031				
	8293284	Jun 30, 2029	U-1286			
	8293284*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
	8282966	Jun 30, 2029	U-1286			
	8282966*PED	Dec 30, 2029				
	8291904	Jan 06, 2031	DP U-1226			
	8291904*PED	Jul 06, 2031				
	8293284	Jun 30, 2029	U-1286			
	8293284*PED	Dec 30, 2029				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705 002	7872049	Mar 14, 2028	DP U-39			
<u>OMACETAXINE MEPEUSUCCINATE - SYNRIBO</u>						
N203585 001	>A> 6987103	Jun 28, 2023	U-1300		NCE	Oct 26, 2017
	>A> 7842687	Mar 16, 2019	DS DP U-1299		ODE	Oct 26, 2019
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N202810 001	>A> 7722898	Apr 13, 2027	DP		NDF	Oct 19, 2015
	>A> 7910131	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N202810 002	>A> 7722898	Apr 13, 2027	DP		NDF	Oct 19, 2015
	>A> 7910131	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N202810 003	>A> 7722898	Apr 13, 2027	DP		NDF	Oct 19, 2015
	>A> 7910131	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	8119148	Dec 19, 2020	DP U-724			
	8119148*PED	Jun 19, 2021				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNYNIN - ANTUROL</u>						
N202513 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
	8241662	Apr 26, 2020	U-318			
<u>OXYBUTYNYNIN CHLORIDE - GELNIQUE</u>						
N022204 001	8241662	Apr 26, 2020	U-318			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
	>A> 8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
	>A> 8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
	>A> 8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
	>A> 8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
	>A> 8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 006	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
	>A> 8337888	Aug 06, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 007	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
	>A> 8337888	Aug 06, 2022	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 001	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A079087 001					>A> PC	Jul 07, 2013
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A079087 003					>A> PC	Jul 07, 2013
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A079087 005					>A> PC	Jul 02, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A079087	007				>A> PC	Jul 07, 2013
<u>PACLITAXEL - ABRAXANE</u>						
N021660	001	5439686	Feb 22, 2013	DP U-1290	I-658	Oct 11, 2015
		5439686	Feb 22, 2013	DP U-1092		
		5498421	Mar 12, 2013	DP U-1092		
		5498421	Mar 12, 2013	DP U-1290		
		5498421	Mar 12, 2013	DP U-634		
		6096331	Feb 22, 2013	DP U-1092		
		6096331	Feb 22, 2013	DP U-1290		
		6096331	Feb 22, 2013	DP U-633		
		6506405	Feb 22, 2013	DP U-1092		
		6506405	Feb 22, 2013	DP U-1290		
		6506405	Feb 22, 2013	DP U-633		
		6537579	Feb 22, 2013	U-632		
		6537579	Feb 22, 2013	U-1290		
		6537579	Feb 22, 2013	U-1092		
		7820788	Mar 03, 2024	DP U-1092		
		7820788	Mar 03, 2024	DP U-1290		
		7923536	Dec 09, 2023	U-1117		
		7923536	Dec 09, 2023	U-1290		
		8034375	Aug 13, 2026	U-1290		
		8138229	Dec 09, 2023	DP U-1092		
		8138229	Dec 09, 2023	DP U-1290		
		8268348	Feb 21, 2026	U-1290		
	>A>	8314156	Dec 09, 2023	U-1290		
		RE41884	Aug 14, 2016	U-1290		
		RE41884	Aug 14, 2016	U-1117		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264	001	5254556	Oct 15, 2013	DS DP U-543	M-119	Aug 29, 2015
		5254556*PED	Apr 15, 2014			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264	002	5254556	Oct 15, 2013	DS DP U-543	M-119	Aug 29, 2015
		5254556*PED	Apr 15, 2014			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264	003	5254556	Oct 15, 2013	DS DP U-543	M-119	Aug 29, 2015
		5254556*PED	Apr 15, 2014			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264	004	5254556	Oct 15, 2013	DS DP U-543	M-119	Aug 29, 2015
		5254556*PED	Apr 15, 2014			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264	005	5254556	Oct 15, 2013	DS DP U-543	M-119	Aug 29, 2015
		5254556*PED	Apr 15, 2014			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725	004				I-625	Apr 30, 2013
					M-93	Jul 29, 2019
					NCE	Apr 30, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 001					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 002					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 003					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 001	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 002	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 003	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 004	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 005	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 006	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N020936 001	>A> 7229640*PED	Jan 19, 2017				
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N020936 002	>A> 7229640*PED	Jan 19, 2017				
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N020936 003	>A> 7229640*PED	Jan 19, 2017				
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N200677 001	>A> 6225284	Jun 28, 2016	DS DP		>A> NCE	Dec 14, 2017
	>A> 7473761	Jul 29, 2025	DS DP		>A> ODE	Dec 14, 2019
	>A> 8299209	Dec 27, 2025	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N200677 002	>A> 6225284	Jun 28, 2016	DS DP		>A> NCE	Dec 14, 2017
	>A> 7473761	Jul 29, 2025	DS DP		>A> ODE	Dec 14, 2019
	>A> 8299209	Dec 27, 2025	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N200677 003	>A> 6225284	Jun 28, 2016	DS DP		>A> NCE	Dec 14, 2017
	>A> 7473761	Jul 29, 2025	DS DP		>A> ODE	Dec 14, 2019
	>A> 8299209	Dec 27, 2025	DS DP			
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 001	>A> 7105530	Oct 19, 2023	DS DP		I-649	Apr 26, 2015
	8114885	Dec 19, 2021	DS DP		ODE	Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 002	>A> 7105530	Oct 19, 2023	DS DP		I-649	Apr 26, 2015
	8114885	Dec 19, 2021	DS DP		ODE	Apr 26, 2019
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 001	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 002	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 001	>A> 7772209	Nov 24, 2021	U-1296		M-122	Oct 17, 2015
	>A> 7772209	Nov 24, 2021	U-1077			
	>A> 7772209*PED	May 24, 2022				
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 002	>A> 7772209	Nov 24, 2021	U-1296		M-122	Oct 17, 2015
	>A> 7772209*PED	May 24, 2022				
<u>PERAMPANEL - FYCOMPA</u>						
N202834 001	>A> 6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 002	>A> 6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 003	>A> 6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 004	>A> 6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 005	>A> 6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 006	>A> 6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 003	6149938	Jul 23, 2018	DP U-1243			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 001	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 002	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 003	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 004	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 001					PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 002					PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 003					PC	Feb 13, 2013
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	8133883	Apr 14, 2023	DP U-282			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N203469 001	>A> 8114874	Dec 22, 2026	DS DP		>A> NCE	Dec 14, 2017
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N203469 002	>A> 8114874	Dec 22, 2026	DS DP		>A> NCE	Dec 14, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POSACONAZOLE - NOXAFIL</u>						
N022003 001	8263600	Apr 01, 2022	DP			
<u>PRALATREXATE - FOLOTYN</u>						
N022468 001	>A> 8299078	May 31, 2025	U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N022468 002	>A> 8299078	May 31, 2025	U-1004			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISONE - RAYOS</u>						
N202020 001	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024	U-1292			
<u>PREDNISONE - RAYOS</u>						
N202020 002	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024				
<u>PREDNISONE - RAYOS</u>						
N202020 003	8168218	Jan 07, 2028	DP U-1269			
	8309124	Apr 23, 2024	U-1292			
<u>PREGABALIN - LYRICA</u>						
N021446 001	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 002	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 003	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 004	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 005	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N021446 006	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 007	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 008	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N022488 001	6001876	Dec 30, 2018	U-819	Y		
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 001	6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 002	6500454	Oct 04, 2021	DP			
<u>RABEPRAZOLE SODIUM - ACIPHEX</u>						
N020973 001	>A> 5045552	May 08, 2013	U-385			
	>A> 5045552*PED	Nov 08, 2013				
<u>RABEPRAZOLE SODIUM - ACIPHEX</u>						
N020973 002	>A> 5045552	May 08, 2013	U-385			
	>A> 5045552*PED	Nov 08, 2013				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001					M-114	Mar 28, 2015
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	8183226	Jun 22, 2019	U-116			
<u>REGORAFENIB - STIVARGA</u>						
N203085 001	7351834	Jan 12, 2020	DS		NCE	Sep 27, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REPAGLINIDE - PRANDIN</u>						
N020741 001	6677358	Jun 12, 2018	DS DP U-1265			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 002	6677358	Jun 12, 2018	DS DP U-1265			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 003	6677358	Jun 12, 2018	DS DP U-1265			
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	RE43390	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	>A> 7125879	Apr 14, 2023	DS DP U-1307			
	>A> 7125879	Apr 14, 2023	DS DP U-1153			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N022560 001	8246989	Jan 16, 2026	DP			
<u>RITONAVIR - NORVIR</u>						
N022417 001	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2925				
<u>RIVAROXABAN - XARELTO</u>						
N022406 001	>A> 7592339	Dec 11, 2020	U-1303		I-662	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1302		I-661	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1301		I-660	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1200			
	>A> 7592339	Dec 11, 2020	U-1167			
<u>RIVAROXABAN - XARELTO</u>						
N022406 002	>A> 7592339	Dec 11, 2020	U-1303		I-662	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1302		I-661	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1301		I-660	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1200		NCE	Jul 01, 2016
	>A> 7592339	Dec 11, 2020	U-1167			
<u>RIVAROXABAN - XARELTO</u>						
N022406 003	>A> 7592339	Dec 11, 2020	U-1303		I-662	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1302		I-661	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1301		I-660	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1200			
	>A> 7592339	Dec 11, 2020	U-1167			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVASTIGMINE - EXELON</u>						
N022083 005	5602176	Feb 11, 2014	DS DP U-322		NS	Aug 31, 2015
	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001	4977138	Aug 22, 2013	DS DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 001	>A> 8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 002	>A> 8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 003	>A> 8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 004	>A> 8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 005	>A> 8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 006	>A> 8303986	Apr 12, 2021	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N021829 004	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 005	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 006	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 001	7750028	Oct 19, 2018	U-106			
<u>RUFINAMIDE - BANZEL</u>						
N021911 002	7750028	Oct 19, 2018	U-106			
<u>RUFINAMIDE - BANZEL</u>						
N021911 003	7750028	Oct 19, 2018	U-106			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	6740669	Nov 14, 2022	DS DP			
	7750028	Oct 19, 2018	U-106			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N022181 001	>A> RE43797	Nov 17, 2024	U-1156			
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			M-61	Aug 30, 2015
					PED	Mar 01, 2016
					PED	Nov 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		M-61	Aug 30, 2015
	5250534*PED	Sep 27, 2012			NDF	Nov 20, 2012
					PED	Mar 01, 2016
					PED	May 20, 2013
<u>SILDENAFIL CITRATE - REVATIO</u>						
N203109 001					NDF	Aug 30, 2015
					PED	Mar 01, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 001	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 002	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 003	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 001	6699871	Jul 26, 2022	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 002	6699871	Jul 26, 2022	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 003	6699871	Jul 26, 2022	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 004	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1191			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1189			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1193			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1189			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 005	6303661	Apr 24, 2017				
	6699871	Jul 26, 2022	DS DP			
	6890898	Feb 02, 2019				
	6890898	Feb 02, 2019				
	6890898	Feb 02, 2019				
	7078381	Feb 02, 2019				
	7125873	Jul 26, 2022	DP			
	7125873	Jul 26, 2022	DP			
	7125873	Jul 26, 2022	DP			
	7125873	Jul 26, 2022	DP			
	7326708	Apr 11, 2026	DS DP			
	7459428	Feb 02, 2019				
	8168637	Jun 26, 2022	DP			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 006	6303661	Apr 24, 2017				
	6699871	Jul 26, 2022	DS DP			
	6890898	Feb 02, 2019				
	6890898	Feb 02, 2019				
	6890898	Feb 02, 2019				
	7078381	Feb 02, 2019				
	7125873	Jul 26, 2022	DP			
	7125873	Jul 26, 2022	DP			
	7125873	Jul 26, 2022	DP			
	7125873	Jul 26, 2022	DP			
	7326708	Apr 11, 2026	DS DP			
	7459428	Feb 02, 2019				
	8168637	Jun 26, 2022	DP			
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N203922 001					ODE	Jan 14, 2018
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	8263650	Dec 22, 2019	DP			
	8263650	Dec 22, 2019	DP			
	>A> 8324275	Dec 22, 2019				
	>A> 8324275	Dec 22, 2019				
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N203923 001					ODE	Jan 14, 2018
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N021148 008	>A> 6716198	Jun 05, 2021	DP			
	>A> 6899699	Jan 02, 2022	DP			
	>A> 7686786	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N021148 009	>A> 6716198	Jun 05, 2021	DP			
	>A> 6899699	Jan 02, 2022	DP			
	>A> 7686786	Aug 03, 2026	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N021148 010	>A> 6716198	Jun 05, 2021	DP			
	>A> 6899699	Jan 02, 2022	DP			
	>A> 7686786	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 004	>A> 6004297	Jan 28, 2019	DP			
	>A> 6235004	Jan 28, 2019	DP			
	>A> RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 005	>A> 6004297	Jan 28, 2019	DP			
	>A> 6235004	Jan 28, 2019	DP			
	>A> RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 006	>A> 6004297	Jan 28, 2019	DP			
	>A> 6235004	Jan 28, 2019	DP			
	>A> RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 007	>A> 6004297	Jan 28, 2019	DP			
	>A> RE41956	Jan 21, 2021	DP			
	>A> RE43834	Jan 28, 2019	DP			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	7776007	Nov 22, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Dec 25, 2025	DP			
	8241244	Nov 21, 2022	DP			
	8267903	Mar 18, 2023	DP			
	>A> 8287489	Dec 06, 2024	DP			
<u>T AFLUPROST - ZIOPTAN</u>						
N202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N022458 001	8227230	Feb 24, 2024	DS DP		NCE	May 01, 2017
<u>TAPENTADOL HYDROCHLORIDE - NUCYN TA</u>						
N203794 001	6071970	Jun 06, 2017		U-1289	NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP	U-1289		
	RE39593	Aug 05, 2022	DS DP	U-1289		
<u>TAPENTADOL HYDROCHLORIDE - NUCYN TA ER</u>						
N200533 001	6071970	Jun 06, 2017		U-1276	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1178		
	7994364	Jun 27, 2025	DS DP	U-1276		
	7994364	Jun 27, 2025	DS DP	U-1178		
	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP	U-1276		
	>A> 8309060	Nov 20, 2023	DP	U-1178		
	RE39593	Aug 05, 2022	DS DP	U-1276		
	RE39593	Aug 05, 2022	DS DP	U-1178		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP U-1276			
	>A> 8309060	Nov 20, 2023	DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP U-1276			
	>A> 8309060	Nov 20, 2023	DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP U-1276			
	>A> 8309060	Nov 20, 2023	DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP U-1276			
	>A> 8309060	Nov 20, 2023	DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAZAROTENE - FABIOR</u>						
N202428 001					NDF	May 11, 2015
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID</u>						
N017858 001					ODE	Aug 13, 2019
<u>TEDUGLUTIDE - GATTEX KIT</u>						
N203441 001					>A> NCE	Dec 21, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		M-61	May 30, 2015
	8026276*PED	Jul 20, 2026			ODE	May 30, 2014
	>A> 8299116	Jul 25, 2023	DP		PED	Nov 30, 2015
	>A> 8299116*PED	Jan 25, 2024			PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001	5922695	Jul 25, 2017	DS U-999		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-250		PED	Jul 18, 2015
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-1275			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-1275			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE	
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>							
N021356 002	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013	
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015	
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015	
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013	
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017	
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017	
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015	
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014	
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013	
	5935946	Jul 25, 2017	DS DP U-999				
	5935946*PED	Jan 25, 2018					
	5977089	Jul 25, 2017	DS DP U-248				
	5977089	Jul 25, 2017	DS DP U-250				
	5977089	Jul 25, 2017	DS DP U-256				
	5977089	Jul 25, 2017	DS DP U-999				
	5977089	Jul 25, 2017	DS DP U-1275				
	5977089*PED	Jan 25, 2018					
	6043230	Jul 25, 2017		U-1275			
	6043230	Jul 25, 2017		U-248			
	6043230	Jul 25, 2017		U-250			
	6043230	Jul 25, 2017		U-256			
	6043230	Jul 25, 2017		U-999			
	6043230*PED	Jan 25, 2018					
	<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
	N021356 003	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
		5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
		5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
		5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
5922695		Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017	
5922695*PED		Jan 25, 2018			PED	Sep 24, 2017	
5935946		Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015	
5935946		Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014	
5935946		Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013	
5935946		Jul 25, 2017	DS DP U-999				
5935946*PED		Jan 25, 2018					
5977089		Jul 25, 2017	DS DP U-248				
5977089		Jul 25, 2017	DS DP U-250				
5977089		Jul 25, 2017	DS DP U-256				
5977089		Jul 25, 2017	DS DP U-999				
5977089		Jul 25, 2017	DS DP U-1275				
5977089*PED		Jan 25, 2018					
6043230		Jul 25, 2017		U-1275			
6043230		Jul 25, 2017		U-248			
6043230		Jul 25, 2017		U-250			
6043230		Jul 25, 2017		U-256			
6043230		Jul 25, 2017		U-999			
6043230*PED		Jan 25, 2018					

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 004	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N022577 001	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-999		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-1275		PED	Sep 24, 2017
	5922695*PED	Jan 25, 2018			PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-999		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-1275		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N202992 001	5459163	Oct 17, 2012	DP		NCE	Sep 12, 2017
	5679709	Oct 21, 2014	DP U-1285			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N202992 002	5459163	Oct 17, 2012	DP		NCE	Sep 12, 2017
	5679709	Oct 21, 2014	DP U-1285			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N022505 002	5861379	May 26, 2015	DS DP U-1100		NCE	Nov 10, 2015
	6020311	May 26, 2015	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 002					NP	Apr 29, 2014
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 003					NP	Apr 29, 2014
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N202763 001					NP	Feb 14, 2015
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
	>A> 8315886	Oct 23, 2020	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
	>A> 8315886	Oct 23, 2020	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
	>A> 8315886	Oct 23, 2020	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
	>A> 8315886	Oct 23, 2020	U-1249			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N203214 001	>A> 6956041	Dec 08, 2020	DP		NCE	Nov 06, 2017
	>A> 6965027	Mar 25, 2023	DS			
	>A> 7091208	Dec 08, 2020	U-247			
	>A> 7265221	Dec 08, 2020	DS			
	>A> 7301023	May 23, 2022	DS			
	>A> RE41783	Dec 08, 2020	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N022275 001	5258510	Nov 02, 2012	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - SAMSCA</u>						
N022275 002	5258510	Nov 02, 2012	DS DP			
<u>TOLVAPTAN - SAMSCA</u>						
N022275 003	5258510	Nov 02, 2012	DS DP			
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002					NPP	Jul 15, 2014
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 001					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 002					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 003					PC	Jun 27, 2012
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001	8273795	Mar 04, 2025		U-1182		
<u>TRAVOPROST - TRAVATAN Z</u>						
N021994 001	8268299	Oct 13, 2029	DP			
	>A> 8323630	Sep 20, 2027	DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	8133893	Mar 13, 2029	DS DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048 001	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029		U-1258		
	8211880	Mar 10, 2029		U-1257		
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N022278 001					ODE	Feb 20, 2016
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N021214 001	>A> 6458836	Jul 09, 2021		U-333		
	>A> 6458836	Jul 09, 2021		U-1315		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 001	8273876	Jul 23, 2027	U-1288			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 002	8273876	Jul 23, 2027	U-1288			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 003	8273876	Jul 23, 2027	U-1288			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 004	8273876	Jul 23, 2027	U-1288			
<u>VEMURAFENIB - ZELBORAF</u>						
N202429 001	8143271	Jun 21, 2026	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VINCRIStINE SULFATE - MARQIBO KIT</u>						
N202497 001	5543152	Jun 20, 2014	DP		NP	Aug 09, 2015
	5741516	Jun 20, 2014	DP		ODE	Aug 09, 2019
	5814335	Jun 20, 2014	DP			
	6723338	Mar 31, 2020	U-1271			
	7247316	Sep 25, 2020	DP			
	7887836	Mar 31, 2020	U-1271			
<u>VISMODEGIB - ERIVEDGE</u>						
N203388 001	7888364	Nov 11, 2028	DS DP		NCE	Jan 30, 2017
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	7456219	Mar 11, 2027	DS			
	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			
	RE38506	Nov 29, 2013	DS DP			
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 001					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 002					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 003					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 004					PC	Aug 29, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N021223 002	>A> 8324189	May 29, 2025	U-53			
	>A> 8324189	May 29, 2025	U-1309			
	>A> 8324189	May 29, 2025	U-1308			
	>A> 8324189*PED	Nov 29, 2025				
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N021223 003	>A> 8324189	May 29, 2025	U-53			
	>A> 8324189	May 29, 2025	U-1309			
	>A> 8324189	May 29, 2025	U-1308			
	>A> 8324189*PED	Nov 29, 2025				
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 001	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 002	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>